product code qty price biologically active … for biosynthesis of penecillin pac-3860-pi-20 c 25 mg...

PEPTIDES INTERNATIONAL

BIOLO

GICALLY ACTIVE PEPTIDES

Order Hotline 1-800-777-4779 502-266-8787 1

PRODUCT CODE QTY PRICE Biologically Active Peptides

NOTE: All Are Acetate Form Unless Otherwise Indicated

Ac-Asp-Glu • H2O (Bulk)(M.W. 304.26 • 18.02) C11H16N2O8 • H2O [3106-85-2] Endogenous Excitatory Neurotransmitter

PDE-4167-20 °C

25 mg100 mg

59166

K.L. Reichert and F. Fonnum, J. Neurochem., 16, 1409 (1969). (Original) K.J. Koller and J.T. Coyle, Eur. J. Pharm., 98, 193 (1984). (Characterization of Receptor) K.J. Koller, et al., J. Neurochem., 43, 1136 (1984). (Localization in Brain)J.H. Neale, et al., J. Neurochem. 75, 443 (2000). (Review)

ACV (Delta-(l-Alpha aminoadipyl)-l-Cysteinyl-Bis-d-Valine)Bis-ACV

Delta-(l-a-aminoadipyl)-l-cysteinyl-bis-d-valine (M.W. 724.86) C28H48N6O12S2 Precursor for Biosynthesis of Penecillin

PAC-3860-PI-20 °C

25 mg100 mg

4231065

Adjuvant PeptideAdjuvant Peptide

N-Ac-Mur-Ala-d-Glu-NH2 (Mur: Muramic acid) (M.W. 492.48) C19H32N4O11 [53678-77-6]

PAD-4031-v-20 °C

0.5 mg vial

49

Adjuvant Peptide (Bulk) N-Ac-Mur-Ala-d-Glu-NH2 • 2H2O (Mur: Muramic acid) (M.W. 492.48 • 36.03 ) C19H32N4O11 • 2H2O [53678-77-6] Muramyl Dipeptide

PAD-4031-20 °C

25 mg 910

F. Ellouz, et al., Biochem. Biophys. Res. Commun., 59, 1317 (1974). (Original) S. Kotani, et al., Biken J., 18, 105 (1975). (Chem. Synthesis and Immun. Activity)

Adrenocorticotropic Hormone (ACTH)ACTH (Human, 1-24) Adrenocorticotropic Hormone (Human, 1-24)

Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val- Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro (M.W. 2933.4) C136H210N40O31S [16960-16-0]

PAC-4109-v-20 °C

0.5 mg vial

295

B. Riniker, et al., Nature (New Biol.), 235, 114 (1972). (Original; Structure)

2 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Adrenomedullins and Related Peptides

K. Kitamura, et al., Drugs, 49, 485 (1995). (Review) D.A. Schell, et al., Trends Endocrinol. Metab., 7, 7 (1996). (Review)M. Julián, et al., Eur. J. Med. Chem., 40, 737 (2005). (Review)

Adrenomedullin (Human)*Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg-Ser-Phe-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Val-Gln-Lys-Leu-Ala- His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn- Val-Ala-Pro-Arg-Ser-Lys-lle-Ser-Pro-Gln-Gly-Tyr-NH2 (Disulfide bond between Cys16-Cys21) (M.W. 6028.7) C264H406N80O77S3 [148498-78-6] Hypotensive Peptide

PAD-4278-s-20 °C

0.1 mg vial

375

K. Kitamura, et al., Biochem. Biophys. Res. Commun., 192, 553 (1993). (Original) K. Kitamura, et al., Biochem. Biophys. Res. Commun., 194, 720 (1993). (Original; cDNA)

Adrenomedullin (Human, 1-25)*Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg-Ser- Phe-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Val-Gln-Lys (Disulfide bond between Cys16-Cys21) (M.W. 2927.3) C125H192N40O36S3 Vasopressor Fragment of Human Adrenomedullin

PAD-4325-v-20 °C

0.5 mg vial

327

T.X. Watanabe, et al., Biochem. Biophys. Res. Commun., 219, 59 (1996). (Original)

Adrenomedullin (Human, 22-52)Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp- Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser- Pro-Gln-Gly-Tyr-NH2 (M.W. 3576.0) C159H252N46O48 [159899-65-7] Adrenomedullin Antagonist

PAD-4302-v-20 °C

0.5 mg vial

407

S. Eguchi, et al., Endocrinology, 135, 2454 (1994). (Original)

Adrenomedullin (Rat)*Tyr-Arg-Gln-Ser-Met-Asn-Gln-Gly-Ser-Arg-Ser-Thr-Gly-Cys- Arg-Phe-Gly-Thr-Cys-Thr-Met-Gln-Lys-Leu-Ala-His-Gln- Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Gly-Met- Ala-Pro-Arg-Asn-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 (Disulfide bond between Cys14-Cys19) (M.W. 5729.4) C242H381N77O75S5 Hypotensive Peptide

PAD-4281-s-20 °C

0.1 mg vial

364

J. Sakata, et al., Biochem. Biophys. Res. Commun., 195, 921 (1993). (Original; cDNA and Biological Activity)

* The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc.


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 3

PRODUCT CODE QTY PRICE Adrenomedullin 2 (Human)Intermedin (Human)

Thr-Gln-Ala-Gln-Leu-Leu-Arg-Val-Gly-Cys-Val-Leu-Gly- Thr-Cys-Gln-Val-Gln-Asn-Leu-Ser-His-Arg-Leu-Trp- Gln-Leu-Met-Gly-Pro-Ala-Gly-Arg-Gln-Asp-Ser-Ala- Pro-Val-Asp-Pro-Ser-Ser-Pro-His-Ser-Tyr-NH2 (Disulfide bond between Cys10 and Cys15) (M.W. 5100.7) C219H349N69O66S3

PAD-4421-s-20 °C

0.1 mgvial

311

Cardiovascular and Renal Regulator / Suppressor for Food Intake and Gastric Emptying M. Ogoshi, et al., Biochem. Biophys. Res. Commun., 311, 1072 (2003). (Takifugu rubripes Adrenomedullins) Y. Takei, et al., FEBS Lett., 556, 53 (2004). (Original; Adrenomedullin 2) J. Roh, et al., J. Biol. Chem., 279, 7264 (2004). (Original; Intermedin) Y. Fujisawa, et al., Eur. J. Pharmacol., 497, 75 (2004). (Pharmacol.)M.M. Taylor, et al., Am. J. Physiol. Regul. Integr. Comp. Physiol., 288, R919 (2005). (Pharmacol.)K. Takahashi, et al., Peptides, 27, 1383 (2006). (Histochem.)D. Bell and B.J. McDermott, Br. J. Pharmacol., 153, S247 (2008). (Review)

Adrenomedullin 2 (Rat)Intermedin (Rat)

PAD-4422-s-20 °C

0.1 mg vial

311

Pro-His-Ala-Gln-Leu-Leu-Arg-Val-Gly-Cys-Val-Leu-Gly-Thr-Cys-Gln- Val-Gln-Asn-Leu-Ser-His-Arg-Leu-Trp-Gln-Leu-Val-Arg-Pro-Ser-Gly- Arg-Arg-Asp-Ser-Ala-Pro-Val-Asp-Pro-Ser-Ser-Pro-His-Ser-Tyr-NH2 (Disulfide bond between Cys10-Cys15) (M.W. 5216.9) C226H361N75O64S2 Potent Cardiovascular and Renal Regulator / Suppressor for Food Intake and Gastric Emptying M. Ogoshi, et al., Biochem. Biophys. Res. Commun., 311, 1072 (2003). (Takifugu rubripes Adrenomedullins) Y. Takei, et al., FEBS Lett., 556, 53 (2004). (Original; Adrenomedullin 2) J. Roh, et al., J. Biol. Chem., 279, 7264 (2004). (Original; Intermedin) Y. Fujisawa, et al., Eur. J. Pharmacol., 497, 75 (2004). (Pharmacol.)M.M. Taylor, et al., Am. J. Physiol. Regul. Integr. Comp. Physiol., 288, R919 (2005). (Pharmacol.)K. Takahashi, et al., Peptides, 27, 1 383 (2006). (Histochem.) D. Bell and B.J. McDermott, Br. J. Pharmacol., 153, S247 (2008). (Review)

PAMP (Human) Proadrenomedullin N-terminal 20 Peptide (Human)

Ala-Arg-Leu-Asp-Val-Ala-Ser-Glu-Phe-Arg-Lys-Lys-Trp-Asn-Lys-Trp-Ala-Leu-Ser-Arg-NH2 (M.W. 2460.8) C112H178N36O27 [150238-87-2] Hypotensive Peptide

PAM-4291-v-20 °C

0.5 mgvial

268

K. Kitamura, et al., Biochem. Biophys. Res. Commun., 194, 720 (1993). (Original; cDNA) H. Washimine, et al., Biochem. Biophys. Res. Commun., 202, 1081 (1994). (Distribution in Human Tissue) K. Kitamura, et al., FEBS Lett., 351, 35 (1994). (Pharmacol.) F. Katoh, et al., J. Neurochemistry, 64, 459 (1995). (Pharmacol.)

PAMP (Rat) Proadrenomedullin N-terminal 20 Peptide (Rat)

Ala-Arg-Leu-Asp-Thr-Ser-Ser-Gln-Phe-Arg-Lys-Lys-Trp-Asn-Lys-Trp-Ala-Leu-Ser-Arg-NH2 (M.W. 2477.8) C111H177N37O28 Hypotensive Peptide

PAM-4292-v-20 °C

0.5 mgvial

268

J. Sakata, et al., Biochem. Biophys. Res. Commun., 195, 921 (1993). (Original; cDNA)

* This product is distributed under the license of Shionogi & Co., Ltd. Its use for any purpose other than research is strictly prohibited.

4 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE PAMP-12 (Human) Proadrenomedullin N-terminal 20 Peptide (Human, 9-20)

Phe-Arg-Lys-Lys-Trp-Asn-Lys-Trp-Ala-Leu-Ser-Arg-NH2 (M.W. 1618.9) C77H119N25O14 Hypotensive Peptide / Major Endogenous Form of PAMPK. Kuwasato, et al., FEBS Lett., 414, 105 (1997). (Original)

PAM-4339-v-20 °C

0.5 mg 118

AdropinAdropin (Human, 34-76 ) (Rat, Mouse)

PAP-4456-s-20 °C

0.1 mgvial

364

Cys-His-Ser-Arg-Ser-Ala-Asp-Val-Asp-Ser-Leu-Ser-Glu-Ser-Ser- Pro-Asn-Ser-Ser-Pro-Gly-Pro-Cys-Pro-Glu-Lys-Ala-Pro-Pro- Pro-Gln-Lys-Pro-Ser-His-Glu-Gly-Ser-Tyr-Leu-Leu-Gln-Pro (Disulfide bond between Cys1-Cys23) (M.W. 4499.8) C190H293N55O68S2 Synthetic Product Regulatory Factor in Energy Homeostasis

Peptides secreted from peripheral organs regulate lipid metabolism in key insulin-target tissues and are important for energy homeostasis and maintaining insulin sensitivity. Much attention has been given to adipokines secreted by adipocytes. While receiving less attention, liver-secreted factors are also critical for energy homeostasis.

Adropin, initially identified during microarray analysis of liver gene expression in mouse models of obesity, is a 76-residue peptide encoded by the energy homeostasis associated gene Enho1). Bio-informatics analysis suggested adropin (34-76) being a secreted form of adropin with high probabil-ity. Thus disulfide-linked adropin (34-76) was chemically synthesized for biological tests; glucose homeostasis and hepatic lipid metabolism were improved in mouse with 90 or 900 nmol/kg/day through intraperitoneal administration. These effects were independent of adiposity or food intake. Considering the alteration of adropin mRNA level associated with obesity, adropin (34-76) may be a powerful peptide in the study of obesity-associated hepatosteatosis and hyperinsulinemia.

K.G. Kumar, et al., Cell Metab., 8, 468 (2008). (Original: Primary Structure/Pharmacol.)

AgeleninAgelenin (Spider, Agelena opulenta)

PAG-4247-s-20 °C

0.1 mgvial

407

Gly-Gly-Cys-Leu-Pro-His-Asn-Arg-Phe-Cys-Asn-Ala-Leu-Ser-Gly-Pro-Arg-Cys- Cys-Ser-Gly-Leu-Lys-Cys-Lys-Glu-Leu-Ser-Ile-Trp-Asp-Ser-Arg-Cys-Leu-NH2 (Disulfide bonds between Cys3-Cys19, Cys10-Cys24 and Cys18-Cys34) (M.W. 3818.4) C160H254N52O45S6 Presynaptic Ca2+ Channel Antagonist K. Hagiwara, et al., Biomedical Res., 11, 181 (1990). (Original) T. Inui, et al., Pept. Res., 5, 140 (1992). (Chem. Synthesis, S-S Bond and Amide)N. Yamaji, et al., FEBS Lett., 581, 3789 (2007). (Solution Structure


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 5

PRODUCT CODE QTY PRICE AG30/5C

Peptides with antimicrobial activity, in addition to angiogenic properties are good candi-dates for wound-healing drugs. One such peptide lead, AG30 (AG: Angiogenic Peptide) was identified in 2009 by the group of Drs. Nakagami and Kaneda of Osaka University.1 Actually, AG30 is predicted by in silico analysis of an angiogenic cDNA clone p3743.2 Through feasibility study and the subsequent clinical investigation of AG30, AG30/5C has just been discovered from the structure-activity relationship study of AG30. In AG30/5C the cationic residues of Arg and Lys replace five neutral amino acids.3 This modification in the primary structure revealed that i) the helical structure is maintained even in the lower extent than that of parental AG30, ii) the potencies are significantly improved in the mi-gration and tube forming ability of human endothelial cells as well as in the antimicrobial activity against P. aeruginosa, Candida, and S. aureus, and iii) wound healing effects are observed in a diabetic mouse model and in a porcine model (100 μg/ml).

In this study, AG30/5C is produced applying the conventional solution method compatible to Good Manufacturing Practice (GMP) guidelines. The structure and characteristics of AG30/5C are similar to those of LL-37, which is known as an antimicrobial peptide with angiogenic properties. AG30/5C, which may facilitate the discovery of novel therapeutic agents, is available from Peptides International.

AG30: MLSLIFLHRLKSMRKRLDRKLRLWHRKNYP AG30/5C: MLKLIFLHRLKRMRKRLKRKLRLWHRKRYKT. Nishikawa, et al., J. Cell. Mol. Med., 13, 535 (2009). (Original; AG30 & Pharmacol.)T. Nishikawa, et al., Hum. Gene Ther., 17, 470 (2006). (Angiogenic cDNA Clone p3743)H. Nakagami, et al., J. Cell. Mol. Med., doi: 10.1111/j.1582-4934.2011.01406.x (Original; AG30/5C & Pharmacol.)

AG30/5CMet-Leu-Lys-Leu-Ile-Phe-Leu-His-Arg-Leu-Lys- Arg-Met-Arg-Lys-Arg-Leu-Lys-Arg-Lys-Leu- Arg-Leu-Trp-His-Arg-Lys-Arg-Tyr-Lys (M.W. 4103.2) C189H330N66O32S2 Antimicrobial Peptide with Angiogenic Properties

AGP-4469-s-20 °C

0.1 mgvial

110

* This product is distributed through Peptide Institute, Inc. under the license of AnGes MG, Inc. Its use for any purpose other than research is strictly prohibited.


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 6

PRODUCT CODE QTY PRICE Agouti-Related Protein

A gene encoding agouti-related protein (AGRP) was isolated in 1997 during a search of the proteins related to agouti protein which was known to affect pigmentation through the melanocortin receptor 1 (MC-1). AGRP shows some sequence similarity to agouti protein, including the distribution of the 10 cysteine residues in the C-terminal domain. However, AGRP and agouti protein bind to distinct types of melanocortin receptors. The receptors for AGRP are reported to be MC-3 and MC-4, which are known to participate in the regulation of feeding, whereby the binding of an antagonist like AGRP stimulates food intake. Some groups have attempted to identify the active domain of a 132 amino acid precursor protein, one of which is AGRP(86-132).1 IC50 values of this peptide in the competitive binding assay for MC-3 and MC-4, expressed in human embryonic kidney cells, were 2 nM and 19 nM, respectively. Competitive inhibition of α-MSH-stimulated cAMP production was also detected for MC-3 and MC-4, but not for MC-1 and MC-5, indicating the selective nature of the action of AGRP(86-132) with respect to melanocortin receptors.

R.D. Rosenfeld, et al., Biochemistry, 37, 16041 (1998). (Original) E.J. Bures, et al., Biochemistry, 37, 12172 (1998). (Structure; S-S Bond) J.R. Shutter, et al., Genes Dev., 11, 593 (1997). (Agouti-Related Transcript Sequence) D.M. Dinulescu and R.D. Cone, J. Biol. Chem., 275, 6695 (2000). (Review)A.M. Wilczynski, et al., Med. Res. Rev., 25, 545 (2005). (Review)O. Ilnytska and G. Argyropoulos, Cell. Mol. Life Sci., 65, 2721 (2008). (Review)

Agouti-Related Protein (Human, 86-132) AGRP (Human, 86-132)

Arg-Cys-Val-Arg-Leu-His-Glu-Ser-Cys-Leu-Gly-Gln-Gln-Val-Pro-Cys-Cys-Asp-Pro-Cys-Ala-Thr-Cys-Tyr-Cys-Arg-Phe-Phe-Asn-Ala-Phe-Cys-Tyr-Cys-Arg-Lys-Leu-Gly-Thr-Ala-Met-Asn-Pro-Cys-Ser-Arg-Thr

PAR-4366-s-20 °C

0.1 mgvial

386

(Reported disulfide bonds between Cys87-Cys102, Cys94-Cys108, Cys101-Cys119, Cys105-Cys129, and Cys110-Cys117) (M.W. 5347.2) C223H339N69O63S11 Melanocortin Receptor-3/4 Antagonist, Appetite Boosting Peptide

AlarinAlarin (Human)

Ala-Pro-Ala-His-Arg-Ser-Ser-Thr-Phe-Pro-Lys-Trp-Val-Thr-Lys-Thr-Glu-Arg-Gly-Arg-Gln-Pro-Leu-Arg-Ser APAHRSSTFPKWVTKTERGRQPLRS (M.W. 2894.3) C127H205N43O35 [909409-86-5] Splice Variant of Galanin-Like Peptide Synthetic Product

PAL-4449-s-20 °C

0.1 mgvial

124

R. Lang, et al., Pharmacol. Ther., 115, 177 (2007). (Review)R. Santic, et al., J. Mol. Neurosci., 29, 145 (2006). (Original)R. Santic, et al., Proc. Natl. Acad. Sci. U.S.A., 104, 10217 (2007). (Original)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 7

PRODUCT CODE QTY PRICE AMP-IBP5

Dr. Minamino and his colleagues of the National Cerebral and Cardiovascular Center Re-search Institute have been performing the proteomics approach to unveil the endogenous peptides. His group has now identified a novel antimicrobial peptide, AMP-IBP5 [named after an antimicrobial peptide derived from insulin-like growth factor-binding protein 5 (IGFBP-5)] using human pancreatic neuroendocrine tumor cell

QGP-1.1 AMP-IBP5 is actually a 22 amino acid residue peptide with dual post-transla-tional modifications: C-terminal amidation and intramolecular disulfide bond formation, the latter of which is a distinct finding because the disulfide linkage of IGFBP-5 has been differently predicted previously. The primary structure of AMP-IBP5 is conserved among many mammals including human, mouse, rat, pig, and cow. AMP-IBP5 is characterized to have a highly basic nature and exerts broad spectra of antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, and fungi (IC50 = μM range), the po-tency of which were comparable to LL-37 (Code 4445-s) and even higher than those of human β-defensin-2 (Code 4338-s). Interestingly, this function is missing in parental IGFBP-5. Major location sites of immunoreactive AMP-IBP5 in rats are clarified as being the pituitary gland, brain, and small intestine.

AMP-IBP5 has the potential to become an essential peptide with antimicrobial activity, along with existing antimicrobial peptides such as defensins and LL-37.

T. Osaki, et al., J. Proteome Res., 10, 1870 (2011). (Original; Primary Structure & Pharmacol.)

AMP-IBP5 (Human) Insulin-Like Growth Factor-Binding Protein 5 (Human, 193-214 Amide)(Porcine, Rat, Mouse, Bovine)

AMP-4468-s-20 °C

0.1 mgvial

118

Ala-Val-Tyr-Leu-Pro-Asn-Cys-Asp-Arg-Lys-Gly-Phe-Tyr-Lys-Arg-Lys-Gln-Cys-Lys-Pro-Ser-Arg-NH2 (Disulfide bond between Cys7-Cys18) (M.W. 2655.1) C117H188N38O29S2 Antimicrobial Peptide

8 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Amylins

G.J.S. Cooper, Endocrinol. Rev., 15, 163 (1994). (Review)J.W.M. Höppener, et al., N. Engl. J. Med., 343, 411 (2000). (Review)S.A. Jayasinghe and R. Langen, Biochim. Biophys. Acta, 1768, 2002 (2007). (Review)L. Haataja, et al., Endocr. Rev., 29, 303 (2008). (Review)

Amylin (Human) IAPP: Islet Amyloid Polypeptide DAP: Diabetes-Associated Peptide

(Trifluoroacetate Form)

PAM-4219-v-20 °C

0.5 mgvial

541

Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser- Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (Disulfide bond between Cys2 and Cys7) (M.W. 3903.3) C165H261N51O55S2 [122384-88-7] Purity Information: Qx See page xivP. Westermark, et al., Proc. Natl. Acad. Sci. USA, 84, 3881 (1987). (Original; 36th A.A. Unknown) G.J.S. Cooper, et al., Proc. Natl. Acad. Sci. U.S.A., 84, 8628 (1987). (Original; Complete Sequence) A. Clark, et al., Lancet, 2, 231 (1987). (Pharmacol; May be Pathogenic)

• U.S. Patent No. 5,367,052. This product is made under license from Amylin Pharmaceuticals, Inc. for sale for noncommercial research use only. For other information and information about licenses for commercial research use may be obtained from Amylin Pharmaceuticals, Inc. at (858) 552-2200.

Amylin (Rat) IAPP: Islet Amyloid Polypeptide DAP: Diabetes-Associated Peptide

PAM-4220-v-20 °C

0.5 mgvial

503

Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-Arg-Ser-Ser- Asn-Asn-Leu-Gly-Pro-Val-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (Disulfide bond between Cys2 and Cys7) (M.W. 3920.4) C167H272N52O53S2 [124447-81-0]J.D. Leffert, et al., Proc. Natl. Acad. Sci. USA, 86, 3127 (1989). (Original; cDNA) J. Asai, et al., Biochem. Biophys. Res. Commun., 164, 400 (1989). (Original; Isolation and Structure)

Amyloid b-Protein Related PeptidesAmyloid b-Protein (Human, 1-40)

(Trifluoroacetate Form)Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val (M.W. 4329.8) C194H295N53O58S [131438-79-4]

PAM-4307-v-20 °C

0.5 mgvial

236

Peptide Deposited in the Brain of Alzheimer’s Disease PatientPurity Information: Qz See page xiv B.A. Yankner, et al., Science, 250, 279 (1990). (Original)

Amyloid b-Protein (Human, 1-40) [HCI Form]

Lyophilized from Dilute HCI Solution

PAB-4379-v-20 °C

0.5 mgvial

268

Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe- Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val (M.W. 4329.8) C194H295N53O58S [131438-79-4] Specific Form Easily Transferrable to β-Structure Purity Information: Qz See page xivI. Kaneko, et al., J. Neurochem., 68, 438 (1997). (Facile b-Structure Formation)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 9

PRODUCT CODE QTY PRICE Amyloid β-Protein (Human, 1-42)

(Trifluoroacetate Form) Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-

PAM-4349-v-20 °C

0.5 mg vial

386

Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn- Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala (M.W. 4514.0) C203H311N55O60S [107761-42-2] Purity Information: Qz See page xiv

D. Goldgaber, et al., Science, 235, 877 (1987). (Original; cDNA)A.E. Roher, et al., Proc. Natl. Acad. Sci. USA, 90, 10836 (1993). (Pathophysiology) N. Suzuki, et al., Science, 264, 1336 (1994). (Pathophysiology) M. Citron, et al., Proc. Natl. Acad. Sci. USA, 93, 13170 (1996). (Biosynthesis)

Amyloid β-Protein (Human, 1-43)(Trifluoroacetate Form)

PAB-4370-v-20 °C

0.5 mgvial

455

Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His- Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val- Gly-Gly-Val-Val-Ile-Ala-Thr (M.W. 4615.1) C207H318N56O62S [134500-80-4] Major Plaque Component in Alzheimer’s Disease Purity Information: Qz See page xivA. Tamaoka, et al., Biochem. Biophys. Res. Commun., 205, 834 (1994). (Pharmacol.) K. Hsiao, et al., Science, 274, 99 (1996). (Pharmacol.) K. Duff, et al., Nature, 383, 710 (1996). (Pharmacol.) T. Kawarabayashi, et al., Brain. Res., 765, 343 (1997). (Pharmacol.)

Amyloid β-Protein (Human, 1-16)Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val- His-His-Gln-Lys (M.W. 1955.0) C84H119N27O28 [131580-10-4] Blocker for Plaque-Induced Microgliosis / Reducer for Brain Inflammation

PAB-4359-v-20 °C

0.5 mgvial

129

D. Giulian, et al., J. Biol. Chem., 273, 29719 (1998). (Original; Pharmacol.)M. Nakamura, et al., Biochemistry, 46, 12737 (2007). (Pharmacol.)

Amyloid β-Protein (Human, 1-28)SP-28 (Human)

PAB-4481-v-20 °C

0.5 mgvial

161

(Trifluoroacetate Form) Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln- Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys (M.W. 3262.5) C145H209N41O46 [109770-29-8] Synthetic Product Amyloidogenic Segment of Amyloid β-Protein Purity Information: Qp See page xivD.A. Kirschner, et al., Proc. Natl. Acad. Sci. U.S.A., 84, 6953 (1987). (Original; Amyloid-Like Fibril Formation)B. Klajnert, et al., Biochem. Biophys. Res. Commun., 345, 21 (2006). (Amyloid Fibril Formation)A. Perálvarez-Marin, et al., J. Mol. Biol., 379, 589 (2008). (Amyloid Fibril Formation)N.G.N. Milton and J.R. Harris, Micron, 40, 800 (2009). (Amyloid Fibril Formation)T. Wasiak, et al., Mol. Pharm., 9, 458 (2012). (Amyloid Fibril Formation & Neurotoxity)J.S. Whitson, et al., Science, 243, 1488 (1989). (Pharmacol.)B.A. Yankner, et al., Science, 250, 279 (1990). (Pharmacol.)

10 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Amyloid β-Protein (Human, 1-38)


PAB-4484-v-20 °C

0.5 mgvial

182

Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln- Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly (M.W. 4131.5) C184H277N51O56S [131438-74-9] Purity Information: Qz See page xiv Endogenous Form of Amyloid β-Protein in Cerebrospinal FluidM. Okochi, et al., Cell Rep., 3, 42 (2013). (γ-Secretase-Mediated Generation)N. Matsumura, et al., J. Biol. Chem., 289, 5109 (2014). (γ-Secretase-Mediated Generation)J.M. Maler, et al., Proteomics, 7, 3815 (2007). (Quantitation in Human Plasma)4) M.E. Lame, et al., Anal. Biochem., 419, 133 (2011). (Quantitation in Human Cerebrospinal Fluid)5) M.P. Mattson, et al., J. Neurosci., 12, 376 (1992). (Pharmacol.: Enhancement of Glutamate Neurotoxicity)

Amyloid β-Protein (Human, 25-35)(Trifluoroacetate Form)Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met (M.W. 1060.3) C45H81N13O14S [131602-53-4] Neurotrophic / Neurodegenerative PeptideB.A. Yankner, et al., Science, 250, 279 (1990). (Original) L. Meda, et al., Nature, 374, 647 (1995). (Pharmacol.) L. Millucci, et al., Curr. Protein Pept. Sci., 11, 54 (2010). (Review)

PAM-4309-v-20 °C

0.5 mg vial

59

[Pyr3]-Amyloid β-Protein (Human, 3-42)(Trifluoroacetate Form)Pyr-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala (M.W. 4309.9) C196H299N53O55S [183449-57-2] Major Neuritic Plaque Component in Alzheimer’s Disease Purity Information: Qz See page xiv

PAB-4367-v-20 °C

0.5 mgvial

386

T.C. Saido, et al., Neuron, 14, 457 (1995). (Pharmacol.; Dominant Deposition in Senile Plaques) T. Iwatsubo, et al., Am. J. Pathol., 149, 1823 (1996). (Histochem.; Distribution in Brains of Patients) Y.-M. Kuo, et al., Biochem. Biophys. Res. Commun., 237, 188 (1997). (Pharmacol.; Form in Neuritic Plaques and Vascular Amyloid Deposits)

Amyloid β-Protein (40-1)Peptide with Reversed Sequence of Amyloid β-Protein (Human, 1-40)

PAB-4413-s-20 °C

0.1 mgvial

129

(Trifluoroacetate Form) Val-Val-Gly-Gly-Val-Met-Leu-Gly-Ile-Ile-Ala-Gly-Lys-Asn-Ser-Gly-Val-Asp-Glu-Ala-Phe- Phe-Val-Leu-Lys-Gln-His-His-Val-Glu-Tyr-Gly-Ser-Asp-His-Arg-Phe-Glu-Ala-Asp (M.W. 4329.8) C194H295N53O58S [144409-99-4] Negative Control Peptide for Amyloid β-Protein (Human, 1-40) Purity Information : QZ See page xiv

Amyloid b-Protein (42-1)Peptide with Reversed Sequence of Amyloid β-Protein (Human, 1-42)

PAB-4420-s-20 °C

0.1 mgvial

241

(Trifluoroacetate Form) Ala-Ile-Val-Val-Gly-Gly-Val-Met-Leu-Gly-Ile-Ile-Ala-Gly-Lys-Asn-Ser-Gly-Val-Asp-Glu-Ala- Phe-Phe-Val-Leu-Lys-Gln-His-His-Val-Glu-Tyr-Gly-Ser-Asp-His-Arg-Phe-Glu-Ala-Asp (M.W. 4514.0) C203H311N55O60S [317366-82-8] Negative Control Peptide for Amyloid β-Protein (Human, 1-42) Purity Information : Qz See page xiv


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 11

PRODUCT CODE QTY PRICE Ac-Leu-Pro-N-Me-Phe-Phe-Asp-NH2β-Sheet Breaker Peptide iAb5p-A1

(M.W. 692.82) C36H48N6O8 Aβ (1-42) Fibrillogenesis Inhibitor, iAβ5p-A1C. Adessi, et al., J. Biol. Chem., 278, 13905, (2003).

PAB-3637-PI-20 °C

5 mg 102

Ac-Leu-Pro-Phe-Phe-Asp-NH2β-Sheet Breaker Peptide iAb5p

(M.W. 678.89) C35H46N6O8 Aβ (1-42) Fibrillogenesis Inhibitor, iAβ5pC. Soto, et al., Nature Medicine, 4, 822 (1998). B. Permanne, et al., FASEB Journal, 16, 862, (2002).

PAB-3632-PI -20 °C

5 mg 91

Ac-Lys-N-Me-Leu-Val-N-Me-Phe-Phe-NH2

(M.W. 721.95) C39H59N7O6 Membrane Permeable Inhibitor of Aβ (1-40) FibrillogenesisD.J. Gordon, et al., Biochemistry, 40, 8237 (2001). D.J. Gordon, et al., J. Pep. Res., 60(1), 37-55 (2002).

PAB-3631-PI-20 °C

1 mg5 mg

70263

β-Sheet Breaker Peptide iAβ5Leu-Pro-Phe-Phe-Asp (M.W. 637.72) C33H43N5O8 [182912-74-9] Inhibitor of Amyloid DepositionC. Soto, et al., Nat. Med., 4, 822 (1998). (Original, Pharmacol.)

PAB-4358-v-20 °C

5 mgvial

204

β-Sheet Breaker Peptide iAβ5 (Bulk)Leu-Pro-Phe-Phe-Asp • AcOH • 4H2O (M.W. 637.74) C33H43N5O8 Inhibitor of Amyloid Deposition

PAB-3615-PI-20 °C

5 mg25 mg

91364

Amphipathic Peptide AntibioticKKALLALALHHLAHLALHLALALKKA

H-Lys-Lys-Ala-Leu-Leu-Ala-Leu-Ala-Leu-His-His-Leu-Ala-His- Leu-Ala-Leu-His-Leu-Ala-Leu-Ala-Leu-Lys-Lys-Ala-OH (M.W. 2779.53) C132H228N38O27 Amphipathic Peptide Antibiotic, LAH4A. Kichler, et al., Proc. Natl. Acad. Sci. USA, 100 (4), 1564 (2003).

PHR-3642-PI-20 °C

1 mg5 mg

134530

12 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Angiotensin and Related Peptides

Ang II is part of the renin-angiotensin system which is responsible for the regulation of blood pressure and fluid balance. It is processed in a series of steps that begins with enzymatic activity of renin on angiotensinogen. Ang II produces many potent effects including vasoconstriction and release of aldosterone which increases reabsorption of electrolytes. Nagata et al. recently isolated a new angiotensinogen-derived peptide with an antibody that binds to the N-terminus of Ang II. The 12 amino acid peptide was named proangiotensin-12 (PAN-4439-v) and may be a precursor to Ang II.1 It was detected in significant concentrations in a number of rat tissues and demonstrated to have constric-tive effects, though its activity was not as potent as Ang II. Its discovery suggests an alternative processing method for Ang II that may be independent of renin.

S. Nagata, et al., Biochem. and Biophys. Res. Commun., 350, 1026 (2006). (Original; Primary Structure & Pharmacol.) I.H. Page and F.M. Bumpus (eds.), Angiotensin, Handbook of Experimental Pharmacology, Vol. 37, Springer-Verlag, Berlin, 1974. (Review) M.J. Peach, Physiol. Rev., 57, 313 (1997). (Review)

H-Ala-Arg-Val-Tyr-Ile-His-Pro-Phe-OHDes-Asp1-[Ala1]-Angiotensin II (Human) ARVYIHPF (M.W. 1002.19) C49H71N13O10 Vasoconstrictive Peptide / Angiotensin Peptide

PAN-3921-PI-20 °C

1 mg5 mg

49209

V. Jankowski, et al., Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 297 ( 2007).

Angiotensin I (Human) (0.5 mg vial)(Porcine, Canine, Rat, Rabbit, Guinea pig) Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu (M.W. 1296.5) C62H89N17O14 [484-42-4]

PAN-4007-v-20 °C

0.5 mgvial

38

Angiotensin I (Human) (Bulk)(Porcine, Canine, Rat, Rabbit, Guinea pig) Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu (M.W. 1296.5) C62H89N17O14 [484-42-4]

PAN-4007-20 °C

25 mg 562

K. Arakawa, et al., Biochem. J., 104, 900 (1967). (Original; Human)H. Akagi, et al., Chem. Pharm. Bull., 30, 2498 (1982). (Original; Porcine etc.)

Angiotensin II (Human)* (0.5 mg vial)Asp-Arg-Val-Tyr-Ile-His-Pro-Phe (M.W. 1046.2) C50H71N13O12 [4474-91-3]

PAN-4001-v-20 °C

0.5 mgvial

38

Angiotensin II (Human)* (Bulk)Asp-Arg-Val-Tyr-Ile-His-Pro-Phe • AcOH • 4H2O

PAN-4001-20 °C

25 mg 510

(M.W. 1046.2 • 60.05 • 72.06) C50H71N13O12 • CH3COOH • 4H2OK. Arakawa, et al., Biochem. J., 104, 900 (1967). (Original)

[N-Me-Asp1]-Angiotensin IIH-N-Me-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH (M.W. 1060.23) C51H73N13O12 Vasoconstrictive Peptide / Angiotensin PeptideR.J. Kokje, et al., Hypertension, 49, 1328 (2007).

PAN-3949-PI-20 °C

1 mg5 mg

59246


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 13

PRODUCT CODE QTY PRICE Angiotensin III (Human)*

Arg-Val-Tyr-Ile-His-Pro-Phe (M.W. 931.09) C46H66N12O9 [13602-53-4]

PAN-4028-v-20 °C

0.5 mg vial

38

Angiotensin III (Human)* (Bulk)Arg-Val-Tyr-lle-His-Pro-Phe • 2AcOH • 4H2O (M.W. 931.09 • 120.11 • 72.06) C46H66N12O9 • 2CH3COOH • 4H2O [100900-06-9]W.B Campbell, et al., Science, 184, 994 (1974). (Original)

PAN-4028-20 °C

25 mg100 mg

4181060

Angiotensin IV (Human)* Angiotensin (Human, 3-8)

PAN-4331-v-20 °C

0.5 mgvial

38

Val-Tyr-Ile-His-Pro-Phe (M.W. 774.91) C40H54N8O8 [23025-68-5]

Angiotensin IV (Human)* (Bulk)Angiotensin (Human, 3-8)

PAN-4331-20 °C

25 mg 391

Val-Tyr-Ile-His-Pro-Phe • ½ AcOH • 3H2O (M.W. 774.91 • 30.03 • 54.05) C40H54N8O8 • ½ CH3COOH • 3H2O R.L. Haberl, et al., Circ. Res., 68, 1621 (1991). (Biological Activity) J.W. Harding, et al., Brain Res., 583, 340 (1992). (Specific Binding Site in Brain) J.M. Hanesworth, et al., J. Pharmacol. Exp. Ther., 266, 1036 (1993). (Specific Binding Site in Heart) M. de Gasparo, et al., Hypertension, 25, 924 (1995). (AT4 Receptor; Non AT½ Recognition, Nomenclature)

[Val5]-Angiotensin I (Bovine)*Asp-Arg-Val-Tyr-Val-His-Pro-Phe-His-Leu (M.W. 1282.4) C61H87N17O14 [484-43-5]

PAN-4069-v-20 °C

0.5 mgvial

43

[Val5]-Angiotensin I (Bovine)* (Bulk)Asp-Arg-Val-Tyr-Val-His-Pro-Phe-His-Leu • AcOH • 5H2O

PAN-4069-20 °C

25 mg 637

(M.W. 1282.4 • 60.05 • 90.08) C61H87N17O14 • CH3COOH • 5H2OD.F. Elliott and W.S. Peart, Biochem. J., 65, 246 (1957). (Original; Heterogenous Renin) H. Akagi, et al., Chem. Pharm. Bull., 30, 2498 (1982). (Original; Homologous Renin) M. Takai, et al., Peptide Chemistry, 1979, 187 (1980). (Chem. Synthesis)

[Asn1, Val5]-Angiotensin II*Asn-Arg-Val-Tyr-Val-His-Pro-Phe (M.W. 1031.2) C49H70N14O11 [53-73-6]

PAN-4036-v-20 °C

0.5 mgvial

38

[Asn1, Val5]-Angiotensin II* (Bulk)Asn-Arg-Val-Tyr-Val-His-Pro-Phe • AcOH • 4H2O

PAN-4036-20 °C

25 mg 589

(M.W. 1031.2 • 60.05 • 72.06) C49H70N14O11 • CH3COOH • 4H2O

Angiotensin (Human, 1-7)*(Canine, Rat)

Asp-Arg-Val-Tyr-Ile-His-Pro (M.W. 899.00) C41H62N12O11 [51833-78-4]

PAN-4332-v-20 °C

0.5 mg vial

38


14 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE [Sar1]-Angiotensin II

H-Sar-Arg-Val-Tyr-Ile-His-Pro-Phe-OH (M.W. 1002.19) C49H71N13O10 Vasoconstrictive Peptide / Angiotensin Peptide

R.J. Kokje, et al., Hypertension, 49, 1328 (2007).

PAN-3948-PI-20 °C

1 mg5 mg

49209

Angiotensin (Human, 1-7)* (Bulk)(Canine, Rat)

PAN-4332-20 °C

25 mg 391

Asp-Arg-Val-Tyr-Ile-His-Pro • AcOH • 4H2O (M.W. 899.00 • 60.05 • 72.06) C41H62N12O11 • CH3COOH • 4H2OM.T. Schiavone, et al., Proc. Natl. Acad. Sci. U.S.A., 85, 4095 (1988). (Original) C.M. Ferrario, et al., Hypertension, 18 (Suppl. III), III-126 (1991). (Review) R.A.S. Santos, et al., Hypertension, 19 (Suppl. II), II-56 (1992). (Metabolic Pathway) A. DelliPizzi, et al., Br. J. Pharmacol., 111, 1 (1994). (Pharmacol.)

[Sar1, Ala8]-Angiotensin IISar-Arg-Val-Tyr-Ile-His-Pro-Ala (M.W. 926.07) C43H67N13O10 [38027-95-11]

PAN-4035-v-20 °C

0.5 mg vial

38

[Sar1, Ala8]-Angiotensin II (Bulk)Sar-Arg-Val-Tyr-Ile-His-Pro-Ala • AcOH • 4H2O

PAN-4035-20 °C

25 mg 487

(M.W. 926.07 • 60.05 • 72.06) C43H67 N13O10 • CH3COOH • 4H2O Angiotensin II Selective Antagonist D.T. Pals, et al., Circ. Res., 29, 673 (1971). (Original) F.M. Bumpus, et al., Circ. Res., 32 and 33 (Suppl. I), 1-150 (1973). (Pharmacol.)

[Sar1, Ile8]-Angiotensin IISar-Arg-Val-Tyr-Ile-His-Pro-Ile (M.W. 968.15) C46H73N13O10 [37827-06-8]

PAN-4016-v-20 °C

0.5 mg vial

38

[Sar1, Ile8]-Angiotensin II (Bulk)Sar-Arg-Val-Tyr-Ile-His-Pro-Ile • AcOH • 4H2O

PAN-4016-20 °C

25 mg 487

(M.W. 968.15 • 60.05 • 72.06) C46H73N13O10 • CH3COOH • 4H2O Angiotensin II Selective AntagonistF.M. Bumpus, et al. Circ. Res., 32 and 33 (Suppl. I), 1-150 (1973). R.K. Türker, et al., Science, 177, 1203 (1972).

[Sar1, Thr8]-Angiotensin IISar-Arg-Val-Tyr-Ile-His-Pro-Thr (M.W. 956.10) C44H69N13O11 [53632-49-8]

PAN-4102-v-20 °C

0.5 mg vial

38

[Sar1, Thr8]-Angiotensin II (Bulk) Sar-Arg-Val-Tyr-Ile-His-Pro-Thr • 2AcOH • 4H2O

PAN-4102-20 °C

25 mg 589

(M.W. 956.101 • 120.10 • 72.06) C44H69N13O11 • 2CH3COOH • 4H2O Angiotensin II Selective Antagonist M.C. Khosla, et al., J. Med. Chem., 17, 1156 (1974). (Original; Chem. Synthesis)

[Sar1, Val5, Ala8]-Angiotensin II*Sar-Arg-Val-Tyr-Val-His-Pro-Ala (M.W. 912.05) C42H65N13O10 [34273-10-4]

PAN-4071-v-20 °C

0.5 mgvial

35



BIOLO


Order Hotline 1-800-777-4779 502-266-8787 15

PRODUCT CODE QTY PRICE [Sar1, Val5, Ala8]-Angiotensin II* (Bulk)

Sar-Arg-Val-Tyr-Val-His-Pro-Ala • AcOH • 4H2O

PAN-4071-20 °C

25 mg 589

(M.W. 912.05 • 60.05 • 72.06) C42H65N13O10 • CH3COOH • 4H2O Angiotensin II Selective Antagonist D.T. Pals, et al., Circ. Res., 29, 673 (1971). (Original)

[Val5]-Angiotensin II* Asp-Arg-Val-Tyr-Val-His-Pro-Phe (M.W. 1032.2) C49H69N13O12 [58-49-1]

PAN-4034-v-20 °C

0.5 mgvial

38

[Val5]-Angiotensin II* (Bulk)Asp-Arg-Val-Tyr-Val-His-Pro-Phe • AcOH • 4H2O (M.W. 1032.2 • 60.05 • 72.06) C49H69N13O12 • CH3COOH • 4H2O [5649-07-0]

PAN-4034-20 °C

25 mg 487

D.F. Elliot and W.S. Peart, Nature, 177, 527 (1956). (Original; Heterogenous Renin) H. Akagi, et al., Chem. Pharm. Bull., 30, 2498 (1982). (Original; Homologous Renin)

Des-Asp1-[Ile8]-Angiotensin IIArg-Val-Tyr-Ile-His-Pro-Ile (M.W. 897.08) C43H68N12O9 [52498-25-6]

PAN-4037-v-20 °C

0.5 mg vial

38

Des-Asp1-[Ile8]-Angiotensin II (Bulk)Arg-Val-Tyr-Ile-His-Pro-Ile • 2AcOH • 4H2O (M.W. 897.08 • 120.10 • 72.06) C43H68N12O9 • 2CH3COOH • 4H2O [102029-49-2] Angiotensin III Selective AntagonistT. Kono, et al., J. Clin. Endocrinol. Metab., 52, 354 (1981). (Pharmacol.)

PAN-4037-20 °C

25 mg 428

CGP 42112Nic-Tyr-Lys(Z-Arg)-His-Pro-Ile (Nic-Nicotinoyl, Z-: Benzyloxycarbonyl) (M.W. 1052.2) C52H69N13O11 [127060-75-7] Angiotensin AT2 Receptor Agonist

PAN-4296-v-20 °C

0.5 mg vial

81

S.E. Whitebread, et al., Biochem. Biophys. Res. Commun., 181, 1365 (1991). B. Buisson, et al., FEBS Lett., 309, 161 (1992). (Pharmacol.) G. Koike, et al., Biochem. Biophys. Res. Commun., 203, 1842 (1994). (Pharmacol.)

Proangiotensin-12 (Rat)**Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Tyr (M.W. 1572.8) C77H109N19O17 [914910-73-9] New Member of Angiotensin Family

PAN-4439-v-20 °C

0.5 mgvial

59

S. Nagata, et al., Biochem. and Biophys. Res. Commun., 350, 1026 (2006). (Original; Primary Structure & Pharmacol.)

* The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc.** This compound is distributed through Peptide Institute, Inc. under the license of University of Miyazaki.

16 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE ANP (Human, 1-28)* A-Type (Atrial) Natriuretic Peptide (Human, 1-28) (Porcine, Bovine, Canine)

PAF-4135-s-20 °C

0.1 mgvial

140

Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly- Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (Disulfide bond between Cys7-Cys23) (M.W. 3080.4) C127H203N45O39S3 [91917-63-4]

A-Type (Atrial) Natriuretic Peptides (ANP) and Related Peptides P. Needleman, et al.,Annu. Rev. Pharmacol. Toxicol., 29, 23 (1989). (Review) A. Rosenzweig and C.E. Seidman, Annu. Rev. Biochem., 60, 229 (1991). (Review)

[Met(O)12]-ANP (Human, 1-28)* [Met(O)12]-A-Type (Atrial) Natriuretic Peptide (Human, 1-28)

PAF-4145-v-20 °C

0.5 mgvial

525

Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met(O)-Asp-Arg- Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (Disulfide bond between Cys7-Cys23) (M.W. 3096.4) C127H203N45O40S3

T.X. Watanabe, et al., Eur. J Pharmacol., 147, 49 (1988). (Pharmacol.)

ANP (Human, 3-28)A-Type (Atrial) Natriuretic Peptide (Human, 5-27)

ANP-3755-PI-20 °C

1 mg5 mg

4281712

H-Lys-Pro-Arg-Arg-Pro-Tyr-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys- Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2 (M.W. 3467.1) C154H257N49O40S [125093-93-8]

I. Gozes, et al., Endocrinology, 125, 2945 (1989). T.W.Moody, et al., Proc. Natl. Acad. Sci. USA, 90, 4345 (1993).

ANP (Human, 5-27)* A-Type (Atrial) Natriuretic Peptide (Human, 5-27)

PAF-4138-v-20 °C

0.5 mgvial

477

Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly- Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg (Disulfide bond between Cys7-Cys23) (M.W. 2404.7) C97H154N34O32S3

T.X. Watanabe, et al., Eur. J. Pharmacol., 147, 49 (1988). (Pharmacol.)


PAF-4137-v-20 °C

0.5 mgvial

477

Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala- Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (Disulfide bond between Cys7-Cys23) (M.W. 2567.8) C106H163N35O34S3

S. Ueda, et al., Biochem. Biophys. Res. Commun., 149, 1055, (1987). (Original) T.X. Watanabe, et al., Eur. J. Pharmacol., 147, 49 (1988). (Pharmacol.)


Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln- Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (Disulfide bond between Cys7-Cys23) (M.W. 2393.7) C100H153N33O30S3

T.X. Watanabe, et al., Eur. J. Pharmacol., 147, 49 (1988).

PAF-4139-v-20 °C

0.5 mgvial

477



BIOLO


Order Hotline 1-800-777-4779 502-266-8787 17

PRODUCT CODE QTY PRICE b-ANP (Human)* b-A-Type (Atrial) Natriuretic Peptide Antiparallel Dimer of ANP (Human, 1-28)

PAF-4168-s-20 °C

0.1 mgvial

386

Ser-Leu-Arg-Arg-Ser-Ser-Cys71-Phe-Gly-Gly-Arg-Met-Asp-Arg-lle-Gly-Ala-Gln-Ser-Gly-

Leu-Gly-Cys231-Asn-Ser-Phe-Arg-Tyr-Tyr-Arg-Phe-Ser-Asn-Cys231-Gly-Leu-Gly-Ser-

Gln-Ala-Gly-lle-Arg-Asp-Met-Arg-Gly-Gly-Phe-Cys71-Ser-Ser-Arg-Arg-Leu-Ser (Disulfide bonds betwen Cys7-Cys231

and Cys71-Cys231) (M.W. 6160.9) C254H406N90O78S6

K. Kangawa, et al., Nature, 313, 397 (1985). (Original) N. Chino, et al., Biochem. Biophys. Res. Commun., 141, 665 (1986). (Chem. Synthesis and Pharmacol.)

ANP (Rat, 1-28)* A-Type (Atrial) Natriuretic Peptide (Rat, 1-28) (Rabbit, Mouse)

Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (Disulfide bond between Cys7-Cys23) (M.W. 3062.4) C128H205N45O39S2 [88898-17-3]

PAF-4151-s-20 °C

0.1 mg vial

140

PAF-4151-v-20 °C

0.5 mg vial

487

T.G. Flynn, et al., Biochem. Biophys. Res. Commun., 117, 859 (1983). (Original) T.X. Watanabe, et al., Eur. J. Pharmacol., 147, 49 (1988). (Pharmacol.)

ANP (Rat, 3-28)* A-Type (Atrial) Natriuretic Peptide (Rat, 3-28)

PAF-4159-v-20 °C

0.5 mg vial

455

Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly- Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (Disulfide bond between Cys7-Cys23) (M.W. 2862.2) C119H189N43O36S2 [90984-99-9]N.G. Seidah, et al., Proc. Natl. Acad. Sci. USA, 81, 2640 (1984). (Original)

Apamin Apamin (Honeybee, Apis mellifera)

PAP-4257-v-20 °C

0.5 mgvial

241

Cys-Asn-Cys-Lys-Ala-Pro-Glu-Thr-Ala-Leu- Cys-Ala-Arg-Arg-Cys-Gln-Gln-His-NH2 (Disulfide bond between Cys1-Cys11 and Cys3-Cys15) (M.W. 2027.3) C79H131N31O24S4 [24345-16-2] Small Conductance Ca2+-Activated K+ Channel BlockerE. Haberman, Pharmacol. Ther., 25, 255 (1984). (Review) A.L. Blatz and K.L. Magleby, Nature, 323, 718 (1986). (Pharmacol.) M.L. Garcia, et al., J. Bioenerg. Biomembr., 23, 615 (1991). (Review)


18 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Apelins

S.C. Sorli, et al., Drug Discov. Today, 11, 1100 (2006). (Review)C. Carpene, et al., J. Physiol. Biochem., 63, 359 (2007 (Review) I. Falcao-Pires, et al., Expert Opin. Ther. Targets, 14, 633 (2010). (Review)

Apelin-36 (Human)Leu-Val-Gln-Pro-Arg-Gly-Ser-Arg-Asn-Gly-Pro-Gly-Pro- Trp-Gln-Gly-Gly-Arg-Arg-Lys-Phe-Arg-Arg-Gln-Arg- Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe (M.W. 4195.8) C184H297N69O43S [252642-12-9] Ligand for APJ Receptor

PAP-4362-s-20 °C

0.1 mgvial

193

K. Tatemoto, et al., Biochem. Biophys. Res. Commun., 251, 471 (1998). (Original; Human and Bovine) M.-X. Zou, et al., FEBS Lett., 473, 15 (2000). (Pharmacol.) M. Hosoya, et al., J. Biol. Chem., 275, 21061 (2000). (Pharmacol.)

[Pyr1]-Apelin-13 (Human, Bovine, Rat)Pyr-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe (M.W. 1533.8) C69H108N22O16S [217082-60-5] Ligand for APJ Receptor

PAP-4361-v-20 °C

0.5 mgvial

91

K. Tatemoto, et al., Biochem. Biophys. Res. Commun., 251, 471 (1998). (Original; Human and Bovine) M.-X. Zou, et al., FEBS Lett., 473, 15 (2000). (Pharmacol.) M. Hosoya, et al., J. Biol. Chem., 275, 21061 (2000). (Pharmacol.) D.K. Lee, et al., J. Neurochem., 74, 34 (2000). cDNA Seq.; Rat)N. De Mota, et al., Proc. Natl. Acad. Sci. U.S.A., 101, 10464 (2004). (Endogenous Apelin 13 in Rat)

Arg-Gly-Asp "RGD" Peptides.

The extracellular matrix (ECM) is central to cell recognition, adhesion and migration. ECM proteins have an arg-gly-asp (RGD) core that allows for receptor recognition. Synthetic peptides containing RGD can compete with ECM protein ligands for receptor binding. GRGDNP (PCI-3909-PI) binds to vitronectin and fibronectin receptors and block interaction to their perspective ligands, though it is a more active inhibitor of fibronectin receptor.1 GRGDNP was found to induce caspase 3 mediated apoptosis in cells and block tumor invasion, implicating fibronectin and vitronectin in tumor metas-tasis.2,3 In addition, these ECM proteins may influence cardiac function as well.4,5

M.D. Pierschbacher and E. Ruoslahti, J. Biol. Chem., 262, 17294 (1987). C.D. Buckley, et al., Nature, 397, 534 (1999). K.R. Gehlsen, et al., J. Cell Biol., 106, 925 (1988). V. Sarin, et al., J. Physiol., 564.2, 603 (2005). J.E. Mogford, et al., J. Clin. Invest., 100, 1647 (1997).

cyclo (Arg-Gly-Asp-d-Phe-Cys)c (RGDfC)

(M.W. 578.65) C24H34N8O7S RGD Tumor Targeting Peptide (linker additions via Cys) (Requires further derivatization before use)

PCI-3686-PI-20 °C

1 mg5 mg

25 mg

64188744

C. Pattillo, et al., Experim. Clin.Therapeutics, Radiation Research Society Meeting (2005)

* This compound is distributed through Peptide Institute, Inc. under license of Takeda Chemical Industries, Ltd.


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 19

PRODUCT CODE QTY PRICE cyclo (Arg-Ala-Asp-d-Phe-Cys)c (RADfC)

(M.W. 592.68) C25H36N8O7S Negative Control Peptide for PCI-3686-PI

PCI-3960-PI-20 °C

1 mg5 mg

25 mg

64188744

cyclo (Arg-Gly-Asp-d-Phe-Glu)c (RGDfE)

(M.W. 604.63) C26H36N8O9

PCI-3687-PI-20 °C

1 mg5 mg

25 mg

53160637

RGD Peptide for Radiolabeling and Imaging (Requires further derivatization before use) G. Thumshirn, et al., Chem. Eur. J., 9, 2717 (2003). T. Poethko, et al., J. Nucl. Med., 45, 892 (2004).

cyclo [Arg-Ala-Asp-d-Phe-Lys(Biotin-PEG-PEG)]c (RADfK(Biotin-PEG-PEG)]

(M.W. 1134.33 C50H79N13O15S Negative control peptide for PCI-3697-PI

PCI-3808-PI-20 °C

1 mg5 mg

74241

cyclo (Arg-Gly-Asp-d-Phe-Lys)c (RGDfK)

(M.W. 603.68) C27H41N9O7

PCI-3661-PI-20 °C

1 mg5 mg

25 mg

53160637

αv β3 Integrin Binding RGD Peptide / RGD Tumor Targeting Peptide (Requires further derivatization before use)M. Kantlehner, et al., Chembiochem., 1, 107 (2000). R.J. Kok, et al., Bioconjug. Chem., 13, 128 (2002).

cyclo (Arg-Gly-Asp-d-Phe-Lys)c (RGDfK)

(Trifluoroacetate Form) (M.W. 603.68) C27H41N9O7

M. Kantlehner, et al., Chembiochem., 1, 107 (2000). R.J. Kok, et al., Bioconjug. Chem., 13, 128 (2002).

PCI-3919-PI-20 °C

1 mg5 mg

25 mg

53160637

cyclo (Arg-Ala-Asp-d-Phe-Lys)c (RADfK)

(M.W. 617.71) C28H43N9O7 Negative Control RGD Peptide for PCI-3661-PIP.K. Dubey, et al., J. Drug Targeting, 12, 257 (2004).

PCI-3883-PI-20 °C

1 mg5 mg

25 mg

49149595

cyclo [Arg-Gly-Asp-d-Phe-Lys (PEG-PEG-Azide)] one of The Clickables

(Trifluoroacetate Form) (M.W. 920.00) C39H61N13O13 Clickable RGD for Dendrimer Constructs

PCI-3759-PI-20 °C

1 mg5 mg

2801199

20 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE cyclo [Arg-Gly-Asp-d-Phe-Lys (Azide)] one of The Clickables

(Trifluoroacetate Form) (M.W. 629.68) C27H39N11O7 Clickable RGD for Dendrimer Constructs

RGD-3749-PI-20 °C

1 mg5 mg

81241

cyclo [Arg-Gly-Asp-d-Phe-Lys(Mal)](Trifluoroacetate Form) (M.W. 754.81) C34H46N10O10

RGD-3795-PI-20 °C

1 mg5 mg

25 mg

64188851

RGD Peptide with 3-Maleimide Propionic Acid Functional Group

cyclo [Arg-Gly-Asp-d-Phe-Lys(PEG-COCH2CH2SH)]

PCI-3977-PI-20 °C

1 mg5 mg

69225

where PEG = 8-Amino-3,6-Dioxaoctanoic Acid (M.W. 836.97) C36H56N10O11S

cyclo [Arg-Gly-Asp-d-Phe-Lys(PEG-PEG)]c(RGDfK(PEG-PEG)) where PEG = 8-Amino-3,6-Dioxaoctanoic Acid

PCI-3696-PI-20 °C

1 mg5 mg

25 mg

64188744

(M.W. 894.00) C39H63N11O13 RGD Peptide equipped with PEG spacers for more efficient binding to lipid surfaces (Requires further derivatization before use)P. Holig, et al., Protein Engin. Design Selection, 17, 433 (2004).

cyclo [Arg-Gly-Asp-d-Phe-Lys(PEG-PEG-Cys) c [RGDfK(PEG-PEG-Cys)]

(M.W. 997.15) C42H68N12O14S

PCI-3823-PI-20 °C

1 mg5 mg

69225

cyclo [Arg-Ala-Asp-d-Phe-Lys(PEG-PEG)]c [RADfK(PEG-PEG)]

(M.W. 908.03) C40H65N11O13 Negative Control Peptide for PCI-3696-PI

PCI-3954-PI-20 °C

1 mg5 mg

25 mg

64188744

cyclo (Arg-Gly-Asp-d-Phe-Lys(Biotin-PEG-PEG))c (RGDfK(Biotin-PEG-PEG)) where PEG = 8-Amino-3,6-Dioxaoctanoic Acid

PCI-3697-PI-20 °C

1 mg5 mg

69225

(Trifluoroacetate Form) (M.W. 1120.30) C49H77N13O15S RGD Peptide Equipped with a Biotin Reporting Tag and PEG Spacers for more Efficient Binding to Lipid Surfaces (Requires further derivatization before use)C. Dolce, et al., J. Dent. Res., 82, 682 (2003). P. Holig, et al., Protein Engin. Design Selection, 17, 433 (2004).


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 21

PRODUCT CODE QTY PRICE cyclo [Arg-Gly-Asp-d-Phe-Lys(Ac-SCH2CO)] c [RGDfK (Ac-SCH2CO)]

PCI-3699-PI-20 °C

1 mg5 mg

25 mg

64188851

(M.W. 719.82) C31H45N9O9S RGD Peptide Equipped with Thioacetyl Group for Linking to Liposomes (Requires further derivatization and deprotection before use) R.J. Kok, et al., Bioconjug. Chem., 13, 128 (2002). R.M. Schiffelers, et al., J. of Controlled Release, 91, 115 (2003). K. Darlak, et al., J. Biol. Chem., 265, 5199 (1990).

cyclo (Arg-Ala-Asp-d-Phe-Lys(Ac-SCH2CO))c (RADfK(Ac-SCH2CO))


PCI-3959-PI-20 °C

1 mg5 mg

25 mg

64188851

Galactosyl-cyclo (Arg-Gly-Asp-d-Phe-Lys) cyclo(-Arg-Gly-Asp-d-Phe-Lys(SAA))

(M.W. 792.85) C34H52N10O12 [922175-70-0] Glycosylated RGD for RadiolabellingHaubner, et al., Bioconjugate Chem., 15, 1, (2004).

RGD-3736-PI-20 °C

1 mg5 mg

4021605

Galacto-RGD2

(M.W. 2149.24) C91H137N29O32, Galacto RGD dimer

RGD-3782-PI-20 °C

1 mg5 mg

214642

S. Ji, Al Czerwinski, Y. Zhou, Gl Shao, F. Valenzuela, P. Sowinski, S. Chauhan, M. Pennington, and S. Liu, Mol. Pharmaceutics, in press

H-dPEG™4-Glu[dPEG™4(cyclo (Arg-Gly-Asp-d-Phe-Lys))]2

(Trifluoroacetate Form)3P-RGD2,PEG4-E[PEG4-c(RGDfK)]2

RGD-3750-PI-20 °C

0.1 mg1 mg5 mg

175295

1180

H-Glu[cyclo (Arg-Ala-Asp-d-Phe-Lys)]2

(Trifluoroacetate Form)Negative Control Peptide for PCI-3651-PI

PCI-3979-PI-20 °C

1 mg5 mg

25 mg

74241851

H-Glu[cyclo (Arg-Gly-Asp-d-Phe-Lys)]2E-[c (RGDfK)2]

(M.W. 1318.47) C59H87N19O16 αv β3 Integrin Binding RGD Peptide RGD Tumor Targeting Peptide (Requires further derivatization before use)M.L. Janssen, et al., Cancer. Res., 62, 6146 (2002). Y. Wu, et al., J. Nucl. Med., 46, 1707 (2005).

PCI-3651-PI-20 °C

1 mg5 mg

25 mg

74241851

22 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE H-Glu{Glu[cyclo (Arg-Gly-Asp-d- Phe-Lys)]2}2

(Trifluoroacetate Form) H-E{E[cRGDfK]2}2 (M.W. 2748.04) C123H179N39O34 Tetrameric RGD PeptideS. Liu, et al., Bioconjugate Chem., 17, 1499 (2006). S. Liu, et al.,Bioconjugate Chem., 18, 438 (2007).

PCI-3975-PI-20 °C

0.5 mg1 mg5 mg

188316

1263

cyclo (Arg-Gly-Asp-d-Phe-Val)c(RGDfV)

ICA-4304-v-20 °C

0.5 mgvial

91

(M.W. 574.63) C26H38N8O7 [137813-35-5] Angiogenesis Inhibitor P.C. Brooks, et al., Cell, 79, 1157 (1994). (Original) M. Friedlander, et al., Proc. Natl. Acad. Sci. USA, 93, 9764 (1996). (Pharmacol.)

cyclo (Arg-Gly-Asp-d-Phe-Val) • AcOH • 2H2O (Bulk)c(RGDfV)

ICA-4304-20 °C

25 mg 749

(M.W. 574.63 • 60.25 • 36.03) • C26H38N8O7 • CH3COOH • 2H2O Angiogenesis Inhibitor

cyclo (Arg-Ala-Asp-d-Phe-Val) c (RADfV)

(M.W. 588.67) C27H40N8O7 Negative Control Peptide for ICA-4304M. Friedlander, et al., PNAS, 93, 9764 (1996).

PCA-3618-PI-20 °C

1 mg5 mg

25 mg

53160637

cyclo (Arg-Gly-Asp-d-Tyr-Cys)c (RGDyC)

(M.W. 594.65) C24H34N8O8S

PCI-3912-PI-20 °C

1 mg5 mg

64188

cyclo (Arg-Ala-Asp-d-Tyr-Cys)c (RADyC)


PCI-3917-PI-20 °C

1 mg5 mg

64188

cyclo (Arg-Gly-Asp-d-Tyr-Glu)c (RGDyE)

(M.W. 620.62) C26H36N8O10 RGD Peptide for Radiolabeling (Requires further derivatization before use)

PCI-3688-PI-20 °C

1 mg5 mg

25 mg

53160637


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 23

PRODUCT CODE QTY PRICE cyclo (Arg-Gly-Asp-d-Tyr-Lys)c (RGDyK)

(M.W. 619.68) C27H41N9O7 αv β3 Integrin Binding RGD Peptide / RGD Tumor Targeting and Tumor Imaging Peptide (Requires further derivatization before use)R. Haubner, et al., J. Nuclear Med., 42, 326 (2001). X. Chen, et al., Nucl. Med. Biol., 31, 179 (2004). X. Chen, et al., Cancer Res., 641, 8009 (2004).

PCI-3662-PI-20 °C

1 mg5 mg

25 mg

53163637

H-Glu[cyclo (Arg-Gly-Asp-d-Tyr-Lys)]2H-E[c (RGDyK)]2

(M.W. 1350.47) C59H87N19O18 RGD Tumor Targeting and Tumor Imaging Peptide (Requires further derivatization before use)

PCI-3899-PI-20 °C

1 mg5 mg

25 mg

74241851

H-AEEEA-Glu[cyclo (Arg-Gly-Asp-d- Tyr-Lys)]2PEG3-c (RGDyK)2

RGD-3766-PI-20 °C

1 mg5 mg

25 mg

96305

1044(Trifluoroacetate Form) (M.W. 1539.68) C67H102N20O22 Byclic RGD peptide for imagingE. Chang, et al., European Journal of Nuclear Medicine and Molecular Imaging, 38, 722 (2010). F.T. Chin, et al., Molecular Imaging and Biology, 14, 88 (2011).

cyclo [Arg-Gly-Asp-d-Phe-Lys(dPEG™4)](Trifluoroacetate Form) (M.W. 850.98) C38H62N10O12

PCI-3790-PI-20 °C

1 mg5 mg

25 mg

64188744

RGD Tumor Targeting (and With Radiolabeling,A Tumor Imaging Peptide)

cyclo (Arg-Gly-Glu-d-Phe-Lys)c (RGEfK)

(M.W. 617.71) C28H43N9O7

PCI-3953-PI-20 °C

1 mg5 mg

25 mg

53160637


24 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Arg-Gly-Asp (RGD) for Cell Adhesion of Biomaterials

Integrins, such as fibronectin, are involved in mediating cell to cell interactions and cell to extracellular matrix interactions. They play a central role in cell adhesion, chemotaxis, cell growth, tissue repair, and tumor development among others. A peptide containing the fibronectin active fragment or cell binding domain was first developed to increase cell attachment to biomaterial or plastic surfaces.1 Ac-GrGDSPASSKGGGGSrLLLLLLr-NH2 also contains a hydrophobic region, SPASSK which acts as a spacer between the cell attachment and biomaterial domains for improved cell attachment to nonbiological surfaces. Additional leucine residues were incorporated to obtain saturated binding. D-arginines were introduced and the N- and C- termini were protected to prevent degrada-tion by endoproteases and exopeptidases respectively.

Ac-GrGDSPASSKGGGGSrLLLLLLr-NH2 has been used as a research application for studying mechanochemical transduction and contractile forces by coating the peptide to magnetic microbeads. This has allowed for the study of contractile forces of airway smooth muscle cells and their role with asthma and mechanical study of the elasticity of alveolar epithelial cells.2,3 Besides its role in understanding cytoskeletal remodeling, the peptide has also been employed to block C. albicans adherence by binding to a fibronectin-like receptor on the yeast cells, reducing the number of pathogens in vitro and in vivo.4 This peptide could also prove useful in cell attachment to nonbiological surfaces for tissue regeneration and implantation associated with therapeutic applications.

W.S. Craig, et al., Biopolymers Peptide Science, 37, 157 (1995). S.S. An, et al., Am. J. Resp. Cell and Molec. Biol., 35, 55 (2006).X. Trepat, et al., Am. J. Physiol. Lung Cell Mol. Physiol., 287, L1025 (2004). S.A. Klotz, et al., Antimicrob. Agents and Chemother., 36, 132 (1992).

Ac-Gly-D-Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys-(Gly)4-Ser-d-Arg-(Leu)6-d-Arg-NH2

Ac-GrGDSPASSKGGGGSrLLLLLLr-Amide (Trifluoroacetate Form) (M.W. 2308.69) C98H174N34O30

PFA-3924-PI-20 °C

1 mg5 mg

81263

H-Arg-Gly-Asp-Ser-Lys-OHRGDSK

PCI-3929-PI-20 °C

1 mg5 mg

81263

(M.W. 561.60) C21H39N9O9 RGD Tumor Targeting PeptideS. Jasseron, et al., Bioorganic & Medicinal Chemistry Letters, 12, 7, (2002).S. Jasseron, et al., Eur J Med Chem, 38, 9, (2003).

H-Arg-Ala-Asp-Ser-Lys-OHRADSK

(M.W. 575.63) C22H41N9O9 Negative Control Peptide for PLI-3929-PI

PCI-3930-PI-20 °C

1 mg5 mg

81263


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 25

PRODUCT CODE QTY PRICE H-[Cys-Arg-Gly-Asp-Arg-Gly-Pro-Asp-Cys]-NH2H-[CRGDRGPDC]-NH2

(Trifluoroacetate Form) (M.W. 975.08) C35H58N16O13S2 (Disulfide bond between Cys1-Cys9) RGD Tumor Targeting PeptideK Sugahara, et al., Science, 328, 1031 (2010).Y. Ye, et al., Bioorg Med Chem Lett., 21, 1146 (2011).

RGD-3762-PI-20 °C

1 mg5 mg

172685

H-[Cys-Arg-Gly-Asp-lys-Gly-Pro-Asp-Cys]-NH2H-[CRGDKGPDC]-NH2

(Trifluoroacetate Form) (M.W. 947.07) C35H58N14O13S2 (Disulfide bond between Cys1-Cys9) RGD Tumor Targeting PeptideK Sugahara, et al., Science, 328, 1031 (2010).Y. Ye, et al., Bioorg Med Chem Lett., 21, 1146 (2011).

RGD-3761-PI-20 °C

1 mg5 mg

172685

Fibronectin Active Fragment (RGDS)Arg-Gly-Asp-Ser

(M.W. 433.42) C15H27N7O8 [91037-65-9]

PFA-4171-v-20 °C

0.5 mg vial

38

Fibronectin Active Fragment (RGDS) (Bulk)Arg-Gly-Asp-Ser • ½AcOH • 2H2O

PFA-4171-20 °C

25 mg 100 mg

305974

(M.W. 433.42 • 30.03 • 36.03) C15H27N7O8 • ½CH3COOH • 2H2O Purity Information: Qp See page xiv M.D. Piershbacher and E. Ruoslahti, Nature, 309, 30 (1984). (Original) D.M. Haverstick, et al., Blood, 66, 946 (1985). (Pharmacol.)

Fibronectin Active Fragment (GRGDS) Gly-Arg-Gly-Asp-Ser

(M.W. 490.47) C17H30N8O9 [96426-21-0]

PFA-4189-v-20 °C

0.5 mg vial

35

Fibronectin Active Fragment (GRGDS)(Bulk) Gly-Arg-Gly-Asp-Ser • ½AcOH • 2H2O

PFA-4189-20 °C

25 mg 100 mg

340910

(M.W. 490.47 • 30.03 • 36.03) C17H30N8O9 • ½CH3COOH • 2H2O S.K. Akiyama and K.M. Yamada, J. Biol. Chem., 260, 10402 (1985). K. Olden, et al., Ann. N.Y. Acad. Sci., 551, 421 (1988).

H-Gly-Arg-Ala-Asp-Ser-Pro-OHGRADSP

(M.W. 601.62) C23H39N9O10 Negative Control Peptide for Fibronectin Inhibitors D.G. Hoyt, et al., Cancer Res., 56, 4146 (1996).

PCI-3910-PI-20 °C

1 mg5 mg

49188

26 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE H-Gly-Arg-Gly-Glu-Ser-OHGRGES

(M.W. 504.50) C18H32N8O9 Negative Control Peptide for PFA-4189-vC.D. Buckley, et al., Nature, 397, 534 (1999)

PFA-3907-PI-20 °C

5 mg25 mg

54241

H-Gly-Arg-Gly-Asp-Asn-Pro-OHGRGDNP

PCI-3909-PI-20 °C

5 mg25 mg

81316

(M.W. 614.62) C23H38N10O10 Inhibitor of Cell Adhesion to Fibronectin. M.D. Pierschbacher and E. Ruoslahti, J. Biol. Chem., 262, 17294 (1987)

H-Gly-Gly-Gly-Gly-Arg-Gly-Asp-Ser- Pro-OH GGGGRGDSP

(M.W. 758.75) C28H46N12O13

PCI-3965-PI-20 °C

5 mg25 mg

91263

Fibronectin Adhesion-Promoting PeptideH-Trp-Gln-Pro-Pro-Arg-Ala-Arg-Ile-OH

(Trifluoroacetate Form) (M.W. 1023.22) C47H74N16O10 [125720-21-0]D.L.Mooradian, et al., Invest. Ophthalmol. Vis. Sci., 34, 153 (1993).A.Woods, et al., Mol. Biol. Cell, 4, 605 (1993).K.L.Hines, et al., Proc. Natl. Acad. Sci. USA, 91, 5187 (1994).

FAP-3758-PI-20 °C

1 mg5 mg

49193

BivalirudinBivalirudin

(Trifluoroacetate Form) d-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly- Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH (M.W. 2180.33) C98H138N24O33 Specific, Reversible, Direct Thrombin Inhibitor; Anti-coagulant

BIV-3767-PI-20 °C

1 mg5 mg

48214

C. Michael, and G. Mckendall, Am. J. Health-System Pharma., 60, 18 (2003). T.E. Warkentin, Thromb. Haemost. 99, 830, 18 (2010).

This is a FDA-regulated product. It is the customer's responsibility to ensure complaince with Federal rules. Peptides International cannot be liable for any infringement of rights made by the user.

BQ-123, BQ-610, and BQ-788 See page 55 and Endothelin Antagonists.

Bovine Adrenal Medulla Dodecapeptide (BAM-12P)BAM-12P Bovine Adrenal Medulla Dodecapeptide

PBM-4119-v-20 °C

0.5 mg vial

86

Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-Glu (M.W. 1424.6) C62H97N21O16S [75513-71-2] K. Mizuno, et al., Biochem. Biophys. Res. Commun., 95, 1482 (1980). (Original)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 27

PRODUCT CODE QTY PRICE BombesinBombesin* (Frog, Bombina bombina)

PBM-4086-v-20 °C

0.5 mgvial

70

Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 (M.W. 1619.8) C71H110N24O18S [31362-50-2]

Bombesin* (Bulk) (Frog, Bombina bombina)

PBM-4086-20 °C

25 mgvial

1284

Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val- Gly-His-Leu-Met-NH2 • AcOH • 7H2O (M.W. 1619.8 • 60.05 • 126.11) C71H110N24O18S • CH3COOH • 7H2OA. Anastasi, et al. Experientia, 27, 166 (1971). (Original) V. Erspamer and P. Melchiorri, Trends Pharmacol. Sci., 1, 391 (1980). (Review) J.G. McCoy and D.D. Avery, Peptides, 11, 595 (1990). (Review) L.K. Malendowicz, Horm. Metab Res., 30, 374 (1998). (Review)

Bradykinin and Related PeptidesE.G. Erdös (ed.) Bradykinin, Kallidin and Kallikrein, Handbook of Experimental Pharmacology, Vol. 25, Springer-Verlag, Berlin, 1970. (Review) E.G. Erdös (ed.) Bradykinin, Kallidin and Kallikrein, Handbook of Experimental Pharmacology, Vol. 25, Suppl., Springer-Verlag, Berlin, 1979. (Review)

Bradykinin* (Human, Bovine, Rat, Mouse)

Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 1060.2) C50H73N15O11 [58-82-2]

PBK-4002-v-20 °C

0.5 mgvial

38

Bradykinin* (Bulk) (Human, Bovine, Rat, Mouse)

PBK-4002-20 °C

25 mg100 mg

354921

Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg • 2AcOH • 3H2O (M.W. 1060.2 • 120.10 • 54.05) C50H73N15O11 • 2CH3COOH • 3H2O

D.F. Elliott, et al., Biochem. J., 76, 16P (1960). (Original; Bovine) E.D. Nicolaides and H.A. DeWald, J. Org. Chem., 26, 3872 (1961). (Chem. Synthesis) J.V. Pierce and M.E. Webster, Biochem. Biophys. Res. Commun., 5, 353 (1961). (Original; Human)

d-Arginyl-[Hyp3,Thi5,d-Tic7,Oic8]-Bradykinin Hoe 140, Icatibant

PKB-4293-v-20 °C

0.5 mgvial

156

d-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-d-Tic-Oic-Arg (Thi: l-Thienylalanine, Tic: 1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid, Oic: (3aS,7aS)-Octahydroindolyl-2-Carboxylic Acid) (M.W. 1304.5) C59H89N19O13S [130308-48-4] Bradykinin B2-Receptor Antagonist


28 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE d-Arginyl-[Hyp3,Thi5,d-Tic7,Oic8]-Bradykinin (Bulk) Hoe 140, Icatibant

PKB-4293-20 °C

25 mg 1926

d-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-d-Tic-Oic-Arg • 2AcOH • 4H2O (Thi: l-Thienylalanine, Tic: 1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid, Oic: (3aS,7aS)-Octahydroindolyl-2-Carboxylic Acid) (M.W. 1304.5 • 120.10 • 72.06) C59H89N19O13S • 2CH3COOH • 4H2O [138614-30-9] Bradykinin B2-Receptor AntagonistF.J. Hock, et al., Br. J. Pharmacol., 102, 769 (1991). (Original; Pharmacol.; in vitro) K. Wirth, et al., Br. J. Pharmacol., 102, 774 (1991). (Original; Pharmacol.; in vivo) A.R. Baydon and B. Woodward, Br. J. Pharmacol., 103, 1829 (1991). (Pharmacol.) G. Wiener, et al., Brain Res., 638 261 (1994). (Pharmacol.; Icatibant)

d-Arginyl-[Hyp3, Thi5,8, d-Phe7]-Bradykinin

d-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-d-Phe-Thi-Arg (Thi: l-Thienylalanine) (M.W. 1294.5) C56H83N19O13S2 [103412-42-6]

PBK-4202-v-20 °C

0.5 mgvial

65

d-Arginyl-[Hyp3,Thi5,8,d-Phe7]-Bradykinin (Bulk)

PBK-4202-20 °C

25 mg 782

d-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-d-Phe-Thi-Arg • 2AcOH • 4H2O (Thi: l-Thienylalanine) (M.W. 1294.5 • 120.11 • 72.06) C56H83N19O13S2 • 2CH3COOH • 4H2O Bradykinin B2-Receptor AntagonistM. Schachter, et al., Br. J. Pharmacol., 92, 851 (1987). (Original) J.M. Stewart and R.J. Vavrek, Adv. Biosci., 65, 73 (1987). (Pharmacol.; pA2) D.C. Perry, Pharmacol. Biochem. Behav., 28, 15 (1987). (Pharmacol.; CNS)

Bradykinin-Potentiator B* (Mamushi, Agkistrodon halys blomhoffii)

IAB-4009-v-20 °C

0.5 mgvial

395

Pyr-Gly-Leu-Pro-Pro-Arg-Pro-Lys-Ile-Pro-Pro (M.W. 1182.4) C56H91N15O13 [30892-86-5] Inhibitor for Peptidyl-Dipeptidase A, Kininase II, and ACE (Angiotensin Converting Enzyme)H. Kato and T. Suzuki, Biochemistry, 10, 972 (1971). (Original)

Bradykinin-Potentiator C (Mamushi, Agkistrodon halys blomhoffii)

IAC-4010-v-20 °C

0.5 mgvial

33

Pyr-Gly-Leu-Pro-Pro-Gly-Pro-Pro-Ile-Pro-Pro (M.W. 1052.2) C51H77N11O13 [30953-20-9] Inhibitor for Peptidyl-Dipeptidase A, Kininase II, and ACE (Angiotensin Converting Enzyme)H. Kato and T. Suzuki, Biochemistry, 10, 972 (1971). (Original)

Des-Arg9-BradykininArg-Pro-Pro-Gly-Phe-Ser-Pro-Phe (M.W. 904.02) C44H61N11O10 [15958-92-6]

PBK-4067-v-20 °C

0.5 mg 38



BIOLO


Order Hotline 1-800-777-4779 502-266-8787 29

PRODUCT CODE QTY PRICE Des-Arg9-Bradykinin (Bulk)

Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe • AcOH • 3H2O

PBK-4067-20 °C

25 mg 552

(M.W. 904.02 • 60.05 • 54.05) C44H61N11O10 • CH3COOH • 3H2O Bradykinin B1-Receptor Agonist D. Regoli, J. Barabe, and W.K. Park, Can. J. Physiol. Pharmacol., 55, 855 (1977). (Original)

Des-Arg10-Kallidin Lysyl-Des-Arg9-Bradykinin

Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe (M.W. 1032.2) C50H73N13O11 [71800-36-7]

PBK-4303-v-20 °C

0.5 mgvial

49

Des-Arg10-Kallidin (Bulk) Lysyl-Des-Arg9-Bradykinin

PBK-4303-20 °C

25 mg 675

Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe • 2AcOH • 4H2O (M.W. 1032.2 • 120.10 • 72.06) C50H73N13O11 • 2CH3COOH • 4H2O Bradykinin B1-Receptor Agonist J.P. Galizzi, et al., Br. J. Pharmacol., 113, 389 (1994). (Original) J.G. Menke, et al., J. Biol. Chem., 269, 21583 (1994). (Pharmacol.) J.S. Zuzack, et al., J. Pharmacol. Exp. Ther., 277, 1337 (1996). (Pharmacol.)

Des-Arg9-[Leu8]-BradykininArg-Pro-Pro-Gly-Phe-Ser-Pro-Leu (M.W. 870.01) C41H63N11O10 [64695-06-3]

PBK-4065-v-20 °C

0.5 mgvial

38

Des-Arg9-[Leu8]-Bradykinin (Bulk)Arg-Pro-Pro-Gly-Phe-Ser-Pro-Leu • AcOH • 3H2O (M.W. 870.01 • 60.05 • 54.05) C41H63N11O10 • CH3COOH • 3H2O [115035-45-5] Bradykinin B1-Receptor Antagonist

PBK-4065-20 °C

25 mg 552

D. Regoli, et al., Can. J. Physiol. Pharmacol., 55, 855 (1977). (Original; pA2 )

Des-Pro2-BradykininArg-Pro-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 963.09 ) C45H66N14O10 [80943-05-1]

IBK-4097-v-20 °C

0.5 mgvial

38

Des-Pro2-Bradykinin (Bulk) IBK-4097-20 °C

25 mg 552

Arg-Pro-Gly-Phe-Ser-Pro-Phe-Arg • 2AcOH • 3H2O (M.W. 963.09 • 120.10 • 54.05) C45H66N14O10 • 2CH3COOH • 3H2O Inhibitor for Peptidyl-Dipeptidase A, Kininase II, and ACE (Angiotensin Converting Enzyme) Purity Information: Qp See page xiv M. Naruse, et al., Chem. Pharm. Bull., 29, 3369 (1981).

30 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE [Hyp3]-Bradykinin (Human)* PBK-4193-v

-20 °C

0.5 mgvial

40

Arg-Pro-Hyp-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 1076.2) C50H73N15O12 [37642-65-2] H. Kato, et al., FEBS Lett., 232, 252 (1988). (Original)

Isoleucyl-Seryl-Bradykinin* T-Kinin (Rat)

PBK-4130-v-20 °C

0.5 mgvial

39

Ile-Ser-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 1260.4) C59H89N17O14 [86030-63-9]

Isoleucyl-Seryl-Bradykinin* (Bulk) T-Kinin (Rat)

PBK-4130-20 °C

25 mg 610

Ile-Ser-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg • 2AcOH • 5H2O (M.W. 1260.4 • 120.10 • 90.08) C59H89N17O14 • 2CH3COOH • 5H2OH. Okamoto and L.M. Greenbaum, Biochem. Biophys. Res. Commun., 112, 701 (1983). (Original)

Lysyl-Bradykinin* Kallidin (Human, Bovine)

PBK-4008-v-20 °C

0.5 mgvial

430

Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 1188.4) C56H85N17O12 [342-10-9]

Lysyl-Bradykinin* (Bulk) Kallidin (Human, Bovine)

PBK-4008-20 °C

25 mg 498

Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg • 3AcOH • 4H2O (M.W. 1188.4 • 180.16 • 72.06) C56H85N17O12 • 3CH3COOH • 4H2O [100900-38-7] J.V. Pierce and M.E. Webster, Biochem. Biophys. Res. Commun., 5, 353 (1961). (Original; Human) D.F. Elliott and G.P. Lewis, Biochem. J., 95, 437 (1965). (Seq.; Bovine)

Lysyl-[Hyp3]-Bradykinin (Human)Lys-Arg-Pro-Hyp-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 1204.4) C56H85N17O13

PBK-4191-v-20 °C

0.5 mgvial

49

M. Sasaguri, et al., Biochem. Biophys. Res. Commun., 150, 511 (1988). (Original)

Methionyl-Lysyl-Bradykinin (Human, Bovine)

Met-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 1319.6) C61H94N18O13S [550-19-6]

PBK-4012-v-20 °C

0.5 mgvial

43

Methionyl-Lysyl-Bradykinin (Human, Bovine) (Bulk)

PBK-4012-20 °C

25 mg 552

Met-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg • 3AcOH • 2H2O (M.W. 1319.6 • 180.16 • 36.03) C61H94N18O13S • 3CH3COOH • 2H2OD.F. Elliott and G.P. Lewis, Biochem. J., 95, 437 (1965). (Original; Bovine) I. Ohkubo, et al., Biochemistry, 23, 5691 (1984). (cDNA Seq.; Human)



BIOLO


Order Hotline 1-800-777-4779 502-266-8787 31

PRODUCT CODE QTY PRICE [Thi5,8, d-Phe7]-Bradykinin

Arg-Pro-Pro-Gly-Thi-Ser-d-Phe-Thi-Arg (Thi: l-Thienylalanine) (M.W. 1122.3) C50H71N15O11S2 [97825-07-5] Bradykinin B2-Receptor AntagonistR.J. Vavrek and J.M. Stewart, Peptides, 6, 161 (1985). (Original)

PBK-4175-v-20 °C

0.5 mgvial

54

[Tyr8]-BradykininArg-Pro-Pro-Gly-Phe-Ser-Pro-Tyr-Arg (M.W. 1076.2) C50H73N15O12 [32222-00-7] For Radioimmunoassay

PBK-4075-v-20 °C

0.5 mgvial

49

M.D. Nielsen, et al., Clinica Chimica Acta, 125, 145 (1982). (Radioimmunoassay) M.J. Fredrick, et al., Life Sci., 37, 331 (1985). (Radioimmunoassay)

Tyrosyl-Bradykinin Tyr-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (M.W. 1223.4) C59H82N16O13 [33289-76-8] For Radioimmunoassay

PBK-4056-v-20 °C

0.5 mgvial

43

R.E. Lewis, et al., Brain Res., 346, 263 (1985). (Radioimmunoassay) M.J. Fredrick, Fet al., Life Sci., 37, 331 (1985). (Radioimmunoassay)

B-Type (Brain) Natriuretic Peptides (BNP)A. Rosenzweig and C.E. Seidman, Annu. Rev. Biochem., 60, 229 (1991). (Review)

BNP-32 (Human)* B-Type (Brain) Natriuretic Peptide-32 (Human)

PBN-4212-v-20 °C

0.5 mgvial

525

Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp- Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His (Disulfide bond between Cys10-Cys26) (M.W. 3464.0) C143H244N50O42S4 [124584-08-03] T. Sudoh, et al., Biochem. Biophys. Res. Commun., 159, 1427 (1989). (Original; cDNA) Y. Kambayashi, et al., FEBS Lett., 259, 341 (1990). (Original; Isolation and Structure)

Tyrosyl-BNP-32 (Human)* Tyrosyl-B-Type (Brain) Natriuretic Peptide-32 (Human)

PBN-4230-v-20 °C

0.5 mgvial

621

Tyr-Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys- Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His (Disulfide bond between Cys10-Cys26) (M.W. 3627.2) C152H253N51O44S4 Purity Information: Qx See page xiv For Radioimmunoassay

BNP-26 (Porcine)* B-Type (Brain) Natriuretic Peptide-26 (Porcine)

Asp-Ser-Gly-Cys-Phe-Gly-Arg-Arg-Leu-Asp-Arg-lle-Gly- Ser-Leu-Ser-Gly-Leu-Gly-Cys-Asn-Val-Leu-Arg-Arg-Tyr (Disulfide bond between Cys4-Cys20) (M.W. 2869.2) C120H198N42O36S2 [114547-28-3]T. Sudoh, et al., Nature, 332, 78 (1988). (Original)

PBN-4200-v-20 °C

0.5 mgvial

525


32 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE BNP-32 (Rat)* B-Type (Brain) Natriuretic Peptide-32 (Rat)

PBN-4213-v-20 °C

0.5 mgvial

525

Asn-Ser-Lys-Met-Ala-His-Ser-Ser-Ser-Cys-Phe-Gly-Gln-Lys-Ile-Asp- Arg-Ile-Gly-Ala-Val-Ser-Arg-Leu-Gly-Cys-Asp-Gly-Leu-Arg-Leu-Phe (Disulfide bond between Cys10-Cys26) (M.W. 3452.9) C146H239N47O44S3 [133448-20-1]M. Kojima, et al., Biochem. Biophys. Res. Commun, 159, 1420 (1989). (Original; cDNA)

BNP-45 (Rat)* B-Type (Brain) Natriuretic Peptide-45 (Rat)

PBN-4218-s-20 °C

0.1 mgvial

182

Ser-Gln-Asp-Ser-Ala-Phe-Arg-Ile-Gln-Glu-Arg-Leu-Arg-Asn-Ser-Lys-Met-Ala-His-Ser-Ser-Ser-Cys-Phe-Gly-Gln-Lys-Ile-Asp-Arg-Ile-Gly-Ala-Val-Ser-Arg-Leu-Gly-Cys-Asp-Gly-Leu-Arg-Leu-Phe (Disulfide bond between Cys23-Cys39) (M.W. 5040.7) C213H349N71O65S3 [123337-89-3] M. Aburaya, et al., Biochem. Biophys. Res. Commun., 163, 226 (1989). (Original) Y. Kambayashi, et al., Biochem. Biophys. Res. Commun., 163, 233 (1989). (Original)

C PeptideC-Peptide (Human)

H-Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val- Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu- Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-OH (M.W. 3020.33) C129H211N35O48 [33017-11-7] Insulin Precursor (57-87) (Human)A.S.C.Ko and D.G.Smyth, Eur. J. Biochem., 20, 190 (1971).P.E.Oyer, et al., J. Biol. Chem., 246, 1375 (1971).K.Igano, et al., Bull. Chem. Soc. Jpn., 54, 3088 (1981).J.Wahren, et al., Exp. Diabesity Res., 5, 15 (2004).J.P.Palmer, et al., Diabetes, 53, 250 (2004).

PCP-3725-PI-20 °C

1 mg5 mg

209835

[Tyr0]-C-Peptide (Human) Tyrosyl Human C-Peptide

PCP-3724-PI-20 °C

1 mg5 mg

6962782

H-Tyr-Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val- Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu- Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-OH (M.W. 3183.50) C138H220N36O50 [57327-90-9] C-Peptide Derivative for Radioimmunoassay. V.K. Naithani, et al., Hoppe Seylers Z. Physiol. Chem., 356, 1305 (1975) N. Yanaihara, et al., Hoppe Seylers Z. Physiol. Chem., 362, 775 (1981) H. Sun, et al., Appl. Biochem. Biotechnol., 55, 167 (1995) V.K. Naithani, et al., Hoppe Seylers Z. Physiol. Chem., 356, 1305 (1975)



BIOLO


Order Hotline 1-800-777-4779 502-266-8787 33

PRODUCT CODE QTY PRICE BNP-32 (Rat)* B-Type (Brain) Natriuretic Peptide-32 (Rat)

PBN-4213-v-20 °C

0.5 mgvial

525

Asn-Ser-Lys-Met-Ala-His-Ser-Ser-Ser-Cys-Phe-Gly-Gln-Lys-Ile-Asp- Arg-Ile-Gly-Ala-Val-Ser-Arg-Leu-Gly-Cys-Asp-Gly-Leu-Arg-Leu-Phe (Disulfide bond between Cys10-Cys26) (M.W. 3452.9) C146H239N47O44S3 [133448-20-1]M. Kojima, et al., Biochem. Biophys. Res. Commun, 159, 1420 (1989). (Original; cDNA)

BNP-45 (Rat)* B-Type (Brain) Natriuretic Peptide-45 (Rat)

PBN-4218-s-20 °C

0.1 mgvial

182

Ser-Gln-Asp-Ser-Ala-Phe-Arg-Ile-Gln-Glu-Arg-Leu-Arg-Asn-Ser-Lys-Met-Ala-His-Ser-Ser-Ser-Cys-Phe-Gly-Gln-Lys-Ile-Asp-Arg-Ile-Gly-Ala-Val-Ser-Arg-Leu-Gly-Cys-Asp-Gly-Leu-Arg-Leu-Phe (Disulfide bond between Cys23-Cys39) (M.W. 5040.7) C213H349N71O65S3 [123337-89-3] M. Aburaya, et al., Biochem. Biophys. Res. Commun., 163, 226 (1989). (Original) Y. Kambayashi, et al., Biochem. Biophys. Res. Commun., 163, 233 (1989). (Original)

C PeptideC-Peptide (Human)

H-Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val- Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu- Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-OH (M.W. 3020.33) C129H211N35O48 [33017-11-7] Insulin Precursor (57-87) (Human)A.S.C.Ko and D.G.Smyth, Eur. J. Biochem., 20, 190 (1971).P.E.Oyer, et al., J. Biol. Chem., 246, 1375 (1971).K.Igano, et al., Bull. Chem. Soc. Jpn., 54, 3088 (1981).J.Wahren, et al., Exp. Diabesity Res., 5, 15 (2004).J.P.Palmer, et al., Diabetes, 53, 250 (2004).

PCP-3725-PI-20 °C

1 mg5 mg

209835

[Tyr0]-C-Peptide (Human) Tyrosyl Human C-Peptide

PCP-3724-PI-20 °C

1 mg5 mg

6962782

H-Tyr-Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val- Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu- Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-OH (M.W. 3183.50) C138H220N36O50 [57327-90-9] C-Peptide Derivative for Radioimmunoassay. V.K. Naithani, et al., Hoppe Seylers Z. Physiol. Chem., 356, 1305 (1975) N. Yanaihara, et al., Hoppe Seylers Z. Physiol. Chem., 362, 775 (1981) H. Sun, et al., Appl. Biochem. Biotechnol., 55, 167 (1995) V.K. Naithani, et al., Hoppe Seylers Z. Physiol. Chem., 356, 1305 (1975)


34 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE CalcitoninCalcitonin (Human)

Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly-Thr- Tyr-Thr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe- Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-NH2 (Disulfide bond between Cys1-Cys7) (M.W. 3417.8) C151H226N40O45S3 [21215-62-3]R. Neher, et al., Helv. Chim. Acta, 51, 1900 (1968). (Original)

PCL-4051-s-20 °C

0.1 mg vial

140

PCL-4051-v-20 °C

0.5 mgvial

455

Y. Nakagawa, et al., Peptide Chemistry 1977, 189 (1978). (Chem. Synthesis)

CART PeptidesP.J. Larsen and R.G. Hunter, Peptides, 27, 1981 (2006). (Review) A. Vicentic and D.C. Jones, J. Pharmacol. Exp. Ther., 320, 499 (2007). (Review)

CART (Human, 55-102) Cocaine-and Amphetamine-Regulated Transcript (Human, 55-102)

PCA-4350-s-20 °C

0.1 mgvial

386

Ile-Pro-Ile-Tyr-Glu-Lys-Lys-Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys-Ala-Val-Arg-Lys-Gly-Ala-Arg-Ile-Gly-Lys-Leu-Cys-Asp-Cys-Pro-Arg-Gly-Thr-Ser-Cys-Asn-Ser-Phe-Leu-Leu-Lys-Cys-Leu (Disulfide bonds between Cys68-Cys86, Cys74-Cys94, and Cys88-Cys101) (M.W. 5245.2) C225H365N65O65S7 [214050-22-3] Food-Intake InhibitorP. Kristensen, et al., Nature, 393, 72 (1998). (Pharmacology; New Anorectic Peptide) J. Douglass and S. Daoud, Gene, 169, 241 (1996). (Original, cDNA) A.J. Kastin and V. Akerstrom, Am. J. Physiol., 277, E901 (1999). (Pharmacol.; across BBB) M.J. Kuhar, et al., Regul. Pept., 89, 1 (2000). (Review)

CART (Rat, 55-102) Cocaine-and Amphetamine-Regulated Transcript (Rat, 55-102)

PCA-4351-s-20 °C

0.1 mgvial

386

Ile-Pro-Ile-Tyr-Glu-Lys-Lys-Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys-Ala-Val-Arg-Lys-Gly-Ala-Arg-Ile-Gly-Lys-Leu-Cys-Asp-Cys-Pro-Arg-Gly-Thr-Ser-Cys-Asn-Ser-Phe-Leu-Leu-Lys-Cys-Leu (Disulfide bonds between Cys68-Cys86, Cys74-Cys94, and Cys88-Cys101) (M.W. 5259.2) C226H367N65O65S7 [209615-79-2] Food-Intake InhibitorP. Kristensen, et al., Nature, 393, 72 (1998). (Pharmacology: New Anorectic Peptide) J. Douglass, A.A. McKinzie, and P. Couceyro, J. Neurosci., 15, 2471 (1995). (Original: cDNA) L. Thim, et al., FEBS Lett., 428, 263 (1998). (Biochem. & Pharmacol.) M.J. Kuhar, et al., Regul. Pept., 89, 1 (2000). (Review)

b-Casomorphinsb-Casomorphin-5 (Bovine)

Tyr-Pro-Phe-Pro-Gly (M.W. 579.64) C30H37N5O7 [72122-63-5]

PEK-4079-v -20 °C

0.5 mgvial

33

b-Casomorphin-5 (Bovine) (Bulk)Tyr-Pro-Phe-Pro-Gly • 2H2O (M.W. 579.64 • 36.03) C30H37N5O7 • 2H2O [72122-63-5]

PEK-4079-20 °C

25 mg100 mg

204610

V. Brantl, et al., Hoppe-Seyler’s Z. Physiol. Chem., 360, 1211 (1979). (Original; Isolation) A. Henschen, et al., Hoppe-Seyler’s Z. Physiol. Chem., 360, 1217 (1979). (Original; Structure)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 35

PRODUCT CODE QTY PRICE b-Casomorphin-7 (Bovine)

Tyr-Pro-Phe-Pro-Gly-Pro-Ile (M.W. 789.92) C41H55N7O9 [72122-62-4]

PEK-4078-v-20 °C

0.5 mgvial

38

V. Brantl, et al., Hoppe-Seyler’s Z. Physiol. Chem., 360, 1211 (1979). (Original; Isolation) A. Henschen, et al., Hoppe-Seyler’s Z. Physiol. Chem., 360, 1217 (1979). (Original; Structure)

Catestatin See Pancreastatins.CCK See Cholecystokinin and Related Peptides.

CEP1CEP1C-Terminally Encoded Peptide 1 (Plant, Arabidopsis)

CEP-4487-s-20 °C

0.1 mgvial

70

Asp-Phe-Arg-Hyp-Thr-Asn-Pro-Gly-Asn-Ser-Hyp-Gly-Val-Gly-His (M.W. 1583.6) C66H98N22O24 Mediator of Systemic N-Demand Signaling in PlantS. Endo, et al., Curr. Opin. Plant Biol., 21, 140 (2014). (Review) Y. Matsubayashi, Annu. Rev. Plant Biol., 65, 385 (2014). (Review) K. Ohyama, et al.i, Plant J., 55, 152 (2008). (Original) R. Tabata, et al., Science, 346, 343 (2014). (Pharmacol.)

CGP 42112 See Code PAN-4296-v.

CGRPCGRP (Human)* Calcitonin Gene Related Peptide (Human) a-CGRP (Human)

Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2 (Disulfide bond between Cys2-Cys7) (M.W. 3789.3) C163H267N51O49S2 [90954-53-3]

PCG-4160-s-20 °C

0.1 mg vial

145

PCG-4160-v-20 °C

0.5 mg vial

455

H.R. Morris, et al., Nature, 308, 746 (1984). (Original)

• This compound is distributed through Peptide Institute, Inc. under the license of The Salk Institute. However, it is not available in the United Kingdom due to patent rights held by Celltech. Ltd.

CGRP (Human, 8-37)* Calcitonin Gene Related Peptide (Human, 8-37) a-CGRP (Human, 8-37)

PCG-4232-v-20 °C

0.5 mgvial

280

Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys- Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2 (M.W. 3125.6) C139H230N44O38 [119911-68-1] Calcitonin Gene Related Peptide (CGRP) AntagonistT. Chiba, et al., Am. J. Physiol., 256, E331 (1989). (Original) S.-P. Han, et al., Biochem. Biophys. Res. Commun., 168, 786 (1990). (Pharmacol.) T. Dennis, et al., J. Pharmacol. Exp. Ther., 254, 123 (1990). (Pharmacol.) S.M. Gardiner, et al., Biochem. Biophys. Res. Commun., 171, 938 (1990). (Pharmacol.)


36 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE CGRP (Rat)* Calcitonin Gene Related Peptide (Rat) a-CGRP (Rat)

Ser-Cys-Asn-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala- Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asp-Asn- Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Glu-Ala-Phe-NH2 (Disulfide bond between Cys2-Cys7) (M.W. 3806.2) C162H262N50O52S2 [83651-90-5]

PCG-4163-s-20 °C

0.1 mg vial

145

PCG-4163-v-20 °C

0.5 mg vial

455

S.G. Amara, et al., Nature, 298, 240 (1982). (Original) M.G. Rosenfeld, et al., Nature, 304, 129 (1983). (Processing and Distribution in Neural Tissue)

Charybotoxin See Code PCB-4227-s in the Toxins subsection.

Chemotactic PeptideChemotactic Peptide PCT-4066-v

-20 °C

0.5 mgvial

33

Chemotactic Peptide (Bulk)For-Met-Leu-Phe FMLP

(M.W. 437.55) C21H31N3O5S [59880-97-6]

PCT-4066-20 °C

25 mg100 mg

106311

L.T. Williams, et al., Proc. Natl. Acad. Sci. USA, 74, 1204 (1977). (Receptor Site on Human Leukocyte)

Chlorotoxin See PCN-4282-v in the Toxins subsection.

Cholecystokinin (CCK) Related PeptidesJ.E. Jorpes and V. Mutt (eds.) Secretin, Cholecystokinin, Pancreozymin and Gastrin, Handbook of Experimental Pharmacology, Vol. 34, Springer-Verlag, Berlin, 1973. (Review)

CCK-Tetrapeptide (30-33)** (Hydrochloride Form)Trp-Met-Asp-Phe-NH2 (M.W. 596.70) C29H36N6O6S

PCK-4083-v-20 °C

0.5 mgvial

33

CCK-Tetrapeptide (30-33)** (Bulk) CCK-4

PCK-4083-20 °C

25 mg100 mg

129386

Trp-Met-Asp-Phe-NH2 • HCI • H2O (M.W. 596.70 • 36.46 • 18.02) C29H36N6O6S • HCI • H2O [5609-49-4]J.F. Rehfeld, et al., Nature, 284, 33 (1980). (Neural Pharmacol.)

CCK-Octapeptide (26-33) (Non-Sulfated Form)* CCK-8 (Non-Sulfated Form)

PCK-4087-v

2

-20 °C

0.5 mgvial

65

(Ammonium Form)Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH (M.W. 1063.2) C49H62N10O13S2 [25679-24-7]M.A. Ondetti, et al., J. Am. Chem. Soc., 92, 195 (1970). (Chem. Synthesis)

* This compound is distributed through Peptide Institute, Inc. under the license of the Salk Institute.* The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc.


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 37

PRODUCT CODE QTY PRICE CCK-Octapeptide (26-33) (Sulfated Form)* CCK-8 (Sulfated Form)

(Ammonium Form)Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2 (M.W. 1143.3) C49H62N10O16S3 [25126-32-3]

PCK-4100-v-20 °C

0.5 mgvial

1610

M.A. Ondetti, et al., J. Am. Chem. Soc., 92, 195 (1970). (Chem. Synthesis)

CCK-33 (Human)* PCK-4201-s-20 °C

0.1 mgvial

552Lys-Ala-Pro-Ser-Gly-Arg-Met-Ser-Ile-Val-Lys-Asn-Leu- Gln-Asn-Leu-Asp-Pro-Ser-His-Arg-Ile-Ser-Asp-Arg- Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2 (M.W. 3945.4) C167H263N51O52S4 [96827-04-2]Y. Takahashi, et al., Proc. Natl. Acad. Sci. U.S.A., 82, 1931 (1987). (Original; Nucleotide Seq.) Y. Kurano, et al., In, Peptides, Proceedings of the 10th American Peptide Symposium, (G.R. Marshall, ed.), ESCOM Science Publishers B.V. 1988, pp. 162-165. (Chem. Synthesis)

CCK-33 (Porcine)* PCK-4176-s-20 °C

0.1 mg vial

552Lys-Ala-Pro-Ser-Gly-Arg-Val-Ser-Met-Ile-Lys-Asn-Leu- Gln-Ser-Leu-Asp-Pro-Ser-His-Arg-Ile-Ser-Asp-Arg- Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2 (M.W. 3918.4) C166H262N50O52S4 [67256-27-3]V. Mutt and J.E. Jorpes, Eur. J. Biochem., 6, 156 (1968). (Original; Partial Structure) V. Mutt and J.E. Jorpes, Biochem. J., 125, 57P (1971). (Original) Y. Kurano, et al., J. Chem. Soc. Chem. Commun., 5, 323 (1987). (Chem. Synthesis)

CD36 Binding PeptideH-Gly-Asp-Gly-Val-d-Ile-Thr-Arg-Ile-Arg-OH

(M.W. 986.15) C41H75N15O13 CD36 Binding PeptideJ.S. Isenberg, et al., J. Biol. Chem., 282, 15404 (2007).

PCI-3964-PI-20 °C

1 mg5 mg

59209

Chromagranin A (Human, 286-301 Amide) See Code PCR-4214-v.

CINC-1/groCINC-1/gro (Rat)Cytokine-Induced Neutrophil Chemoattractant-1/ Growth-Related Oncogene (Rat)

PIL-4233-v-20 °C

20 µgvial

391

Ala-Pro-Val-Ala-Asn-Glu-Leu-Arg-Cys-Gln-Cys-Leu-Gln-Thr-Val-Ala-Gly-Ile-His-Phe-Lys-Asn-Ile-Gln-Ser-Leu-Lys-Val-Met-Pro-Pro-Gly-Pro-His-Cys-Thr-Gln-Thr-Glu-Val-Ile-Ala-Thr-Leu-Lys-Asn-Gly-Arg-Glu- Ala-Cys-Leu-Asp-Pro-Glu-Ala-Pro-Met-Val-Gln-Lys-Ile-Val-Gln-Lys-Met-Leu-Lys-Gly-Val-Pro-Lys (Disulfide bonds between Cys9-Cys35 and Cys11-Cys51) (M.W. 7845.3) C343H572N98O97S7

K. Watanabe, et al., J. Biol. Chem., 264, 19559 (1989). (Original) Y. Nishiuchi, et al., (J.A. Smith and J.E Rivier eds.) Peptides: Chemistry and Biology (Proceeding of the 12th American Peptide Symposium), Escom, Lieden, 1992, pp. 911-913. (Chem. Synthesis) H. Nakagawa, et al., Biochem. J., 301, 545 (1994). (CINC Family)


38 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE ColivelinColivelin

H-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Gly-Ala-Ser-Arg- Leu-Leu-Leu-Leu-Thr-gly-Glu-Ile-Asp-Leu-Pro-OH SALLRSIPAPAGASRLLLLTGEIDLP (M.W. 2645.16) C119H206N32O35 Neuroprotective Peptide in Alzheimer’s Disease ResearchT. Chiba, et al. J. Neuroscience, 25 10252 (2005).

PHN-3901-PI-20 °C

0.5 mg1.0 mg

209358

Corticotropin-Releasing Factor / Hormones (CRF/CRH)C.L. Rivier and P.M. Plotsky, Annu. Rev. Physiol., 48, 475 (1986). (Review) F.A. Antoni, Endocrinol. Rev., 7, 351 (1986). (Review) M.J. Owens and C.B. Nemeroff, Pharmacol. Rev., 43, 425 (1991). (Review) M. Schaefer, et al., Eur. J. Pharmacol., 323, 1 (1997). (Review)

CRF (Human, Rat) Corticotropin-Releasing Factor (Human, Rat)

Ser-Glu-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu- Leu-Arg-Glu-Val-Leu-Glu-Met-Ala-Arg-Ala-Glu-Gln-Leu-Ala- Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Met-Glu-Ile-Ile-NH2 (M.W. 4757.5) C208H344N60O63S2 [86784-80-7]

PCR-4136-s-20 °C

0.1 mg vial

156

PCR-4136-v-20 °C

0.5 mg vial

525

J. Spiess, et al., Biochemistry, 22, 4341 (1983). (Original; Rat) S. Shibahara, et al., The EMBO Journal, 2, 775 (1983). (Original; Human)

CRF (Ovine) Corticotropin-Releasing Factor (Ovine)

Ser-Gln-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Thr-Lys-Ala-Asp-Gln-Leu-Ala- Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Leu-Asp-Ile-Ala-NH2 (M.W. 4670.3) C205H339N59O63S [79804-71-0]

PCR-4111-s-20 °C

0.1 mg vial

156

PCR-4111-v-20 °C

0.5 mg vial

525

W. Vale, et al., Science, 213, 1394 (1981). (Original)

Tyrosyl-CRF (Human, Rat) Tyrosyl-Corticotropin-Releasing Factor (Human, Rat)

PCR-4141-s-20 °C

0.1 mgvial

177

Tyr-Ser-Glu-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu- Leu-Arg-Glu-Val-Leu-Glu-Met-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln- Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Met-Glu-Ile-Ile-NH2 (M.W. 4920.6) C217H353N61O65S2 [100513-58-4] For Radioimmunoassay Purity Information: Qx: See page xivP.C. Wynn, et al., Biochem. Biophys. Res. Commun., 110, 602 (1983). (Biochem.)

* This compound is distributed through Peptide Institute, Inc. under the license of The Salk Institute.


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 39

PRODUCT CODE QTY PRICE CortistatinCortistatin (Rat) CST-14 (Rat)

Pro-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys-Lys (Disulfide bond between Cys2-Cys13) (M.W. 1721.0) C81H113N19O19S2 Neuronal Depressant and Sleep-Modulating PeptideL. De Lecea, et al., Nature, 381, 242 (1996). (Original) L. De Lecea, et al., J. Neurosci., 17, 5868 (1997). (Biochem.) M. Connor, et al, Br. J. Pharmacol., 122, 1567 (1997) (Pharmacol.) A.D. Spier and L. de Lecea, Brain Res. Rev., 33, 228 (2000). (Review)

PCN-4329-v-20 °C

0.5 mgvial

193

C-Type Natriuretic Peptide (CNP)A. Rosenzweig and C.E. Seidman, Annu. Rev. Biochem., 60, 229 (1991). (Review)

CNP-22 (Human)* C-Type Natriuretic Peptide-22 (Human) (Porcine, Rat, Mouse)

PCT-4229-v-20 °C

0.5 mgvial

466

Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys (Disulfide bond between Cys6-Cys22) (M.W. 2197.6) C93H157N27O28S3 [127869-51-6]T. Sudoh, et al., Biochem. Biophys. Res. Commun., 168, 863 (1990). (Original; Porcine) Y. Tawaragi, et al., Biochem. Biophys. Res. Commun., 175, 645 (1991). (cDNA Seq.; Human) M. Kojima, et al., FEBS Lett., 276, 209 (1990). (cDNA Seq.; Rat) Y. Ogawa, et al., Genomics, 24, 383 (1994). (Nucleotide Seq.; Mouse)

CNP-53 (Human)*C-Type Natriuretic Peptide-53 (Human)

PCT-4241-s-20 °C

0.1 mgvial

418

Asp-Leu-Arg-Val-Asp-Thr-Lys-Ser-Arg-Ala-Ala-Trp-Ala-Arg-Leu-Leu-Gln-Glu- His-Pro-Asn-Ala-Arg-Lys-Tyr-Lys-Gly-Ala-Asn-Lys-Lys-Gly-Leu-Ser-Lys-Gly- Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys (Disulfide bond between Cys37-Cys53) (M.W. 5801.7) C251H417N81O71S3 [141294-77-1]Y. Tawaragi, et al., Biochem. Biophys. Res. Commun., 175, 645 (1991). (Original)

CNP-53 (Porcine, Rat)* C-Type Natriuretic Peptide-53 (Porcine, Rat)

PCT-4240-s-20 °C

0.1 mgvial

359

Asp-Leu-Arg-Val-Asp-Thr-Lys-Ser-Arg-Ala-Ala-Trp-Ala-Arg- Leu-Leu-His-Glu- His-Pro-Asn-Ala-Arg-Lys-Tyr-Lys-Gly-Gly-Asn-Lys-Lys-Gly-Leu-Ser-Lys-Gly- Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys (Disulfide bond between Cys37-Cys53) (M.W. 5796.7) C251H414N82O70S3

N. Minamino, et al., Biochem. Biophys. Res. Commun., 170, 973 (1990). (Original; Porcine) Y. Tawaragi, et al., Biochem. Bipophys. Res. Commun., 172, 627 (1990). (Original; Porcine Nucleotide Seq.) M. Kojima, et al., FEBS Lett., 276, 209 (1990). (Original; Rat cDNA)


40 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Tyrosyl-CNP-22 (Human) Tyrosyl-C-Type Natriuretic Peptide-22 (Human)

PCT-4251-v-20 °C

0.5 mgvial

552

Tyr-Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys (Disulfide bond between Cys6-Cys22) (M.W. 2360.8) C102H166N28O30S3 [142878-79-3] For Radioimmunoasay J. Brown and Z. Zuo, Am. J. Physiol., 266, R1383 (1994). (Pharmacol.) J. Zhao, et al., Kidney Int., 46, 717 (1994). (Pharmacol.)

CyclorasinsCyclorasin 12A

cyclo(Arg-Phe(4-F)-Arg-Trp-Arg-d-Ala-Gln-Arg-Arg-2-d-Nal) (M.W. 1528.78) C71H102N27O11F P. Upadhyay, et al., Angew. Chem. Int. Ed., 54, 1 (2015) (Sup. Inf.)

IRA-3829-PI-20 °C

1 mg5 mg

4821926

Cyclorasin 9A5 IRA-3854-PI-20 °C

1 mg5 mg

3481391cyclo(Trp-Thr-d-Ala-Arg-Arg-Arg-d-2-Nal-Arg-4-F-Phe-d-Nle-Gln)

(M.W.1586.86) C75H108N25O13F Inhibitor of K-Ras and Lung Cancer Growth. Activates Apoptosis.P. Upadhyay, et al., Angew. Chem. Int. Ed., 54, 1 (2015).

Cyclorasin 9A54cyclo(Arg-Phe(3,4-Di-F)-d-Nle-Gln-Trp-Tle-d- Val-Arg-Arg-Arg-2-d-Nal) (M.W. 1644.95) C79H115N25O12F2

P. Upadhyay, et al., Angew. Chem. Int. Ed., 54, 1 (2015).

IRA-3828-PI-20 °C

1 mg5 mg

4821926

cyclo (Arg-Gly-Asp) Peptides See Arg-Gly-Asp Peptides. DAP (Diabetes-Associated Peptide) See Amylin.cyclo (d-Trp-d-Asp-Pro-d-Val-Leu) See BQ -123 Sodium Salt.

d-, l-Peptide with Antitumor ActivityKL-d-Leu-RLL-d-Lys-d-Lys-L-d-Leu-RL-d-Leu-LK-NH2

PDL-3643-PI-20 °C

1 mg5 mg

124509

Lys-Leu-d-Leu-Arg-Leu-Leu-d-Lys-d-Lys-Leu-d-Leu-Arg-Leu-d-Leu-Leu-Lys-NH2 (M.W. 1860.56) C90H174N26O15 d-,l- Peptide with Antitumor ActivityN. Papo, M. Shahar, L. Eisenbach, and Y. Shai, J. Biol. Chem., 278, 21018 (2003).

Deamino-Dicarba-Arginine-Vasopressin See Code PVP-4026-v [Asu1,6, Arg8]-Vasopressin.Deamino-Dicarba-Arginine-Vasotocin See Code PVP-4027-v [Asu1,6, Arg8] Vasotocin.Deamino-Dicarba-Oxytocin See Code POX-4025-v [Asu1,6]-Oxytocin.


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 41

PRODUCT CODE QTY PRICE DecorsinDecorsin (Leech, Macrobdella decora)

PDC-4269-s-20 °C

0.1 mgvial

321

Ala-Pro-Arg-Leu-Pro-Gln-Cys-Gln-Gly-Asp-Asp-Gln-Glu-Lys-Cys-Leu-Cys-Asn-Lys- Asp-Glu-Cys-Pro-Pro-Gly-Gln-Cys-Arg-Phe-Pro-Arg-Gly-Asp-Ala-Asp-Pro-Tyr-Cys-Glu (Disulfide bonds between Cys7-Cys15, Cys17-Cys27, and Cys22-Cys38) (M.W. 4377.8) C179H271N55O62S6 Glycoprotein IIb / IIIa Antagonist, Platelet Aggregation InhibitorJ.L. Seymour, et al., J. Biol. Chem., 265, 10143 (1990). A.M. Krezel, et al., Science, 264, 1944 (1994). (S-S Bond)

Defensin Peptides

Human α-defensins are composed of 6 peptides: 4 human neutrophil peptides [HNP-1 (PDF-4271-s), HNP-2, HNP-3 (PDF-4416-s), and HNP-4 (PDF-4431-s)] and 2 human defensins [HD-5 (PDF-4415-s) and HD-6 (PDF-4458-s)]. Among them, the primary structures of HNP-1, HNP-2 and HNP-3 differ only at the amino-terminal residue, in which the first residue is Ala for HNP-1 and Asp for HNP-3, whereas HNP-2 lacks this position, resulting in the 29-residue peptide.1,2 Recent studies by mass spectroscopic analysis clarified that HNP-2 is the second major component in squamous cell carcinoma of human tongue3 and gingival crevicular fluid from periodontitis patients and healthy controls4, where HNP-1 is the most abundant and HNP-3 is the least. Taking this fact into account, it is speculated that HNP-2 is produced post-translationally from HNP-3. Concerning the activity, HNP-2 is revealed to be as active as HNP-1 in neutralizing anthrax lethal toxin5 and blocking papillomavirus infection6, although some differences were pointed out in the candidacidal activity among HNPs7.

T. Ganz, et al., J. Clin. Invest., 76, 1427 (1985). M.E. Selsted, et al. J. Clin. Invest., 76, 1436 (1985). F.T. Lundy, et al., Am. J. Pathol., 160, 1311 (2002). F.T. Lundy, et al., Oral Oncol., 40, 139 (2004). C. Kim, et al., Proc. Natl. Acad. Sci., U.S.A., 102, 4830 (2005). C.B. Buck, et al., Proc. Natl. Acad. Sci., U.S.A., 103, 1516 (2006).R.I. Lehler, J. Clin. Invest., 81, 1829 (1988). (Pharmacol.; Activity difference in HNP)

a-Defensin-1 (Human) HNP-1 (HNP: Human Neutrophil Peptide)

PDF-4271-s-20 °C

0.1 mgvial

284

Ala-Cys-Tyr-Cys-Arg-Ile-Pro-Ala-Cys-Ile-Ala-Gly-Glu-Arg-Arg- Tyr-Gly-Thr-Cys-Ile-Tyr-Gln-Gly-Arg-Leu-Trp-Ala-Phe-Cys-Cys (Disulfide bonds are formed between Cys2-Cys30, Cys4-Cys19, and Cys9-Cys29) (M.W. 3442.0) C150H222N44O38S6 Antimicrobial Peptide / Chemoattractant for MonocytesT. Ganz, et al., J. Clin. Invest., 76, 1427 (1985). (Original; Isolation) M.E. Selsted, et al., J. Clin. Invest., 76, 1436 (1985). (Original; Structure)

a-Defensin -2 (Human)HNP-2 (Human Neutrophil Peptide-2)

PDF-4428-s-20 °C

0.1 mgvial

257

Cys-Tyr-Cys-Arg-Ile-Pro-Ala-Cys-Ile-Ala-Gly-Glu-Arg-Arg-Tyr- Gly-Thr-Cys-Ile-Tyr-Gln-Gly-Arg-Leu-Trp-Ala-Phe-Cys-Cys (Disulfide bonds between Cys1-Cys29, Cys3-Cys18, and Cys8-Cys28) (M.W. 3371.0) C147H217N43O37S6 Antimicrobial Peptide

42 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE

a−Defensin-3 (Human)HNP-3 (Human Neutrophil Peptide-3)

PDF-4416-s-20 °C

0.1 mgvial

257

Asp-Cys-Tyr-Cys-Arg-Ile-Pro-Ala-Cys-Ile-Ala-Gly-Glu-Arg-Arg- Tyr-Gly-Thr-Cys-Ile-Tyr-Gln-Gly-Arg-Leu-Trp-Ala-Phe-Cys-Cys (Disulfide bonds between Cys2-Cys30, Cys4-Cys19, and Cys9-Cys29) (M.W. 3486.0) C151H222N44O40S6 Antimicrobial Peptide

HNP-1 to HNP-3 are the major components in azophilic granules of human neutrophils.1, 2 The primary structures of HNP-1 to HNP-3 differ by only one amino acid residue at posi-tion 1; HNP-2 corresponds to positions 2 through 30 of HNP-1 (des-Ala1-HNP-1) while HNP-3 is Asp1-HNP-1. Interesting publications using HNP include: i) HNP-1 to HNP-3 may show anti-HIV-1 activity3, and ii) HNP-1 to HNP-3 are overexpressed in squamous cell carcinomas of the human tongue, representing a possible role in innate host defense against tumor invasion4. It has been reported that expression of HNP-1 to HNP-3 is not upregulated by lipopolysaccharide5, while they locate in intestinal epithelial cells in cases of inflammatory bowel disease6.

T. Ganz, et al., J. Clin. Invest., 76, 1427 (1985). (Original; Isolation of HNP 1-3)M.E. Selsted, et al., J. Clin. Invest., 76, 1436 (1985). (Original; Structure of HNP 1-3)C.E. Mackewicz, et al., AIDS, 17, F23 (2003). (Pharmacol.; Anti–HIV–1 Activity)F.T. Lundy, et al., Oral Oncol., 40, 139 (2004). (Pharmacol.; Role in Tumor Invasion)X.-M. Fang, et al., Eur. J. Clin. Invest., 33, 82 (2003). (Histochem.; Regulation of Expression)R.N. Cunliffe, Mol. Immunol., 40, 463 (2003). (Histochem.; α-Defensin in Gastrointestinal Tract)

a-Defensin-4 (Human) HNP-4 (Human Neutrophil Peptide-4)

PDF-4431-s-20 °C

0.1 mgvial

316

Val-Cys-Ser-Cys-Arg-Leu-Val-Phe-Cys-Arg-Arg-Thr-Glu-Leu-Arg-Val-Gly- Asn-Cys-Leu-Ile-Gly-Gly-Val-Ser-Phe-Thr-Tyr-Cys-Cys-Thr-Arg-Val (Disulfide bonds between Cys2-Cys30, Cys4-Cys19, and Cys9-Cys29) (M.W. 3709.40) C157H255N49O43S6 Synthetic Product Antimicrobial Peptide

Four a-defensins in neutrophils are called human neutrophil peptide-1 (HNP-1) to HNP-4, in which primary structures of HNP-1 to HNP-3 are similar; Ala and Asp are the first residue of HNP-1 (PDF-4271) and HNP-3 (PDF-4416), respectively, whereas HNP-2 (PDF-4428) lacks the corresponding amino acid residue at position 1. In contrast to these HNPs, α-defensin-4 (HNP-4) shows marked difference in its primary structure although all six Cys residues are con-served.1,2 Activities of HNP-4 reported so far include: i) inhibition of the ACTH action in rat adrenal cell suspension (ID50 = 7.0 X 10-7 M)1, ii) distinct antimicrobial activity3,4, iii) antiviral activity against X4 and R5 HIV-1 strains5, and iv) inhibition of Bacillus anthracis lethal factor (IC50 = 811 nM)6. In the HIV-1 inhibition, it is proposed that HNP-4 exerts the activity by the lectin-independent property with CD4 and/or gp120, which is different from that of HNP-1 to HNP-35). Although the research using HNP-4 seems to be proceeding relatively slowly at the moment, partly because HNP-4 is a minor component in the granulocytes HNPs, our synthetic HNP-4 will contribute significantly to clarify the total activity of HNPs in the body.A. Singh, et al., Biochem. Biophys. Res. Commun., 155, 524 (1988). (Original; Primary Structure / Anti-ACTH Activity)C.G. Wilde, et al., J. Biol. Chem., 264, 11200 (1989). (Original; Structure / HNP-4 / Antimicrobial Activity)Z. Wu, et al., J. Pept. Res., 64, 118 (2004). (Pharmacol; Antimicrobial Activity)B. Ericksen, et al., Antimicrob. Agents Chemother., 49, 269 (2005). (Pharmacol; Antimicrobial Activity)Z. Wu, et al., FEBS Lett., 579, 162 (2005). (Pharmacol.; HIV-1 Inhibitory Activity)G. Wei, et al., J. Biol. Chem., 284, 29180 (2009). (Pharmacol.;Iinhibition of Bacillus anthracis Lethal Factor)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 43


a-Defensin-5 (Human)HD-5 (Human Defensin-5)

PDF-4415-s-20 °C

0.1 mgvial

284

Ala-Thr-Cys-Tyr-Cys-Arg-Thr-Gly-Arg-Cys-Ala-Thr-Arg-Glu-Ser-Leu- Ser-Gly-Val-Cys-Glu-Ile-Ser-Gly-Arg-Leu-Tyr-Arg-Leu-Cys-Cys-Arg (Disulfide bonds between Cys3-Cys31, Cys5-Cys20, and Cys10-Cys30) (M.W. 3582.1) C144H238N50O45S6 Antimicrobial Peptide in Paneth Cells

HD-5 is expressed in Paneth cells in intestinal epithelium, thus, falls into a distinct subclass of human α-defensin.1, 2 The in vivo role of HD-5 was studied in transgenic mouse models injected by an HD-5 minigene, confirming that HD-5 expression was specific to Paneth cells and resulted in resistance to bacterial challenge.3 In patients with HIV-related cryptosporidi-osis, HD-5 immunoreactivity was reduced in association with Paneth cell granule depletion.4 In inflammatory bowel disease, HD-5 was expressed in metaplastic Paneth cells in the co-lon.5 These evidences together point to HD-5 as being an essential factor in the defense against intestinal inflammation.D.E. Jones and C.L. Bevins, J. Biol. Chem., 267, 23216 (1992). (Original; Human Defensin-5)E.M. Porter, et al., FEBS Lett., 434, 272 (1998). (Pharmacol.; Endogenous Form)N.H. Salzman, et al., Nature, 422, 522 (2003). (Pharmacol.)P. Kelly, et al., Clin. Exp. Immunol., 135, 303 (2004). (Histochem.; Location in AIDS Patients)R.N. Cunliffe, Mol. Immunol., 40, 463 (2003). (Histochem.; α-Defensin in Gastrointestinal Tract)

44 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES


a-Defensin-6 (Human)[HD-6 (Human Defensin-6)]

PDF-4458-s-20 °C

0.1 mgvial

316

Ala-Phe-Thr-Cys-His-Cys-Arg-Arg-Ser-Cys-Tyr-Ser-Thr-Glu-Tyr-Ser- Tyr-Gly-Thr-Cys-Thr-Val-Met-Gly-Ile-Asn-His-Arg-Phe-Cys-Cys-Leu (Disulfide bonds between Cys4-Cys31, Cys6-Cys20, and Cys10-Cys30)(M.W. 3708.2) C156H228N46O46S7 Antimicrobial Peptide in Paneth Cells

Six α-defensins have been identified in the human; four of which are found in neutro-philes and thus named human neutrophil peptide-1, HNP-1 (PDF-4271-s), HNP-2 (PDF-4428-s), HNP-3 (PDF-4416-s) and HNP-4 (PDF-4431-s). The remaining two are called human defensin-5 (HD-5, PDF-4415-s) and human defensin-6 (HD-6)1, which are identi-fied in intestinal Paneth cells. HD-6 was isolated from ileal neobladder urine as a 32-resi-due peptide.2 It appeared in the initial study that HD-6 was practically inactive against some bacteria and fungi.3 However, the experimental results proving HD-6 to be an anti-microbial peptide have been accumulating: i) Helicobacter pylori infection increases HD-6 expression in the fundus4, ii) HD-6 inhibits herpes simplex virus infection5, iii) HD-6 has influenza A virus neutralizing ability6, and iv) the HD-6 level is reduced in small intestinal Crohn’s disease7. In contrast to these positive effects in the host defense system, Neis-seria gonorrhoeae-induced HD-6 enhances HIV infectivity, showing how complex HD-6 activity may be.8 Anyhow, these specific characteristics observed in HD-6 are attractive in the study of human innate immunity.

D.E. Jones and C.L. Bevins, FEBS Lett., 315,187 (1993). (Original; mRNA Seq. )E.M. Porter, et al., FEBS Lett., 434, 272 (1998). (Endogenous Form)B. Ericksen, et al., Antimicrob. Agents Chemother., 49, 269 (2005). (Pharmacol.; No Antibacterial Activity)J. Wehkamp, et al., J. Clin. Pathol., 56, 352 (2003). (Pharmacol.; Enhanced Expression in Helicobacter pylori Infection)E. Hazrati, et al., J. Immunol., 177, 8658 (2006). (Pharmacol.; Inhibition of Herpes Simplex Virus Infection)M. Doss, et al., J. Immunol., 182, 7878 (2009). (Pharmacol.; Influenza A Virus Neutralizing Activity)M.J. Koslowski, et al., Int. J. Med. Microbiol., 300, 34 (2010). (Minireview; Antimicrobial Host Defense in Small Intestinal Crohn’s Disease)M.E. Klotman, et al., J. Immunol., 180, 6176 (2008). (Pharmacol.; Enhancement of HIV Infectivity)

β-Defensin-1 (Human) hBD-1

PDF-4337-s-20 °C

0.1 mgvial

279

Asp-His-Tyr-Asn-Cys-Val-Ser-Ser-Gly-Gly-Gln-Cys-Leu-Tyr- Ser-Ala-Cys-Pro-Ile-Phe-Thr-Lys-Ile-Gln-Gly-Thr-Cys-Tyr-Arg-Gly-Lys-Ala-Lys-Cys-Cys-Lys (Disulfide bonds between Cys5-Cys34, Cys12-Cys27, and Cys17-Cys35) (M.W. 3928.5) C167H256N48O50S6 Antimicrobial PeptideK.W. Bensch, et al., FEBS Lett., 368, 331 (1995). (Original) M.J. Goldman, et al., Cell, 88, 553 (1997). (Pharmacol.; Inactivated in Cystic Fibrosis) T. Hiratsuka, et al., Nephron, 85, 34 (2000). (Pharmacol.)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 45

PRODUCT CODE QTY PRICE β-Defensin-2 (Human) hBD-2

PDF-4338-s-20 °C

0.1 mgvial

300

Gly-Ile-Gly-Asp-Pro-Val-Thr-Cys-Leu-Lys-Ser-Gly-Ala-Ile-Cys- His-Pro-Val-Phe-Cys-Pro-Arg-Arg-Tyr-Lys-Gln-Ile-Gly-Thr-Cys- Gly-Leu-Pro-Gly-Thr-Lys-Cys-Cys-Lys-Lys-Pro (Disulfide bonds between Cys8-Cys37, Cys15-Cys30, and Cys20-Cys38) (M.W. 4328.2) C188H305N55O50S6 Antibacterial Peptide Specific for Gram-Negative Bacteria / Also Effective for Candida albicansJ. Harder, et al., Nature, 387, 861 (1997). (Original) T. Hiratsuka, et al., Biochem. Biophys. Res. Commun., 249, 943 (1998). (Pharmacol.) D.M. Hoover, et al., J. Biol. Chem., 275, 32911 (2000). (S-S Bond) T. Hiratsuka, et al., Thorax, 58, 425 (2003). (Pharmacol.; Activity against Pseudomonas aeruginosa)S. Yanagi, et al., Respiratory Res., 6, 130 (2005). (Pharmacol. & Immunohistochem.)

β-Defensin-3 (Human) hBD-3

PDF-4382-s-20 °C

0.1 mgvial

311

Gly-Ile-Ile-Asn-Thr-Leu-Gln-Lys-Tyr-Tyr-Cys-Arg-Val-Arg-Gly-Gly- Arg-Cys-Ala-Val-Leu-Ser-Cys-Leu-Pro-Lys-Glu-Glu-Gln-Ile-Gly- Lys-Cys-Ser-Thr-Arg-Gly-Arg-Lys-Cys-Cys-Arg-Arg-Lys-Lys (Disulfide bonds between Cys11-Cys40, Cys18-Cys33, and Cys23-Cys41) (M.W. 5155.1) C216H371N75O59S6 Antimicrobial Peptide / Staphylococcus aureus-Killing Factor

The human defensins represent an important family of antimicrobial peptides. They are composed of two subclasses: α-defensins and β-defensins (hBD), which are character-ized by their distinct arrangement of three disulfide bonds. Following the discovery of hBD-1 (PDF-4337-s) and hBD-2 (PDF-4338-s) in 1995 and 1997, respectively, hBD-3 was included in 2001.1 hBD-3 was identified in lesional psoriatic scales, from which hBD-2 was also isolated. Peptide and DNA chemistry revealed hBD-3 to be a 45 amino acid residue peptide. The antimicrobial activity of hBD-3 is characterized by: i) a broad spec-trum of antimicrobial activity against many pathogenic microbes such as multi-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium without hemo-lytic activity, ii) salt-insensitivity up to 200 mM NaCl, iii) expression of activity through cell wall perforation, and iv) regulation by TNF-α and contact with bacteria.1 Later, although the data was obtained using the amino-terminally truncated peptide, hBD-3 (6-45), the following interesting findings were reported: i) hBD-3 is stimulated by interferon-γ, and ii) hBD-3 has monocyte activating function and elicits ion channel activity.2 It is also reported that unlike hBD-1 and hBD-2, hBD-3 mRNA expression is inhibited by corticosteroids.3 Significant amounts of these peptides are distributed in the following tissues: skin, tonsil, trachea, placenta, testis, thymus, and heart.1,2,4 With respect to the structural aspects of hBD-3, an amphipathic dimeric structure was proposed in solution, which is different from those of hBD-1 and hBD-2. This might be responsible for the bactericidal activity against Staphylococcus aureus.5 Thus, the hBD-3, as well as the other defensins, are useful tools for understanding their defense mechanisms against various microorganisms.

J. Harder, et al, J. Biol. Chem., 276, 5707 (2001). (Original) J.-R.C. García, et al., Cell Tissue Res., 306, 257 (2001). (Original; Amino-Terminally Truncated Peptide) L.A. Duits, et al., Biochem. Biophys. Res. Commun., 280, 522 (2001). (Pharmacol.) H.P. Jia, et al., Gene, 263, 211 (2001). (DNA Seq/Tissue Distribution) D.J. Schibli, et al., J. Biol. Chem., 277, 8279 (2002). (Solution Structure) S. Yanagi, et al., Respiratory Res., 6, 130 (2005). (Pharmacol. & Immunohistochem.)

46 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE β-Defensin-4 (Human)hBD-4

PDF-4406-s-20 °C

0.1 mgvial

279

Glu-Leu-Asp-Arg-Ile-Cys-Gly-Tyr-Gly-Thr-Ala-Arg-Cys-Arg-Lys-Lys-Cys-Arg-Ser- Gln-Glu-Tyr-Arg-Ile-Gly-Arg-Cys-Pro-Asn-Thr-Tyr-Ala-Cys-Cys-Leu-Arg-Lys (Disulfide bonds between Cys6-Cys33, Cys13-Cys27, and Cys17-Cys34) (M.W. 4366.0) C180H295N63O52S6 Antimicrobial Peptide / Chemoattractant for Monocytes

28 Human β-defensins were predicted in five gene clusters using a computational search approach.1 Among others, hBD-4, was proposed based on the cDNA sequence analysis, the precursor of which is composed of 72 amino acid residues. Although natural hBD-4, as far as we know, has not yet been isolated, hBD-4 was tentatively designed as the peptide cor-responding to the positions between 25 and 61 in the precursor sequence [hereafter the term “hBD-4” is used for this peptide. Chemically synthesized hBD-4 was confirmed to share the conserved disulfide connectivity of the β-defensin family of peptides by the combination of enzymatic digestions and Edman degradation reaction2). Using this chemically synthesized hBD-4, the following observations were reported2): i) hBD-4 elicits salt-sensitive antimicro-bial activities against both Gram-positive and Gram-negative bacteria in human respiratory epithelial cells; ii) the most active antimicrobial activity is detected against Pseudomonas aeruginosa at 4.1 μg/ml; and iii) hBD-4 is a chemoattractant for human blood monocytes at 10 nM, but not for neutrophiles and eosinophiles. Interestingly, antimicrobial activities in the lungs were inducible by the infection and subsequent activation of protein kinase C, thus differing from the activation mechanism from hBD-2 and hBD-3, which are induced in re-sponse to the stimulation by TNF-α, IL-1α, IL-6 or interferon α. hBD-4 mRNA was expressed abundantly in testis and the stomach, and to a lesser extent but significantly in the uterus, neutrophiles thyroid, lungs, and kidney. hBD-4, which is regulated by specific stimulation that differs from those in hBD-2 and hBD-3, should be an essential component in clarifying the host defense mechanism in humans. Later, the existence of the immunoreactive hBD-4 in the body was reported3). Also, hBD-4 induces mast cell degranulation, prostaglandin D2 production, intracellular Ca2+ mobilization and chemotaxis4).B.C. Schutte, et al., Proc. Natl. Acad. Sci., USA, 99, 2129 (2002). (b-Defensin Family Peptides) J.R.C. García, et al., FASEB J., 15, 1819 (2001). (Original: hBD-4 & S-S Bond)S. Yanagi, et al., Respiratory Res., 6, 130 (2005). (Pharmacol. & Immunohistochem.)X. Chen, et al., Eur. J. Immunol., 37, 434 (2007). (Pharmacol.)

Delta Sleep-Inducing Peptide (DSIP)Delta Sleep-Inducing Peptide (DSIP)

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (M.W. 848.81) C35H48N10O15 [62568-57-4]

PDS-4054-v-20 °C

0.5 mgvial

59

Delta Sleep-Inducing Peptide (DSIP) (Bulk)

PDS-4054-20 °C

25 mg 637

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu • 4H2O (M.W. 848.81 • 72.06) C35H48N10O15 • 4H2O [62568-57-4]G.A. Schoenenberger and M. Monnier, Proc. Natl. Acad. Sci., USA., 74, 1282 (1977). (Original) M. Monnier, et al., Experientia, 33, 548 (1977). (Pharmacol.)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 47

PRODUCT CODE QTY PRICE Dermcidin- 1L / DCDDermcidin- 1L (Human)DCD-1L (Human)

PDL-4454-s-20 °C

0.1 mgvial

289

Ser-Ser-Leu-Leu-Glu-Lys-Gly-Leu-Asp-Gly-Ala-Lys-Lys-Ala-Val- Gly-Gly-Leu-Gly-Lys-Leu-Gly-Lys-Asp-Ala-Val-Glu-Asp-Leu-Glu-Ser- Val-Gly-Lys-Gly-Ala-Val-His-Asp-Val-Lys-Asp-Val-Leu-Asp-Ser-Val-Leu (M.W. 4818.4) C210H359N57O71 Synthetic Product Antimicrobial Peptide in Sweat Glands

Dermcidin is a constitutively secreted antimicrobial peptide in human sweat.1 Dermcidin is revealed to be a 110-residue protein by cDNA analysis, which is proteolytically processed to several components with variable charges. Dermcidin-1L is one of such processed peptides with anionic property, which corresponds to the carboxyl-terminal 48-residues of the precursor protein.1,2 Studies using dermcidin-1L reported so far include: i) dermcidin-1L is active against Gram-positive and negative bacteria and fungus (1-100 μg/ml) 1, ii) in patients with atopic dermatitis the amounts of dermicidin-1L and other dermcidin-derived peptides are reduced3, and iii) dermcidin-1L activates human keratinocytes, inducing the generation of cytokines and chemokines (2.5-20 μg/ml).4 Dermcidin-1L does not show membrane permeability, thus, the mechanism exerting antimicrobial activity of dermcidin-1L is distinct from that of other antimicrobial peptide, LL-37 (PLL-4445-s).5 Dermcidin-1L in sweat may be essential for the battle with infectious pathogens on the human body surface, therefore it will be an important tool in the host defense research.

B. Schittek, et al., Nat. Immunol., 2, 1133 (2001). (Original; Antimicrobial Peptide)S. Rieg, et al., J. Immunol., 174, 8003 (2005). (Endogenous Form)H. Steffen, et al., Antimicrob. Agents Chemother., 50, 2608 (2006). (Pharmacol.)F. Niyonsaba, et al.,Br. J. Dermatol.,160,243 (2009). (Pharmacol.)I. Senyurek, et al., Antimicrob. Agents Chemother., 53, 2499 (2009). (Pharmacol.)

Diabetes-Associated Peptide (DAP) See Codes PAM-4219-v Amylin (Human) and PAM-4220-v Amylin (Rat).

DynorphinsJ. Hughes, Br. Med. Bull., 39, 17 (1983). (Review) A.P. Smith and N.M. Lee, Annu. Rev. Pharmacol. Toxicol., 28, 123 (1988). (Review) M. Simonato and P. Romualdi, Prog. Neurobiol., 50, 557 (1996). (Review)

Dynorphin A (Human, 1-13) (Porcine, Rat, Bovine)

PDY-4080-v-20 °C

0.5 mgvial

86

Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys (M.W. 1604.0) C75H126N24O15 [72957-38-1] A. Goldstein, et al., Proc. Natl. Acad. Sci. U.S.A., 76, 6666 (1979). (Original; Porcine) S. Horikawa, et al., Nature, 306, 611 (1983). (Nucleotide Seq.; Human)

Dynorphin A (Human) (Porcine, Rat, Bovine)

PDY-4108-v-20 °C

0.5 mgvial

161

Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln (M.W. 2147.5) C99H155N31O23 [80448-90-4]S. Tachibana, et al., The 1981 International Narcotic Research Conference, Kyoto, July 1981. (Original) A. Goldstein, et al., Proc. Natl. Acad. Sci. USA, 78, 7219 (1981). (Original; Porcine) S. Horikawa, et al., Nature, 306, 611 (1983). (Nucleotide Seq.; Human) O. Civelli, et al., Proc. Natl. Acad. Sci. U.S.A., 82, 4291 (1985). (Nucleotide Seq.; Rat)

48 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Echistatin See Code ECT-3760-PI in the Toxins subsection.

ElafinElafin (Human) PEL-4243-v

-20 °C

20 mg vial

402

Ala-Gln-Glu-Pro-Val-Lys-Gly-Pro-Val-Ser-Thr-Lys-Pro-Gly- Ser-Cys-Pro-Ile-Ile-Leu-Ile-Arg-Cys-Ala-Met-Leu-Asn-Pro- Pro-Asn-Arg-Cys-Leu-Lys-Asp-Thr-Asp-Cys-Pro-Gly-Ile-Lys- Lys-Cys-Cys-Glu-Gly-Ser-Cys-Gly-Met-Ala-Cys-Phe-Val-Pro-Gln (Disulfide bonds between Cys16-Cys45, Cys23-Cys49, Cys32-Cys44, and Cys38-Cys53) (M.W. 5999.1) C254H416N72O75S10 Elastase-Specific Inhibitor from Human Skin / Innate Immune FactorO. Wiedow, et al., J. Biol. Chem., 265, 14791 (1990). (Original) O. Wiedow, et al., J. Biol. Chem., 266, 3356 (1991). (Correction of Sequence) M. Tsunemi, et al., Biochem. Biophys. Res. Commun., 185, 967 (1992). (Chem. Synthesis & Biochem.) M. Tsunemi, et al., Biochem. Biophys. Res. Commun., 185, 967 (1992). (Chem. Synthesis & Biochem.) M. Tsunemi, et al., Biochemistry, 35, 11570 (1996). (Biochem.; Crystal Structure of Elafin-Pancreatic Elastase Complex)L. Marischen, et al., Scand. J. Immunol., 70, 547 (2009). (Pharmacol.)S.M. Iqbal, et al., AIDS, 23, 1669 (2009). (Pharmacol.)

Eledoisin Related PeptideEledoisin Related Peptide

Lys-Phe-Ile-Gly-Leu-Met-NH2 (M.W. 706.94) C34H58N8O6S [2990-43-4]

PEL-4003-v-20 °C

0.5 mg vial

35

Eledoisin Related Peptide (Bulk) PEL-4003-20 °C

25 mg100 mg

311921Lys-Phe-Ile-Gly-Leu-Met-NH2 • 2AcOH • 3H2O

(M.W. 706.94 • 120.10 • 54.05) C34H58N8O6S • 2CH3COOH • 3H2OS. Sakakibara and M. Fujino, Bull. Chem. Soc. Japan, 39, 947 (1966). (Chem. Synthesis)

EndokininsEndokinin C (Human) PND-4411-v

-20 °C

0.5 mgvial

106

Lys-Lys-Ala-Tyr-Gln-Leu-Glu-His-Thr-Phe-Gln-Gly-Leu-Leu-NH2 (M.W. 1674.9) C78H123N21O20 Peptide in α-Tachykinin Precursor 4N.M. Page, et al., Proc. Natl. Acad. Sci. USA, 100, 6245 (2003). (Original) J.N. Pennefather, et al., Life Sci., 74, 1445 (2004). (Review) N.M. Page, Cell. Mol. Life Sci.; 61, 1652 (2004). (Review) R. Naono, et al., Brain Res., 1165, 71 (2007). (Pharmacol.) Y. Yang and S. Dong, Peptides, 31, 94 (2010). (Pharmacol.)

Endokinin D (Human) PND-4412-v-20 °C

0.5 mg vial

106

Val-Gly-Ala-Tyr-Gln-Leu-Glu-His-Thr-Phe-Gln-Gly-Leu-Leu-NH2 (M.W. 1574.8) C73H111N19O20 Peptide in b-Tachykinin Precursor 4N.M. Page, et al., Proc. Natl. Acad. Sci. USA, 100, 6245 (2003). (Original)J.N. Pennefather, et al., Life Sci., 74, 1445 (2004). (Review)N.M. Page, Cell. Mol. Life Sci.; 61, 1652 (2004). (Review)R. Naono, et al., Brain Res., 1165, 71 (2007). (Pharmacol.)Y. Yang and S. Dong, Peptides, 31, 94 (2010). (Pharmacol.)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 49

PRODUCT CODE QTY PRICE Endorphins

A. Goldstein, Ann. N.Y. Acad. Sci., 311, 49 (1978). (Review) F. Bloom, et al., Adv. Biochem. Psychopharm., 22, 619 (1980). (Review) P.A. Berger, H. Akil, S.J. Watson, and J.D. Barchas, Annu. Rev. Med., 33, 397 (1982). (Review) F.E. Bloom, Annu. Rev. Pharmacol. Toxicol., 23, 151 (1983). (Review)

a-Endorphin b-Lipotropin (61-76)

PEN-4055-v-20 °C

0.5 mgvial

124

Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr (M.W. 1745.9) C77H120N18O26S [59004-96-5] N. Ling, et al., Proc. Natl. Acad. Sci. USA, 73, 3942 (1976). (Original; Porcine)

b-Endorphin (Human) b-Lipotropin (Human, 61-91)

PEN-4060-v-20 °C

0.5 mgvial

247

Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr- Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu (M.W. 3465.0) C158H251N39O46S [61214-51-5]C.H. Li and D. Chung, Nature, 260, 622 (1976). (Original; Human) C.H. Li, et al., J. Med. Chem., 20, 325 (1977). (Chem. Synthesis & Biological Activity)

b-Endorphin (Equine)H-Tyr-Gly-Gly-Phe-Met-Ser-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-His-Lys-Lys-Gly-Gln-OH (M.W. 3424.01) C154H248N42O44S [79495-86-6]C.H. Li, et al., Int. J. Peptide Protein Res., 18, 242 (1981).

END-3756-PI-20 °C

1 mg5 mg

3101240

g-Endorphin b-Lipotropin (61-77)

PEN-4089-v-20 °C

0.5 mgvial

145

Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu (M.W. 1859.1) C83H131N19O27S N. Ling, et al., Proc. Natl. Acad. Sci. USA, 73, 3942 (1976). (Original; Porcine)

EndothelinsM. Yanagisawa and T. Masaki, Trends Pharmacol. Sci., 10, 374 (1989). (Review) T. Sakurai, et al., Trends Pharmacol. Sci., 13, (1992). (Review) A.F. James, et al., and M. Takai, Cardiovasc. Drug Rev., 11, 253 (1993). (Review)

Endothelin-1 (Human)* (Porcine, Canine, Rat, Mouse, Bovine)

Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu- Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 2491.9) C109H159N25O32S5 [117399-94-7]

PED-4198-s-20 °C

0.1 mgvial

198

PED-4198-v-20 °C

0.5 mgvial

578

M. Yanagisawa, et al., Nature, 332, 411 (1988). (Original) A. Inoue, et al., Proc. Natl. Acad. Sci. U.S.A., 86, 2863 (1989). (Naming) T.X. Wantanabe, et al., J. Cardiovasc, Pharmocal., 17 (Suppl. 7), S5 (1991). (Pharmacol.)

* This compound is distributed through Peptide Institute, Inc., under the license of Takeda Chemical Industries, Ltd. and the National Institute of Advanced Industrial Science and Technology (AIST).* The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc.

50 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Endothelin-1 (1-31) (Human)* PED-4360-s

-20 °C

0.1 mg vial

247Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe- Cys-His-Leu-Asp-Ile-Ile-Trp-Val-Asn-Thr-Pro-Glu-His-Val-Val-Pro-Tyr (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 3628.2) C162H236N38O47S5 [133972-52-8] A. Nakao, et al., J. Immunol., 159, 1987 (1997). (Original; New Endogenous Form) F. Kishi, et al., Biochem. Biophys. Res. Commun., 248, 387 (1998). (Pharmacol.) M. Yoshizumi, et al., Eur. J. Pharmacol., 348, 305 (1998). (Pharmacol.) M. Yoshizumi, et al., Br. J. Pharmacol., 125, 1019 (1998). (Pharmacol.)

Endothelin-2 (Human)** (Canine)

PED-4209-s-20 °C

0.1 mgvial

193

Cys-Ser-Cys-Ser-Ser-Trp-Leu-Asp-Lys-Glu- Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 2546.9) C115H160N26O32S4 [123562-20-9] A. Inoue, et al., Proc. Natl. Acad. Sci. U.S.A., 86, 2863 (1989). (Original; Human Nucleotide Seq.) Y. Itoh et al., Nucleic Acids Res., 17, 5386 (1989). (Original; Canine cDNA)

Big Endothelin-3 (Human, 1-41 Amide)Big ET-3 (human)

PED-3739-PI-20 °C

1 mg5 mg

13005200

Big ET-3 (human), Big Endothelin-3 (1-41), amide, human, Big ET-3 (1-41) amide (human) H-Cys-Thr-Cys-Phe-Thr-Tyr-Lys-Asp-Lys-Glu-Cys-Val-Tyr-Tyr-Cys-His-Leu-Asp-Ile-Ile-Trp- Ile-Asn-Thr-Pro-Glu-Gln-Thr-Val-Pro-Tyr-Gly-Leu-Ser-Asn-Tyr-Arg-Gly-Ser-Phe-Arg-NH2 (M.W. 4923.65) C223H322N56O63S4 [133551-97-0] (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) Vasoactive Peptide; Blood Pressure RegulationK.D. Bloch, et al., J. Biol. Chem., 264, 18156 (1989). (Original; cDNA)T. Kosaka, et al., J. Biochem., 116, 443 (1994). (Original; Biosynthesis)M. Yanagisawa and T. Masaki, Trends Pharmacol. Sci., 10, 374 (1989). (Review)T. Sakurai, et al., Trends Pharmacol. Sci., 13, 103 (1992). (Review)

Endothelin-3 (Human)* ** (Porcine, Rat, Rabbit, Mouse)

Cys-Thr-Cys-Phe-Thr-Tyr-Lys-Asp-Lys-Glu- Cys-Val-Tyr-Tyr-Cys-His-Leu-Asp-Ile-Ile-Trp (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 2643.0) C121H168N26O33S4 [117399-93-6]

PED-4199-s-20 °C

0.1 mg vial

193

PED-4199-v-20 °C

0.5 mg vial

568

M. Yanagisawa, et. al., Proc. Natl. Acad. Sci., U.S.A., 85, 6964 (1988). (Original) A. Inoue, et al., Proc. Natl. Acad. Sci. U.S.A., 86, 2863 (1989). (Naming) K. Nakajima, et. al., J. Cardiovasc. Pharmacol., 13, (Suppl. 5), S8 (1989). (Chem. Synthesis and S-S Bond) K. Saida, et al., Peptide Chemistry 1996, 133 (1997). (cDNA Seq.; Mouse)

* The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc.* *This compound is distributed through Peptide Institute, Inc., under the license of Takeda Chemical Industries, Ltd. and the National Institute of Advanced Industrial Science and Technology (AIST).


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 51

PRODUCT CODE QTY PRICE Big-Endothelin-1 (Human, 1-38)*

Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr- Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-Val-Asn-Thr-Pro-Glu- His-Val-Val-Pro-Tyr-Gly-Leu-Gly-Ser-Pro-Arg-Ser (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 4282.9) C189H282N48O56S5 [120796-97-6]Y. ltoh, et al., FEBS Lett., 231, 440 (1988). (Original) T. Kashiwabara, et al., FEBS Lett., 247, 73 (1989). (Pharmacol.)

PED-4208-s-20 °C

0.1 mg vial

273

PED-4208-v-20 °C

0.5 mg vial

717

Big Endothelin-1 (Porcine, 1-39)* **Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-Val-Asn-Thr-Pro-Glu-His-Ile- Val-Pro-Tyr-Gly-Leu-Gly-Ser-Pro-Ser-Arg-Ser (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 4384.0) C193H289N49O58S5 [120796-99-8]

PED-4207-s-20 °C

0.1 mg vial

268

PED-4207-v-20 °C

0.5 mg vial

723

Y. Itoh, et al., FEBS Letters, 231, 440 (1988). (Original) T. Kashiwabara, et al., FEBS Letters, 247, 73 (1989). (Pharmacol.)

Big Endothelin-1 (Rat, 1-39)* ** PED-4266-s-20 °C

0.1 mgvial

289Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe- Cys-His-Leu-Asp-Ile-Ile-Trp-Val-Asn-Thr-Pro-Glu-Arg-Val-Val- Pro-Tyr-Gly-Leu-Gly-Ser-Pro-Ser-Arg-Ser (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 4389.0) C192H292N50O58S5

T. Sakurai, et al., Biochem. Biophys. Res. Commun., 175, 44 (1991). (Original; cDNA)

Big-Endothelin-2 (Human, 1-37)* ** PED-4222-s-20 °C

0.1 mgvial

268Cys-Ser-Cys-Ser-Ser-Trp-Leu-Asp-Lys-Glu-Cys-Val-Tyr-Phe- Cys-His-Leu-Asp-Ile-Ile-Trp-Val-Asn-Thr-Pro-Glu-Gln-Thr-Ala- Pro-Tyr-Gly-Leu-Gly-Asn-Pro-Pro (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 4183.7) C188H269N45O56S4 [132699-72-0]

S. Ohkubo, et al., FEBS Lett., 274, 136 (1990). (Original; cDNA)

Big-Endothelin-2 (Human, 1-38)** PED-4253-s-20 °C

0.1 mg vial

289

Cys-Ser-Cys-Ser-Ser-Trp-Leu-Asp-Lys-Glu-Cys-Val-Tyr-Phe- Cys-His-Leu-Asp-Ile-Ile-Trp-Val-Asn-Thr-Pro-Glu-Gln-Thr-Ala- Pro-Tyr-Gly-Leu-Gly-Asn-Pro-Pro-Arg (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 4339.9) C194H281N49O57S4

T. Kosaka, et al., J. Biochem., 116, 443 (1994). (Biosynthesis.) S. Ohkubo, et al., FEBS Lett., 274, 136 (1990). (Original; cDNA)

* The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc.** This compound is distributed through Peptide Institute, Inc., under the license of Takeda Chemical Industries, Ltd.

52 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Big-Endothelin-3 (Human, 1-41 Amide)* ** PED-4223-s

-20 °C

0.1 mg vial

279Cys-Thr-Cys-Phe-Thr-Tyr-Lys-Asp-Lys-Glu-Cys-Val-Tyr-Tyr- Cys-His-Leu-Asp-Ile-Ile-Trp-Ile-Asn-Thr-Pro-Glu-Gln-Thr-Val- Pro-Tyr-Gly-Leu-Ser-Asn-Tyr-Arg-Gly-Ser-Phe-Arg-NH2 (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 4923.5) C223H322N56O63S4

K.D. Bloch, et al., J. Biol. Chem., 264, 18156 (1989). (Original; cDNA) T. Kosaka, et al., J. Biochem., 116, 443 (1994). (Original; Biosynthesis.)

Big Endothelin-3 (Rat, 1-41 Amide)* ** PED-4267-s-20 °C

0.1 mg vial

289Cys-Thr-Cys-Phe-Thr-Tyr-Lys-Asp-Lys-Glu-Cys-Val-Tyr-Tyr- Cys-His-Leu-Asp-Ile-Ile-Trp-Ile-Asn-Thr-Pro-Glu-Gln-Thr-Val- Pro-Tyr-Gly-Leu-Ser-Asn-His-Arg-Gly-Ser-Leu-Arg-NH2 (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 4863.5) C217H322N58O62S4

R. Shiba, et al., Biochem. Biophys. Res. Commun., 186, 588 (1992). (Original; cDNA)

Suc-[Glu9, Ala11,15]-Endothelin-1 (8-21)* ‡ IRL 1620

PED-4285-v-20 °C

0.5 mg vial

166

Suc-Asp-Glu-Glu-Ala-Val-Tyr-Phe-Ala- His-Leu-Asp-Ile-Ile-Trp (Suc: Succinyl) (M.W. 1820.9) C86H117N17O27 [142569-99-1] ETb Receptor Selective AgonistM. Takai, et al.a, Biochem. Biophys. Res. Commun., 184, 953 (1992). (Original) S.S. Shetty, et al., Biochem. Biophys. Res. Commun., 191, 459 (1993). (Pharmacol.) W.G. Haynes, et al., Trends Pharmacol. Sci., 14, 225 (1993). (Report; 3rd Int. Conf. Endothelin) A.F. James, et al., Cardiovasc. Drug Rev., 11, 253 (1993). (Review)

VIC (Mouse)* ** Vasoactive Intestinal Contractor (Mouse)

PED-4211-s-20 °C

0.1 mgvial

193

Cys-Ser-Cys-Asn-Ser-Trp-Leu-Asp-Lys-Glu- Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 2573.9) C116H161N27O32S4

N. Ishida, et al., FEBS Lett., 247, 337 (1989). (Original) K. Saida, et al., J. Biol. Chem., 264, 14613 (1989). (Original; Nucleotide Seq.)

* The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc.** This compound is distributed through Peptide Institute Inc., under the license of Takeda Chemical Industries, Ltd. ‡ This product is distributed under the technical and scientific advices of International Research Laboratories of Novartis Pharma K.K.


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 53

PRODUCT CODE QTY PRICE Endothelin Inhibitors Also see the Enzyme Inhibitors and Substrates section.

BQ-123 (Sodium Salt)

cyclo (d-Trp-d-Asp-Pro-d-Val-Leu) Endothelin Antagonist (M.W. 610.72) C31H42N6O7

PED-3512-PI-20 °C

1 mg5 mg

70209


Homopiperdinyl-CO-Leu-d-Trp(CHO)-d-Trp-OH (M.W. 656.79) C36H44N6O6 ETA-Selective Antagonist

PED-3610-PI-20 °C

1 mg5 mg

81295


N-cis-2,6-Dimethylpiperidinocarbonyl-l-γ-Me-Leu-d-Trp(COOCH3)-d-Nle (M.W. 663.80) C34H50N5O7Na ETB-Selective Antagonist

PED-3788-PI-20 °C

1 mg5 mg

193772

Enfuviritide (Alternative names: Fuzeon; T20; Pentafuside)

EnfuviritideTAc-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu- Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2 (M.W. 4491.98) C204H301N51O64 [159519-65-0]

ENF-3787-PI-20 °C

1 mg5 mg

110450

H.B.Fung and Y.Guo, Clin. Ther., 26, 352 (2004). R.Manfredi and S.Sabbatani, Curr. Med. Chem., 13, 2369 (2006). J.Ruof, et al., Clin. Drug Investig., 27, 469 (2007). A.Streinu-Cercel, et al., HIV Clin. Trials, 9, 375 (2008).

Note: Bolar Exemption applies. This is a FDA-regulated product. It is the responsibility of the customer to ensure that he/she is complying with Federal rules. Peptides International cannot be liable for infringement of rights made by the user. (US patent ended in Jun 2013)

EnkephalinsLeucine-Enkephalin(Human, Porcine, Bovine, Rat, Mouse)

Tyr-Gly-Gly-Phe-Leu (M.W. 555.62) C28H37N5O7 [58822-25-6]

PEK-4043-v-20 °C

0.5 mg vial

33

Leucine-Enkephalin (Bulk) (Human, Porcine, Bovine, Rat, Mouse)

Tyr-Gly-Gly-Phe-Leu • H2O (M.W. 555.62 • 18.02) C28H37N5O7 • H2O [58822-25-6]

PEK-4043-20 °C

25 mg100 mg

140396

J. Hughes, et al., Nature, 258, 577 (1975). (Original; Porcine) M. Comb, et al., Nature, 295, 663 (1982). (cDNA Seq.; Human) M. Noda, et al., Nature, 295, 202 (1982). (cDNA Seq.; Bovine) K. Yoshikawa, et al., J. Biol. Chem., 259, 14301 (1984). (cDNA Seq.; Rat)

54 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Leucine-Enkephalin (Sulfated Form)

Tyr(SO3H)-Gly-Gly-Phe-Leu (M.W. 635.69) C28H37N5O10S [80632-52-6]C.D. Unsworth and J. Hughes, Nature, 295, 519 (1982). (Original)

PEK-4118-v-20 °C

0.5 mgvial

59

Methionine-Enkephalin (Human, Porcine, Bovine, Rat, Mouse)

Tyr-Gly-Gly-Phe-Met (M.W. 573.66) C27H35N5O7S [58569-55-4]

PEK-4042-v-20 °C

0.5 mgvial

33

Methionine-Enkephalin (Bulk) (Human, Porcine, Bovine, Rat, Mouse)

Tyr-Gly-Gly-Phe-Met • H2O (M.W. 573.66 • 18.02) C27H35N5O7S • H2O [58569-55-4]

PEK-4042-20 °C

25 mg100 mg

193552

J. Hughes, et al., Nature, 258, 577 (1975). (Original; Porcine) M. Comb, et al., Nature, 295, 663 (1982). (cDNA Seq.; Human) M. Noda, et al., Nature, 295, 202 (1982). (cDNA Seq.; Bovine) K. Yoshikawa, et al., J. Biol. Chem., 259, 14301 (1984). (cDNA Seq.; Rat)

(Met(O)5)-EnkephalinH-Tyr-Gly-Gly-Phe-Met(O)-OH (M.W. 589.67) C27H35N5O8S [60283-51-4] Enkephalin Analog

PEK-3807-PI-20 °C

5 mg25 mg

209835

[d-Ala2, d-Leu5]-EnkephalinTyr-d-Ala-Gly-Phe-d-Leu (M.W. 569.65) C29H39N5O7 [63631-40-3]

PEK-4115-v-20 °C

0.5 mgvial

33

[d-Ala2, d-Leu5]-Enkephalin (Bulk) PEK-4115-20 °C

25 mg100 mg

300840Tyr-d-Ala-Gly-Phe-d-Leu • AcOH • H2O

(M.W. 569.65 • 60.05 • 18.02) C29H39N5O7 • CH3COOH • H2O [94825-57-7]E.T. Wei, et al. Life Sci., 21, 321 (1977). (Original)

[d-Ala2, Met5]-EnkephalinTyr-d-Ala-Gly-Phe-Met (M.W. 587.69 ) C28H37N5O7S [61370-87-4]

PEK-4116-v-20 °C

0.5 mgvial

33

[d-Ala2, Met5]-Enkephalin (Bulk) Tyr-d-Ala-Gly-Phe-Met • AcOH • H2O (M.W. 587.69 • 60.05 • 18.02 ) C28H37N5O7S • CH3COOH • H2O [100929-62-6]

PEK-4116-20 °C

25 mg 300

D.H. Coy, et al., Biochem. Biophys. Res. Commun., 73, 632 (1976). (Original; Chem. Synthesis)

[d-Ala2, Met5]-EnkephalinamideTyr-d-Ala-Gly-Phe-Met-NH2 (M.W. 586.70) C28H38N6O6S [61090-95-7]

PEK-4117-v-20 °C

0.5 mgvial

33

D.H. Coy, et al., Biochem. Biophys. Res. Commun., 73, 632 (1976). (Original; Chem. Synthesis) C.B. Pert, et al., Science, 194, 330 (1976). (Original)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 55

PRODUCT CODE QTY PRICE Epitope Tag Peptide (Flag Peptide)H-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-OH

(M.W. 1012.99) C41H66N10O20 Epitope Tag Peptide

PTG-3976-PI -20 °C

5 mg 95

F. Coussen, et al. J. Biol. Chem., 276, 27881 (2001). M. Zhao, et al., Mol. Cell. Biol., 23, 8982 (2003).S. Da Cruz, et al., J. Biol. Chem., 278, 4156 (2003). J. Carrillo, et al., J. Biol. Chem., 278, 42578 (2003). M. Hiromura, et al., J. Biol. Chem., 279, 53407 (2004).

EptifibatideEptifibatide EPT-3786-PI

-20 °C

1 mg5 mg

52161(Trifluoroacetate Form)

(M.W. 831.98) C35H49N11O9S2 [188627-80-7]G.L. Plosker, , et al., Pharmacoeconomics, 21, 885 (2003). Shea and Tcheng, Expert Opin.Pharmacother., 3, 1199 (2002).

Note: Bolar Exemption applies. This is a FDA-regulated product. It is the responsibility of the customer to ensure that he/she is complying with Federal rules. Peptides International cannot be liable for infringement of rights made by the user.

ExendinExendin (5-39) (Lizard, Heloderma horridum)

PEX-4345-v-20 °C

0.5 mgvial

380

Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala- Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (M.W. 3806.2) C169H262N44O54S GLP-1 Receptor AntagonistC. Montrose-Rafizadeh, et al., J. Biol. Chem., 272, 21201 (1997). (Original; Potent Antagonist)J.-I. Oka,et al., Brain Res., 878, 194 (2000). (Pharmacol.)

Exendin-4 PEX-3784-PI-20 °C

1 mg5 mg

4821926H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-

Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys- Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (M.W. 4186.66) C184H282N50O60S [141758-74-9] GLP-1 (Glucagon-Like Peptide-1) Receptor R Göke, et al., J Biol Chem., 26, 19650 (1993). B. Thorens, et al., Diabetes, 42, 1678, (1993). A. Alcántara, et al., Arch Biochem Biophys.341: 1, 1997


56 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Experimental Autoimmune Encephalomyelitis Products

Experimental autoimmune encephalomyelitis (EAE) has been used as a model for study-ing multiple sclerosis (MS) due to the clinical and histopathological similarities of the inflammatory diseases affecting the central nervous system. Both Myelin PLP (PLP-3602-PI) and MOG (PMG-3660-PI) are antigenic peptides that induce EAE by binding to MHC-II molecules on antigen presenting cells where they are recognized by class-II restricted T cells.PI expands its line of antigenic peptides to now include: MOG (40-54) (PMG-3962-PI) and vesicular stomatitis virus octopeptide (52-59) or VS-8 (PVS-3961-PI).1 This antigen binds to Kb MHC-1 where the antigen is presented to T cells. It has been used in the past to study vacuolar processing of exogenous Ag and the role of TAP (transporter associ-ated with antigen processing) during this event.2 An understanding of events accompa-nying the processing and presentation of viral Ags can help assist in vaccine design and in the study of inflammatory-related diseases.

G.M. van Bleek and S.G. Nathenson, Nature (Lond.), 348, 213 (1990).P.J. Chefalo and C.V. Harding, J. Immunol., 167, 1274 (2001).

* Bulk quantities and other EAE peptides are available, please inquire.

Acetyl-Myelin Basic Protein (Mouse, 1-11)Ac-MBP (1-11)

Ac-Ala-Ser-Gln-Lys-Arg-Pro-Ser-Gln-Arg-Ser-Lys-OH (M.W. 1314.48) C53H95N21O18 Encephalitogenic DeterminantS.D. Wolf, et al., J. Exp. Med., 184, 2271 (1996).

PMB-3657-PI-20 °C

1 mg5 mg

102402

Acetyl-Myelin Basic Protein (Human, Rat, 1-11)Ac-MBP (Human, Porcine, Rat 1-11)

Ac-Ala-Ser-Gln-Lys-Arg-Pro-Ser-Gln-Arg-His-Gly-OH (M.W. 1293.42) C52H88N22O17 Encephalitogenic DeterminantJ.E. Fenyk-Melody, et al. J. Immunol., 160, 2940 (1998).

PMB-3658-PI-20 °C

1 mg5 mg

102402

Myelin Basic Protein (1-20)MBP (1-20)

PMB-3972-PI-20 °C

1 mg5 mg

102423

H-Ala-Ser-Gln-Lys-Arg-Pro-Ser-Gln-Arg-Ser-Lys- Tyr-Leu-Ala-Thr-Ala-Ser-Thr-Met-Asp-OH (M.W. 2226.51) C92H156N30O32S Immunogenic Peptide

Myelin Basic Protein (87-99)MBP (87-99)

H-Val-His-Phe-Phe-Lys-Asn-Ile-Val-Thr-Pro-Arg-Thr-Pro-OH (M.W. 1555.86) C74H114N20O17 Encephalitogenic Determinant

PMB-3973-PI-20 °C

1 mg5 mg

134530


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 57

PRODUCT CODE QTY PRICE Myelin Basic Protein (111-129)MBP (111-129)

PMB-3974-PI-20 °C

1 mg5 mg

91348

H-Leu-Ser-Arg-Phe-Ser-Trp-Gly-Ala-Glu-Gly- Gln-Arg-Pro-Gly-Phe-Gly-Tyr-Gly-Gly-OH (M.W. 2029.22) C92H129N27O26 Encephalitogenic Determinant

MOG (40-54)Myelin Oligodendrocyte Protein (40-54)

PMG-3962-PI-20 °C

1 mg5 mg

65241

H-Tyr-Arg-Ser-Pro-Phe-Ser-Arg-Val-Val-His-Leu-Tyr-Arg-Asn-Gly-OH (M.W. 1851.12) C84H127N27O21

D. Sun, et al., Int. Immunol., 15, 261 (2003)

MOG (92-106)Myelin Oligodendrocyte Protein (92-106)

PMG-3968-PI-20 °C

1 mg5 mg

81316

H-Asp-Glu-Gly-Gly-Tyr-Thr-Cys-Phe-Phe-Arg-Asp-His-Ser-Tyr-Gln-OH (M.W. 1823.91) C80H104N21O27S Encephalitogenic Determinant

MOG (Rat, Mouse, 35-55)Myelin Oligodendrocyte Protein (35-55)

PMG-3660-PI-20 °C

1 mg5 mg

134530

H-Met-Glu-Val-Gly-Trp-Tyr-Arg-Ser-Pro-Phe-Ser-Arg-Val-Val-His-Leu-Tyr-Arg-Asn-Gly-Lys-OH (M.W. 2582.01) C118H177N35O29S Encephalitogenic DeterminantM Ichikawa, et al., J. Immunol. 157, 919-926 (1996). H.-C. von Büdingen, et al., J. Clin. Immunol., 21, 155 (2001).

Myelin PLP (57–70)Myelin Proteolipid Protein (57-70)

YEYLINVIHAFQYV H-Tyr-Glu-Tyr-Leu-Ile-Asn-Val-Ile-His-Ala-Phe-Gln-Tyr-Val-OH (M.W. 1772.05) C87H122N18O22 Encephalitogenic Determinant

PLP-3970-PI-20 °C

1 mg5 mg

91348

Myelin PLP (139-151)Myelin Proteolipid Protein (139-151)

PLP-3602-PI-20 °C

1 mg5 mg

103411

(Acetate Form)H-His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe-OH (M.W. 1521.76) C72H104N20O17 Encephalitogenic DeterminantV.K. Kuchroo, et al., J. Immunol., 153, 3326 (1994).


(Trifluoroacetate Form)H-His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe-OH (M.W. 1521.76) C72H104N20O17 Encephalitogenic DeterminantV.K. Kuchroo, et al., J. Immunol., 153, 3326 (1994).

PLP-3812-PI-20 °C

1 mg5 mg

81316

58 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Myelin PLP (178-191)Myelin Proteolipid Protein (178-191)

PLP-3967-PI-20 °C

1 mg5 mg

81316

NTWTTCQSIAFPSK H-Asn-Thr-Trp-Thr-Thr-Cys-Gln-Ser-Ile-Ala-Phe-Pro-Ser-Lys-OH (M.W. 1583.80) C70H106N18O22S Encephalitogenic Determinant


PLP-3966-PI-20 °C

1 mg5 mg

102423

WTTCQSIAFPSKTSASIGSL H-Trp-Thr-Thr-Cys-Gln-Ser-Ile-Ala-Phe-Pro-Ser-Lys-Thr-Ser-Ala-Ser-Ile-Gly-Ser-Leu-OH (M.W. 2805.38) C92H145N23O30S Encephalitogenic Determinant

H-Arg-Gly-Tyr-Val-Tyr-Gln-Gly-Leu-OHRGYVYQGL (M.W. 955.09) C44H66N12O12 Vesicular Stomatitis Virus (VSV)Nucleoprotein (52 - 59), VSV - 8

PVS-3961-PI-20 °C

1 mg5 mg

81316

VP2 (70-86)Viral Protein 2 (70-86)

PVP-3971-PI-20 °C

1 mg5 mg

81316

WTTSQEAFSHIRIPLPH H-Trp-Thr-Thr-Ser-Gln-Glu-Ala-Phe-Ser-His-Ile-Arg-Ile-Pro-Leu-Pro-His-OH (M.W. 2020.30) C93H138N26O25 Encephalitogenic DeterminantRichard K. Burt, et al., Blood, 94, 2915 (1999).

FMRF-Amide See Code PFM-4142 Molluscan Cardioexitatory Neuropeptide.Fibronectin Active Fragment See Code PFA-4171 Arg-Gly-Asp-Ser. and Code PFA-4189 Gly-Arg-Gly-Asp-Ser.

Fibrinopeptide B[Glu1]-Fibrinopeptide B Glu-Fibrinopeptide B

PFB-3742-PI-20 °C

1 mg5 mg

130520

(Trifluoroacetate Form)H-Glu-Gly-Val-Asn-Asp-Asn-Glu-Glu-Gly-Phe-Phe-Ser-Ala-Arg-OH (M.W. 1570.60) C66H95N19O26 [103213-49-6] Mass Spec Standard for Proteomic ResearchC. Fu, et al., Mol. Cell. Proteomics, 8, 1674, (2009). J.B. Young and L Li, Anal Chem, 79, 5927 (2007). G.M. Janini, et al., Anal Chem, 75, 1615 (2003).


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 59

PRODUCT CODE QTY PRICE Galanins and Related Peptides

J.N. Crawley and G.L. Wenk, Trends Neurosci., 12, 278 (1989). (Review) T. Bartfai, et al., Trends Pharmacol. Sci., 13, 312 (1992). (Review) R. Lang, et al., Pharmacol. Ther., 115, 177 (2007). (Review) I. Mechenthaler, Cell. Mol. Life Sci., 65, 1826 (2008). (Review)

Galanin [PGA-4245-v (human) and PGA-4244-v (rat)] is one of the brain-gut peptides having various biological activities including feeding regulation. This peptide is known to be a food intake stimulator which interacts with both of the galanin receptor subtypes 1 and 2 (GalR1 and GalR2, respectively) in a relatively non-selective manner. GalR1 is primarily expressed in the central nervous system (CNS), whereas GalR2 is expressed in both peripheral tissue and the CNS. In 1999, scientists at Takeda Pharmaceutical Company Limited discovered the GalR2-selective ligand in porcine hypothalamus. At the same time, they proposed the primary structures of the rat and human orthologues from the corresponding cDNA sequences.1 This newly identified peptide, known as galanin-like peptide (GALP), is composed of 60 amino acid residues. GALP (9-21) is identical to galanin (1-13) and the sequence homology among the species is high. When 125I-labeled rat galanin is used as a ligand, porcine GALP interacts with GalR2 with an IC50 value of 0.24 nM, while the corresponding value for GalR1 is 4.3 nM, clearly indicating the recep-tor selectivity of GALP. Since then, additional data concerning the role of rat GALP in feeding have been reported dealing with: i) stimulation of food intake in rats2,3, ii) control of its expression by leptin4), and iii) crossing the blood brain barrier.5 Recently review articles concerning the function of GALP in relation to galanin and the galanin receptor have also been published.6-8

T. Ohtaki, et al., J. Biol. Chem., 274, 37041 (1999). (Original) Y. Matsumoto, et al., Neurosci. Lett., 322, 67 (2002). (Stimulation of Food Intake) H.-M. Tan, et al., Neuropeptides, 39, 333 (2005). (Pharmacol.; Exaggerated Feeding Response)A. Juréus, et al., Endocrinology, 141, 2703 (2000). (Pharmacol.) A.J. Kastin, V. Akerstrom, and L. Hackler, Neuroendocrinology, 74, 423 (2001). (Brain Entry) A.L. Gundlach, Eur. J. Pharmacol., 440, 255 (2002). (Review)P.S. Man and C.B. Lawrence, Neuropharmacology, 55, (2008). (Review)C.B. Lawrence, Physiol. Behav., 97, 515 (2009). (Review)

* This compound is distributed through Peptide Institute, Inc. under the license of Takeda Chemical Industries, Ltd

Galanin (Human)* PGA-4245-v-20 °C

0.5 mgvial

450Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala- Val-Gly-Asn-His-Arg-Ser-Phe-Ser-Asp-Lys-Asn-Gly-Leu-Thr-Ser (M.W. 3157.4) C139H210N42O43 [119418-04-1]M. Bersani, et al., FEBS Lett., 283, 189 (1991). (Original)

Galanin (Rat)*(Mouse)

PGA-4244-v-20 °C

0.5 mg vial

450

Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Ile- Asp-Asn-His-Arg-Ser-Phe-Ser-Asp-Lys-His-Gly-Leu-Thr-NH2 (M.W. 3164.4) C141H211N43O41 [114547-31-8]M.E. Vrontakis,et al., J. Biol. Chem., 262, 16755 (1987). (Original; cDNA-Pituitary Tumor) L.M. Kaplan, et al., Proc. Natl. Acad. Sci. USA, 85, 1065 (1988). (Original; cDNA-Hypothalamus)J. Lundkvist, et al., Neurosci. Lett., 200, 121 (1995). (Original; Mouse Hypothalamic cDNA)


60 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Galanin-like Peptide (Human, 1-60)GALP (Human, 1-60)

PGL-4391-s-20 °C

0.1 mg vial

359

Ala-Pro-Ala-His-Arg-Gly-Arg-Gly-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly- Pro-Val-Leu-His-Leu-Pro-Gln-Met-Gly-Asp-Gln-Asp-Gly-Lys-Arg-Glu-Thr-Ala-Leu-Glu- Ile-Leu-Asp-Leu-Trp-Lys-Ala-Ile-Asp-Gly-Leu-Pro-Tyr-Ser-His-Pro-Pro-Gln-Pro-Ser (M.W. 6500.3) C292H451N83O84S Ligand for Galanin Receptor 2 / Target Peptide for Feeding Regulation by Leptin

Gastrins and Related PeptidesJ.E. Jorpes and V. Mutt (eds.) Secretin, Cholecystokinin, Pancreozymin and Gastrin, Handbook of Experimental Pharmacology, Vol. 34, Springer-Verlag, Berlin, 1973. (Review)

Big Gastrin (Human) (Ammonium Form)

PGR-4183-s-20 °C

0.1 mgvial

166

Pyr-Leu-Gly-Pro-Gln-Gly-Pro-Pro-His-Leu-Val-Ala-Asp-Pro-Ser-Lys- Lys-Gln-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 (M.W. 3849.2) C176H251N43O53S [60675-77-6]A.M. Choudhury, et al., Hoppe-Seyler’s Z. Physiol. Chem., 361, 1719 (1980). (Original; Chem. Synthesis)

Gastrin I (Human) PGR-4143-v-20 °C

0.5 mgvial

332(Ammonium Form)Pyr-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 (M.W. 2098.2) C97H124N20O31S [10047-33-3]H. Gregory, et al., Nature, 204, 931 (1964). (Original) J.C. Anderson, et al., Nature, 204, 933 (1964). (Chem. Synthesis)

Gastrin Related Peptide (Bulk) PGR-4004-20 °C

25 mg100 mg

124316Aoc-Trp-Met-Asp-Phe-NH2

(Aoc: t-Amyloxycarbonyl) (M.W. 710.84) C35H46N6O8SY. Ishii and H. Shinozaki, Japan J. Pharmacol., 18, 93 (1968). (Pharmacol.)

GIP (Human) Gastric Inhibitory Polypeptide (Human)Glucose-Dependent Insulinotropia Polypeptide (Human)

Tyr-Ala-Glu-Gly-Thr-Phe-lle-Ser-Asp-Tyr-Ser-lle-Ala-Met-Asp-Lys-lle-His-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-lle-Thr-Gln (M.W. 4983.5) C226H338N60O66S [100040-31-1]

PGR-4178-s-20 °C

0.1 mg vial

156

PGR-4178-v-20 °C

0.5 mg vial

105

A.J. Moody, et al., FEBS Lett.,172, 142 (1984). (Original) N. Fujii, et al., Chem. Pharm. Bull., 34, 2397 (1986). (Glucose-dependent Insulinotropic Polypeptide)

GRP (Human) Gastrin Releasing Peptide (Human)

Val-Pro-Leu-Pro-Ala-Gly-Gly-Gly-Thr-Val-Leu-Thr-Lys-Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 (M.W. 2859.4) C130H204N38O31S2 [93755-85-2]

PGR-4164-v-20 °C

0.5 mgvial

418

E.R. Spindel, et al. , Proc. Natl. Acad. Sci. USA, 81, 5699 (1984). (Original; cDNA)



BIOLO


Order Hotline 1-800-777-4779 502-266-8787 61

PRODUCT CODE QTY PRICE GIF See Code PSI-4023 Somatostatin.

Ghrelin and Related Peptides

Ghrelin was discovered in 1999 as the endogenous ligand of growth-hormone secreta-gogue receptor1: i) ghrelin is a 28 residue peptide with an n-octanoyl group on Ser3 and ii) the major ghrelin producing organ is the stomach. Since then, many researches have been carried out using synthetic ghrelin, clarifying that ghrelin is a multifunctional peptide. These functions include i) regulation of appetite, ii) cardiovascular functions, and more.3-12

M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, and K. Kangawa, Nature, 402, 656 (1999). (Original)P.L. Jeffery,et al., Endocrinology, 146, 432 (2005). (Mouse RNA Seq.)C. Dieguez and F.F. Casanueva, Eur. J. Endocrinol., 142, 413 (2000). (Review)G.Muccioli, et al., Eur. J. Pharmacol., 440, 235 (2002). (Review)G. Wang, H.-M. Lee, E. Englander, and G.H. Greeley, Jr., Regul. Pept., 105, 75 (2002). (Review)

Ghrelin (Human)H-Gly-Ser-Ser(n-Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH (M.W. 3370.94) C149H249N47O42 [258279-04-8] Orexigenc and GH Releasing Peptide

PGH-3741-PI-20 °C

1 mg5 mg

242968

Ghrelin (Human)* PGH-4372-s-20 °C

0.1 mgvial

289(Trifluoroacetate Form)Gly-Ser-Ser(n-Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln- Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg (M.W. 3370.9) C149H249N47O42 [258279-04-8] Appetite Stimulating Peptide with Energy Homeostasis Regulation

Ghrelin (Rat)*(Mouse)

PGH-4373-s-20 °C

0.1 mgvial

289

(Trifluoroacetate Form)Gly-Ser-Ser(n-Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln- Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg (M.W. 3314.8) C147H245N45O42 [258338-12-4] Appetite Stimulating Peptide with Energy Homeostasis RegulationM. Kojima, et al., Nature, 402, 656 (1999). (Original) C. Dieguez and F.F. Casanueva, Eur. J. Endocrinol., 142, 413 (2000). (Review) G. Muccioli, et al., Eur. J. Pharmacol., 440, 235 (2002). (Review) G. Wang, et al., Regul. Pept., 105, 75 (2002). (Review)

Des-Acyl Ghrelin (Human)Des-n-Octanoyl Ghrelin (Human)

PGH-4436-s-20 °C

0.1 mgvial

130

(Trifluoroacetate Form)Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu- Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg (M.W. 3244.7) C141H235N47O41 Des-Octanoylated Ghrelin with Distinct Effect on Food Intake

* This compound is distributed through Peptide Institute under license agreement with Dr. Kangawa.

62 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Des-Acyl Ghrelin (Rat)Des-n-Octanoyl Ghrelin (Rat)

PGH-4437-s-20 °C

0.1 mgvial

140

(Trifluoroacetate Form)Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Gln-Arg-Lys-Glu- Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg (M.W. 3188.6) C139H231N45O41 Des-Octanoylated Ghrelin with Distinct Effect on Food Intake

Des-n-Octanoyl-[Ser3]-Ghrelin (Human)Non-Acylated Ghrelin (Human)

PGH-3653-PI-20 °C

0.5 mgvial

156

H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln- Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH (M.W. 3244.74) C141H235N47O41 Counteracts Metabolic Effects of Acylated GhrelinF. Broglio, et al., J. Clin. Endoc. and Metabolism, 89, 3062 (2004). C. Gauna, et al.,, J. Clin. Endoc. and Metabolism, 89, 5035 (2004). A. Asakawa, et al., Gut, 54, 18 (2005).

Des-n-Octanoyl-[Ser3]-Ghrelin (Rat)Non-Acylated Ghrelin (Rat)

PGH-3654-PI-20 °C

0.5 mgvial

156

H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Gln- Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH (M.W. 3188.67) C139H231N45O41 Counteracts Metabolic Effects of Acylated GhrelinH Hosoda, et al., Biochem. Biophys. Res. Commun., 279, 909 (2000). F. Broglio,et al., J. Clin. Endoc. and Metabolism, 89, 3062 (2004). C. Gauna, et al., J. Clin. Endoc. and Metabolism, 89, 5035 (2004). A. Asakawa, et al., Gut, 54, 18 (2005).

H-His-d-Trp-d-Lys-Trp-d-Phe-Lys-NH2[D-Lys3]-Growth Hormone Releasing Peptide-6 (GHRP-6)

(M.W. 930.13) C49H63N13O6 Ghrelin AntagonistK. Fujino, et al., J. Physiol., 550, 227 (2003).

PGH-3656-PI-20 °C

1 mg5 mg

2753

H-His-d-Trp-Ala-Trp-d-Phe-Lys-NH2[His1,Lys6]-Growth Hormone Releasing Peptide (GHRP-6)

(M.W. 873.04) C46H56N12O6

C.Y. Bowers, et al., Endocrinol., 114, 1537 (1984).

PGH-3694-PI-20 °C

1 mg5 mg

2770

Ghrelin (Human, 1-18) H-Gly-Ser-Ser(n-Octanoyl)-Phe-Leu-Ser-Pro-Glu- His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-NH2 (M.W. 2225.51) C96H157N31O30

M.A. Bednarek, et al., J. Med. Chem., 43, 4370 (2000).

PGH-3625-PI-20 °C

1 mg5 mg

102305


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 63

PRODUCT CODE QTY PRICE Ghrelin (Human, 1-14)

H-Gly-Ser-Ser(n-Octanoyl)-Phe-Leu-Ser- Pro-Glu-His-Gln-Arg-Val-Gln-Gln-OH (M.W. 1725.94) C76H121N22O24


PGH-3626-PI-20 °C

1 mg5 mg

81241

Ghrelin (Human, Rat, 1-10) H-Gly-Ser-Ser(n-Octanoyl)-Phe-Leu-Ser- Pro-Glu-His-Gln-NH2 (M.W. 1213.37) C55H84N14O17


PGH-3627-PI-20 °C

1 mg5 mg

65193

Ghrelin (Human, Rat, 1-5) H-Gly-Ser-Ser(n-Octanoyl)-Phe-Leu-NH2 (M.W. 634.78) C31H50N6O8

M.A. Bednarek, et al.,, J. Med. Chem., 43, 4370 (2000).

PGH-3628-PI-20 °C

1 mg5 mg

49145

Des-n-Octanoyl-[Ser3]-Ghrelin (Human, 1-18)

H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val- Gln-Gln-Arg-Lys-Glu-Ser-NH2 (M.W. 2099.31) C88H143N31O29 Non-acylated Analog of Ghrelin (Human, 1-18)

PGH-3645-PI-20 °C

1 mg5 mg

70209

Des-n-Octanoyl-[Ser3]-Ghrelin (Human, 1-14)

H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His- Gln-Arg-Val-Gln-Gln-OH (M.W. 1599.74) C68H106N22O23 Non-acylated Analog of Ghrelin (Human, 1-14)

PGH-3646-PI-20 °C

1 mg5 mg

59166

Des-n-Octanoyl-[Ser3]-Ghrelin (Human, Rat, 1-10)

H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-NH2 (M.W. 1087.17) C47H70N14O16 Non-acylated Analog of Ghrelin (Human, 1-10)

PGH-3647-PI-20 °C

1 mg5 mg

49134

Des-n-Octanoyl-[Ser3]-Ghrelin (Human, Rat, 1-5)

H-Gly-Ser-Ser-Phe-Leu-NH2 (M.W. 508.58) C23H36N6O7 Non-acylated Analog of Ghrelin (Human, 1-5)

PGH-3648-PI-20 °C

1 mg5 mg

38102

[Dap3]-Ghrelin (Human, Rat, 1-5)H-Gly-Ser-Dap(n-Octanoyl)-Phe-Leu-NH2 Dap = 2,3-Diaminopropionic acid (M.W. 633.79) C31H51N7O7

PGH-3681-PI-20 °C

1 mg5 mg

59204

Growth-Hormone Releasing Peptide Ghrelin Analog Active FragmentM.A. Bednarek, et al., J. Med. Chem., 43, 4370-4376 (2000).

64 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE [Dap3]-Ghrelin (Rat)

H-Gly-Ser-Dap(n-Octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH

PGH-3680-PI-20 °C

0.5 mgvial

165

Dap = 2, 3-Diaminopropionic acid (M.W. 3313.88) C147H246N46O41 Growth-Hormone Releasing Peptide / Ghrelin AnalogM.A. Bednarek, et al., J. Med. Chem., 43, 4370 (2000).

[Trp3, Arg5]-Ghrelin (1-5) PGH-3902-PI-20 °C

1 mg5 mg

89353H-Gly-Ser-Trp-Phe-Arg-OH

M.W. 651.73) C31H41N9O7 Growth-Hormone Secretogue (GHS) Receptor Agonist / Stimulates Food-IntakeK. Ohinata, K. Kobayashi, M. Yoshikawa, Peptides, 27, 1632 (2006).

GlucagonGlucagon (Human) PGL-4098-s

-20 °C

0.1 mgvial

156His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp- Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr (M.W. 3482.7) C153H225N43O49S [16941-32-5] P.J. Lefebvre and R.H. Unger (eds.), Glucagon, Pergamon Press, Oxford, 1972. (Review)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 65

PRODUCT CODE QTY PRICE Glucagon-Like Peptide 2 (Human) GLP-2 (Human)

PGL-4376-v-20 °C

0.5 mgvial

396

His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn- Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp (M.W. 3766.1) C165H254N44O55S [223460-79-5]

The proglucagon gene encodes glucagon, glucagon-like peptide 1 (GLP-1) and GLP-2 tandemly. Among these, the location and function of GLP-1 have long been studied, showing that GLP-1 is one of the typical brain-gut peptides and has pleiotropic functions, including stimulation of insulin gene expression, regulation of food and water intake, etc. The chemical structure of GLP-2 in human ileum was reported to be identical to the 33 amino acid residue peptide corresponding to proglucagon (126-158).1 GLP-2 is present in human plasma, the concentration of which was shown to be elevated 3- to 4-fold after ingestion of a meal.1 Further studies revealed that GLP-2’s immunoreactivity was distributed in rat brain, especially in the ventral part of the dorsomedial hypothalamic nucleus (DMH) (and also found in the paraventricular and arcuate nuclei). Central administration of GLP-2 decreases food intake in ad libitum-fed rats at concentrations above 5 μg.2 This inhibition is effective for a short-duration. Surprisingly the GLP-1 receptor antagonist, exendin (9-39), reverses the GLP-2 induced anorexia, although the GLP-2 receptor is expressed in the compact part of the DMH. In addition, GLP-2 decreases NPY-induced food intake by 40%, but this peptide does not affect angiotensin II-induced drinking behavior.2

B. Hartmann, et al., Peptides, 21, 73 (2000). (Pharmacol.)M. Tang-Christensen, et al., Nat. Med., 6, 802 (2000). (Pharmacol.)D.J. Drucker, Gut, 50, 428 (2002). (Review)K. Wallis, et al., Aliment. Pharmacol. Ther., 25, 365 (2007). (Review)P.E. Dube and P.L. Brubaker, Am. J. Physiol. Endocrinol, Metab., 293, E460 (2007). (Review)K.J. Rowland and P.L. Brubaker, Mol. Cell. Endocrinol., 288, 63 (2008). (Review)

Glutathione Disulfide (GSSG) Methyl Ester

(M.W. 668.75) C24H40N6O12S2 GSSG is an oxidized glutathione; By-product of Free glutathi-one or GSH ( Œ≥-Glu-Cys-Gly) metabolism H.A. Park, et al., Cell Death Differ.,16,1167 (2009).

GLU-3809-PI-20 °C

5 mg25 mg

70268

GO-CoA-Tat (Rat, Mouse) PGH-3792-PI-20 °C

0.5 mg1 mg

8831605H-Gly-Ser-α-Dap-β-(2-CoA-Octanoyl)-Phe-Leu-Ser-Pro-Glu-

His-Gln-Ahx-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-OH (M.W. 3633.92) C146H245N54O47P3S Inhibitor of Ghrelin O-Acyltransferase (GOAT)

66 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Growth Hormone Releasing Factor (GRF, GH-RH) and Growth Hormone Related Peptides

Growth hormone releasing peptide-2 or H-d-Ala-d-Nal(2’)-Ala-Trp-d-Phe-Lys-NH2 (GHRP-2) (PGH-3911-PI) is part of the growth hormone secretagogue (GHS) family first identified nearly 20 years ago. Ghrelin was later isolated and like GHRPs, were found to stimulate release of growth hormone.1,2 Ghrelin and GHRPs act on growth hormone secretagogue receptor type 1a (GSR1a) in a synergistic manner, and both can stimu-late increase of food intake in humans.3-6 Besides its role in energy balance, GHRP-2 has been implicated to have anti inflammatory effects in arthritic rats due to its ability to decrease IL-6 in serum, a major mediator of tissue destruction in this disease.7 Cardio protective functions have been observed as well.8

GSR1a was found to exhibit high basal activity independent of ghrelin activation.9 Constitutive, ligand independent activation of GSR1a is physiologically important, and inverse agonists would be helpful in studies focused on such activity. [d-Arg1,d-Phe5,d-Trp7,9,Leu11]-substance P (PGH-3652-PI) is a selective inverse agonist for GSR1a with low antagonist activity.10 The pentapeptide core required for inverse agonist activity was determined to be wFwLL.11 Addition of a positive charged amino acid led to a novel pep-tide KwFwLL (PGH-3908-PI); the most potent and shortest inverse agonist for GSR1a.http://pepnet.com/products/ghrelin_obestatin.pdf

GRF (Human) Growth Hormone Releasing Factor (Human)

Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys- Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln- Asp-lle-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln- Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 (M.W. 5039.7) C215H358N72O66S [83930-13-6]

PGR-4127-s-20 °C

0.1 mgvial

156

PGR-4127-v-20 °C

0.5 mgvial

525

R. Guillemin, et al., Science, 218, 585 (1982). (Original; Pancreatic Tumor) N. Ling, et al., Proc. Natl. Acad. Sci. USA, 81, 4302 (1984). (Original; Hypothalamus)

H-d-Ala-d-Nal(2’)-Ala-Trp-d-Phe-Lys-NHGHRP-2

(M.W. 818) C45H55N9O6 Growth Hormone Releasing Peptide / Food Intake Stimulator

PGH-3911-PI -20 °C

1 mg5 mg

49198

H-Lys-d-Trp-Phe-d-Trp-Leu-Leu-NH2KwFwLL

(M.W. 891.14) C49H66N10O6 Potent Full Inverse Agonist for Ghrelin Receptor

PGH-3908-PI -20 °C

1 mg5 mg

49198

Phytosulfokine (0.1 mg vial)PSK

PGR-4477-s-20 °C

0.1 mgvial

54

Tyr(SO3H)-Ile-Tyr(SO3H)-Thr-Gln (Ammonium Form) (M.W. 846.88) C33H46N6O16S2 [179667-62-0] Potent Mitogenic Factor in PlantsY. Matsubayashi and Y. Sakagami, Proc. Natl. Acad. Sci. U.S.A., 93, 7623 (1996). (Original) Y. Matsubayashi, et al., Science, 296, 1470 (2002). (Pharmacol.) H. Motose, et al., Plant Physiol., 150, 437 (2009). (Pharmacol.)

* This product is distributed through Peptide Institute, Inc. under the license of The Salk Institute.


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 67

PRODUCT CODE QTY PRICE Guanylins and Uroguanylins

L.R. Forte and M.G. Currie, FASEB J., 9, 643 (1995). (Review) L.R. Forte, et al., Am. J. Kidney Dis., 28, 296 (1996). (Review) L.R. Forte, Jr., Pharmacol. Ther., 104, 137 (2004). (Review)

Guanylin (Human) PGN-4274-s-20 °C

0.1 mgvial

140Pro-Gly-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys (Disulfide bonds between Cys4-Cys12 and Cys7-Cys15) (M.W. 1458.7) C58H87N15O21S4 [183200-12-6] Guanylate Cyclase C ActivatorR.C. Wiegand, et al., FEBS Lett., 311, 150 (1992). (Original; cDNA) F.J. de Sauvage, et al., Proc. Natl. Acad. Sci. USA, 89, 9089 (1992). (Original; cDNA) M. Kuhn, et al., FEBS Lett., 318, 205 (1993). (Circulating Form) O. Hill, et al., Proc. Natl. Acad. Sci. U.S.A., 92, 2046 (1995). (Immunohistochem.)

Guanylin (Rat, Mouse) PGN-4275-s-20 °C

0.1 mgvial

140Pro-Asn-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys (Disulfide bonds between Cys4-Cys12 and Cys7-Cys15) (M.W. 1515.7) C60H90N16O22S4 Guanylate Cyclase C ActivatorM.G. Currie, et al., Proc. Natl. Acad. Sci. USA, 89, 947 (1992). (Original; Rat) R.C. Wiegand, et al., Biochem. Biophys. Res. Commun., 185, 812 (1992). (Original; Rat cDNA) S. Schults, et al., J. Biol. Chem. 267, 16019 (1992). (Tissue distribution) F.J. de Sauvage, et al., Proc. Natl. Acad. Sci. USA, 89, 9089 (1992). (Original; Mouse cDNA)

Uroguanylin (Rat) PUG-4354-s-20 °C

0.1 mgvial

129Thr-Asp-Glu-Cys-Glu-Leu-Cys-Ile-Asn-Val-Ala-Cys-Thr-Gly-Cys (Disulfide bonds between Cys4-Cys12 and Cys7-Cys15) (M.W. 1569.8) C60H96N16O25S4 Guanylate Cyclase C Activator / Natriuretic Factor M. Nakazato, et al., Endocrinology, 139, 5247 (1998). (Original) H. Ieda, S. Naruse, M. Kitagawa, H. Ishiguro, and T. Hayakawa, Regul. Pept., 79, 165 (1999). (Pharmacol.) M. Kikuchi, et al, J. Am. Soc. Nephrol., 16, 392 (2005). (Pharmacol.; Natriuretic Activity)

Uroguanylin (Human)(Trifluoroacetate Form)

PUG-3772-PI-20 °C

1 mg5 mg

5692354

H-Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH (Disulfide bonds between Cys4-Cys12 and Cys7-Cys15) (M.W. 1667.89) C64H102N18O26S4 [154525-25-4] T. Kita, et al., Am. J. Physiol., 266, F342 (1994). J. Beltowski, et al., 52, 351 (2001). LR Forte, et al., J. Clin. Invest., 112, 1138 (2003).

68 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Uroguanylin Isomer A (Human) PUG-4295-s

-20 °C

0.1 mgvial

145(Trifluoroacetate Form) Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu (Disulfide bonds between Cys4-Cys12 and Cys7-Cys15) (M.W. 1667.9) C64H102N18O26S4 [154525-25-4] Guanylate Cyclase C Activator Purity Information: Qz See page xiv T. Kita, et al., Am. J. Physiol., 266, F342 (1994). (Original) M. Nakazato, et al., Biochem. Biophys. Res. Commun., 220, 586 (1996). (Biologically Active/Inactive Isomer) H. Kinoshita, et al., Kidney Int., 52, 1028 (1997). (Urine/Plasma Level; Renal Disease) N. Chino, et al., FEBS Lett., 421, 27 (1998). (Biochem.; Topological Isomers) N.G. Moss, et al., Hypertension, 53, 867 (2009). (Natriuretic Activity of Topological Isomers)

Uroguanylin Isomer B (Human) PUG-4463-s-20 °C

0.1 mgvial

113(Trifluoroacetate Form)Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu (Disulfide bonds between Cys4-Cys12 and Cys7-Cys15) (M.W. 1667.9) C64H102N18O26S4 Natriuretic Factor

Uroguanylin is a well-known activator of guanylyl cyclase-C (GC-C) in the intestine. Regulation of natriuresis in the kidney postprandial is another important function of this peptide.1 In the case of human uroguanylin,2 the so-called topological isomers (isomer A and isomer B in this catalog) are generated because of the carboxyl-terminal extension of Leu residue from the core structure formed by two disulfide bonds in a 1-3/2-4 pattern resulting in the stabilization of two topological stereoisomers. Isomer A (PUG-4295-s) stimulates GC-C, whilst isomer B is a weak agonist in this assay.3 What is the biological role of isomer B? The answer was obtained that isomer B possesses natriuretic activity4 with a sigmoidal dose-response curve (ED50 = 20 nmol/kg in rats). It is of interest that isomer A also shows natriuretic activity at 25 nmol/kg, however, a distinct bell-shaped dose-response curve was observed. Furthermore, co-administration of isomer A (100 nmol/kg) and isomer B (35 nmol/kg) induced almost as efficient natriuretic response as that of a mere administration of isomer A, indicating that a large amount of coexisting isomer A antagonize, even in part, the natriuretic activity of isomer B. Considering the report that uroguanylin and guanlylin exert natriuretic activity in mice even lacking the GC-C receptor,5 the natriuresis of uroguanylin might be mediated by a novel receptor other than GC-C. The availability of synthetic human uroguanylin isomer A and isomer B should allow for more precise research to help clarify the complicated biological response of the individual topological isomers. Please note: It has been reported that isomer A and isomer B of human uroguanylin are interconvertible in solution.6 Keeping the prepared solution at low temperature (below 4 °C) should help avoid this possible interconversion.

L.R. Forte, J. Clin. Invest., 112. 1138 (2003). (Review: Natriuretic Factor) T. Kita, et al., Am. J. Physiol., 266, F342 (1994). (Original) M. Nakazato, et al., Biochem. Biophys. Res. Commun., 220, 586 (1996). (GC-C Stimulating Activity of Topological Isomers) N.G. Moss, et al., Hypertension, 53, 867 (2009). (Natriuretic Activity of Topological Isomers) S.L. Carrithers, et al., Kidney Int., 65, 40 (2004). (GC-C-Independent Natriuretic Activity) N. Chino, et al., FEBS Lett., 421, 27 (1998). (Interconversion of Topological Isomers)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 69

PRODUCT CODE QTY PRICE Gurmarin GUR-3810-PI

-20 °C

1 mg5 mg

6962782(Acetate Form)

Pyr-Gln-Cys-Val-Lys-Lys-Asp-Glu-Leu-Cys-Ile-Pro-Tyr-Tyr-Leu-Asp-Cys-Cys- Glu-Pro-Leu-Glu-Cys-Lys-Lys-Val-Asn-Trp-Trp-Asp-His-Lys-Cys-Ile-Gly-OH (M.W. 4208.95) C187H276N46O53S6(Disulfide bonds Cys3-Cys18, Cys10-Cys23, and Cys17-Cys33)J.I. Fletcher, et al., Eur. J. Biochem., 264, 525 (1999). Y. Ninomiya, et al., Am J Physiol., 274, R1324 (1998).M. Sigoillot, et al., Appl. Microbiol. Biotechnol., 96, 619 (2012). A. Shiyovich, et al., Am. J. Med. Sci., 340, 514 (2010).

H-Phe-Ile-Arg- Angiogenic PeptidesH-Phe-Ile-Arg-Gly-Gly-Met- Tyr-Glu-Gly-Lys-Lys-OH

TSP-3874-PI-20 °C

1mg5mgl

180720

(Trifluoroacetate Form)FIRGGMYEGKK (M.W. 1285.54) C58H92N16O15S Control Peptide for CD47-Binding Peptide 7N3 (TSP-3873-PI)S. Kaur, et al., J. Biol. Chem., 285, 38923 (2010).

H-Phe-Ile-Arg-Val-Val-Met- Tyr-Glu-Gly-Lys-Lys-OH

TSP-3873-PI-20 °C

1mg5mgl

180720

(Trifluoroacetate Form)FIRVVMYEGKK (M.W. 1369.70) C64H104N16O15S D47 Binding Peptide Derived from Thrombospondin 1; Inhibitor of Angiogenic ResponsesS. Kaur, et al., J. Biol. Chem., 285, 38923 (2010)

70 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Hepcidin

Hepcidin is an antimicrobial peptide and negative regulator of iron homeostasis.1 Both iron loading and inflammation can stimulate hepcidin production in the liver.2,3 Humans have one copy of the hepcidin gene while mice contain 2 copies; hepcidin 1 and 2. Overexpression of hepcidin 1 but not 2 in mice led to anemia, suggesting the former is the predominant regulator of iron metabolism.4 In addition, disruption of hepcidin 1 in mice caused severe multivisceral iron overload and hemo-chromatosis.5

C.H. Park, et al., J. Biol. Chem., 276, 7806 (2001). C. Pigeon, et al., J. Biol. Chem., 276, 7811 (2001) G. Nicholas, et al., J. Clin. Invest., 110, 1037 (2002) D.-Q. Lou, et al., Blood, 103, 2816 (2004). J.-C. Lesbordes-Brion, et al., Blood, 108, 1402 (2006).

[13C18,15N3]-Hepcidin (Human) PLP- 3405-v-20 °C

0.02 mgvial

279

(Trifluoroacetate Form) Asp-Thr-His-[13C9,15N]Phe-Pro-Ile-Cys-Ile-[13C9,15N]Phe- Cys-Cys-[15N]Gly-Cys-Cys-His-Arg-Ser-Lys-Cys-Gly-Met-Cys-Cys-Lys-Thr (Reported disulfide bonds between Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, and Cys14-Cys22) (M.W. 2810.20) C9513C18H170N3115N3O31S9 Stable Isotope-Labeled Peptide for Mass Spectrometric Detection of Hepcidin (Human)N. Murao, et al., Rapid Commun. Mass Spectrom., 21, 4033 (2007).T. Hosoki, et al., Proteomics Clin. Appl., 3, 1256 (2009).

Hepcidin (Baboon) PLP-3745-PI -20 °C

1 mg5 mg


Liver-Expressed Antimicrobial Peptide (Baboon) H-Asp-Thr-His-Phe-Pro-Ile-Cys-Ile-Phe-Cys-Cys-Gly-Cys-Cys- His-Arg-Ser-Lys-Cys-Gly-Met-Cys-Cys-Arg-Thr-OH (Disulfide bonds between Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, and Cys14-Cys22) (M.W. 2817.41) C113H170N36O31S9G.M. Morrison, et al., Mol Biol Evol., 20, 460 (2003).

Hepcidin (Crocodile) Liver-Expressed Antimicrobial Peptide (Crocodile)

PLP-3789-PI -20 °C

1 mg5 mg

7492996

H-Asn-Ser-His-Phe-Pro-Ile-Cys-Ser-Tyr-Cys-Cys-Asn-Cys- Cys-Arg-Asn-Lys-Gly-Cys-Gly-Leu-Cys-Cys-Arg-Thr-OH (Disulfide bonds between Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, and Cys14-Cys22) (M.W. 2778.27) C100H165N37O33S8 Iron Homestasis Regulator

Hepcidin (Dog)Liver-Expressed Antimicrobial Peptide (Dog)

PLP-3785-PI -20 °C

1 mg5 mg

6692675

H-Asp-Thr-His-Phe-Pro-Ile-Cys-Ile-Phe-Cys-Cys-Gly-Cys-Cys- Lys-Thr-Pro-Lys-Cys-Gly-Leu-Cys-Cys-Lys-Thr-OH (Disulfide bonds between Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, and Cys14-Cys22) Iron Homestasis RegulatorM.M. Fry, et al., Vet. Clin. Pathol., 33, 223 (2004).


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 71

PRODUCT CODE QTY PRICE Hepcidin 1 (Mouse)Liver-Expressed Antimicrobial Peptide 1 (Mouse)

PLP-4434-s -20 °C

0.1 mgvial

279

Asp-Thr-Asn-Phe-Pro-Ile-Cys-Ile-Phe-Cys-Cys-Lys-Cys- Cys-Asn-Asn-Ser-Gln-Cys-Gly-Ile-Cys-Cys-Lys-Thr (Disulfide bonds undetermined) (M.W. 2754.2) C111H169N31O35S8 Iron-Regulatory Hormone

Hepcidin (Mouse) (Bulk)Liver-Expressed Antimicrobial Peptide 1 (Mouse)


PLP-3773-PI -20 °C

1 mg5 mg

16057223

Hepcidin-9 (Mouse)(Trifluoroacetate Form)H-Asp-Thr-Asn-Phe-Pro-Ile-Cys-Ile-Phe-NH2 (M.W.1068.27) C50H73N11O13S

PLP-3858-PI-20 °C

1 mg5 mg

241963

Hepcidin (Rat) (50 µg vial)Liver-Expressed Antimicrobial Peptide (Rat)

PLP-4467-v -20 °C

0.05 mgvial

365

H-Asp-Thr-Asn-Phe-Pro-Ile-Cys-Leu-Phe-Cys-Cys Lys-Cys- Cys-Lys-Asn-Ser-Ser-Cys-Gly-Leu-Cys-Cys-Ile-Thr (Disulfide bonds undetermined) (M.W. 2712.2) C111H169N31O35S8 Synthetic Product Iron-Regulatory Hormone C. Pigeon, et al., J. Biol. Chem., 276, 7811 (2001). (Primary structure: GenBank accession No. AF344185)

Hepcidin (Rat) (Bulk)Liver-Expressed Antimicrobial Peptide (Rat)

PLP-3769-PI -20 °C

1 mg5 mg

16057223

(Trifluoroacetate Form) H-Asp-Thr-Asn-Phe-Pro-Ile-Cys-Leu-Phe-Cys-Cys Lys- Cys- Cys-Lys-Asn-Ser-Ser-Cys-Gly-Leu-Cys-Cys-Ile-Thr (Disulfide between Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, Cys14-Cys22) (M.W. 2712.2) C111H169N31O35S8 Synthetic Product Iron-Regulatory Hormone

Phe4,9 [Ring D5]-Hepcidin (Rat) PLP-3780-PI-20 °C

0.1 mgvial

300

H-Asp-Thr-Asn-Phe(D5)-Pro-Ile-Cys-Leu-Phe(D5)-Cys-Cys-Lys- Cys-Cys-Lys-Asn-Ser-Ser-Cys-Gly-Leu-Cys-Cys-Ile-Thr-OH (Disulfide bonds between Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, and Cys14-Cys22) (M.W. 2722.37) C111H161D10N29O34S8 Deuterium Stable Isotope-Labeled Hepcidin for Internal Standard

72 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Hepcidin/LEAP-1 (Human)Liver-Expressed Antimicrobial Peptide

PLP-4392-s-20 °C

0.1 mg vial

241

Asp-Thr-His-Phe-Pro-Ile-Cys-Ile-Phe-Cys-Cys-Gly-Cys- Cys-His-Arg-Ser-Lys-Cys-Gly-Met-Cys-Cys-Lys-Thr (Disulfide bonds between Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, and Cys14- Cys22) (M.W. 2789.4) C113H170N34O31S9 Liver-Specific Antimicrobial Peptide / Iron-Regulatory Hormone M. Zasloff, Nature, 475, 389 (2002). (Review) A. Krause, et al., FEBS Lett., 480, 147 (2000). (Original; LEAP-1) C.H. Park, et al., J. Biol. Chem., 276, 7806 (2001). (Original; Hepcidin) H.N. Hunter, et al., J. Biol. Chem., 277, 37597 (2002). (S-S Bond) R.E. Fleming and W.S. Sly, Proc. Natl. Acad. Sci. USA, 98, 8160 (2001). (Regulation of Iron Homeostasis)

Hepcidin/LEAP-1 (Human) contains 8 Cys residues, disulfide connectivity of which was first determined to be Cys7-Cys23, Cys10-Cys22, Cys11-Cys19, and Cys13-Cys14 based on the results from NMR analysis of the synthetic peptide. Recently, this connectivity has been revised to be Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, and Cys14-Cys22 using the natural peptide from urine, two recombinant peptides expressed in CHO cells or E. coli, and the chemically synthesized peptide.5 Methods applied to determine this newly reported connectivity include: NMR, X-ray crystallography of the anti-hepcidin/LEAP-1 antibody Fab complex, and disulfide mapping by partial reduction/alkylation procedure. Based on these experimental facts, we have now changed the disulfide connectivity of our hepcidin/LEAP-1 (Human) to the newly reported one. (Reported disulfide bonds between Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, and Cys14-Cys22).

A. Krause, et al., FEBS Lett., 480, 147 (2000). (Original; LEAP-1)C.H. Park, et al., J. Biol. Chem., 276, 7806 (2001). (Original; Hepcidin)T. Ganz and E. Nemeth, Am. J. Physiol., 290, G199 (2006). (Review)H.N. Hunter, et al., J. Biol. Chem., 277, 37597 (2002). (Previously published S-S Bond Connectivity)J.B. Jordan, et al., J. Biol. Chem., 284, 24155 (2009). (Newly published S-S Bond Connectivity)

Hepcidin/LEAP-1 (Human) (Bulk)Liver-Expressed Antimicrobial Peptide

PLP-3771-PI-20 °C

1 mg5 mg

7492996

(Trifluoroacetate Form) Asp-Thr-His-Phe-Pro-Ile-Cys-Ile-Phe-Cys-Cys-Gly-Cys-Cys-His-Arg-Ser-Lys-Cys-Gly-Met-Cys-Cys-Lys-Thr (Disulfide bonds between Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, and Cys14- Cys22) (M.W. 2789.4) C113H170N34O31S9 [342790-21-0] Liver-Specific Antimicrobial Peptide / Iron-Regulatory Hormone A. Krause, et al., FEBS Lett., 480, 147 (2000). (Original; LEAP-1) C.H. Park, et al., J. Biol. Chem., 276, 7806 (2001). (Original; Hepcidin) T Gan, et al., J. Physiol. Gastrointest. Liver Physiol, 290, G199 (2006).H.N. Hunter, et al., J. Biol. Chem., 277, 37597 (2002). (S-S Bond) JB Jordan, et al., J. Biol. Chem., 284, 24155 (2009).

LEAP-2 (Human)Liver-Expressed Antimicrobial Peptide 2 (Human) Prepro-LEAP-2 (Human, 38-77)

PLP-4405-s-20 °C

0.1 mg vial

279

Met-Thr-Pro-Phe-Trp-Arg-Gly-Val-Ser-Leu-Arg-Pro-Ile-Gly-Ala-Ser-Cys-Arg-Asp-Asp- Ser-Glu-Cys-Ile-Thr-Arg-Leu-Cys-Arg-Lys-Arg-Arg-Cys-Ser-Leu-Ser-Val-Ala-Gln-Glu (Disulfide bonds between Cys17-Cys28 and Cys23-Cys33) (M.W. 4581.3) C191H316N64O57S5 Antimicrobial PeptideA. Krause, et al., Protein Sci., 12, 143 (2003). (Original & S-S Bond).


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 73

PRODUCT CODE QTY PRICE Hepcidin-20 (Human) PLP-3777-PI

-20 °C

1 mg5 mg

6422568

(Trifluoroacetate Form) H-Ile-Cys-Ile-Phe-Cys-Cys-Gly-Cys-Cys-His-Arg-Ser-Lys-Cys-Gly-Met-Cys-Cys-Lys-Thr-OH (Disulfide bonds between C7-C23, C10-C13, C11-C19, and C14-C22

(M.W. 2191.77) C85H135N27O23S9

Hepcidin-22 (Human) PLP-3776-PI-20 °C

1 mg5 mg


H-Phe-Pro-Ile-Cys-Ile-Phe-Cys-Cys-Gly-Cys-Cys-His-Arg-Ser-Lys-Cys-Gly-Met-Cys-Cys-Lys-Thr-OH (Disulfide bonds between C7-C23, C10-C13, C11-C19, and C14-C22

(M.W. 2436.06) C99H151N29O25S9

Hepcidin-24 (Human)Des-Asp Hepcidin-24

PLP-3779-PI-20 °C

1 mg5 mg

6422569

(Trifluoroacetate Form) H-Thr-His-Phe-Pro-Ile-Cys-Ile-Phe-Cys-Cys-Gly-Cys-Cys- His-Arg-Ser-Lys-Cys-Gly-Met-Cys-Cys-Lys-Thr-OH (Disulfide bonds between Cys6- Cys22, Cys9-Cys12, Cys10- Cys18, and Cys13-Cys21 (M.W. 2674.31) C109H165N33O28S9 An internal standard for hepcidin assays D.W. Swinkels, et al., PLoS ONE, 3: e2706 (2008).

Lys18 [(AEEA)2-5-FITC]-Hepcidin (Human) PLP-3793-PI-20 °C

0.5 mg1 mg

626974H-Asp-Thr-His-Phe-Pro-Ile-Cys-Ile-Phe-Cys-Cys-Gly-Cys-Cys-His-

Arg-Ser-Lys(AEEA-AEEA-5-FITC)-Cys-Gly-Met-Cys-Cys-Lys-Thr-OH (Disulfide bonds between Cys7-Cys23, Cys10-Cys13, Cys11-Cys19, and Cys14-Cys22) (M.W. 3469.11) C146H203N37O42S10 FITC-Labeled Hepcidin

HistatinHistatin 5 (Human)

Asp-Ser-His-Ala-Lys-Arg-His-His-Gly-Tyr-Lys-Arg-Lys- Phe-His-Glu-Lys-His-His-Ser-His-Arg-Gly-Tyr (M.W. 3036.3) C133H195N51O33 [104339-66-4] Parotid Histidine-rich Protein / Salivary Antimicrobial Peptide

PHS-4270-s-20 °C

0.1 mgvial

182

F.G. Oppenheim, et al., J. Biol. Chem., 263, 7472 (1988). (Original) P.A. Raj, et al., J. Biol. Chem., 265, 3898 (1990). (Pharmacol.) Y. Murakami, et al., Arch. Oral Biol., 35, 775 (1990). (Pharmacol.) M. Nishikata, et al., Biochem. Biophys. Res. Commun., 174, 625 (1991). (Pharmacol.)

74 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Humanin

I. Nishimoto, et al., Trends Mol. Med., 10, 102 (2004). (Review) T. Arakawa, et al., Curr. Med. Chem., 15, 2086 (2008). (Review)

Humanin (Trifluoroacetate Form) Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu- Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-Ala (M.W. 2687.2) C119H204N34O32S2 [330936-69-1] Endogenous Rescue Factor Abolishing Neuronal Cell Death Purity Information: Qz See page xiv

PHN-4384-v-20 °C

0.5 mgvial

327

[Gly14]-Humanin PHN-4385-v-20 °C

0.5 mgvial

140

(Trifluoroacetate Form) Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu- Thr-Gly-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-Ala (M.W. 2657.2) C118H202N34O31S2 [330936-70-4] Potent Rescue Factor Abolishing Neuronal Cell Death Purity Information: Qz See page xivY. Hashimoto, et al., Proc. Natl. Acad. Sci. USA, 98, 6336 (2001). (Original) Y. Hashimoto, et al., Biochem. and Biophys. Res. Comm., 283, 460 (2001). (Pharmacol.) T. Mamiya and M. Ukai, Br. J. Pharmacol., 134, 1597 (2001). (Pharmacol.) S. Kariya, et al., Neurochemistry, 13, 903 (2002). (Pharmacol.) S.S. Jung and W.E. Van Nostrand, J. Neurochem., 84, 266 (2003). (Pharmacol.)

InsulinE. Dorzbach (ed.), Insulin I, Handbook of Experimental Pharmacology, Vol. 32 (1), Springer-Verlag, Berlin, 1971. (Review) A. Hasselblatt and F.V. Bruchhausen (eds.), Insulin II, Handbook of Experimental Pharmacology, Vol. 32 (2), Springer-Verlag, Berlin, 1975. (Review)

4-[D10]Leu-Insulin (Human) See Code PLP-3404-s on page 221.

Insulin (Human) Enzymatically Derived from Porcine InsulinA-chain: Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser-Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Asn

PlN-4088-s-20 °C

0.1 mg vial

166

PlN-4088-v-20 °C

0.5 mg vial

562

B-chain: Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu- Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Thr (Disulfide bonds between CysA6-CysA11,CysA7-CysB7, and CysA20-CysB19) (M.W. 5807.6) C257H383N65O77S6 [11061-68-0]K. Morihara, et al., Nature, 280, 412 (1979). (Semi-Synthesis) K. Morihara, et al., Biochem. Biophys. Res. Commun., 92, 396 (1980). (Semi-Synthesis)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 75

PRODUCT CODE QTY PRICE Joining PeptidesJoining Peptide (Rat)

Ala-Glu-Glu-Glu-Thr-Ala-Gly-Gly-Asp-Gly-Arg- Pro-Glu-Pro-Ser-Pro-Arg-Glu-NH2 (M.W. 1882.9) C75H119N25O32 Pivotal Neuropeptide in Cardiovascular RegulationT. Hamakubo, et al., Am. J. Physiol., 265, R1184 (1993). (Original) M. Yoshida, et al., Am. J. Physiol., 266, R802 (1994). (Pharmacol.)

PJP-4288-v-20 °C

0.5 mgvial

257

Kallidin See Code PBK-4008 Lysyl-Bradykinin on page 30.

Kisspeptins/Metasins

Metastasis suppressor gene KiSS-1 encodes a peptide with multiple biological functions such as inhibition of cancer metastasis, vasoconstriction, reproduction, and so on. In human and rat, the encoded mature peptide is composed of 54 and 52 amino acid resi-dues, respectively, which is named metastin or kisspeptin.1,2,3 Kisspeptin-10 (Human) / Metastin (Human, 45-54) is an active segment of the human peptide from the C-terminal portion and is already available from our catalog (PMT-4389-v). Very recently, in collabo-ration with Dr. Tsukamura and her colleagues in Nagoya University, Ihe Peptide Institute has successfully clarified that the corresponding rat 10-residue peptide, Kisspeptin-10 (Rat) / Metastin (Rat, 43-52), exerts the luteinizing hormone (LH) releasing activity in male rats4). Actually, intracerebroventricular or intravenously administration at a dose of 1 nmol/kg or 10 nmol/kg stimulates LH release and significantly increases plasma LH level in male rats. Now the precise experiment using Kisspeptin-10 (Rat) / Metastin (Rat, 43-52) is possible in rat studies.

T. Ohtaki, et al., Nature, 411, 613 (2001). (Metastin)M. Kotani, et al., J. Biol. Chem., 276, 34631 (2001). (Kisspeptin)Y. Terao, et al., Biochim. Biophys. Acta, 1678, 102 (2004). (Original; Rat Metastin)V. Pheng, et al., J. Reprod. Dev., 55, 378 (2009). (Pharmacol.)M.L. Gottsch, et al., Peptides, 30, 4 (2009). (Review)

Kisspeptin-10 (Human) / Metastin (Human, 45-54)*

PMT-4389-v-20 °C

0.5 mgvial

97

Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 (M.W. 1302.4) C63H83N17O14 [374675-21-5] Ligand for hOT7T175 / GPR54T. Ohtaki, et al., Nature, 411, 613 (2001). (Original; Metastin) A.I. Muir, et al., J. Biol. Chem., 276, 28969 (2001). (Original; Kisspeptin) M. Kotani, et al., J. Biol. Chem., 276, 34631 (2001). (Original; Kisspeptin) A. Hori, et al., Biochem. Biophys. Res. Commun., 286, 958 (2001). (Pharmacol.) M. Kinoshita, et al., Endocrinology, 146, 4431 (2005). (Pharmacol.) S. Ramaswamy, et al. Endocrinology, 148, 3364 (2007). (Pharmacol.) S.B. Seminara and U.B. Kaiser, Endocrinology, 146, 1686 (2005). (Minireview) K.I. Maeda, et al., Rev. Endocrinol. Metab. Disord., 8, 21 (2007). (Review)

* This compound is distributed through Peptide Institute, Inc. under the license of Takeda Pharmaceutical Company Limited.

76 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Kisspeptin-54 (Human) / Metastin (Human, 1-54)

PKS-4446-s-20 °C

0.5 mgvial

295

[Kp-54 (Human) / KiSS-1 Gene Product (Human, 68-121 Amide)]

Gly-Thr-Ser-Leu-Ser-Pro-Pro-Pro-Glu-Ser-Ser-Gly-Ser-Arg-Gln-Gln-Pro-Gly-Leu- Ser-Ala-Pro-His-Ser-Arg-Gln-Ile-Pro-Ala-Pro-Gln-Gly-Ala-Val-Leu-Val-Gln-Arg-Glu- Lys-Asp-Leu-Pro-Asn-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 (M.W. 5857.4) C258H401N79O78 Stimulator of Hypothalamic-Pituitary Gonadal Axis

Kisspeptin-52 (Human) / Metastin (Human, 1-52) Kp-52 (Rat) / KiSS-1 Gene Product (Rat, 68-119 Amide)

PMT-4447-s-20 °C

0.1 mgvial

375

Thr-Ser-Pro-Cys-Pro-Pro-Val-Glu-Asn-Pro-Thr-Gly-His-Gln-Arg-Pro-Pro-Cys- Ala-Thr-Arg-Ser-Arg-Leu-Ile-Pro-Ala-Pro-Arg-Gly-Ser-Val-Leu-Val-Gln-Arg- Glu-Lys-Asp-Met-Ser-Ala-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Tyr-NH2 (Disulfide bond between Cys4-Cys18) (M.W. 5836.6) C254H398N80O73S3 Stimulator of Hypothalamic-Pituitary Gonadal AxisY. Terao, et al., Biochim. Biophys. Acta.,1678,102 (2004). (Original; Rat Metastin)

Kisspeptin-10 (Rat) / Metastin (Rat, 43-52) Kp-10 (Rat) / KiSS-1 Gene Product (Rat, 110-119 Amide)

Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Tyr-NH2 (M.W. 1318.4) C63H83N17O15 Ligand for hOT7T175 / GPR54

PKS-4453-v-20 °C

0.5 mgvial

85

Laminin Laminin Pentapeptide YIGSR-NH2

Tyr-lle-Gly-Ser-Arg-NH2 (M.W. 593.68) C26H43N9O7 [110590-65-3]

PLP-4194-v-20 °C

0.5 mgvial

35

Laminin Pentapeptide YIGSR-NH2 (Bulk)Tyr-lle-Gly-Ser-Arg-NH2 • 2AcOH • 2H2O (M.W. 593.68 • 120.10 • 36.03) C26H43N9O7 • 2CH3COOH • 2H2OY. Iwamoto, et al., Science, 238, 1132 (1987). (Original)

PLP-4194-20 °C

25 mg100 mg

295824

Leu-Pro-Leu-Arg-Phe-NH2 • 2AcOH • 2H2O*

(M.W. 643.82 • 120.11 • 36.03) C32H53N9O5 • 2CH3COOH • 2H2O Chicken Brain PeptideG.J. Dockray, et al., Nature, 305, 328 (1983). (Original)

PBC-4144-20 °C

25 mg100 mg

327889


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 77

PRODUCT CODE QTY PRICE Linaclotide LinaclotideLinzess or Constella

LIN-3796-PI-20 °C

1 mg5 mg

6692675

(Trifluoroacetate Form)H-Cys-Cys-Glu-Tyr-Cys-Cys-Asn-Pro-Ala-Cys-Thr-Gly-Cys-Tyr-OH; (Disulfide bonds between Cys1-Cys6, Cys2-Cys10, Cys5-Cys13) (M.W. 1526.76) C59H79N15O21S6 [851199-59-2] Peptide Agonist of Gaunylate Cyclase 2c

Note: Bolar Exemption applies. This is a FDA-regulated product. It is the responsibility of the customer to ensure that he/she is complying with Federal rules. Peptides International cannot be liable for infringement of rights made by the user. W.D. Chey, et al., Am. J. Gastroenterol., 107, 1702 (2012). S. Rao, et al., Am. J. Gastroenterol., 107, 1714 ((2012). J.M. Johnston, et al., The Amer. J. of Gastroent., 104, 125 (2009).A.J. Lembo, et al., N. Eng. J. Med., 365, 527 (2011). G.F. Longstreth, et al., Gastroenterology, 130, 1480 (2006).

Liraglutide(Lys(γ-Glu-Palmitoyl)26,Arg34)-GLP-1 (7-37)

PGL-3781-PI-20 °C

1 mg5 mg

241963

H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu- Gly-Gln-Ala-Ala-Lys(γ-Glu-palmitoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH (M.W. 3751.29) C17H265N43O51 Glucagon-Like-Peptide-1 (GLP-1) Receptor AgonistJ.J.Neumiller, J. Am. Pharm. Assoc., 49, S16 (2009) M.C.Rossi and A.Nicolucci, Acta Biomed., 80, 93 (2009) C.F.Deacon, Vasc. Health Risk Manag., 5, 199 (2009)

Liraglutide is a long-acting analog of GLP-1 that has been developed for type-2 diabe-tes. Palmitoylation of a side chain elongated Lys residue facilitates bind to albumin. Cir-culating plasma albumin serves as a central slow-release reservoir for the noncovalently-bound Liraglutide which improves its half-life by reducing degradation by DPP IV and neutral endopeptidase (NEP). This GLP-1 agonist acts in a glucose-dependent manner and has been shown in studies to decrease appetite and maintain body weight. It may play an important role in the treatment of type 2 diabetes.

Note: Bolar Exemption applies. This is a FDA-regulated product. It is the responsibility of the customer to ensure that he/she is complying with Federal rules. Peptides International cannot be liable for infringement the user.

Liver-Cell Growth FactorLiver-Cell Growth Factor (Bulk) PLC-4022

-20 °C

25 mg100 mg

97204Gly-His-Lys • AcOH • H2O

(M.W. 340.38 • 60.05 • 18.02) C14H24N6O4 • CH3COOH • H2O [72957-37-0]

L. Pickart, et al., Biochem. Biophys. Res. Commun., 54, 562 (1973). (Original)

78 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE LixisenatideLixisenatide

H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-

LIX-3799-PI-20 °C

1 mg5 mg

4931980

Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH2 H-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2 (M.W. 4858.49) C215H347N61O65S [827033-10-3] GLP-1 Receptor Agonist

Note: Bolar Exemption applies. This is a FDA-regulated product. It is the responsibility of the customer to ensure that he/she is complying with Federal rules. Peptides International cannot be liable for infringement the user. M. Christensen, et al., IDrugs, 12, 503 (2009).

LL-37 Cathelicidin Antimicrobial PeptideLL-37 (Human)

Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile- Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp- Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser (M.W. 4493.30) C205H340N60O53 Cathelicidin Antimicrobial Peptide

PLL-4445-s-20 °C

0.1 mgvial

150

Antimicrobial peptides (often abbreviated as AMPs) play essential roles in self-defense systems. Defensins are potential protecting factors against microbial infection and members of AMPs in human: we have been offering α-defensin-1 (PDF-4271), -2 (PDF-4428), -3 (PDF-4416), -4 (PDF-4431), -5 (PDF-4415), and -6 (PDF-4458), as well as β-defensin-1 (PDF-4337), -2 (PDF-4338), -3 (PDF-4382), and -4 (PDF-4406) as our catalog items. Another member of AMP in human is LL-37, the so-called cathelicidin AMP.1,2 Cathelicidins are one family of multifunctional AMPs, characterized by conserved pro-peptide sequences that have been identified in several mammalian species. On the contrary to disulfide cross-linked defensins, LL-37 is a linear, amphipathic peptide with α-helical structure. LL-37 is reported to exert not only antimicrobial activity but also immunomodulatory activity.2,3 Recent papers describe the involvement of LL-37 in toll-like receptor (TLR) activation: i) vitamin D receptor-mediated induction of LL-37 through TLR2/1L activation was observed in human monocyte4 and ii) LL-37 interacts to self-DNA in psoriasis, after which the complex formed triggers TLR9, resulting in the induction of interferon-α production.5 In the latter special case, LL-37 might be the pathogenic factor of psoriasis, one of the autoimmune diseases, although LL-37, together with β-defensin-2, is reported to be highly expressed in psoriasis to protect the infection with Staphylococcus aureus.6 Thus, LL-37 should be valuable in the research of human defense systems, especially to clarify the mechanism of innate immunity and LL-37’s role in autoimmunity and cancer.7

G.H. Gudmundsson, et al., Eur. J. Biochem., 238, 325 (1996). (Original)R. Bals and J.M. Wilson, Cell. Mol. Life Sci., 60, 711 (2003). (Review)M. Zanetti, J. Leukoc. Biol., 75, 39 (2004). (Review)P.T. Liu, et al., Science, 311, 770 (2006). (Pharmacol.)R. Lande, et al., Nature, 449, 564 (2007). (Pharmacol.)P.Y. Ong, et al., New Engl. J. Med., 347, 1151 (2002). (Pharmacol.)D.W. Hoskin and A. Ramamoorthy, Biochim. Biophys. Acta, 1778, 357 (2008). (Review)Y.P. Lai and R.L. Gallo, Trends Immunol., 30, 131 (2009). (Review)M.F. Burton and P.G. Steel, Nat. Prod. Rep., 26, 1572 (2009). (Review)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 79

PRODUCT CODE QTY PRICE LugduninLugdunin


LUG-3871-PI-20 °C

0.5 mg1 mg

6421605

cyclo(d-Leu-Val-d-Val-2-[1S-1-amino-2-methylpropyl]-Thiapro-D-Val-Trp) (M.W. 783.05) C40H62N8O6SAntibiotic Produced by S. lugdunensis; Shown to Inhibit Growth of S. aureus and Prevent its Colonization.

A. Zipperer, et al., Nature, 535, 511 (2016).

Luteinizing Hormone-Releasing Hormone (LH-RH) LH-RH (Human) Luteinizing Hormone Releasing Hormone (Human) (GnRH (Gonadotropin-Releasing Hormone) (Human) (Porcine, Rat)

Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 (M.W. 1182.3) C55H75N17O13 [33515-09-2]

PLR-4013-v-20 °C

0.5 mgvial

35

LH-RH (Human) (Bulk) Luteinizing Hormone Releasing Hormone (Human) (GnRH (Gonadotropin-Releasing Hormone) (Human) (Porcine, Rat)

PLR-4013-20 °C

25 mg100 mg

4351150

Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 • 2AcOH • 4H2O (M.W. 1182.3 • 120.10 • 72.06) C55H75N17O13 • 2CH3COOH • 4H2O [71447-49-9]H. Matsuo, et al., Biochem. Biophys. Res. Commun, 43, 1334 (1971). (Original)

b-Lipotropin (61-76) See Code PEN-4055-v a-Endorphin.b-Lipotropin (61-77) See Code PEN-4089-v γ-Endorphin.b-Lipotropin (Human, 61-91) See Code PEN-4060-v b-Endorphin (Human).

MagaininMagainin 1 (Frog, Xenopus laevis)

Gly-Ile-Gly-Lys-Phe-Leu-His-Ser-Ala-Gly-Lys-Phe- Gly-Lys-Ala-Phe-Val-Gly-Glu-Ile-Met-Lys-Ser (M.W. 2409.8) C112H177N29O28S [108433-99-4] Antimicrobial PeptideM. Zasloff, Proc. Natl. Acad. Sci. USA, 84, 5449 (1987). (Original)

PMG-4196-v-20 °C

0.5 mgvial

310

Mambalgin-1 See Code MAM-3778-PI.

MastoparanMastoparan (Wasp, Vespula lewisii)

Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2 (M.W. 1478.9) C70H131N19O15 [72093-21-1]

PMS-4107-v-20 °C

0.5 mgvial

81

80 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Mastoparan (Bulk) (Wasp, Vespula lewisii)

PMS-4107-20 °C

25 mg 1418

Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2 • 4AcOH • 6H2O (M.W. 1478.9 • 240.21 • 108.09) C70H131N19O15 • 4CH3COOH • 6H2O Y. Hirai, et al., Chem. Pharm. Bull., 27, 1942 (1979). (Original; Chem. Synthesis)

a-Mating Factora-Mating Factor* (Yeast, Saccharomyces cerevisiae)

Trp-His-Trp-Leu-Gln-Leu-Lys-Pro-Gly-Gln-Pro-Met-Tyr (M.W. 1684.0) C82H114N20O17S [59401-28-4]

PMF-4076-v-20 °C

0.5 mgvial

91

D. Stöetzler, et al., Eur. J. Biochem., 69, 397 (1976). (Original) T. Tanaka, et al., J. Biochem., 82, 1681 (1977). (Original) Y. Masui, et al., Biochem. Biophys. Res. Commun., 78, 534 (1977). (Chem. Synthesis)

Mast Cell Degranulating Peptide (MCD)MCD-Peptide** Mast Cell Degranulating Peptide (Honeybee, Apis mellifera)

PMC-4258-v-20 °C

0.5 mgvial

320

Ile-Lys-Cys-Asn-Cys-Lys-Arg-His-Val-Ile-Lys-Pro-His-Ile-Cys-Arg-Lys-Ile-Cys-Gly-Lys-Asn-NH2 (Disulfide bonds between Cys3-Cys15 and Cys5-Cys19) (M.W. 2587.2) C110H192N40O24S4 [32908-73-9] Voltage-Dependent K+ Channel BlockerE. Haberman, Science, 177, 314 (1972). (Review) M.R. Ziai, et al., J. Pharm. Pharmacol., 42, 457 (1990). (Review)

* This compound is distributed through Peptide Institute Inc., under the license of Suntory Limited.** This compound is distributed through Peptide Institute, Inc. under the license of The Salk Institute.** The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc.


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 81

PRODUCT CODE QTY PRICE Melanin-Concentrating Hormone and Related PeptidesMelanin-Concentrating Hormone (Human) MCH (Human)

PMC-4369-v-20 °C

0.5 mgvial

193

(Rat, Mouse) Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-Gln-Val (Disulfide bond between Cys7-Cys16) (M.W. 2386.8) C105H160N30O26S4 [128315-56-0] Appetite Boosting Peptide

Melanin-Concentrating Hormone (MCH) was isolated from salmon pituitary and was found to induce aggregation of melanin granules in melanophores. Later, a mammalian homolog was identified in rat hypothalamus as a 19 amino acid peptide with a single disulfide bond [Endocrinology, 125, 1660 (1989)]. Subsequently, the human MCH se-quence was found to be the same as that of the rat peptide.1 Interestingly, the MCH of hypothalamus was reported in 1996 to be involved in the regulation of body weight.2 Actually, the injection of MCH into the lateral ventricles increased food consumption in rats. Further evidence in the literature indicates that MCH-deficient mice are lean due to hypophagia.3

1 K.M. Knigge, et al., Peptides, 17, 1063 (1996). (Review) 2. D. Qu, et al., Nature, 380, 243 (1996). (Pharmacol.) 3. M. Shimada, et al., Nature, 396, 670 (1998). (Pharmacol.)4. J. Chambers, et al., Nature, 400, 261 (1999). (Pharmacol.; Ligand for Orphan SLC-1 Receptor)5. Y, Saito, et al., Nature, 400, 265 (1999). (Pharmacol.; Ligand for Orphan SLC-1 Receptor)

Ac-Arg-[Cys-Met-Ava-Arg- Val-Tyr-Ava-Cys]-NH2

Disulfide bond between Cys2 and Cys9

(M.W. 1167.49) C49H82N16O11S3 Ava = Aminovaleric acid Melanin Concentrating Hormone Receptor 1 Antagonist.M.A. Bednarek, et al., Biochemistry, 41, 6383 (2002)

PMC-3881-PI-20 °C

1 mg5 mg

85320

Ac-d-Arg-[Cys-Met-Leu-Asn-Arg- Val-Tyr-Arg-Pro-Cys]-NH2

Disulfide bond between Cys2 and Cys11

(M.W. 1449.80) C60H100N22O14S3 Melanin Concentrating Hormone Receptor 1 AgonistM.A. Bednarek, et al., J. Biol. Chem., 277, 13821 (2002).

PMC-3886-PI-20 °C

1 mg5 mg

3311322


82 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Melanocyte Stimulating Hormone (MSH) and Related Peptides

a-MSH a-Melanocyte Stimulating Hormone (Human, Porcine, Bovine, Rat, Mouse)

PMR-4057-v-20 °C

0.5 mgvial

75

Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg- Trp-Gly-Lys-Pro-Val-NH2 (M.W. 1664.9) C77H109N21O19S [581-05-5]T.H. Lee and A.B. Lerner, J. Biol. Chem., 221, 943 (1956). (Original; Porcine) R.A. Boissonnas, et al., Helv. Chim. Acta, 41, 1867 (1958). (Chem. Synthesis) R. Schwyzer, et al., Helv. Chim. Acta, 46, 870 (1963). (Chem. Synthesis) A.C.Y. Chang, et al., Proc. Natl. Acad. Sci. U.S.A., 77, 4890 (1980). (Nucleotide Seq.; Human)

MSH-Release Inhibiting Factor* (Bulk)(MIF)

PMI-4024-20 °C

25 mg100 mg

3361

Pro-Leu-Gly-NH2 • ½H2O (M.W. 284.35 • 9.01) C13H24N4O3 • ½ H2O [2002-44-0]A. Vivas and M.E. Celis, J. Endocrinol., 78, 1 (1978). (Pharmacol.)

[Nle4, d-Phe7]-b-MSH-Amide PMC-3669-PI-20 °C

1 mg5 mg

73292Ac-Ser-Tyr-Ser-Nle-Glu-His-d-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2

(M.W. 1646.88) C78H111N21O19 Melanocyte Stimulating Hormone Agonist / Melanocortin 1, 3, 4, and 5 Receptor AgonistT.K. Sawyer, et al., Proc. Natl. Acad. Sci., 77, 5754 (1980).

Ac-His-d-Phe(p-Iodo)-Arg-Trp-NH2

(M.W. 811.69) C34H42N11O5I Melanocortin Receptor 1/4/5 Agonist / Receptor 3 Antagonist J.R. Holder, et al., J. Med. Chem., 45, 3073-3081 (2002).

PMC-3684-PI-20 °C

1 mg5 mg

73209

Ac-Nle-cyclo [Asp-His-d- Phe-Arg-Trp-Lys]-NH2Melanotan II, MT-II

(M.W. 1024.2) C50H69N15O9 Potent Melanocortin 1, 3, 4 and 5 Receptor Agonist F. Al-Obeidi, et al., J. Med. Chem., 32, 174 (1989).

PMC-3683-PI-20 °C

1 mg5 mg

73292

Ac-Tyr-Val-Nle-Gly-His-d-Phe- Arg-Trp-Asp-Arg-Phe-Gly-NH2

(M.W. 1593.83) C77H104N22O16 Melanocortin 1, 3, 4 and 5 Receptor AgonistM. Cai, et al., J. Med. Chem., 48, 1839 (2005).

PMC-3685-PI-20 °C

1 mg5 mg

53209

cyclo [CO-(CH2)2-CO-d- Nal(2’)-Arg-Trp-Lys]-NH2

(M.W. 766.88) C40H48N9O7 Melanocortin 4 Receptor AntagonistM.A. Bednarek, et al., J. Med. Chem., 44, 3665 (2001).

PMC-3887-PI-20 °C

1 mg5 mg

53209



BIOLO


Order Hotline 1-800-777-4779 502-266-8787 83

PRODUCT CODE QTY PRICE Metastin See Kisspeptin.

MHC-class I-restricted epitope in hgp100

Cytotoxic T cells or CD8+ T cells play an important role in the immune defense and destruction of tumor and infected cells. They are capable of recognizing antigen (Ag) associated with major histo compatibility complex (MHC) class I molecules on these target cells. Following Ag stimula-tion, T cells are selected to undergo clonal selection and proliferation in the thymus if they have low autoreactivity to self antigens, leading to an appropriate immune response. Recognition of tumor antigens by T cells has prompted interest and research in antigen-based cancer vaccines. Progress was initially hampered by the lack of responsiveness to tumor antigens in clinical trials by T cells, probably because these Ags are expressed on normal as well as tumor cells; therefore the level of autoreactivity is too high to lead to clonal selection of specific T cells. One of these candidate Ags is gp100; an antigen expressed on normal melanocytes as well as malignant melanomas. Later studies observed that xenogeneic immunization of mice with human gp100 (hgp100) could activate gp100 specific T cells, while mouse gp100 (mgp100) could not.1 In addition, in vivo studies found that reactive gp100 specific T cells followed by recombinant IL-2 treatment dramatically reduced pulmonary metastases.1 Further investigation determined Db to be the MHC class I molecule restricting gp100 recognition and its epitope to be hgp100 (25-33).1 The peptide epitope hgp100 (25-33) was observed to have stronger binding affinity to Db than mgp100 (25-33) and could be used to activate T cells for adoptive therapy in the syngeneic mouse melanoma model.1,2 The peptide epitope can be referred to as a heteroclitic epitope or an altered peptide that is more efficient at inducing T cell activation. Immunization of mice with a minigene encoding the heteroclitic epitope produced specific T cells that protected mice challenged with B16 melanoma, just as effectively as mice immunized with full length hgp100 DNA.

W.W. Overwijk, et al., J. Exper. Med., 188, 277 (1998).J.S. Gold, et al., J. Immunol., 170, 5188 (2003).

H-Lys-Val-Pro-Arg-Asn- Gln-Asp-Trp-Leu-OHKVPRNQDWL

Human GP 100 (25–33) (M.W. 1155.33) C52H82N16O14 MHC-class I-Restricted Epitope in hgp100 Heteroclitic MHC Class I Epitope in hgp100.

W.W. Overwijk, et al., J. Exp. Med., 188, 277 (1998).J.S. Gold, et al., J. Immunol., 170, 5188 (2003)

PCP-3922-PI-20 °C

1 mg5 mg

59209

84 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE MidkinesMidkine (Human)* **

Lys-Lys-Lys-Asp-Lys-Val-Lys-Lys-Gly-Gly-Pro-Gly-Ser-Glu-Cys-Ala-Glu-Trp-Ala-Trp-Gly-Pro-Cys-Thr-Pro-Ser-Ser-Lys-Asp-Cys-Gly-Val-Gly-Phe-Arg-Glu-Gly-Thr-Cys-Gly-Ala-Gln-Thr-Gln-Arg-Ile-Arg-Cys-Arg-Val-Pro-Cys-Asn-Trp-Lys-Lys-Glu-Phe-Gly-Ala-Asp-Cys-Lys-Tyr-Lys-Phe-Glu-Asn-Trp-Gly-Ala-Cys-Asp-Gly-Gly-Thr-Gly-Thr-Lys-Val-Arg-Gln-Gly-Thr-Leu-Lys-Lys-Ala-Arg-Tyr-Asn-Ala-Gln-Cys-Gln-Glu-Thr-Ile-Arg-Val-Thr-Lys-Pro-Cys-Thr-Pro-Lys-Thr-Lys-Ala-Lys-Ala-Lys-Ala-Lys-Lys-Gly-Lys-Gly-Lys-Asp

PMK-4298-v-20 °C

50 µgvial

428

(Disulfide bonds between Cys15-Cys39, Cys23-Cys48, Cys30-Cys52, Cys62-Cys94, and Cys72-Cys104) (M.W. 13240.1) C570H915N177O167S10 [170138-17-7] Heparin-Binding Growth/Differentiation Factor (Neurotrophic Factor, Neurite Outgrowth-Promoting Factor) Plasminogen Activator Activity EnhancerJ.-I. Tsutsui, et al., Biochem. Biophys. Res. Commun., 176, 792 (1991). H. Muramatsu, et al., Biochem. Biophys. Res. Commun., 203, 1131 (1994). T. Inui, et al., J. Peptide Sci., 2, 28 (1996). (Chem. Synthesis) G.S.P. Yu, et al., Neurosci. Lett., 254, 128 (1998). (Pharmacol.; Inhibition of b-amyloid cytotoxicity)

Midkine (Human, 60-121)**Ala-Asp-Cys-Lys-Tyr-Lys-Phe-Glu-Asn-Trp-Gly-Ala-Cys-Asp-Gly-Gly-Thr-Gly-Thr-Lys-Val-Arg-Gln-Gly-Thr-Leu-Lys-Lys-Ala-Arg-Tyr-Asn-Ala-Gln-Cys-Gln-Glu-Thr-Ile-Arg-Val-Thr-Lys-Pro-Cys-Thr-Pro-Lys-Thr-Lys-Ala-Lys-Ala-Lys-Ala-Lys-Lys-Gly-Lys-Gly-Lys-Asp

PMK-4299-s-20 °C

0.1 mgvial

428

(Disulfide bonds between Cys62-Cys94 and Cys72-Cys104) (M.W. 6788.8) C292H483N91O87S4 Heparin-Binding Growth/Differentiation Factor Active-Domain (Neurite Outgrowth-Promoting Factor) Plasminogen Activator Activity Enhancer J.-i. Tsutsui, et al., Biochem. Biophys. Res. Commun., 176, 792 (1991). (Original)H. Muramatsu, et al., Biochem. Biophys. Res. Commun., 203, 1131 (1994). T. Inui, et al., J. Peptide Sci., 2, 28 (1996). (Chem. Synthesis)G.S.P. Yu, et al., Neurosci. Lett., 254, 128 (1998). (Pharmacol.; Inhibition of b-amyloid cytotoxicity)

Molluscan Cardioexcitatory NeuropeptideFMRF-Amide* Molluscan Cardioexcitatory Neuropeptide

PFM-4142-v-20 °C

0.5 mgvial

33

Phe-Met-Arg-Phe-NH2 (M.W. 598.76) C29H42N8O4S [64190-70-1]

FMRF-Amide* (Bulk) PFM-4142-20 °C

25 mg100 mg

295846

Phe-Met-Arg-Phe-NH2 • 1½ AcOH • 2H2O (M.W. 598.76 • 90.08 • 36.03) C29H42N8O4S • 11⁄2CH3COOH • 2H2OD.A. Price and M.J. Greenberg, Science, 197, 670 (1977). (Original)

* The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc.** This product is distributed under the license of Prof. Takashi Muramatsu. Its use for any purpose other than research is strictly prohibited.


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 85

PRODUCT CODE QTY PRICE Morphine Tolerance PeptideMorphine Tolerance Peptide (Bulk)

cyclo (Leu-Gly) (M.W. 170.21 ) C8H14N2O2 [5845-67-0]R. Walter, et al., Proc. Natl. Acad. Sci. USA, 76, 518 (1979). (Original)

PMT-4070-20 °C

25 mg100 mg

540140

MotilinMotilin (Human, Porcine)

Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu-Gln-Arg- Met-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Gly-Gln (M.W. 2699.0) C120H188N34O35S [52906-92-0]

PML-4147-v-20 °C

0.5 mgvial

375

J.C. Brown, et al., Can. J. Biochem., 51, 533 (1973). (Original; Porcine) H. Schubert and J.C. Brown, Can. J. Biochem., 52, 7 (1974). (Correction of Sequence; Gln14) Y. Seino, et al., FEBS Lett., 223, 74 (1987). (Original; Human-cDNA) C.H.S. McIntosh and J.C. Brown, Adv. Metab. Dis., 11, 439 (1988). (Review)

MSH See Code PMI-4024 MSH-Release Inhibiting Factor.Muramyl Dipeptide See Code PAD-4031 Adjuvant Peptide.

Neuroendocrine Regulatory Peptides

“Peptidome”, one of the principle research fields in the post-genome era, is a powerful method to discover novel peptides. One such study has been reported recently from the collaboration of several groups including National Cardiovascular Center Research Institute and University of Miyazaki. The peptides disclosed are neuroendocrine regula-tory peptide-1 and -2 (abbreviated as NERP-1 and NERP-2, respectively). Both peptides were isolated either from medullary thyroid carcinoma TT cells or rat brain applying mod-ern techniques of peptide chemistry / biochemistry. Human and rat NERP-1 are com-posed of 26 and 25 amino acid residues, respectively, and NERP-2 of both species are composed of 38 amino acid residues, all contain the carboxyl-terminal amide functional-ity. Interestingly, these peptides were the segments of the neurosecretory protein VGF, suggesting a unique processing signal for NERP-2.

NERP-1 (Human): RPESALLGGSEAGERLLQQGLAQVEA-NH2NERP-1 (Rat): LEGSFLGGSEAGERLLQQGLAQVEA-NH2NERP-2 (Human): <EAEATRQAAAQEERLADLASDLLLQYLLQGGARQRGLG-NH2NERP-2 (Rat): <EAEATRQAAAQEERLADLASDLLLQYLLQGGARQRDLG-NH2

Biological activity reported is: i) suppression of vasopressin release induced by intracere-broventricular administration of angiotensin II in rat and ii) suppression of basal and an-giotensin II-induced vasopressin secretion from the paraventricular and supraoptic nuclei of rat hypothalamus in vitro. Considering the fact that NERPs coexist with vasopressin in the hypothalamus, these newly identified peptides may be “potent endogenous suppres-sor of vasopressin release”, thus implying an essential role in body fluid homeostasis.

H. Yamaguchi, et al., J. Biol., Chem., 282, 26354 (2007). (Original)E. Mishiro-Sato, et al., J. Neurochem., 114, 1097 (2010). (Processing & Histochem.)

* These compounds are distributed through Peptide Institute, Inc. under the license of Takeda Pharmaceutical Co. Ltd.

86 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Neuroendocrine Regulatory Peptide-1 (Human) NERP-1 (Human)

PNR-4441-s-20 °C

0.1 mgvial

113

RPESALLGGSEAGERLLQQGLAQVEA-NH2 H-Arg-Pro-Glu-Ser-Ala-Leu-Leu-Gly-Gly-Ser-Glu-Ala-Gly-Glu- Arg-Leu-Leu-Gln-Gln-Gly-Leu-Ala-Gln-Val-Glu-Ala-NH2 (M.W. 2679.0) C113H192N36O39 [954420-50-9] Endogenous Suppressor of Vasopressin ReleaseH. Yamaguchi, et al., J. Biol. Chem., 282, 26354 (2007). (Original)

Neuroendocrine Regulatory Peptide-1 (Rat) NERP-1 (Rat)

LEGSFLGGSEAGERLLQQGLAQVEA-NH2 H-Leu-Glu-Gly-Ser-Phe-Leu-Gly-Gly-Ser-Glu-Ala-Gly-Glu-Arg-Leu-Leu-Gln-Gln-Gly-Leu-Ala-Gln-Val-Glu-Ala-NH2 (M.W. 2558.8) C110H180N32O38 Endogenous Suppressor of Vasopressin ReleaseH. Yamaguchi, et al., J. Biol. Chem., 282, 26354 (2007). (Original)

PNR-4442-s-20 °C

0.1 mgvial

113

Neuroendocrine Regulatory Peptide-2 (Human) NERP-2 (Human)

PNR-4443-s-20 °C

0.1 mgvial

161

EAEATRQAAAQEERLADLASDLLLQYLLQGGARQRGLG-NH2 Pyr-Ala-Glu-Ala-Thr-Arg-Gln-Ala-Ala-Ala-Gln-Glu-Glu-Arg-Leu-Ala-Asp-Leu-Ala-Ser- Asp-Leu-Leu-Leu-Gln-Tyr-Leu-Leu-Gln-Gly-Gly-Ala-Arg-Gln-Arg-Gly-Leu-Gly-NH2

(M.W. 4064.5) C173H288N56O57 Endogenous Suppressor of Vasopressin ReleaseH. Yamaguchi, et al., J. Biol. Chem., 282, 26354 (2007). (Original)

Neuroendocrine Regulatory Peptide-2 (Rat) NERP-2 (Rat)

PNR-4444-s-20 °C

0.1 mgvial

161

EAEATRQAAAQEERLADLASDLLLQYLLQGGARQRDLG-NH2 Pyr-Ala-Glu-Ala-Thr-Arg-Gln-Ala-Ala-Ala-Gln-Glu-Glu-Arg-Leu-Ala-Asp-Leu-Ala-Ser- Asp-Leu-Leu-Leu-Gln-Tyr-Leu-Leu-Gln-Gly-Gly-Ala-Arg-Gln-Arg-Asp-Leu-Gly-NH2 (M.W. 4122.5) C175H290N56O59 Endogenous Suppressor of Vasopressin Release H. Yamaguchi, et al., J. Biol. Chem., 282, 26354 (2007). (Original)

Neo-Endorphins

a-Neo-Endorphin (Porcine) PEN-4090-v-20 °C

0.5 mgvial

86

Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro-Lys (M.W. 1228.4) C60H89N15O13

K. Kangawa, et al., Biochem. Biophys. Res. Commun., 99, 871 (1981). (Original)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 87

PRODUCT CODE QTY PRICE b-Neo-Endorphin (Porcine)

Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro (M.W. 1100.3) C54H77N13O12 [77739-21-0]

PEN-4091-v -20 °C

0.5 mg vial

86

N. Minamino, et al., Biochem. Biophys. Res. Commun., 99, 864 (1981). (Original)

NesfatinsNesfatin-1 (Human)Nucleobindin-2 (25-106) (Human), NUCB2 (25-106) (Human),DNA-Binding Protein NEFA (25-106) (Human), Gastric Cancer Antigen Zg4 (25-106) (Human)

NES-3863-PI-20 °C

0.5 mg1 mg

25684494

H-Val-Pro-Ile-Asp-Ile-Asp-Lys-Thr-Lys-Val-Gln-Asn-Ile-His-Pro-Val-Glu-Ser-Ala-Lys-Ile-Glu-Pro-Pro-Asp-Thr-Gly-Leu-Tyr-Tyr-Asp-Glu-Tyr-Leu-Lys-Gln-Val-Ile-Asp-Val-Leu-Glu-Thr-Asp-Lys-His-Phe-Arg-Glu-Lys-Leu-Gln-Lys-Ala-Asp-Ile-Glu-Glu-Ile-Lys-Ser-Gly-Arg-Leu-Ser-Lys-Glu-Leu-Asp-Leu-Val-Ser-His-His-Val-Arg-Thr-Lys-Leu-Asp-Glu-Leu-OH (M.W. 9551.95) C427H691N113O134 NEFA Encoded Satiety and Fat-Influencing Protein I.S. Oh, et al., Nature, 443, 709 (2006). M.G.Myers, Jr., Nat Med, 12, 1248 (2006).

Nesfatin-1 (30-59) (Human) NES-3740-PI-20 °C

1 mg5 mg

200800H-Tyr-Asp-Glu-Tyr-Leu-Lys-Gln-Val-Ile-Asp-Val-Leu-Glu-Thr-Asp-

Lys-His-Phe-Arg-Glu-Lys-Leu-Gln-Lys-Ala-Asp-Ile-Glu-Glu-Ile-OH (M.W. 3709.20) C167H263N41O54 Active Fragment of Nesfatin-1; Anorexigenic PeptideI.S. Oh, et al., Nature, 443, 709 (2006). A.Stengel, et al., Peptides, 35, 143 (2012). M.G.Myers, Jr., Nat Med, 12, 1248 (2006). M.Goebel, et al., Peptides, 32, 36 (2011).

Nesfatin-1 (Rat)NEFA Encoded Satiety and Fat-Influencing Protein DNA-Binding Protein NEFA (1-82) (Rat)

NES-3864-PI-20 °C

0.5 mg1 mg

25684494

H-Val-Pro-Ile-Asp-Val-Asp-Lys-Thr-Lys-Val-His-Asn-Val-Glu-Pro-Val-Glu-Ser-Ala-Arg-Ile- Glu-Pro-Pro-Asp-Thr-Gly-Leu-Tyr-Tyr-Asp-Glu-Tyr-Leu-Lys-Gln-Val-Ile-Glu-Val-Leu-Glu- Thr-Asp-Pro-His-Phe-Arg-Glu-Lys-Leu-Gln-Lys-Ala-Asp-Ile-Glu-Glu-Ile-Arg-Ser-Gly-Arg- Leu-Ser-Gln-Glu-Leu-Asp-Leu-Val-Ser-His-Lys-Val-Arg-Thr-Arg-Leu-Asp-Glu-Leu-OH (M.W. 9582.88) C424H684N116O136

I.S. Oh, et al., Nature, 443, 709 (2006). M.G.Myers, Jr., Nat Med, 12, 1248 (2006).

Nesfatin-1 Like Peptide (Mouse)H-Val-Pro-Val-Asp-Arg-Ala-Ala-Pro-Pro-Gln-Glu-Asp-Ser-Gln-Ala-Thr-Glu-Thr-Pro-Asp-Thr-Gly-Leu-Tyr-Tyr-His-Arg-Tyr-Leu-Gln-Glu-Val-Ile-Asn-Val-Leu-Glu-Thr-Asp-Gly-His-Phe-Arg-Glu-Lys-Leu-Gln-Ala-Ala-Asn-Ala-Glu-Asp-Ile-Lys-Ser-Gly-Lys-Leu-Ser-Gln-Glu-Leu-Asp-Phe-Val-Ser-His-Asn-Val-Arg-Thr-Lys-Leu-Asp-Glu-Leu-OH

NES-3865-PI-20 °C

0.5 mg1 mg

25684494

(M.W. 8738.67) C382H599N107O128

N. Ramesh, et al., Gen. Comp. Endocrinol., 216, 182 (2015).

88 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE NeurokininsNeurokinin A* Neuromedin L, Substance K (Human, Porcine, Rat, Mouse)

PNK-4154-v-20 °C

0.5 mgvial

54

His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2 (M.W. 1133.3) C50H80N14O14S [86933-74-6]

Neurokinin A* (Bulk) PNK-4154-20 °C

25 mg 760

His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2 • 2AcOH • 5H2O (M.W. 1133.3 • 120.10 • 90.08) C50H80N14O14S • 2CH3COOH • 5H2O NK2 Receptor Selective Agonist S. Kimura, et al., Proc. Jpn. Acad., 59 (B), 101 (1983). (Original; Porcine Neurokinin A) K. Kangawa, et al., Peptide Chemistry 1983, 309 (1984). (Original; Porcine Neuromedin L) H. Nawa, et al., Nature, 306, 32 (1983). (Original; Porcine Substance K) A.J. Harmar, et al., FEBS Lett., 208, 67 (1986). (cDNA Seq.; Human)

Neurokinin B (Neuromedin K)Neurokinin B

Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2 (M.W. 1210.4) C55H79N13O14S2 [86933-75-7]

PNP-4317-v-20 °C

0.5 mgvial

54

Neurokinin B (Bulk) Neuromedin K (Human, Porcine, Bovine, Rat, Mouse)

PNP-4317-20 °C

25 mg 760

Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2 • 1/2AcOH • 4H2O (M.W. 1210.4 • 30.03 • 72.06) C55H79N13O14S2 • 1/2CH3COOH • 4H2O NK3 Receptor Selective AgonistS. Kimura, et al., Proc. Jpn. Acad., 59 (B), 101 (1983). (Original; Porcine Neurokinin B) K. Kangawa, et al., Biochem. Biophys. Res. Commun., 114, 533 (1983). (Original; Porcine Neuromedin K) M.K. et al., J. Comp. Neurol., 384, 429 (1997). (Neurokinin B Nucleotide Seq.; Human) T.I. Bonner., et al., Mol. Brain Res., 2, 243 (1987). (cDNA Seq.; Rat)

NeuromedinsCPN-116

3-Cyclohexylpropionyl-Leu-Leu-A2pr-Pro-Arg-Asn-NH2

PNM-3408-v-20 °C

0.5 mgvial

100

A2pr =L-2,3-Diaminopropionic acid (M.W. 835.05) C39H70N12O8 Selective Agonist for Neuromedin U Receptor Type 2K. Takayama, et al., J. Med. Chem., 57, 6583 (2014)

Neuromedin B*Gly-Asn-Leu-Trp-Ala-Thr-Gly-His-Phe-Met-NH2 (M.W. 1132.3) C52H73N15O12S [87096-84-2]

PNM-4152-v-20 °C

0.5 mgvial

54



BIOLO


Order Hotline 1-800-777-4779 502-266-8787 89

PRODUCT CODE QTY PRICE Neuromedin B* (Bulk) (Human, Porcine, Rat)

PNM-4152-20 °C

25 mg 760

Gly-Asn-Leu-Trp-Ala-Thr-Gly-His-Phe-Met-NH2 • AcOH • 5H2O (M.W. 1132.3 • 60.05 • 90.08) C52H73N15O12S • CH3COOH • 5H2ON. Minamino, et al., Biochem. Biophys. Res. Commun., 114, 541 (1983). (Original; Porcine) I.M. Krane, et al., J. Biol. Chem., 263, 13317 (1988). (cDNA Seq.; Human) E. Wada, et al., J. Neurosci., 10, 2917 (1990). (cDNA Seq.; Rat)

Neuromedin C* Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2

PNM-4153-v-20 °C

0.5 mgvial

54

(M.W. 1120.3) C50H73N17O11S [81608-30-2]

Neuromedin C* (Bulk) Gastrin Releasing Peptide (Human, 18-27) GRP (18-27) (Human, Porcine, Canine)

PNM-4153-20 °C

25 mg 760

Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 • 2AcOH • 5H2O (M.W. 1120.3 • 120.11 • 90.08) C50H73N17O11S • 2CH3COOH • 5H2OK.A. Roth, et al., Biochem. Biophys. Res. Commun., 112, 528 (1983). (Original; GRP (18-27)) N. Minamino, et al., Biochem. Biophys. Res. Commun., 119, 14 (1984). (Original; Porcine Neuromedin C) M.S. Orloff, et al., Peptides, 5, 865 (1984). (Seq.; Human) J.R. Reeve, Jr., et al., J. Biol. Chem., 258, 5582 (1983). (Isolation & Seq.; Canine Bombesin-like Peptide)

Neuromedin S (Human)NMS (Human)

Ile-Leu-Gln-Arg-Gly-Ser-Gly-Thr-Ala-Ala-Val-Asp-Phe-Thr-Lys-Lys-Asp-His-Thr-Ala-Thr-Trp-Gly-Arg-Pro-Phe-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 (M.W. 3791.3) C173H265N53O44 Food Intake Suppressor / Regulator of Circadian Rhythm

PNM-4426-s-20 °C

0.1 mgvial

145

Neuromedin S (Rat)NMS (Rat)

Leu-Pro-Arg-Leu-Leu-His-Thr-Asp-Ser-Arg-Met-Ala-Thr-Ile-Asp-Phe-Pro-Lys-Lys-Asp-Pro-Thr-Thr-Ser-Leu-Gly-Arg-Pro-Phe-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 (M.W. 4241.9) C193H307N57O49S Food Intake Suppressor / Regulator of Circadian Rhythm

PNM-4427-s-20 °C

0.1 mgvial

156

Neuromedin U (Human) PNM-4490-v-20 °C

0.5 mgvial

200

NMU-25 (Human) Phe-Arg-Val-Asp-Glu-Glu-Phe-Gln-Ser-Pro-Phe- Ala-Ser-Gln-Ser-Arg-Gly-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 (M.W. 3080.4) C141H203N41O38 Food Intake Suppressor / Insulin Secretion SuppressorV.G. Martinez and L. O'Driscoll, Clin. Chem., 61, 471 (2015). (Review) R.W. Alfa, et al., Cell Metab., 21, 323 (2015). (Pharmacol.; Suppression of Insulin Secretion) C. Austin, et al., J. Mol. Endocrinol., 14, 157 (1995). (Original) P.J. Brighton, et al., Pharmacol. Rev., 56, 231 (2004). (Review)


90 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Neuromedin U (Mouse)

NMU-23 (Mouse) Phe-Lys-Ala-Glu-Tyr-Gln-Ser-Pro-Ser-Val-

PNM-4491-v-20 °C

0.5 mgvial

200

Gly-Gln-Ser-Lys-Gly-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 (M.W. 2706.0) C125H185N35O33 Food Intake SuppressorP.J. Brighton, et al., Pharmacol. Rev., 56, 231 (2004). (Review) V.G. Martinez and L. O'Driscoll, Clin. Chem., 61, 471 (2015). (Review)

Neuromedin U (Rat) NMU-23 (Rat)

Tyr-Lys-Val-Asn-Glu-Tyr-Gln-Gly-Pro-Val-Ala-Pro-Ser- Gly-Gly-Phe-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 (M.W. 2643.0) C124H180N34O31 [117505-80-3] Food Intake Suppressor

PNM-4377-v-20 °C

0.5 mgvial

268

J.M. Conlon, et al., J. Neurochem., 51, 988 (1988). (Original; Primary Structure) N. Minamino, et al., Biochem. Biophys. Res. Commun., 156, 355 (1988). (Original; Primary Structure) A.D. Howard, et al., Nature, 406, 70 (2000). (Pharmacol.) M. Nakazato, et al., Biochem. Biophys. Res. Commun., 277, 191 (2000). (Pharmacol.)

H-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2Neuromedin U8 Porcine

PNM-3698-PI -20 °C

1 mg5 mg

38149

YFLFRPRN-Amide (M.W. 1111.32) C54H78N16O10 NeuropeptideN. Minamino, et al., Biochem. Biophys. Res. Commun., 130, 1078 (1985).

* This compound is distributed through Peptide Institute, Inc. under the license of National Cardiovascular Center and Takeda Pharmaceutical Company Limited


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 91

PRODUCT CODE QTY PRICE NeuronostatinNeuronostatin-13 (Human) (Chimpanzee, Porcine, Canine, Ovine, Bovine, Chicken)

PNS-4452-v

-20 °C

0.5 mgvial

105

Leu-Arg-Gln-Phe-Leu-Gln-Lys-Ser-Leu-Ala-Ala-Ala-Ala-NH2 (M.W. 1415.7) C64H110N20O16 Brain/Gut Hormone in Pro-Somatostatin with Neuronal/Neuroendocrine/Cardiovascular Activity

In the post-genome era, a novel peptide called neuronostatin-13 has been predicted in pro-somatostatin gene sequence based on bioinformatics method. Neuronostatin-13 was purified from porcine tissue by immuno-affinity procedure and then confirmed to be an endogenous peptide. Actually, neuronostatin-13 is a 13 amino acid residue peptide with carboxyl-terminal amidation, the primary structure of which is conserved in human, chimpanzee and some other mammals.The biological functions of neuronostatin-13 reported so far include: i) intracerebroventric-ular administration of neuronostatin-13 in rats increased blood pressure but suppressed food intake and water drinking (0.3 nmol per rat)1), ii) in both brain and gastric cells, neuronostatin-13 stimulates c-Fos expression and cell proliferation/migration1, and iii) this peptide depresses cardiac contractile function.2 Thus, neuronostatin-13 might be a new member of brain/gut hormones. In addition, the function of neuronostatin-13 is not mediated by somatostatin receptors. Neuronostatin-13 with "diverse neuronal, neuroen-docrine, and cardiovascular actions" could be of interest in the research field of hormonal regulation of the body.

W.K. Samson, et al., J. Biol. Chem., 283, 31949 (2008). (Original; Structure & Pharmacol.)Y. Hua, et al., Am. J. Physiol. Regul. Integr. Comp. Physiol., 297, 682 (2009). (Pharmacol.)

NeuropeptidesNeuropeptide B-29 (Rat) (Non-Brominated Form)NPB-29 (Rat)

PNP-4459-v

-20 °C

0.5 mgvial

445

Trp-Tyr-Lys-Pro-Ala-Ala-Gly-Ser-His-His-Tyr-Ser-Val-Gly-Arg- Ala-Ala-Gly-Leu-Leu-Ser-Ser-Phe-His-Arg-Phe-Pro-Ser-Thr (M.W. 3188.5) C147H211N43O38 Synthetic Product Ligand of NPBWR1 (GPR7)R. Fujii, et al., J. Biol. Chem., 277, 34010 (2002). (Original; cDNA Sequence)H. Tanaka, et al., Proc. Natl. Acad. Sci. U.S.A., 100, 6251 (2003). (Pharmacol.)S. Aikawa, et al., Regul. Pept.,151,147 (2008). (Pharmacol.; Food Intake Regulatory Activity)N. Hirashima, et al., Sleep, 1, 31 (2011). (Pharmacol.; Slow Wave Sleep Induction Activity)

Neuropeptide S (Human)NPS (Human)

PNP-4425-v-20 °C

0.5 mgvial

2735

Ser-Phe-Arg-Asn-Gly-Val-Gly-Thr-Gly-Met-Lys- Lys-Thr-Ser-Phe-Gln-Arg-Ala-Lys-Ser (M.W. 2187.5) C93H155N31O28S [412938-67-1] Novel Modulator of Arousal and Anxiety / Food Intake SuppressorY.L. Xu, et al., Neuron, 43, 487 (2004). (Original)R.K. Reinscheid and Y.-L. Xu, FEBS J., 272, 5689 (2005). (Minireview)B. Beck, et al., Biochem. Biophys. Res. Commun., 332, 859 (2005). (Pharmacol.)K.L. Smith, et al., Endocrinology, 147, 3510 (2006). (Pharmacol.)A. Fedeli, et al., Eur. J. Neurosci., 30, 1594 (2009). (Pharmacol.)

92 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Neuropeptide W-30 (Human)* **NPW30 (Human) hL8C

PNP-4403-v-20 °C

0.5 mgvial

423

Trp-Tyr-Lys-His-Val-Ala-Ser-Pro-Arg-Tyr-His-Thr-Val-Gly-Arg- Ala-Ala-Gly-Leu-Leu-Met-Gly-Leu-Arg-Arg-Ser-Pro-Tyr-Leu-Trp (M.W. 3543.1) C165H249N49O37S [383415-80-3] Food Intake-Regulating Peptide / GPR7 / GPR8 Ligand

Neuropeptide W-30 (Rat)* **NPW30 (Rat), rL8C

PNP-4404-v-20 °C

0.5 mgvial

423

Trp-Tyr-Lys-His-Val-Ala-Ser-Pro-Arg-Tyr-His-Thr-Val-Gly-Arg- Ala-Ser-Gly-Leu-Leu-Met-Gly-Leu-Arg-Arg-Ser-Pro-Tyr-Leu-Trp (M.W. 3559.1) C165H249N49O38S [383415-90-5] Food Intake-Regulating Peptide / GPR7 / GPR8 Ligand Y. Shimomura, et al., J. Biol. Chem., 277, 35826 (2002). (Original; NPW) S. Brezillon, et al., J. Biol. Chem., 278, 776 (2003). (Original; hL8C) H. Tanaka, et al., Proc. Natl. Acad. Sci. USA, 100, 6251 (2003). (cDNA) M.S. Mondal, et al., Endocrinology, 144, 4729 (2003). (Pharmacol.) F. Takenoya, et al., Regul. Pept., 145, 159 (2008) (Pharmacol.)

Neuropeptide Y (NPY) and Related PeptidesY. Dumont, et al., Progr. Neurobiol., 38, 125 (1992). (Review). C. Wahlestedt and D.J. Reis, Annu. Rev. Pharmacol. Toxicol., 32, 309 (1993). (Review)

NPY (Human, Rat)* Neuropeptide Y (Human, Rat)

Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala- Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu- Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 (M.W. 4271.7) C189H285N55O57S [90880-35-6] Purity Information: Qp See page xiv

PNP-4158-s-20 °C

0.1 mg vial

156

PNP-4158-v-20 °C

0.5 mg vial

525

C.D. Minth, et al., Proc. Natl. Acad. Sci. U.S.A., 81, 4577 (1984). (Original; Human cDNA) D. Larhammer, et al., Proc. Natl. Acad. Sci. U.S.A., 84, 2068 (1987). (Original; Rat Nucleotide Seq.)

NPY (Porcine, Bovine)* Neuropeptide Y (Porcine, Bovine)

Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro- Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His- Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 (M.W. 4253.6) C190H287N55O57 [83589-17-7] Purity Information: Qp See page xiv

PNP-4162-s-20 °C

0.1 mg vial

156

PNP-4162-v-20 °C

0.5 mg vial

525

K. Tatemoto, Proc. Natl. Acad. Sci. USA, 79, 5485 (1982). (Original)

* This compound is distributed through Peptide Institute, Inc. under license of Takeda Chemical Industries, Ltd.** The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc.


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 93

PRODUCT CODE QTY PRICE [Leu31,Pro34]-NPY (Porcine) [Leu31,Pro34]-Neuropeptide Y (Porcine) (Bovine)

PNP-4314-s-20 °C

0.1 mg vial

156

Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-Ala- Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 (M.W. 4222.6) C190H286N54O56 [125580-28-1] NPY Y1-Receptor Selective Agonist Purity Information: Qp See page xiv J. Fuhlendorff, et al., Proc. Natl. Acad. Sci. USA, 87, 182 (1990). (Original) S.P. Sheikh, Am. J. Physiol., 261, G701 (1991). (Pharmacol.)

NPY (Porcine, 13-36) Neuropeptide Y (Porcine, 13-36) (Bovine)

PNP-4315-s-20 °C

0.1 mg vial

81

Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 (M.W. 2982.4) C135H209N41O36 [113662-54-7] NPY Y2-Receptor Selective Agonist M.W. Walker and R.J. Miller, Mol. Pharmacol., 34, 779 (1988). (Pharmacol.) J. Fuhlendorff, et al., Proc. Natl. Acad. Sci. USA, 87, 182 (1900). (Pharmacol.) S.P. Sheikh, Am. J. Physiol., 261, G701 (1991). (Pharmacol.)

NeurotensinsNeurotensin (Human, Bovine, Canine, Mouse)

Pyr-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu (M.W. 1672.9) C78H121N21O20 [55508-42-4]

PNT-4029-v-20 °C

0.5 mgvial

43

Neurotensin (Bulk) (Human, Bovine, Canine, Mouse)

PNT-4029-20 °C

25 mg 637

Pyr-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu • 2AcOH • 6H2O (M.W. 1672.9 • 120.10 • 108.09) C78H121N21O20 • 2CH3COOH • 6H2OR. Carraway and S.E. Leeman, J. Biol. Chem., 248, 6854 (1973). (Original; Bovine) R.A. Hammer, et al., J. Biol. Chem., 255, 2476 (1980). (Original; Human) P.R. Dobner, et al., Proc. Natl. Acad. Sci. U.S.A., 84, 3516 (1987). (cDNA Seq.; Canine) P.R. Dobner, et al., Proc. Natl. Acad. Sci. U.S.A., 98, 8048 (2001). (cDNA Seq.; Mouse)

VIP Antagonist(Trifluroacetate Form)

PVA-3757-PI-20 °C

1 mg5 mg

3401,360

H-Lys-Pro-Arg-Arg-Pro-Tyr-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys- Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2 (M.W. 3764.13) C154H257N49O40S [125093-93-8]

I.Gozes, et al., Endocrinology, 125, 2945 (1989) T.W.Moody, et al., Proc. Natl. Acad. Sci. USA, 90, 4345 (1993)

94 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE NociceptinNociceptin (Human) Orphanin FQ (Rat, Mouse, Bovine, Porcine)

PNO-4318-v-20 °C

0.5 mg vial

1930

Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln (M.W. 1809.0) C79H129N27O22 [170713-75-4] Agonist of Opioid Receptor-Like-1 (ORL1) ReceptorJ.-C. Meunier, et al., Nature, 377, 532 (1995). (Original; Nociceptin-ORL1 Receptor Agonist) R.K. Reinscheid, et al., Science, 270, 792 (1995). (Original; Orphanin FQ) C. Mollereau, et al., Proc. Natl. Acad.Sci. U.S.A., 93, 8666 (1996). (Original; Human, Rat, & Mouse Nociceptin-Nucleotide Seq.) J.C. Meunier, Eur. J. Pharmacol., 340, 1 (1997). (Review)G. Csaba and K. Tekes, Brain Dev., 27, 465 (2005). (Review)Z.S. Zadori, et al., Peptides, 29, 2257 (2008). (Pharmacol.)

NocistatinsNocistatin (Human)

Met-Pro-Arg-Val-Arg-Ser-Leu-Phe-Gln-Glu-Gln- Glu-Glu-Pro-Glu-Pro-Gly-Met-Glu-Glu-Ala- Gly-Glu-Met-Glu-Gln-Lys-Gln-Leu-Gln (M.W. 3561.9) C149H238N42O53S3 Endogenous Allodynia / Hyperalgesia-Blocking Peptide Nociceptin Action Blocking Peptide

PNO-4355-v-20 °C

0.5 mgvial

3860

T. Minami, et al., Br. J. Pharmacol., 124, 1016 (1998). (Original; Pharmacol.) C. Mollereau, et al, Proc. Natl. Acad. Sci. U.S.A., 93, 8666 (1996). (Original; Prepronociceptin Nucleotide Seq.) T.-L. Lee, et al., NeuroReport, 10,1537 (1999). (Original; Identification in Human) Z.S. Zadori, et al., Peptides, 29, 2257 (2008). (Pharmacol.)

Nocistatin (Bovine)(Ammonium Form) Thr-Glu-Pro-Gly-Leu-Glu-Glu-Val-Gly- Glu-Ile-Glu-Gln-Lys-Gln-Leu-Gln (M.W. 1927.1) C82H135N21O32 Endogenous Allodynia / Hyperalgesia-Blocking Peptide Nociceptin Action Blocking Peptide

PNO-4336-v-20 °C

0.5 mgvial

257

E. Okuda-Ashitaka, et al., Nature, 392, 286 (1998). (Original) B. Nicol, et al., Eur. J. Pharmacol., 356, R1 (1998). (Pharmacol.) T. Nakagawa, et al., Neurosci. Lett., 265, 64 (1999). (Pharmacol.) H. Nakano, et al., J. Pharmacol. Exp. Ther., 292, 331 (2000). (Pharmacol.) M. Fantin, et al., Br. J. Pharmacol., 152, 549 (2007). (Pharmacol.)

Obestatin and Related AnalogsObestatin (Human)(Human, Monkey)

H-Phe-Asn-Ala-Pro-Phe-Asp-Val-Gly-Ile-Lys-Leu-Ser-Gly-Val-Gln-Tyr-Gln-Gln-His-Ser-Gln-Ala-Leu-NH2 FNAPFDVGIKLSGVQYQQHSQAL-NH2 (M.W. 2546.89) C116H176N32O33 Suppressor of Food Intake and Gastric EmptyingJ.V. Zhang, et al., Science, 310, 996 (2005). M. Kojima, et al., Nature, 402, 656 (1999).

PGH-3890-PI-20 °C

1 mg5 mg

4281712


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 95

PRODUCT CODE QTY PRICE Obestatin (Rat, Mouse)

H-Phe-Asn-Ala-Pro-Phe-Asp-Val-Gly-Ile-Lys-Leu-Ser- Gly-Ala-Gln-Tyr-Gln-Gln-His-Gly-Arg-Ala-Leu-NH2 FNAPFDVGIKLSGAQYQQHGRAL-NH2 (M.W. 2516.87) C114H174N34O31 Suppressor of Food Intake and Gastric EmptyingJ.V. Zhang, et al., Science, 310, 996 (2005). M. Kojima, et al., Nature, 402, 656 (1999).

PGH-3891-PI-20 °C

1 mg5 mg

4281712

Des 1-10 Obestatin (Human)Obestatin (Human, 11-23)

H-Leu-Ser-Gly-Val-Gln-Tyr-Gln-Gln-His-Ser-Gln-Ala-Leu-NH2 H-LSGVQYQQHSQAL-NH2 (M.W. 1457.62) C63H100N20O20 Truncated Analog of ObestatinJ.V. Zhang, et al., Science, 310, 996 (2005). M. Kojima, et al., Nature, 402, 656 (1999).

PGH-3892-PI-20 °C

1 mg5 mg

64246

Des 1-10 Obestatin (Rat, Mouse) Obestatin (Rat, Mouse, 11-23)

H-Leu-Ser-Gly-Ala-Gln-Tyr-Gln-Gln-His-Gly-Arg-Ala-Leu-NH2 H-LSGAQYQQHGRAL-NH2 (M.W. 1427.60) C61H98N22O18 Truncated Analog of ObestatinJ.V. Zhang, et al., Science, 310, 996 (2005). M. Kojima, et al., Nature, 402, 656 (1999).

PGH-3893-PI-20 °C

1 mg5 mg

64246

OrexinsT. Sakurai, Regul. Pept., 85, 25 (1999). (Review) J.M. Siegel, Cell, 98, 409 (1999). (Review) L. De Lecea and J.G. Sutcliffe, Cell. Mol. Life Sci., 56, 473 (1999). (Review) R.J. Rodgers, et al., Neuropeptides, 36, 303 (2002). (Review)N. Tsujino and T. Sakurai, Pharmacol. Rev., 61, 162 (2009). (Review)M. Mieda and T. Sakurai, CNS Neurol. Disord. Drug Targets, 8, 281 (2009). (Review)B.C. Baccari, Curr. Protein Pept. Sci., 11, 148 (2010). (Review)

Orexin-A (Human) (Rat, Mouse, Bovine)

Pyr-Pro-Leu-Pro-Asp-Cys-Cys-Arg-Gln-Lys-Thr-Cys-Ser-Cys-Arg-Leu-Tyr-Glu-Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH2 (Disulfide bonds between Cys6-Cys12 and Cys7-Cys14) (M.W. 3561.1) C152H243N47O44S4 [205640-90-0] Appetite-Boosting Peptide / Sleep-Wakefulness State Regulator

POR-4346-s-20 °C

0.1 mgvial

250

T. Sakurai, et al., Cell, 92, 573 (1998). (Original) L. de Lecea, et al., Proc. Natl. Acad. Sci. U.S.A., 95, 322 (1998). (cDNA; Same Sequence [Hypocretin]) N. Takahashi, et al., Biochem. Biophys. Res. Commun., 254, 623 (1999). (Pharmacol.) T. Ida, et al. Biochem. Biophys. Res. Commun., 270, 318 (2000). (Pharmacol.)

96 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Orexin-A (Human, 17-33) (0.1 mg vial)OXA (17-33)

Tyr-Glu-Leu-Leu-His-Gly-Ala-Gly-Asn-His- Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH2 (M.W.1749.0) C79H125N23O22 [343268-91-7] Orexin-1 Receptor Selective Agonist

POR-4482-s-20 °C

0.1 mgvial

86

N.A. German, et al., ACS Med. Chem. Lett., 4, 1224 (2013). (Original; Structure-Activity Relationship & Pharmacol.)S. Asahi, et al., Bioorg. Med. Chem. Lett., 13, 111 (2003). (Original; Structure-Activity Relationship & Pharmacol.)J. Putura, et al., Neurosci. Lett., 494, 57 (2011). (Pharmacol.)

Orexin-B (Human)Arg-Ser-Gly-Pro-Pro-Gly-Leu-Gln-Gly-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Ala-Ser-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Met-NH2 (M.W. 2899.3) C123H212N44O35S [205640-91-1]

POR-4348-s-20 °C

0.1 mgvial

134

Appetite-Boosting Peptide / Sleep-Wakefulness State RegulatorT. Sakurai, et al., Cell, 92, 573 (1998). (Original) L. de Lecea, et al., Proc. Natl. Acad. Sci. U.S.A., 95, 322 (1998). (cDNA; Same Sequence [Hypocretin]) N. Takahashi, et al., Biochem. Biophys. Res. Commun., 254, 623 (1999). (Pharmacol.)

Orexin-B (Rat, Mouse)Hypocretin 2 (Rat, Mouse)

Arg-Pro-Gly-Pro-Pro-Gly-Leu-Gln-Gly-Arg-Leu-Gln-Arg-Leu-

POR-4347-s-20 °C

0.1 mgvial

134

Leu-Gln-Ala-Asn-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Met-NH2 (M.W. 2936.4) C126H215N45O34S [202801-92-1] Appetite-Boosting Peptide / Sleep-Wakefulness State Regulator Purity Information: Qp See page xivT. Sakurai, et al., Cell, 92, 573 (1998). (Original) L. de Lecea, et al., Proc. Natl. Acad. Sci. U.S.A., 95, 322 (1998). (cDNA; Same Sequence [Hypocretin]) N. Takahashi, et al., Biochem. Biophys. Res. Commun., 254, 623 (1999). (Pharmacol.) M.S. Mondal, et al., Biochem. Biophys. Res. Commun., 256, 495 (1999). (Distribution)

[Ala11, D-Leu15]-Orexin B (Human) Arg-Ser-Gly-Pro-Pro-Gly-Leu-Gln-Gly-Arg-Ala-Gln-Arg-Leu-D-Leu-Gln-Ala-Ser-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Met-NH2

POR-4483-s-20 °C

0.1 mgvial

107

(M.W. 2857.3) C120H206N44O35S [532932-99-3] Orexin-2 Receptor Selective AgonistN.A. German, et al., ACS Med. Chem. Lett., 4, 1224 (2013). (Original; Structure-Activity Relationship & Pharmacol.)S. Asahi, et al., Bioorg. Med. Chem. Lett., 13, 111 (2003). (Original; Structure-Activity Relationship & Pharmacol.)J. Putura, et al., Neurosci. Lett., 494, 57 (2011). (Pharmacol.)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 97

PRODUCT CODE QTY PRICE OsteocalcinsGla17,21,24-Osteocalcin (Human)* Osteocalcin (Human, Gla17,21,24)

POS-4262-s-20 °C

0.1 mgvial

1627

(Ammonium Form)Tyr-Leu-Tyr-Gln-Trp-Leu-Gly-Ala-Pro-Val-Pro-Tyr-Pro-Asp-Pro-Leu-Gla-Pro-Arg-Arg-Gla-Val-Cys-Gla-Leu-Asn-Pro-Asp-Cys-Asp-Glu-Leu-Ala-Asp-His-Ile-Gly-Phe-Gln-Glu-Ala-Tyr-Arg-Arg-Phe-Tyr-Gly-Pro-Val (Gla: l-γ-Carboxyglutamic acid) (Disulfide bond between Cys23-Cys29) (M.W. 5929.4) C269H381N67O82S2 [136461-80-8] Bone Gla Protein Purity Information: Qx See page xiv J.W. Poser, et al., J. Biol. Chem., 255, 8685 (1980). (Original) M. Nakao, et al., Pept. Res., 7, 171 (1994). (Chem. Synthesis) P.V. Hauschka, et al., Physiol. Rev., 69, 990 (1989). (Review)

Glu17,Gla21,24-Osteocalcin (Human)* Osteocalcin (Human, Glu17,Gla21,24)

POS-4261-s-20 °C

0.1 mgvial

1627

(Ammonium Form)Tyr-Leu-Tyr-Gln-Trp-Leu-Gly-Ala-Pro-Val-Pro-Tyr-Pro-Asp-Pro-Leu-Glu-Pro-Arg-Arg-Gla-Val-Cys-Gla-Leu-Asn-Pro-Asp-Cys-Asp-Glu-Leu-Ala-Asp-His-Ile-Gly-Phe-Gln-Glu-Ala-Tyr-Arg-Arg-Phe-Tyr-Gly-Pro-Val (Gla: l-γ-Carboxyglutamic acid) (Disulfide bond between Cys23-Cys29) (M.W. 5885.4) C268H381N67O80S2 Bone Gla Protein Purity Information: Qx See page xivJ.W. Poser, et al., J. Biol. Chem., 255, 8685 (1980). (Original) M. Nakao, et al., Pept. Res., 7, 171 (1994). (Chem. Synthesis) P.V. Hauschka, et al., Physiol. Rev., 69, 990 (1989). (Review)

OVA Peptide Fragment Also see MOG and Ac-MBP Fragments.OVA Peptide (257-264)Chicken Ovalbumin Fragment (257-264)

H-Ser-Ile-Ile-Asn-Phe-Glu-Lys-Leu-OH (M.W. 963.15) C45H74N10O13 T-cell Activating PeptideF.R. Carbone, et al., Int. Immunol. 4, 861 (1992).

POV-3659-PI-20 °C

1 mg5 mg

54209

OVA Peptide (323-339)‡

Chicken Ovalbumin Fragment (323-339)H-Ile-Ser-Gln-Ala-Val-His-Ala-Ala-His- Ala-Glu-Ile-Asn-Glu-Ala-Gly-Arg-OH (M.W. 1773.94) C74H120N26O25 T-cell Activating PeptideF. De Mattia, et al., J. Immunol., 163, 5929, (1999). S.-J. Sung, et al., J. Immunol., 166, 1261, (2001).

POV-3636-PI-20 °C

1 mg5 mg

95375

* This compound is produced by Peptide Institute, Inc. under the license of Mitsubishi Chemical Corporation and is distributed exclusively through Mitsubishi Chemical Corporation.‡ The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc.

98 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Oxyntomodulin, Glucagon-37 (Human, Mouse, Rat)Preproglucagon (53-89); Proglucagon (33-69); OXM

PGL-3826-PI-20 °C

1 mg5 mg

6422568

H-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala- Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-Lys-Arg-Asn-Arg-Asn-Asn-Ile-Ala-OH (M.W. 4449.93) C192H295N61O60S [159002-68-3] Inhibitor of Gastric Acid and Pancreatic Enzyme Secretions; Shown to Reduce Food Intake and Increase Energy Expenditure in Humans

Oxyntomodulin, Glucagon-37 (Porcine)H-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-Lys-Arg-Asn-Lys-Asn-Asn-Ile-Ala-OH

PGL-3827-PI-20 °C

1 mg5 mg

6422568

(M.W. 4421.92) C192H295N59O60S [62340-29-8] Inhibitor of Gastric Acid and Pancreatic Enzyme Secretion; Shown to Reduce Food Intake, and Increase Energy Expediture in HumansD.Bataille, et al., Peptides, 2, 41, (1981).D.Bataille, et al., Ann. N.Y. Acad. Sci., 527, 168 (1988).M.A.Cohen, et al., J. Clin. Endocrinol. Metab., 88, 4696 (2003).A. Pocai, Mol. Meta., b3, 241 (2014).

OxytocinsB. Berde (ed.), Neurohypophysial Hormones and Similar Polypeptides, Handbook of Experimental Pharmacology, Vol. 23, Springer-Verlag, Berlin, 1968. (Review)

Oxytocin* (Human, Porcine, Bovine, Rat, Ovine)

POX-4084-v-20 °C

0.5 mgvial

54

Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (Disulfide bond between Cys1-Cys6) (M.W. 1007.2) C43H66N12O12S2 [50-56-6]V. Du Vigneaud, et al., J. Biol. Chem., 205, 949 (1953). (Original) R.A. Boissonnas, et al., Helv. Chim. Acta, 38, 1491 (1955). (Chem. Synthesis) M. Zaoral and J. Rudinger, Collection Czech. Chem. Commun., 20, 1183 (1955). (Chem. Synthesis) A. Light and V. Du Vigneaud, Proc. Soc. Exp. Biol. Med., 98, 692 (1958). (Original; Human)

[Asu1,6]-Oxytocin* (Deamino-Dicarba-Oxytocin)

POX-4025-v-20 °C

0.5 mgvial

65

cyclo (Tyr-lle-Gln-Asn-Asu)-Pro-Leu-Gly-NH2 (cyclic form between Asu w-Carboxyl group and Tyr a-amino group) (Asu: l-a-Aminosuberic acid) (M.W. 956.10) C45H69N11O12 [14317-68-1] T. Yamanaka, et al., Mol. Pharmacol., 6, 474 (1970). (Original)



BIOLO


Order Hotline 1-800-777-4779 502-266-8787 99

PRODUCT CODE QTY PRICE PancreastatinsCatestatin (Human) (0.5 mg vial)Chromogranin A (Human, 352-372)

CHR-4470-v-20 °C

0.5 mgvial

180

Ser-Ser-Met-Lys-Leu-Ser-Phe-Arg-Ala-Arg-Ala- Tyr-Gly-Phe-Arg-Gly-Pro-Gly-Pro-Gln-Leu (M.W. 2326.70) C104H164N32O27S Antimicrobial Peptide/Regulator of Blood Pressure/Cardiac Function Synthetic Product D.S. Konecki, et al., J. Biol. Chem., 262, 17026 (1987). (Original; Chromogranin A cDNA) J. Briolat, et al., Cell. Mol. Life Sci., 62, 377 (2005). (Pharmacol.) B.S. Sahu, et al., Cell. Mol. Life Sci., 67, 861 (2010). (Review) S.K. Mahata, et al., Regul. Pept.,162,33 (2010). (Review)

Chromogranin A (Human, 286-301 Amide)

PCR-4214-v-20 °C

0.5 mgvial

145

(Hydrochloride Form) Glu-Glu-Glu-Glu-Glu-Met-Ala-Val-Val-Pro-Gln-Gly-Leu-Phe-Arg-Gly-NH2 (M.W. 1819.0) C78H123N21O27S [133605-57-9] Purity Information: Qe See page xivD.S. Konecki, U.M. Benedum, H.H. Gerdes, and W.B. Huttner, J. Biol. Chem., 262, 17026 (1987). (Original; cDNA)

[Pyr33]-Pancreastatin (Porcine, 33-49)Pyr-Glu-Glu-Glu-Glu-Glu-Thr-Ala-Gly- Ala-Pro-Gln-Gly-Leu-Phe-Arg-Gly-NH2 (M.W. 1829.9) C77H116N22O30

K. Tatemoto, et al., Nature, 324, 476 (1986). (Original)

PPP-4186-v -20 °C

0.5 mgvial

140

Parathyroid Hormone (PTH) and Related PeptidesParathyroid Hormone (Human, 1-84) PTH (Human, 1-84)

PTH-4134-v-20 °C

20 µgvial

257

Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu- Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-Ala-Pro-Leu-Ala-Pro-Arg- Asp-Ala-Gly-Ser-Gln-Arg-Pro-Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Glu-Lys-Ser- Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asn-Val-Leu-Thr-Lys-Ala-Lys-Ser-Gln PTH (1-84); Parathyrin (M.W. 9424.6) C408H674N126O126S2 [68893-82-3]G.N. Hendy, et al., Proc. Natl. Acad. Sci. U.S.A., 78, 7365 (1981). (Original; cDNA Sequence) T. Kimura, et al., Biochem. Biophys. Res. Commun., 114, 493 (1983). (Chem. Synthesis) H. Takasu, et al., Endocrinology, 137, 5537 (1996). (Pharmacol.)

Parathyroid Hormone (Human, 1-37) PTH (Human, 1-37)

PTH-3753-PI-20 °C

1 mg5 mg

3601439

(Trifluoroacetate Form)H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu- Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-OH (M.W. 4401.18) C195H316N58O54S2 [136799-54-7]C.P. Schmitt, et al., Kidney Int., 57, 1484 (2000).

100 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Parathyroid Hormone (Human, 1-34) PTH (Human, 1-34)

Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly- Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu- Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe (M.W. 4117.7) C181H291N55O51S2 [52232-67-4]

PTH-4068-v-20 °C

0.5 mgvial

396

M. Takai, et al., Peptide Chemistry 1979, 187 (1980). (Chem. Synthesis)

Parathyroid Hormone (Human, 1-31 Amide) PTH (Human, 1-31 Amide)

PTH-4324-v-20 °C

0.5 mgvial

386

Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn- Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-NH2 (M.W. 3718.3) C162H270N50O46S2 Adenylate Cyclase- / Bone Growth Stimulating PeptideR.H. Rixon, et al., J. Bone Miner. Res., 9, 1179 (1994) (Original) W. Neugebauer,et al., Biochemistry, 34, 8835 (1995). (Biochem.) J.F. Whitfield, and P. Morley, Trends Pharmacol. Sci., 16, 382 (1995). (Review) J.F. Whitfield, et al., Calcif. Tissue Int., 58, 81 (1996). (Pharmacol.)


PTH-4094-v-20 °C

0.5 mgvial

525

Ser-Val-Ser-Glu-lle-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu- Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-Ala-Pro-Leu-Ala-Pro-Arg (M.W. 5063.9) C225H366N68O61S2 [85568-24-7] Purity Information: Qx See page xiv T. Kimura, et al., Biopolymers, 20, 1823 (1981). (Chem. Synthesis)


Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp- Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe (M.W. 2808.2) C125H199N39O33S [81306-64-1]

PTH-4106-v-20 °C

0.5 mgvial

279

R. Nakamura, et al., Endocrinol. Jpn., 28, 547 (1981). (Pharmacol.; Hypotension) K. Sakaguchi, et al., J. Bone Miner. Res., 2, 83 (1987). (Pharmacol.)


PTH-4124-v-20 °C

0.5 mgvial

466

(Hydrochloride Form)Ala-Pro-Leu-Ala-Pro-Arg-Asp-Ala-Gly-Ser-Gln-Arg-Pro-Arg-Lys- Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Glu-Lys-Ser-Leu-Gly (M.W. 3285.6) C139H234N46O46 Purity Information: Qx See page xiv P. D’Amour, et al., J. Immunoass., 10, 191 (1989). (Radioimmunoassay) T. Yamaguchi, et al., Acta Endocrinol., 127, 267 (1992). (Biochem.; PTH Degradation) T. Yamaguchi, et al., Life Sci., 54, 381 (1994). (Biochem.; PTH Degradation)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 101

PRODUCT CODE QTY PRICE Parathyroid Hormone (Human, 39-84) PTH (Human, 39-84)

PTH-4169-v-20 °C

0.5 mgvial

525

Ala-Pro-Leu-Ala-Pro-Arg-Asp-Ala-Gly-Ser-Gln-Arg-Pro-Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu- Ser-His-Glu-Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asn-Val-Leu-Thr-Lys-Ala-Lys-Ser-Gln (M.W. 4984.5) C211H357N67O72 [90880-43-6]P. D’Amour, et al., J. Immunoass., 10, 191 (1989). (Biochem.; Presence in Circuration) T. Yamaguchi, M. Arao, and M. Fukase, Acta Endocrinol., 127, 267 (1992). (Biochem.; PTH Degradation) T. Yamaguchi, et al., Life Sci., 54, 381 (1994). (Biochem.; PTH Degradation)


PTH-4170-v-20 °C

0.5 mgvial

161

(Hydrochloride Form)Glu-Ala-Asp-Lys-Ala-Asp-Val-Asn-Val-Leu-Thr-Lys-Ala-Lys-Ser-Gln (M.W. 1716.9) C72H125 N21O27 Purity Information: Qe See page xivP. D’Amour, et al., J. Immunoass., 10, 191 (1989). (Radioimmunoassay) H. Takasu, et al., Endocrinology, 137, 5537 (1996). (Pharmacol.)

[Nle8,18,Tyr34]-Parathyroid Hormone (Human, 1-34) [Nle8,18,Tyr34]-PTH (Human, 1-34)

PTH-4129-v-20 °C

0.5 mgvial

446

Ser-Val-Ser-Glu-Ile-Gln-Leu-Nle-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser- Nle-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Tyr (Nle: l-Norleucine) (M.W. 4097.6) C183H295N55O52

T. Noda, et al., The 41st Annual Meeting of Chemical Society of Japan, Osaka, April 1980, Abstr. No 4S12. (Original)

[Nle8,18,Tyr34]-Parathyroid Hormone (Human, 18 1-34 Amide) [Nle8,18,Tyr34]-PTH (Human, 1-34 Amide)

PTH-4180-v-20 °C

0.5 mgvial

466

Ser-Val-Ser-Glu-Ile-Gln-Leu-Nle-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Nle- Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Tyr-NH2 (Nle: l-Norleucine) (M.W. 4096.7) C183H296N56O51

M. Rosenblatt, et al., J. Biol. Chem., 251, 159 (1976). (Chem. Synthesis & Biological Activity) M.L. Thomas and L.R. Forte, Comp. Biochem. Physiol., 73A, 691 (1982). (Biological Activity) I. Yamamoto, et al., Endocrinology, 122, 1208 (1988). (Radioimmunoassay)

[Nle8,18,Tyr34]-Parathyroid Hormone (Human, 3-34 Amide) [Nle8,18,Tyr34]-PTH (Human, 3-34 amide)

PTH-4181-v-20 °C

0.5 mgvial

4665

Ser-Glu-Ile-Gln-Leu-Nle-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Nle-Glu- Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Tyr-NH2 (Nle: l-Norleucine) (M.W. 3910.4) C175H282N54O48

S.R. Goldring, et al., J. Endocrinol. Metab., 48, 655 (1979). (Pharmacol.) T.C. Chen, et al., Biochem. Biophys. Res. Commun., 94, 1227 (1980). (Pharmacol.) D.A. Gray, et al., Br. J. Pharmacol., 76, 259 (1982). (Pharmacol.)

102 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE [Tyr34]-Parathyroid Hormone (Bovine, 1-34 Amide) [Tyr34]-PTH (Bovine, 1-34 Amide)

PTH-4179-v-20 °C

0.5 mgvial

466

Ala-Val-Ser-Glu-Ile-Gln-Phe-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ser-Ser-Met- Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Tyr-NH2 (M.W. 4123.7) C183H289N55O50S2

M. Rosenblatt, Pathobiol. Annu., 11, 53 (1981). (Review)

[Tyr34]-Parathyroid Hormone (Bovine, 7-34 Amide) [Tyr34]-PTH (Bovine, 7-34 Amide)

PTH-4185-v-20 °C

0.5 mgvial

466

Phe-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ser-Ser-Met-Glu-Arg-Val- Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Tyr-NH2 (M.W. 3496.0) C156H244N48O40S2 [86292-93-5] PTH AntagonistN. Horiuchi, et al., Science, 220, 1053 (1987). (Original)

PTH-rP(Human, 1-34 Amide) (Human, 1-34 Amide) (Rat, Mouse)

PTH-4205-v-20 °C

0.5 mgvial

396

Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu- Arg-Arg-Arg-Phe-Phe-Leu-His-His-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-NH2 (M.W. 4016.6) C180H288N58O47 [112955-31-4] Parathyroid Hormone Related ProteinL.J. Suva, et al., Science, 237, 893 (1987). (Original; cDNA) N. Horiuchi, et al., Science, 238, 1566 (1987). (Pharmacol.; Synthetic PTH-rP Amide) B.E. Kemp, et al., Science, 238, 1568 (1987). (Pharmacol.; Synthetic PTH-rP Amide)

PTH-rP(Human, 7-34 Amide) Parathyroid Hormone Related Protein (Human, 7-34 Amide)

PTH-4215-v-20 °C

0.5 mgvial

396

Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg- Arg-Phe-Phe-Leu-His-His-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-NH2 (M.W. 3364.9) C153H247N49O37 [115695-30-2] PTH-rP AntagonistK. Nagasaki, et al., Biochem. Biophys. Res. Comun., 158, 1036 (1989). (Original) L.J. Suva, et al., Science, 237, 893 (1987). (Original; cDNA)

TIP39 Tuberoinfundibular Peptide of 39 Residues (Human, Bovine)

PTH-4479-v-20 °C

0.1 mgvial

198

Ser-Leu-Ala-Leu-Ala-Asp-Asp-Ala-Ala-Phe-Arg-Glu-Arg-Ala-Arg-Leu-Leu-Ala-Ala-Leu- Glu-Arg-Arg-His-Trp-Leu-Asn-Ser-Tyr-Met-His-Lys-Leu-Leu-Val-Leu-Asp-Ala-Pro (M.W. 4504.2) C202H325N61O54SM.R. John, et al., Endocrinology, 143, 1047 (2002). (Original)L. Coutellier and T.B. Usdin, Behav. Brain Res., 222, 265 (2011). (Pharmacol.)E.L. Dimitrov, et al., Proc. Natl. Acad. Sci. U.S.A., 110, 13156 (2013). (Pharmacol.)A. Dobolyi, et al., Prog. Neurobiol., 90, 29 (2010). (Review)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 103

PRODUCT CODE QTY PRICE Peptide 234

Ac-D-Ala-Asn-Trp-Asn-Gly-Phe-Gly-D-Trp-Arg-Phe-NH2 (M.W. 1295.4) C63H78N18O13 Synthetic Kisspeptin AntagonistA.K. Roseweir, et al., J. Neurosci., 29, 3920 (2009). (Pharmacol.)X.-F. Li, et al. PLoS One., 4, e8334 (2009). (Pharmacol.) R. Pineda, et al., Endocrinology, 151, 722 (2010). (Pharmacol.)

PPT-4460-v-20 °C

0.5 mgvial

99

Peptide Histidine-Methionine (PHM)PHM-27(Human) Peptide Histidine-Methionine

PPM-4177-v-20 °C

0.5 mgvial

428

His-Ala-Asp-Gly-Val-Phe-Thr-Ser-Asp-Phe-Ser-Lys-Leu-Leu- Gly-Gln-Leu-Ser-Ala-Lys-Lys-Tyr-Leu-Glu-Ser-Leu-Met-NH2 (M.W. 2985.4) C135H214N34O40S [87403-73-4]N. Itoh, et al., Nature, 304, 547 (1983). (Original)

Peptide TPeptide T

Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr (M.W. 857.86) C35H55N9O16

PPT-4188-v-20 °C

0.5 mgvial

385

Peptide T (Bulk)Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr • 4H2O (M.W. 857.86 • 72.06) C35H55N9O16 • 4H2OM.R. Ruff, et al., FEBS Lett., 211, 17 (1987). (Pharmacol.) C.B. Pert, et al., Proc. Natl. Acad. Sci. USA, 83, 9254 (1986). (Original)

PPT-4188-20 °C

25 mg 685

Peptide YYPeptide YY (Dog, Mouse, Porcine, Rat, 3-36) PYY (Dog, Mouse, Porcine, Rat, 3-36)

PYY-3726-PI-20 °C

1 mg5 mg

2601040

H-Ala-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Ser-Arg- Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2 (M.W. 3980.45) C176H272N52O54 [126339-09-1] Physiological inhibitor for food intake/ Y2-receptor agonist D.Grandt, et al., Regul. Peptides, 40, 161 (1992). R.L.Batterham, et al., Nature, 418, 650 (2002). R.L.Batterham, et al. N. Engl. J. Med., 349, 941 (2003). Y. Shechter, et al., FEBS Lett., 579, 2439 (2005). I.G.Halatchev and R.D.Cone, Cell Metab., 1, 159 (2005). C.Acuna-Goycolea and A.N.van den Pol, J. Neurosci., 25, 10510 (2005). G.H.Ballantyne, Obes. Surg., 16, 651 (2006) P.K. Chelikani, et al., Am. J Phyiol Regul Integr Comp Physiol, 293, R39 (2007).

104 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Peptide YY (Human, 3-36) PYY (Human, 3-36)

PYY-4400-v-20 °C

0.5 mgvial

487

Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr- Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2 (M.W. 4049.5) C180H279N53O54 Physiological Inhibitor for Food Intake / NPY Y2-Receptor AgonistR.L. Batterham, et al., Nature, 418, 650 (2002). (Original; Inhibition of Food Intake) G.A. Eberlein, et al., Peptides, 10, 797 (1989). (Original; Endogenous Form) D.A. Keire, et al., Am. J. Physiol., 279, G126 (2000). (Original; NPY Y2 Receptor Selectivity) S. Chamorro, et al., Int. J. Obesity., 26, 281 (2002). (Review; Y2 R Selectivity) A. Sainsbury, et al., Proc. Natl. Acad. Sci. USA, 99, 8938 (2002). (Pharmacol.; Food intake Regulation through Y2R)

PhysalaeminPhysalaemin* (Frog, Physalaemus fuscumaculatus)

PPY-4030-v-20 °C

0.5 mgvial

43

Pyr-Ala-Asp-Pro-Asn-Lys-Phe-Tyr-Gly-Leu-Met-NH2 (M.W. 1265.4) C58H84N14O16S [2507-24-6]

Physalaemin* (Bulk) (Frog, Physalaemus fuscumaculatus)

PPY-4030-20 °C

25 mg 632

Pyr-Ala-Asp-Pro-Asn-Lys-Phe-Tyr-Gly-Leu-Met-NH2 • AcOH • 3H2O (M.W. 1265.4 • 60.05 • 54.06) C58H84N14O16S • CH3COOH • 3H2OV. Erspamer, et al., Experientia, 20, 489 (1964). (Original) L. Bernardi, et al., Experientia, 20, 490 (1964). (Chem. Synthesis)

Pituitary Adenylate Cyclase Activating Polypeptide (PACAP)A. Arimura, Peptides, 28, 1617 (2007). (Review)J. Watanabe, et al., Peptides, 28, 1713 (2007). (Review)M. Nakata and T. Yada, Curr. Pharm. Des., 13, 1105 (2007). (Review)D. Vaudry, et al., Pharmacol. Rev., 61, 283 (2009). (Review)

PACAP38 (Human)* ** Pituitary Adenylate Cyclase Activating Polypeptide 38 (Human)(Ovine, Rat)

PPA-4221-v-20 °C

0.5 mgvial

418

His-Ser-Asp-Gly-lle-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys- Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2 (M.W. 4534.3) C203H331N63O53SA. Miyata, et al., Biochem Biophys. Res. Commun., 164, 567 (1989). (Original)

* The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc.** This compound is distributed through Peptide Institute, Inc. under the license of Tulane University.


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 105

PRODUCT CODE QTY PRICE PACAP27 (Human, 1-27 Amide)* ** Pituitary Adenylate Cyclase Activating Polypeptide 27 (Human, 1-27 Amide) (Ovine, Rat)

PPA-4231-v-20 °C

0.5 mgvial

279

His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg- Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-NH2 (M.W. 3147.6) C142H224N40O39S [127317-03-7]A. Miyata, et al., Biochem. Biophys. Res. Commun., 170, 643 (1990). (Original) C. Kimura, et al., Biochem. Biophys. Res. Commun., 166, 81 (1990). (Original; Human and Bovine cDNA) K. Ogi, et al., Biochem. Biophys. Res. Commun., 173, 1271 (1990). (Original: Rat cDNA)

PACAP (Human, 6-38) Pituitary Adenylate Cyclase Activating Polypeptide (Human, 6-38) (Ovine, Rat)

PPA-4286-v-20 °C

0.5 mgvial

418

Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr- Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2 (M.W. 4024.7) C182H300N56O45S [143748-18-9] PACAP Selective AntagonistP. Robberecht,et al., Eur. J. Biochem., 207, 239 (1992). (Original) A. Vandermeers, et al., Eur. J. Biochem., 208, 815 (1992). (Pharmacol.)

Platelet Factor-4 Related PeptidePlatelet Factor-4 (Human, 58-70)

Pro-Leu-Tyr-Lys-Lys-Ile-Ile-Lys-Lys-Leu-Leu-Glu-Ser (M.W. 1573.0) C76H133N17O18 [82989-21-7] Angiogenesis InhibitorT.E. Maione, et al., Science, 247, 77 (1990). (Original)

IPF-4305-v-20 °C

0.5 mgvial

65

* The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc. ** This compound is distributed through Peptide Institute, Inc. under the license of Tulane University.

106 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Plectasin

Plectasin (PDF-4432-s) is a newly discovered defensin and the first to be isolated from a fungus, Pseudoplectania nigrella.1 This peptide was shown to cure mice of S. pneumoniae induced, ex-perimental peritonitis and pneumonia just as well as antibiotic treatment. The same concentration of plectasin that alters microbial growth also effectively kills the bacteria, suggesting the process is irreversible. Plectasin is also effective against antibiotic resistant strains of S. pneumoniae and exhibits low toxicity in mice models. This peptide should prove to be an exciting new addition to our growing number of antimicrobial products.

Mygind, et al., Nature, 437, 975 (2005). (Original ; Structure & Antimicrobial Activity)

Plectasin(Fungus, Pseudoplectania nigrella)

PDF-4432-s-20 °C

0.1 mgvial

295

Gly-Phe-Gly-Cys-Asn-Gly-Pro-Trp-Asp-Glu-Asp-Asp-Met-Gln-Cys-His-Asn-His-Cys-Lys- Ser-Ile-Lys-Gly-Tyr-Lys-Gly-Gly-Tyr-Cys-Ala-Lys-Gly-Gly-Phe-Val-Cys-Lys-Cys-Tyr (M.W. 4401.9) C189H267N53O56S7 Antimicrobial PeptideP.H. Mygind, et al., Nature, 437, 975 (2005). (Original; Structure & Antimicrobial Activity)S. Hara, et al., Biochem. Biophys. Res. Commun., 374, 709 (2008). (Pharmacol.)K. Mandal, et al., Protein Sci., 18, 1146 (2009). (X-ray Structure)T. Schneider, et al., Science, 328, 1168 (2010). (Pharmacol.)

PleiotrophinPleiotrophin (Human) PTN (Human)

PTN-4335-v-20 °C

50 µgvial

386

Gly-Lys-Lys-Glu-Lys-Pro-Glu-Lys-Lys-Val-Lys-Lys-Ser-Asp-Cys-Gly-Glu-Trp-Gln-Trp-Ser- Val-Cys-Val-Pro-Thr-Ser-Gly-Asp-Cys-Gly-Leu-Gly-Thr-Arg-Glu-Gly-Thr-Arg-Thr-Gly-Ala- Glu-Cys-Lys-Gln-Thr-Met-Lys-Thr-Gln-Arg-Cys-Lys-Ile-Pro-Cys-Asn-Trp-Lys-Lys-Gln-Phe- Gly-Ala-Glu-Cys-Lys-Tyr-Gln-Phe-Gln-Ala-Trp-Gly-Glu-Cys-Asp-Leu-Asn-Thr-Ala-Leu-Lys- Thr-Arg-Thr-Gly-Ser-Leu-Lys-Arg-Ala-Leu-His-Asn-Ala-Glu-Cys-Gln-Lys-Thr-Val-Thr-Ile-Ser- Lys-Pro-Cys-Gly-Lys-Leu-Thr-Lys-Pro-Lys-Pro-Gln-Ala-Glu-Ser-Lys-Lys-Lys-Lys-Lys-Glu-Gly- Lys-Lys-Gln-Glu-Lys-Met-Leu-Asp (Disulfide bonds between Cys15-Cys44, Cys23-Cys53, Cys30-Cys57, Cys67-Cys99, and Cys77-Cys109) (M.W. 15302.6) C658H1079N197O198S12 Heparin-Binding Growth Factor (Neurite Outgrowth-Promoting Factor)Y.-S. Li, et al., Science, 250, 1690 (1990). (Primary Structure) P.G. Milner, et al., Biochemistry, 31, 12023 (1992). (Nucleotide Seq.; Human) F. Czubayko, et al., Proc. Natl. Acad. Sci. U.S.A., 93, 14753 (1996). (Pharmacol.) T. Inui, et al., J. Pept. Res., 55, 384 (2000). (Chem. Synthesis & S-S Bond)

PLTX-II See Code PPL-4300-s in the Toxins section.


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 107

PRODUCT CODE QTY PRICE Pramlintide[Pro25,28,29]-Amylin (Human, 1-37) Tripro-Amylin

H-Lys-(Cys-Asn-Thr-Ala-Thr-Cys)-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (M.W. 3949.47) C171H267N51O53S2 [151126-32-8] (Disulfide bonds between C2 and C7)

PAM-3824-PI-20 °C

1 mg5 mg

26801,070


Prolactin-Releasing Peptides

B. Sun, et al., Regul. Pept., 126, 27 (2005). (Review)S. Fukusumi, et al., Peptides, 27, 1073 (2006). (Review)D.A. Bechtold and S.M. Luckman, J. Endocrinol., 192, 3 (2007). (Review)

Prolactin-Releasing Peptide (Human)* PrRP31 (Human)

PPR-4352-v-20 °C

0.5 mgvial

327

Ser-Arg-Thr-His-Arg-His-Ser-Met-Glu-Ile-Arg-Thr-Pro-Asp-Ile-Asn- Pro-Ala-Trp-Tyr-Ala-Ser-Arg-Gly-Ile-Arg-Pro-Val-Gly-Arg-Phe-NH2 (M.W. 3664.1) C160H252N56O42S Multifunctional Peptide in Neuroendocrinology S. Hinuma, et al., Nature, 393, 272 (1998). (Original, cDNA) F. Satoh, et al., Br. J. Pharmacol., 129, 1787 (2000). (Pharmacol.)

Prolactin-Releasing Peptide (Rat)* PrRP31 (Rat)

PPR-4353-v-20 °C

0.5 mgvial

327

Ser-Arg-Ala-His-Gln-His-Ser-Met-Glu-Thr-Arg-Thr-Pro-Asp-Ile-Asn- Pro-Ala-Trp-Tyr-Thr-Gly-Arg-Gly-Ile-Arg-Pro-Val-Gly-Arg-Phe-NH2 (M.W. 3594.0) C156H242N54O43S Multifunctional Peptide in Neuroendocrinology S. Hinuma, et al., Nature, 393, 272 (1998). (Original; cDNA) M. Maruyama, et al., Neurosci. Lett., 276, 193 (1999). (Pharmacol.) F. Satoh, et al., Br. J. Pharmacol., 129, 1787 (2000). (Pharmacol.) H. Matsumoto, et al., Neurosci. Lett., 285, 234 (2000). (Pharmacol.)

Prolactin Releasing Hormone See Code PTR-4011 TRH.Renin Substrate See Code MRP-3110 Suc-Arg-Pro-Phe-His-Leu-Leu-Val-Tyr-MCA in the Enzyme Inhibitors and Substrates section.Renin Substrate See Code SDH-4133 Asp-Arg-Val-Tyr-lle-His-Pro-Phe-His-Leu-Val-Ile-His in the Enzyme Inhibitors and Substrates section.

* This compound is distributed through Peptide Institute, Inc. under the license of Takeda Chemical Industries, Ltd.

108 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Protease-Activated Receptor (PAR) Peptides

N. Vergnolle, Br. J. Pharmacol., 141, 1264 (2004). (Review)

Proteinase-activated receptor (PAR) is a unique member of the G protein-coupled re-ceptor (GPCR) family that is activated primarily by proteases. PAR2 is activated by trypsin cleavage which can lead to a diverse number of physiological responses. For example, PARs have been reported to relax tracheal and bronchial smooth muscle cells and par-ticipate in hypotension, arterial vasodilation in diabetes, and gastric secretions.1-4 PAR participation in tissue repair, cell survival, and inflammation following injury indicates that it may play an important role in controlling inflammatory-mediated diseases as well. In addition, PAR2 is expressed by a wide number of tumor cells including breast and colon cancers, suggesting a role in angiogenesis.5,6

A. Kawabata, et al., J. Pharmacol. Exp. Ther., 311,402 (2004).. Cicala, et al., THE FASEB J., 10, 1996 (2001). F. Roviezzo, et al., Arteriosclerosis, Thrombosis, and Vasc. Biol., 25, 2349 (2005). Kawao, et al., British J. of Pharm., 135, 1292 (2002). D. Darmoul, et al., Am. J. Patho., 162, 1503 (2003). S. Even-Ram, et al., Nat. Med., 4, 909 (1998).

Protease-Activated Receptor 1 (PAR1) H-Ala-Phe(para-Fluoro)-Arg-Cha-Cit-Tyr-NH2H-Ala-Phe(4-F)-Arg-Cha-Cit-Tyr-Amide

(M.W. 883.04) C42H63N12O8F Protease-Activated Receptor 1 (PAR1) AgonistA. Kawabata, et al., J. of Pharm. and Exper. Therap., 288, 358 (1999)

PAR-3931-PI -20 °C

1 mg5 mg

209835

H-Phe-Leu-Leu-Arg-Asn-OHFLLRN

(M.W. 661.81) C31H51N9O7 Protease-Activated Receptor 1 (PAR1) Antagonist R.R. Vassallo, Jr, et al.s, J. Biol. Chem., 267, 6081 (1992)

PAR-3944-PI -20 °C

1 mg5 mg

38149

H-Ser-Phe-Leu-Leu-Arg-NH2SFLLR-Amide

(M.W. 633.80) C30H51N9O6 Protease-Activated Receptor 1 (PAR1) Antagonist MD. Hollenberg, et al., Mol. Pharmacol., 42, 186 (1992).

PAR-3942-PI -20 °C

1 mg5 mg

38149

H-Ser-Phe-Leu-Leu-Arg-OHSFLLR

(M.W. 634.78) C30H50N8O7 Acid Form of PAR-3942-PIH.-S. Ahn, et al., Mol. Pharmacol., 51, 350 (1997). M.D. Hollenberg, et al., Mol. Pharmacol., 42, 186 (1992).

PAR-3936-PI -20 °C

1 mg5 mg

59236


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 109

PRODUCT CODE QTY PRICE H-Phe-Thr-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-NH2FTLLRNPNDK-Amide

PAR-3926-PI -20 °C

1 mg5 mg

64241

(M.W. 1216.42) C54H89N17O15 Protease-Activated Receptor 1 (PAR1) Negative Control Peptide for PAR1 Agonist PAR-3925-PIB.D. Blackhart, et al., J. Biol. Chem., 271, 16466 (1996).

H-Ser-Phe-Leu-Leu-Arg-Asn-OHSFLLRN

(M.W. 748.89) C34H56N10O9 Acid Form of PAR-3676-PIH.-S. Ahn, et al., Mol. Pharmacol., 51, 350 (1997). R.R. Vassallo, Jr, et al., J. Biol. Chem., 267, 6081 (1992).

PAR-3943-PI -20 °C

1 mg5 mg

38149

H-Ser-Phe-Leu-Leu-Arg-Asn-Pro-OHSFLLRNP

(M.W. 846.00) C39H63N11O10 Protease-Activated Receptor 1 (PAR1) Agonist

M.L. Webb, et al., Biochem. Pharmacol., 45, 1577 (1993).

PAR-3945-PI -20 °C

1 mg5 mg

59236

H-Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe-NH2SFLLRNPNDKYEPF-Amide

PAR-3935-PI -20 °C

1 mg5 mg

59236

(M.W. 1738.98) C81H119N21O22

J.R. Ngaiza and E.A. Jaffe, Biochem. Biophys. Res. Commun., 179, 1656 (1991).D.M. Feng, et al., J. Med. Chem.,38,4125 (1995).

H-Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe-OHSFLLRNPNDKYEPF

PAR-3934-PI -20 °C

1 mg5 mg

59236

(M.W. 1739.96) C81H118N20O23 Acid Form of PAR-3935-PIH.-S. Ahn, et al., Mol. Pharmacol., 51, 350 (1997).J.R. Ngaiza and E.A. Jaffe, Biochem. Biophys. Res. Commun., 179, 1656 (1991).D.M. Feng, et al., J. Med. Chem.,38, 4125 (1995).

H-Ser-Phe-Leu-Leu-Cit-OHSFLLcit

(M.W. 635.77) C30H49N7O8 Protease-Activated Receptor 1 (PAR1) AgonistT. Sabo, et al., Biochem. Biophys. Res. Commun., 188, 604 (1992).

PAR-3941-PI -20 °C

1 mg5 mg

59236

H-Thr-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-NH2TFLLRNPNDK-Amide

(M.W. 1216.42) C54H89N17O15 Protease-Activated Receptor 1 (PAR1) Agonist.B.D. Blackhart, et al., J. Biol. Chem., 271, 16466 (1996)

PAR-3925-PI -20 °C

1 mg5 mg

649241

110 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE H-Ser-Phe-Leu-Leu-Arg-Asn-NH2SFLLRN-Amide

(M.W. 747.90) C34H57N11O8 Selective Protease-Activated Receptor 1 (PAR1) Agonist R.R. Vassallo, Jr., et al., J. Biol. Chem., 267, 6081 (1992).

PAR-3676-PI-20 °C

1 mg5 mg

49192

H-Thr-Phe-Leu-Leu-Arg-NH2TFLLR-Amide

(M.W. 647.82) C31H53N9O6 Protease-Activated Receptor 1 (PAR1) AgonistM.D. Hollenberg, et al., Can. J. Physiol. Pharmacol., 75, 832 (1997).

PAR-3665-PI-20 °C

1 mg5 mg

70209

H-Arg-Leu-Leu-Phe-Thr-NH2RLLFT-Amide

PAR-3695-PI-20 °C

1 mg5 mg

70209

(M.W. 647.82) C31H53N9O6 Protease-Activated Receptor 1 (PAR1) Negative Control PeptideS. Asfaha, et al., Br. J. Pharmacol., 135, 1101 (2002). M. Fang, et al., Physiol., 549, 903 (2003).

Protease-Activated Receptor 2 (PAR2) 2-Furoyl-Orn-Leu-Arg-Gly-Ile-Leu-NH22-Furoyl-OrnLRGIL-Amide

(M.W. 777.97) C36H63N11O8

PAR-3951-PI -20 °C

1 mg5 mg

81231

Protease-Activated Receptor 2 (PAR2 ) Negative Control Peptide for PAR-3663-PI J.J. McGuire, et al., J. of Pharm. Exp. Ther., 309, 1124 (2004).

2-Furoyl-Leu-Ile-Gly-Arg-Leu-Orn-NH22-Furoyl-LIGRLO-Amide

PAR-3663-PI-20 °C

1 mg5 mg

81231

(M.W. 777.97) C36H63N11O8 Potent and Selective Protease-Activated Receptor 2 (PAR2) AgonistJ.J. McGuire, et al., J Pharmacol. Exp. Ther., 309, 1124 (2004).

3-Mercaptopropionyl-Phe-Cha-Cha-Arg-Lys-Pro-Asn-Asp-Lys-NH23-Mercaptopropionyl-F-Cha-Cha-RKNDK-Amide

PAR-3677-PI-20 °C

1 mg5 mg

1244930

(M.W. 1297.64) C61H100N16O13S. Protease-Activated Receptor 1 (PAR1) Antagonist / Protease-Activated Receptor 2 (PAR2) AgonistA. Kawabata,et al., J. Pharmacol. and Experim. Therapeutics, 88, 358 (1999). S.M. Seiler, et al., Biochem. Pharmacol., 49, 519 (1995)

H-Ser-Leu-Ile-Gly-Arg-Leu-NH2 SLIGRL-Amide

PAR-3664-PI-20 °C

1 mg5 mg

49192

(M.W. 656.83) C29H56N10O7 Protease-Activated Receptor 2 (PAR2) AgonistB. Al-Ani, M. Saifeddine, and M.D. Hollenberg, Can. J. of Physiol. Pharmacol., 73, 1203 (1995).


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 111

PRODUCT CODE QTY PRICE H-Leu-Ser-Ile-Gly-Arg-Leu-NH2LSIGRL-Amide

PAR-3913-PI -20 °C

1 mg5 mg

49192

(M.W. 656.83) C29H56N10O7 Protease-Activated Receptor 2 (PAR2) Negative Control for PAR-3664-PIH. Nishikawa, et al., J. Pharm. and Experim. Therap., 312, 324 (2005).

H-Ser-Leu-Ile-Gly-Arg-Leu-OH SLIGRL

PAR-3940-PI -20 °C

1 mg5 mg

38149

(M.W. 657.82) C29H55N9O8 Acid Form of PAR-3664-PIA. Bhattacharya, et al., J. Pharmacol. Exp. Ther., 297, 573 (2001). B. Al-Ani, et al., Can. J. of Physiol. Pharmacol., 73, 1203 (1995).

H-Ser-Leu-Ile-Gly-Arg-NH2 SLIGR-Amide

(Trifluoroacetate Form)(M.W. 543.67) C23H45N9O6 PAR2 AgonistR.M. Scarborough, Curr. Med. Chem., 1, 73 (2003). B. Al-Ani, et al., J. Pharmacol. And Experim Therapm., 290, 753 (1999).

PAR-3743-PI-20 °C

1 mg5 mg

49192

H-Phe-Ser-Leu-Leu-Arg-Tyr-NH2FSLLRY-Amide

PAR-3888-PI -20 °C

1 mg5 mg

38149

(M.W. 796.98) C39H60N10O8 Selective Antagonist for Protease-Activated Receptor 2 (PAR2) Agonist FSLLRY-NH2 blocks trypsin but not SLIGRL-NH2 activation of PAR2 in receptor-expressing KNRK cells.B. Al-Ani, et al., J. Pharmacol. Exp. Ther., 300, 702 (2002).S.Wilson, et al., Biochem. J., 388, 967 (2005).

H-Ser-Leu-Ile-Gly-Lys-Val-NH2SLIGKV-Amide

PAR-3889-PI-20 °C

1 mg5 mg

38149

(M.W. 614.79) C25H54N8O7 PAR2 Tethered Ligand (Human) / Protease-Activated Receptor 2 (PAR2) AgonistS.K. Bohm, et al., Biochem. J., 314, 1009 (1996).

H-Leu-Ser-Ile-Gly-Lys-Val-NH2LSIGKV-Amide

PAR-3920-PI

-20 °C

1 mg5 mg

49188

(M.W. 614.79) C28H54N8O7 Protease-Activated Receptor 2 (PAR2) Negative Control Peptide for PAR-3889-PII.A. Akers, et al., Am. J. Physiol. Lung Cell. Mol. Physiol., 278, L193 (2000). S. Miyata, et al. J. Biol. Chem., 275, 4592 (2000). S. Miike, et al., J. Immunol., 167, 6615 (2001).

H-Ser-Leu-Ile-Gly-Lys-Val-OHSLIGKV

(M.W. 615.78) C28H53N7O8 Acid Form of PAR-3889-PIS.K. Bohm,et al., Biochem. J., 314, 1009 (1996).W.R. Ferrell, et al., J. Clin. Invest., 111, 35 (2003)..

PAR-3938-PI

-20 °C

1 mg5 mg

38149

112 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Protease-Activated Receptor 3 PAR3

H-Thr-Phe-Arg-Gly-Ala-Pro-NH2TFRGAP-Amide

(M.W. 646.75) C29H46N10O7 PAR3 Tethered Ligand (Human) / Activates PAR1 and PAR2

K.K. Hansen, et al., Immunology, 112, 183 (2004).

PAR-3689-PI -20 °C

1 mg5 mg

49192

H-Ser-Phe-Asn-Gly-Gly-Pro-NH2SFNGGP-Amide

(M.W. 576.61) C25H36N8O8 PAR3 Tethered Ligand (Murine) / Activates PAR1 and PAR2

K.K. Hansen, et al., Immunology, 112, 183 (2004).

PAR-3691-PI-20 °C

1 mg5 mg

49192

Protease-Activated Receptor 4 (PAR4) H-Gly-Tyr-Pro-Gly-Lys-Phe-NH2GYPGKF-Amide

PAR-3672-PI-20 °C

1 mg5 mg

49192

(M.W. 666.78) C33H46N8O7 PAR4 Tethered Ligand (Murine) / Protease-Activated Receptor 4 (PAR4) AgonistM.L. Kahn, et al., Nature, 394, 690 (1998). M.L. Kahn, et al., J. Clin. Invest., 103, 879 (1999). M.D. Hollenberg, et al., Can. J. Physiol. Pharmacol., 77, 458 (1999).

H-Gly-Tyr-Pro-Gly-Gln-Val-NH2GYPGQV-Amide

PAR-3673-PI-20 °C

1 mg5 mg

49192

(M.W. 618.70) C28H42N8O8 PAR4 Tethered Ligand (Human) / Protease-Activated Receptor 4 (PAR4) AgonistW. Xu, et al., Proc. Nat’l. Acad. Sci. U.S.A., 95, 6642 (1998). M.D. Hollenberg, et al., Can. J. Physiol. Pharmacol., 77, 458 (1999).

H-Ala-Tyr-Pro-Gly-Lys-Phe-OHAYPGKF

(M.W. 681.80) C34H47N7O8 Acid form of PAR-3674-PIE.A. Lidington, et al., Am J Physiol Cell Physiol, 289, C1437 (2005).M.D. Hollenberg, et al., Br. J. Pharmacol., 143, 443 (2004)

PAR-3939-PI -20 °C

1 mg5 mg

38149

H-Ala-Phe(para-Fluoro)-Arg-Cha-homo Arg-Tyr-NH2H-Ala-Phe(4-F)-Arg-Cha-homoArg-Tyr-Amide

Thrombin Receptor Activating PeptideD.M. Feng, et al., J. Med. Chem.,38, 4125 (1995).H.-S. Ahn, et al., Mol. Pharmacol., 51, 350 (1997).

PAR-3932-PI -20 °C

1 mg5 mg

209835

H-Ala-Tyr-Pro-Gly-Lys-Phe-NH2AYPGKF-Amide

(M.W. 680.81) C34H48N8O7 Selective Protease-Activated Receptor 4 (PAR4) Agonist.M.D. Hollenberg, et al., Can. J. Physiol. Pharmacol., 77, 458 (1999). T.R. Faruqi, et al., J. Biol. Chem., 275, 19728 (2000). M.D. Hollenberg, et al., Br. J. Pharmacol., 143, 443 (2004)

PAR-3674-PI-20 °C

1 mg5 mg

49192


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 113

PRODUCT CODE QTY PRICE H-Tyr-Ala-Pro-Gly-Lys-Phe-NH2YAPGKF-Amide

PAR-3933-PI -20 °C

1 mg5 mg

385149

(M.W. 680.81) C34H48N8O7 Protease-Activated Receptor 4 (PAR4) Negative Control Peptide for PAR-3674-PIM.D. Hollenberg, et al., Br. J. Pharmacol., 143, 443 (2004).

trans-Cinnamoyl-Tyr-Pro-Gly-Lys-Phe-NH2trans-Cinnamoyl-YPGKF-Amide

PAR-3675-PI-20 °C

1 mg5 mg

705209

(M.W. 739.88) C40H49N7O7 Selective Protease-Activated Receptor 4 (PAR4) AgonistL. Ma, et al., Br. J. Pharmacol., 134, 701 (2001). M.D. Hollenberg and M. Saifeddine, Can. J. Physiol. Pharmacol., 79, 439 (2001).

Pyroglutamylated RFamide Peptide

The group of Takeda Pharmaceutical Company Limited has long been involved in discov-ering orphan receptor ligands and identified a novel peptide in human utilizing the recently established gene database. Actually, they searched the database to detect peptides with the carboxyl-terminal Arg-Phe-NH2 (RFamide) moiety in the mature peptide. As a result, the peptide termed Pyroglutamylated RFamide peptide (QRFP) was identified by ana-lyzing the expressed peptide in Chinese hamster ovary cells as a 43 amino acid residue peptide.1 The peptide corresponding to the carboxyl-terminal 26 amino acid residues of QRFP was also predicted by another group using a similar approach and then termed P518.2 Both of these peptides were found to interact with an orphan receptor (AQ27/SP9155/GPR103; all of these denote the same orphan receptor of interest). Human 26RFa was proposed by another group based on the primary structure of their deter-mined frog peptide in which 26RFa is identical to P518.3 The biological activities of QRFP and 26RFa reported are: i) upon intravenous administration in rats at doses between 40 and 400 nmol/kg, QRFP induced aldosterone secretion in a dose-dependent manner, ii) intracerebroventricular administration of 26RFa in mice (after partial food deprivation for 18 h) stimulated food intake at doses of 100 and 1000 ng/mouse, iii) central QRFP (rat QRFP is used in this report) administration evoked feeding, behavioral arousal, and elevation of blood pressure in mice4, and iv) intracerebroventricular infusion of QRFP in-creased fat mass and decreased rectal temperature in mice.5 QRFP might have variable activities other than those identified, thus, it should serve as an essential member of the RFamide family peptides in humans.

S. Fukusumi, et al., J. Biol. Chem., 278, 46387 (2003). (Original: QRFP)Y. Jiang, et al., J. Biol. Chem., 278, 27652 (2003). (Orphan Receptor Ligand / 26-Residue Peptide, P518)N. Chartrel, et al., Proc. Natl. Acad. Sci. U.S.A., 100, 15247 (2003). (26-Residue Peptide, 26RFa)S. Takayasu, et al. Proc. Natl. Acad, Sci. U.S.A., 103, 7438 (2006). (Pharmacol.)R. Moriya, et al., Endocrinology, 147, 2916 (2006). (Pharmacol.)S. Fukusumi, R. Fujii, and S. Hinuma, Peptides, 27, 1073 (2006). (Review)D.A. Bechtold and S.M. Luckman, J. Endocrinol., 192, 3 (2007). (Review)

Pyroglutamylated RFamide Peptide (Human)QRFP (Human)

PRF-4419-s-20 °C

0.1 mgvial

172

Pyr-Asp-Glu-Gly-Ser-Glu-Ala-Thr-Gly-Phe-Leu-Pro-Ala-Ala-Gly-Glu-Lys-Thr-Ser-Gly-Pro-Leu-Gly-Asn-Leu-Ala-Glu-Glu-Leu-Asn-Gly-Tyr-Ser-Arg-Lys-Lys-Gly-Gly-Phe-Ser-Phe-Arg-Phe-NH2 (M.W. 4503.8) C199H301N55O65 Endogenous Ligand for AQ27 / SP9155 / GPR103

114 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Pyr-Lys-Arg-Pro-Ser-Gln-Arg-Ser-Lys-Tyr-Leu See Code SKL-4237-v.QRFP (Human) See Code PRF-4419-s Pyroglutamylated RFamide Peptide (Human).Renin Substrate See Code MRP-3110. Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His See Code SDH-4133-v.

RF Amide Related PeptidesRFamide-Related Peptide-1 (Human)*RFRP-1 (Human)

PRF-4380-s-20 °C

0.1 mgvial

161

Ser-Leu-Asn-Phe-Glu-Glu-Leu-Lys-Asp-Trp-Gly-Pro-Lys-Asn-Val-Ile-Lys-Met-Ser- Thr-Pro-Ala-Val-Asn-Lys-Met-Pro-His-Ser-Phe-Ala-Asn-Leu-Pro-Leu-Arg-Phe-NH2 (M.W. 4256.9) C195H304N52O51S2 Endogenous Ligand for OT7T022 / FF1 D.A. Price and M.J. Greenberg, Science, 197, 670 (1977). (Original: FMRF-Amide) S. Fukusumi, et al., Biochim. Biophys. Acta, 1540, 221 (2001). (Endogenous Form) S. Hinuma, et al., Nat. Cell Biol., 2, 703 (2000). (Original: cDNA & Pharmacol. of RFRP-1) Q. Liu, et al., . Biol. Chem., 276, 36961 (2001). (Original: NPSF) T. Yano, et al., Brain Res., 982, 156 (2003). (Histochem.)A. Pertovaara, et al., Neuroscience, 134, 1023 (2005). (Pharmacol.)S. Fukusumi, et al., Peptides, 27, 1073 (2006). (Review)D.A. Bechtold and S.M. Luckman, J. Endocrinol., 192, 3 (2007). (Review)

RFamide-Related Peptide-3 (RFRP-3)

RFamide-Related Peptide-3 (RFRP-3) was discovered from the cDNA sequences, in which two other family peptides, RFRP-1 (Code 4380-s for one of the endogenous forms) and RFRP-2 are encoded.1,2 Endogenous forms of human and rat RFRP-3 were determined to be an 8- and 18-residue peptide, respectively.3,4 Biological activities of RFRP-3 include:

• function as gonadotropin inhibitory hormone (GnIH), resulting in the reduction in LH secretion • increase in food intake and growth hormone secretion• no effect on Kiss-1 mRNA expression.5,6

RFRP-3 should be especially valuable research tools in reproduction and puberty studies. S. Hinuma, et al., Nat.Cell Biol., 2, 703 (2000). (Original: Human & Rat cDNA)I.J. Clarke, et al., Endocrinology, 149, 5811 (2008). (Original: Ovine cDNA)T. Ubuka, et al., PLoS One., 4, e8400 (2009). (Endogenous Form: Human RFRP-3)K. Ukena, et al.,, FEBS Lett., 512, 255 (2002). (Endogenous Form: Rat RFRP-3) I.J. Clarke, et al., Front.Neuroendocrinol., 30, 371 (2009). (Review: Pharmacol.)M.A. Johnson and G.S. Fraley, Neuroendocrinology, 88, 305 (2008). (Pharmacol.)

RFamide-Related Peptide-3 (Human)RFRP-3 (Human) (Ovine)

Val-Pro-Asn-Leu-Pro-Gln-Arg-Phe-NH2 (M.W. 969.14) C45H72N14O10 Gonadotropin-Inhibitory Hormone

PRF-4461-v -20 °C

0.5 mgvial

80

* This compound is distributed through Peptide Institute, Inc. under the license of Takeda Chemical Industries, Ltd.


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 115

PRODUCT CODE QTY PRICE RFamide-Related Peptide-3 (Rat)RFRP-3 (Rat)

PRF-4462-v-20 °C

0.5 mgvial

110

Ala-Asn-Met-Glu-Ala-Gly-Thr-Met-Ser-His- Phe-Pro-Ser-Leu-Pro-Gln-Arg-Phe-NH2(M.W. 2020.30) C88H134N26O25S2 Gonadotropin-Inhibitory HormoneS. Hinuma, et al., Endocrinology, 149, 5811 (2008). (Original: Ovine cDNA) T. Yamamoto, et al., Nat. Cell Biol., 2, 703 (2000). (Original: cDNA)K. Ukena, et al., FEBS Lett., 512, 255 (2002). (Identification of RERP-3 in Rat Hypothalamus)M.A. Johnson, et al., Horm. Behav., 51,171 (2007). (Pharmacol.)M.A. Johnson and G.S. Fraley, Neuroendocrinology, 88,305 (2008). (Pharmacol.)E. Ducret, et al., Endocrinology, 150, 2799 (2009). (Pharmacol.)

Salusins

Salusin-a (Human)Ser-Gly-Ala-Leu-Pro-Pro-Ala-Pro-Ala-Ala-Pro-Arg-Pro-Ala-Leu-Arg-Ala-Gln-Arg-Ala-Gly-Pro-Ala-Gly-Pro-Gly-Ala-Lys-NH2 (M.W. 2603.0 ) C114H192N40O30 Hypotensive / Mitogenic Peptide

PSL-4417-s-20 °C

0.1 mgvial

161

Salusin-b (Human)Ala-Ile-Phe-Ile-Phe-Ile-Arg-Trp-Leu-Leu-Lys-Leu- Gly-His-His-Gly-Arg-Ala-Pro-Pro (M.W. 2342.8 ) C115H176N32O21 Hypotensive / Mitogenic PeptideM. Shichiri, et al., Nat. Med., 9, 1166 (2003). (Original)

PSL-4418-s-20 °C

0.1 mg vial

129

Schizophrenia Related PeptideSchizophrenia Related Peptide* (Bulk) PSC-4061

-20 °C

25 mg100 mg

106220Thr-Val-Leu

(M.W. 331.41) C15H29N3O5

C.E. Frohman, Chem. Eng. News, 1977, 35. (Original)

SecretinJ.E. Jorpes and V. Mutt (eds.) Secretin, Cholecystokinin, Pancreozymin and Gastrin, Handbook of Experimental Pharmacology, Vol. 34, Springer-Verlag, Berlin, 1973. (Review)

Secretin (Human)His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg- Glu-Gly-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val-NH2 (M.W. 3039.4) C130H220N44O40 [108753-74-8]M. Carlquist, et al.t, IRCS Med. Sci., 13, 217 (1985). (Original) K. Iguchi, et al., Peptide Chemistry 1985, 191 (1986). (Chem. Synthe-sis and Biological Activity)

PSE-4165-v-20 °C

0.5 mgvial

375

Secretin (Porcine) His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Asp-Ser-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val-NH2 (M.W. 3055.4) C130H220N44O41 [17034-35-4]

PSE-4112-v-20 °C

0.5 mgvial

375


116 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Semaglutide

H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-

GLP-3875-PI-20 °C

0.5 mg1 mg

225325

Leu-Glu-Gly-Gln-Ala-Ala-Lys[(AEEA)2-ϒ-Glu-N-(17-Carboxy-1- Oxoheptadecyl)]-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH (M.W. 4113.67) C187H291N45O59 [910463-68-2] Glucagon-like peptide-1 (GLP-1) Analog Shown to Stimulate Insulin and Suppress Glucagon Secretion in a Glucose-Dependent MannerS.P. Marso, et al., N. Engl. J. Med., 375, 1834 (2016). J. Lau, et al., J. Med. Chem., 58, 7370 (2015). C.F. Gotfredsen, et al., Diabetes, 63, 2486: (2014).

Note: Bolar Exemption applies. This is a FDA-regulated product. It is the responsibility of the customer to ensure that they are complying with Federal rules. Peptides International cannot be liable for infringement of rights made by the user.

Serum Thymic FactorSerum Thymic Factor

Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn (M.W. 858.85) C332H54N12O15 [63958-90-7]

PST-4058-v-20 °C

0.5 mgvial

49

Serum Thymic Factor (Bulk)Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn • AcOH • 2H2O (M.W. 858.85 • 60.05 • 36.03) C33H54N12O15 • CH3COOH • 2H2O

PST-4058-20 °C

25 mg 637

J.F. Bach, et al., Nature, 266, 55 (1977). (Original)

SNX-482 See Code PCB-4363-s in the Toxins subsection.

Sodium Potassium ATPase Inhibitor-1 (SPAI-1)SPAI-1 (Porcine) Sodium Potassium ATPase Inhibitor-1 (Porcine) Na+, K+-ATPase Inhibitor-1 (Porcine)

PSP-4216-s-20 °C

0.1 mgvial

295

Leu-Leu-Ser-Lys-Arg-Gly-His-Cys-Pro-Arg-Ile-Leu-Phe-Arg-Cys-Pro-Leu-Ser-Asn-Pro-Ser-Asn-Lys-Cys-Trp-Arg-Asp-Tyr-Asp-Cys-Pro-Gly-Val-Lys-Lys-Cys-Cys-Glu-Gly-Phe-Cys-Gly-Lys-Asp-Cys-Leu-Tyr-Pro-Lys (Disulfide bonds are between Cys8-Cys37, Cys15-Cys41, Cys24-Cys36, and Cys30-Cys45) (M.W. 5628.6) C245H378N72O65S8

K. Araki, et al., Biochem. Biophys. Res. Commun., 164, 496 (1989). (Original) K. Araki, et al., Biochem. Biophys. Res. Commun., 172, 42 (1990). (S-S Bond) H. Nishio, et al., Pept. Res., 5, 227 (1992). (Chem. Synthesis)

Somatostatin (SRIF) and Related PeptidesOctreotide

Phe-Cys-Phe-Trp-Lys-Thr-Cys-Thr-ol (Disulfide bond between Cys2-Cys7) (M.W. 1019.24) C49H66N10O10S2 [83150-76-9] Somatostatin Analog

PCI-3738-PI-20 °C

1 mg5 mg

75300

Note: Bolar Exemption applies. This is a FDA-regulated product. It is the responsibility of the customer to ensure that they are complying with Federal rules. Peptides International cannot be liable for infringement of rights made by the user.



BIOLO


Order Hotline 1-800-777-4779 502-266-8787 117

PRODUCT CODE QTY PRICE Somatostatin SRIF: (Somatotropin Release Inhibiting Factor) GIF: (Growth Hormone Release Inhibiting Factor) (Human, Ovine, Porcine, Rat, Mouse)

Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys (Disulfide bond between Cys3-Cys14) (M.W. 1637.9) C76H104N18O19S2 [38916-34-6]

PSI-4023-v-20 °C

0.5 mgvial

118

Somatostatin (Bulk) PSI-4023-20 °C

25 mg 1231

Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys • 2AcOH • 6H2O (Disulfide bond between Cys3-Cys14) (M.W. 1637.9 • 120.10 • 108.09) C76H104N18O19S2 • 2CH3COOH • 6H2OP. Brazeau, et al., Science, 179, 77 (1973). (Original; Ovine) A. Arimura, et al., Science, 189, 1007 (1975). (Pharmacol.)L.-P. Shen, et al., Proc. Natl. Acad. Sci. U.S.A., 79, 4575 (1982). (cDNA Seq.; Human)D.J. Koerker, et al., Science, 184, 482 (1974). (Pharmacol.)

Somatostatin-28(Trifluoroacetate Form)

PSI-3747-PI-20 °C

1 mg5 mg

4551819

H-Ser-Ala-Asn-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-Lys- Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys (Disulfide bond Cys17-Cys 28) (M.W. 3148.62) C137H207N41O39S3 [73032-94-7]

[d-Trp8]-SomatostatinAla-Gly-Cys-Lys-Asn-Phe-Phe-d-Trp-Lys-Thr-Phe-Thr-Ser-Cys (Disulfide bonds between Cys3-Cys14) (M.W. 1637.9) C76H104N18O19S2 [58976-46-8]

PSI-4101-v-20 °C

0.5 mgvial

156

J. Rivier, et al., Biochem. Biophys. Res. Commmun., 65, 746 (1975). (Original)

[Tyr1]-SomatostatinTyr-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys (Disulfide bonds between Cys3-Cys14) (M.W. 1730.0) C82H108N18O20S2 For Radioimmunoassay Purity Information: Qx See page xivA. Arimura, et al., Proc. Soc. Exp. Biol. Med., 148, 784 (1975). (Original)

PSI-4038-v-20 °C

0.5 mgvial

140

Spantide See Code PSP-4173 (d-Arg1,d-Trp7,9, Leu11)-Substance P.

118 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Src Homology 2 Domain LigandSrc Homology 2 Domain Ligand (Biotinylated)

SRC-3737-PI-20 °C

1 mg 5 mg

5192076

Biotinyl-ε-aminocaproyl-Glu-Pro-Gln-Tyr(PO3H2)-Glu-Glu-Ile-Pro-Ile-Tyr-Leu- (M.W. 1813.01) C82H122N15O27SP [215876-01-0] Src Homology 2 Domain LigandL.M.Sonatore, et al., Anal Biochem, 240, 289 (1996). R-H Yeh, T.R. Lee, and D.S. Lawrence, J. Biol Chem, 276, 12235 (2001). X. Liu, et al., Bull Korean Chem Soc, 27, 1353 (2006). S.-H. Park, J. Wona, and K.-H. Lee, J. Med. Chem., 43, 1173 (2000).

Substance K See Code PNK-4154 Neurokinin A.

Stresscopins / Urocortin and Related PeptidesStresscopin (Human) PST-4387-s

-20 °C

0.1 mgvial

190

Thr-Lys-Phe-Thr-Leu-Ser-Leu-Asp-Val-Pro-Thr-Asn-Ile-Met-Asn-Leu-Leu-Phe-Asn-Ile- Ala-Lys-Ala-Lys-Asn-Leu-Arg-Ala-Gln-Ala-Ala-Ala-Asn-Ala-His-Leu-Met-Ala-Gln-Ile-NH2 (M.W. 4367.1) C195H326N56O53S2 Selective Ligand for Type 2 CRF ReceptorsS.Y. Hsu and A.J.W. Hsueh, Nat. Med., 7, 605 (2001). (Original) F.M. Dautzenberg and R.L. Hauger, Trends Pharmacol. Sci., 23, 71 (2002). (Review) V. Martínez,et al., J. Pharmacol. Exp. Ther., 301, 611 (2002). (Pharmacol.) A. Chanalaris, et al., J. Mol. Cell. Cardiol., 35, 1295 (2003). (Pharmacol.)

Stresscopin-Related Peptide (Human) PST-4388-s-20 °C

0.1 mgvial

220

(Hydrochloride Form) His-Pro-Gly-Ser-Arg-Ile-Val-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Leu-Gln-Ile-Leu-Leu-Glu- Gln-Ala-Arg-Ala-Arg-Ala-Ala-Arg-Glu-Gln-Ala-Thr-Thr-Asn-Ala-Arg-Ile-Leu-Ala-Arg-Val-NH2 (M.W. 4687.5) C205H358N68O57 Selective Ligand for Type 2 CRF Receptors S.Y. Hsu and A.J.W. Hsueh, Nat. Med., 7, 605 (2001). (Original) F.M. Dautzenberg and R.L. Hauger, Trends Pharmacol. Sci., 23, 71 (2002). (Review) V. Martínez, et al., J. Pharmacol. Exp. Ther., 301, 611 (2002). (Pharmacol.) A. Chanalaris, et al., J. Mol. Cell. Cardiol., 35, 1295 (2003). (Pharmacol.)

Urocortin (Human)Asp-Asn-Pro-Ser-Leu-Ser-Ile-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Thr-Leu-Leu-Glu-Leu-Ala-Arg-Thr-Gln-Ser-Gln-Arg-Glu-Arg-Ala-Glu-Gln-Asn-Arg-Ile-Ile-Phe-Asp-Ser-Val-NH2(M.W. 4696.2) C204H337N63O64 [176591-49-4] Ligand for Type 1 / Type-2 CRF Receptors

PUC-4328-s-20 °C

0.1 mgvial

165

C.J. Donaldson, et al., Endocrinology, 137, 2167 (1996). (Original; cDNA & Pharmacol.) D.P. Behan, et al., Brain Res., 725, 263 (1996). (Biochem.) Y. Murakami, et al., Endocr. J., 44, 627 (1997). (Pharmacol.) K. Takahashi, et al., Peptides, 19, 643 (1998). (Immunohistochem.)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 119

PRODUCT CODE QTY PRICE Urocortin (Rat) (Mouse)

Asp-Asp-Pro-Pro-Leu-Ser-Ile-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Thr-Leu-Leu-Glu-Leu-Ala-Arg-Thr-Gln-Ser-Gln-Arg-Glu-Arg-Ala-Glu-Gln-Asn-Arg-Ile-Ile-Phe-Asp-Ser-Val-NH2(M.W. 4707.3) C206H338N62O64 [171543-83-2] Ligand for Type 1 / Type-2 CRF Receptors

PUC-4327-s-20 °C

0.1 mgvial

177

J. Vaughan, et al., Nature, 378, 278 (1995). (Original, cDNA & Pharmacol.) A.V. Turnbull, et al., Eur. J. Pharmacol., 03, 213 (1996). (Pharmacol.; Inhibition of Edema) M. Spina, et al., Science, 273, 1561 (1996). (Pharmacol.; Suppresion of Appetite) L.Y. Zhao, et al., Genomics, 50, 23 (1998). (Nucleotide Seq.; Mouse)

Urocortin II (Mouse)Val-Ile-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Leu-Arg-Ile-Leu-Leu-Glu-Gln-Ala-Arg-Tyr-Lys-Ala-Ala-Arg-Asn-Gln-Ala-Ala-Thr-Asn-Ala-Gln-Ile-Leu-Ala-His-Val-NH2 (M.W. 4152.9) C187H320N56O50 Selective Ligand for Type 2 CRF Receptors

PUC-4383-s-20 °C

0.1 mg vial

182

C.J. Donaldson, et al., Endocrinology, 137, 2167 (1996). (Original; Human Urocortin) T.M. Reyes, et al., Proc. Natl. Acad. Sci. USA, 98, 2834 (2001). (Original; Urocortin II) K. Lewis, C. et al., Proc. Natl. Acad. Sci. USA, 98, 7570 (2001). (Original; Urocortin II) S.Y. Hsu and A.J.W. Hsueh, Nat. Med., 7, 605 (2001). (Original; Stresscopin & Stresscopin Related Peptides) F.M. Dautzenberg and R.L. Hauger, Trends Pharmacol. Sci., 23, 71 (2002). (Review) M. Million, et al., Am. J. Physiol., 282, G34 (2002). (Pharmacol.) C. Li, et al., J. Neurosci., 22, 991 (2002). (Histochem.) V. Martínez, et al., J. Pharmacol. Exp. Ther., 301, 611 (2002). (Pharmacol.)

Substance P and Related PeptidesD. Regoli, et al., Pharmacol. Rev., 46, 551 (1994). (Review)

Substance P* (Human, Bovine, Rat, Mouse)

PSP-4014-v-20 °C

0.5 mgvial

40

Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 (M.W. 1347.6) C63H98N18O13S [33507-63-0]

Substance P* (Bulk) (Human, Bovine, Rat, Mouse)

PSP-4014-20 °C

25 mg 637

Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 • 3AcOH • 5H2O (M.W. 1347.6 • 180.16 • 90.08) C63H98N18O13S • 3CH3COOH • 5H2O Purity Information: Qp See page xiv U.S. von Euler and J.H. Gaddum, J. Physiol., 72, 74 (1931). (Naming) M.M. Chang, et al., Nature New Biol., 232, 86, (1971). (Original; Bovine) A.J. Harmar, et al., FEBS Lett., 208, 67 (1986). (cDNA Seq.; Human)

[d-Arg1,d-Pro2,d-Trp7,9,Leu11]-Substance P(Hydrochloride Form)d-Arg-d-Pro-Lys-Pro-Gln-Gln-d-Trp-Phe-d-Trp-Leu-Leu-NH2 (M.W. 1497.8) C75H108N20O13 [84676-91-5]

PSP-4172-v-20 °C

0.5 mgvial

59


120 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE [d-Arg1,d-Phe5,d-Trp7,9,Leu11]-Substance P PGH-3652-PI

-20 °C

1 mg 59

d-Arg-Pro-Lys-Pro-d-Phe-Gln-d-Trp-Phe-d-Trp-Leu-Leu-NH2 (M.W. 1516.87) C79H109N19O12 Ghrelin Antagonist / Potent Ghrelin Inverse Agonist Bombesin AntagonistP.J. Woll and E. Rozengurt, Proc. Natl. Acad. Sci. USA, 85, 1859 (1988). (Original: Bombesin Antagonist) B. Holst, et al., Mol. Endocrin. In Press. (2003). (Original: Ghrelin Antagonist)

[d-Arg1,d-Pro2,d-Trp7,9,Leu11]-Substance P (Bulk)

PSP-4172-20 °C

25 mg 1680

d-Arg-d-Pro-Lys-Pro-Gln-Gln-d-Trp-Phe-d-Trp-Leu-Leu-NH2 • 3HCl • 8H2O (M.W. 1497.8 • 109.38 • 144.12) C75H108N20O13 • 3HCI • 8H2O Bombesin Receptor Antagonist Purity Information: Qp See page xivR.T. Jensen, et al., Nature, 309, 61 (1984). (Original; Bombesin Antagonist)

[d-Arg1,d-Trp7,9,Leu11]-Substance P Spantide

(Hydrochloride Form) d-Arg-Pro-Lys-Pro-Gln-Gln-d-Trp-Phe-d-Trp-Leu-Leu-NH2 (M.W. 1497.8) C75H108N20O13 [91224-37-2]

PSP-4173-v-20 °C

0.5 mgvial

59

[d-Arg1,d-Trp7,9,Leu11]-Substance P (Bulk) Spantide

PSP-4173-20 °C

25 mg 1680

d-Arg-Pro-Lys-Pro-Gln-Gln-d-Trp-Phe-d-Trp-Leu-Leu-NH2 • 3HCl • 8H2O (M.W. 1497.8 • 109.38 • 144.12) C75H108N20O13 • 3HCI • 8H2O Substance P Antagonist Purity Information: Qp See page xiv K. Folkers, et al., Br. J. Pharmacol., 83, 449 (1984). (Original)

[d-Pro2,d-Trp7,9]-Substance P (Hydrochloride Form)Arg-d-Pro-Lys-Pro-Gln-Gln-d-Trp-Phe-d-Trp-Leu-Met-NH2 (M.W. 1515.8) C74H106N20O13S [80434-86-2]

PSP-4113-v-20 °C

0.5 mgvial

59

[d-Pro2,d-Trp7,9]-Substance P* (Bulk)Arg-d-Pro-Lys-Pro-Gln-Gln-d-Trp-Phe-d-Trp-Leu-Met-NH2 • 3HCI • 6H2O

PSP-4113-20 °C

25 mg 1680

(M.W. 1515.8 • 109.38 • 108.12) C74H106N20O13S • 3HCI • 6H2O Substance P Antagonist Purity Information: Qp See page xivG. Engberg, et al., Nature, 293, 222 (1981). (Original)

[d-Pro4,d-Trp7,9]-Substance P (4-11)d-Pro-Gln-Gln-d-Trp-Phe-d-Trp-Leu-Met-NH2l (M.W. 1134.4) C57H75N13O10S [81039-85-2] Substance P AntagonistS. Caranikas, et al., Eur. J. Pharmacol., 77, 205 (1982). (Original)

PSP-4114-v-20 °C

0.5 mgvia

54



BIOLO


Order Hotline 1-800-777-4779 502-266-8787 121

PRODUCT CODE QTY PRICE [Tyr8]-Substance P*

Arg-Pro-Lys-Pro-Gln-Gln-Phe-Tyr-Gly-Leu-Met-NH2 (M.W. 1363.6) C63H98N18O14S [55614-10-3] For Radioimmunoassay Purity Information: Qx See page xiv

PSP-4059-v-20 °C

0.5 mgvial

65

[D-Leu7]-(-)-Ternatin

Professor Uemura of Nagoya University isolated (-)-ternatin from the mushroom Coriolus versicolor and determined its structure by the combination of NMR analysis and total chemical synthesis.1 The inhibitory effects of this highly N-methylated cyclic 7-peptide, (-)-ternatin, in both adipogenesis and lipid metabolism, have been clarified in vitro as well as in vivo.2,3 These include: i) a fat accumulation inhibitory effect and cell viability in 3T3-L1 murine adipocytes (IC50 = 0.027 μM and 0.28 μM, respectively) and ii) suppression of body weight gain and fat accumulation in C57BL/6J mice at a dose of 5 mg/kg/day, together with iii) mechanism for exerting these inhibitory activity.Later, his group found [D-Leu7]-(-)-ternatin as a useful derivative of (-)-ternatin during a structure-activity relationship study. Actually, this peptide, a deletion analog of β-OH group from the 7th amino acid, β-OHD-Leu, maintains not only fat accumulation inhibitory activity with only an 8-fold-lower potency, but also the structural integrity of the parent mol-ecule.4,5 This specific analog, [D-Leu7]-(-)-ternatin, may be an alternative to (-)-ternatin in the study to combat metabolic diseases in the modern world. [D-Leu7]-(-)-Ternatin is now available from Peptides International, Inc. under an agreement with Professor Uemura.

K. Shimokawa, et al., Tetrahedron Lett., 47, 4445 (2006). ((-)-Ternatin; Structure Determination / Biological Activity in vitro)K. Shimokawa, et al., Bioorg. Med. Chem. Lett., 17, 4447 (2007).((-)-Ternatin; Biological Activity in vivo)M. Ito, et al., Peptides, 30, 1074 (2009). ((-)-Ternatin; Mechanism of Inhibitory Activity)K. Shimokawa, et al., Org. Biomol. Chem., 6, 58 (2008). (D-Leu7-(-)-Ternatin; Biological Activity in vivo)K. Shimokawa, et al., Org. Biomol. Chem., 7, 777 (2009). (D-Leu7-(-)-Ternatin; Conformation-Biological Activity Relationship)

[D-Leu7]-(-)-Ternatin**cyclo(-d-aIle-MeAla-MeLeu-Leu-MeAla-D-MeAla-d-Leu-) (M.W. 721.97)) C37H67N7O7 Fat Accumulation Inhibitor against 3T3-L1 Adipocytes

TNN-4464-v-20 °C

1 mgvial

330

T-Kinin See Code PBK-4130 Isoleucyl-Seryl-Bradykinin.Thrombin Receptor Activating Peptide See Code PAR-3932-PI H-Ala-Tyr-Pro-Gly-Lys-Phe-OH.

Thyrotropin Releasing Hormone (TRH)TRH * Thyrotropin Releasing Hormone (Human, Ovine, Porcine, Rat)

Pyr-His-Pro-NH2 (M.W. 362.38) C16H22N6O4 [24305-27-9]

PTR-4011-v-20 °C

0.5 mgvial

27

* The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc.** This compound is distributed through Peptide Institute, Inc. under the license of Nagoya University

122 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE TRH* (Bulk) Thyrotropin Releasing Hormone (Human, Ovine, Porcine, Rat)

PTR-4011-20 °C

25 mg100 mg

595161

Pyr-His-Pro-NH2 • H2O (M.W. 362.38 • 18.02) C16H22N6O4 • H2OR. Burgus, et al., C.R. Acad. Sci. Paris, 269, 1870 (1969). (Original; Ovine) J. Bøler, et al., Biochem. Biophys. Res. Commun., 37, 705 (1969). (Original; Porcine) M. Yamada, et al., Mol. Endocrinol., 4, 551 (1990). (cDNA Seq.; Human)

TMRIA-K4TMRIA-K4 PTM-3401-v

-20 °C

0.5 mgvial

185(Trifluoroacetate Form) S-[2-({4-[3,6-Bis(dimethylamino)xanthylium-9-yl]-3-carboxyphenyl} amino)-2-oxoethyl]-Cys-(Lys-Ile-Ala-Ala-Leu-Lys-Glu)4 (M.W. 3578.40) C169H282N40O42S Fluorophore Peptide in Coiled-Coil Tag-Probe Labeling System Y. Yano, et al., ACS Chem. Biol., 3, 341 (2008). (TMR-K4; Reference Paper to TMRIA-K4)

δ-melusineTM Synthetic Venom LibraryAtheris Laboratories, a world leader in venomics, venom-related research and analytical services, has partnered with Peptides International to offer a unique library of synthetic peptides derived from animal venoms for high-throughput screening against known key therapeutic targets, orphan receptors and ion channels. The libraries contain peptides which have been refolded and desalted around known structural scaffolds. These unique collections are constructed from 3 sources:

• Public domain peptides, sequences available in public databases (SwissProt/UniProt, GeneBank, etc.).

• Proprietary peptides of natural sequence identified by Atheris using NextGen venom gland transcriptomics (RNAseq) and/or peptidomic/proteomic techniques.

• Proprietary peptides designed by Atheris using algorithms of its proprietary lead optimization bioinformatics platform.

δ-melusineTM Synthetic Venom LibrarySynthetic venom libraries

DML-8000-PI-20 °C

Please Inquire

These libraries can be ordered in either a 96 or 384 well format to conveniently fit any screening platform, designed to achieve a high hit rate and, most importantly, unprecedented success rates in lead generation. Please contact Peptides International for details.



BIOLO


Order Hotline 1-800-777-4779 502-266-8787 123


w-AgatoxinsB.M. Olivera, et al., Annu. Rev. Biochem., 63, 823 (1994). (Review) O.D. Uchitel, Toxicon, 35, 1161 (1997). (Review)

w-Agatoxin IVA* w-Aga-IVA(Funnel Web Spider, Agelenopsis aperta)

PAG-4256-s-20 °C

0.1 mgvial

407

Lys-Lys-Lys-Cys-Ile-Ala-Lys-Asp-Tyr-Gly-Arg-Cys-Lys-Trp-Gly-Gly-Thr-Pro-Cys-Cys-Arg-Gly-Arg-Gly- Cys-Ile-Cys-Ser-Ile-Met-Gly-Thr-Asn-Cys-Glu-Cys-Lys-Pro-Arg-Leu-Ile-Met-Glu-Gly-Leu-Gly-Leu-Ala (Disulfide bonds between Cys4-Cys20, Cys12-Cys25, Cys19-Cys36 and Cys27-Cys34) (M.W. 5202.2) C217H360N68O60S10 P-type Ca2+ Channel Selective BlockerI.M. Mintz, et al., Nature, 355, 827 (1992). (Original) T.J. Turner, et al., Science, 258, 310 (1992). (Pharmacol.) H. Nishio, et al., Biochem. Biophys. Res. Commun., 196, 1447 (1993). (Chem. Synthesis & Biological Activity)

ω-Agatoxin TK**Omega-Agatoxin IVB, ω-Aga-TK, ω-Aga-IVB(Funnel Web Spider, Agelenopsis aperta)

PAG-4294-s-20 °C

0.1 mgvial

482

Glu-Asp-Asn-Cys-Ile-Ala-Glu-Asp-Tyr-Gly-Lys-Cys-Thr-Trp-Gly-Gly-Thr-Lys-Cys-Cys-Arg-Gly-Arg-Pro-Cys-Arg-Cys-Ser-Met-Ile-Gly-Thr-Asn-Cys-Glu-Cys-Thr-Pro-Arg-Leu-Ile-Met-Glu-Gly-Leu-d-Ser-Phe-Ala (Disulfide bonds between Cys4-Cys20, Cys12-Cys25,Cys19-Cys36 and Cys27-Cys34) (M.W. 5273.0) C215H337N65O70S10 [145017-83-0] P-type Ca2+ Channel Selective Blocker Purity Information: Qe See page xivM. Kuwada, et al., Mol. Pharmacol., 46, 587 (1994). (Original) Y. Shikata, et al., J. Biol. Chem., 270, 16719 (1995). (l-Ser to d-Ser Isomerase) M.E. Adams, et al., Mol. Pharmacol., 38, 681 (1990). (Original; ω-Aga-IVB)S.D. Heck, et al., J. Am. Chem. Soc., 116, 10426 (1994). (S-S Bond; ω-Aga-IVB) T. Teramoto, et al., Brain Res., 756, 225 (1997). (Pharmacol.) S.P. Lieske and J.-M. Ramirez, J. Neurophysiol., 95, 1323 (2006). (Pharmacol.) M. E. Adams, I. M. Mintz, M. D. Reily, V. Thanabal, and B. P. Bean,Molecular Pharmacology , 44 (4), 681 (1993).

Biotinyl-w-Agatoxin IVA Biotinyl-w-Aga-IVA

PAG-3402-s-20 °C

0.1 mgvial

430

(Trifluoroacetate Form)Biotinyl-Lys-Lys-Lys-Cys-Ile-Ala-Lys-Asp-Tyr-Gly-Arg-Cys-Lys-Trp-Gly-Gly-Thr-Pro-Cys-Cys-Arg-Gly-Arg-Gly-Cys-Ile-Cys-Ser-Ile-Met-Gly-Thr-Asn-Cys-Glu-Cys-Lys-Pro-Arg-Leu-Ile-Met-Glu-Gly-Leu-Gly-Leu-Ala (Disulfide bonds between Cys4-Cys20, Cys12-Cys25, Cys19-Cys36 and Cys27-Cys34) (M.W. 5428.5) C227H374N70O62S11 Reagent for Localization Study of w-Agatoxin IVA Binding SiteH. Nishio, et al.,Biochem. Biophys. Res. Commun., 196, 1447 (1993). (Chem. Synthesis & Biological Activity)S. Nakanishi, et al., J. Neurosci. Res., 41, 532 (1995). (Biochem.: Distribution of Binding Sites)

* This compound is distributed exclusively through Peptides International under license agreement with the University of Utah.** This product is distributed under the license of Eisai Co., Ltd. Its use for any purpose other than research is strictly prohibited.

124 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Calcicludine (CaC)* (Green Mamba, Dendroaspis angusticeps)

PCC-4310-s-20 °C

0.1 mgvial

380

Trp-Gln-Pro-Pro-Trp-Tyr-Cys-Lys-Glu-Pro-Val-Arg-Ile-Gly-Ser-Cys-Lys-Lys-Gln-Phe-Ser-Ser-Phe-Tyr-Phe-Lys-Trp-Thr-Ala-Lys-Lys-Cys-Leu-Pro-Phe-Leu-Phe-Ser-Gly-Cys-Gly-Gly-Asn-Ala-Asn-Arg-Phe-Gln-Thr-Ile-Gly-Glu-Cys-Arg-Lys-Lys-Cys-Leu-Gly-Lys (Disulfide bonds between Cys7-Cys57, Cys16-Cys40, and Cys32-Cys53) (M.W. 6980.1) C321H476N86O78S6 Neuronal L-type Ca2+ Channel BlockerH. Schweitz, et al., Proc. Natl. Acad. Sci. USA, 91, 878 (1994). (Original) H. Nishio, et al., Peptide Chemistry 1995, 113 (1996). (Chem. Synthesis & Pharmacol.) O.D. Uchitel, Toxicon, 35, 1161 (1997). (Review)J. Santos-Torres, et al., J. Neurosci. Res., 85, 634 (2007). (Pharmacol.)

Calciseptine* (Black mamba, Dendroaspis polylepis polylepis)

PCL-4255-s-20 °C

0.1 mg vial

407

Arg-Ile-Cys-Tyr-Ile-His-Lys-Ala-Ser-Leu-Pro-Arg-Ala-Thr-Lys-Thr-Cys-Val-Glu-Asn-Thr-Cys-Tyr-Lys-Met-Phe-Ile-Arg-Thr-Gln-Arg-Glu-Tyr-Ile-Ser-Glu-Arg-Gly-Cys-Gly-Cys-Pro-Thr-Ala-Met-Trp-Pro-Tyr-Gln-Thr-Glu-Cys-Cys-Lys-Gly-Asp-Arg-Cys-Asn-Lys (Disulfide bonds are between Cys3-Cys22, Cys17-Cys39, Cys41-Cys52, and Cys53-Cys58) (M.W. 7036.1) C299H468N90O87S10 [134710-25-1] L-type Ca2+ Channel BlockerJ.R. De Weille, et al., Proc. Natl. Acad. Sci. USA, 88, 2437 (1991). (Original) H. Kuroda, et al., Pept. Res., 5, 265 (1992). (Chem. Synthesis) T.X. Watanabe, et al., Jpn. J. Pharmacol., 68, 305 (1995). (Pharmacol.) N. Teramoto, et al., Pflügers Arch., 432 (1996). (Pharmacol.)

CharybdotoxinM.L. Garcia, et al., Am. J. Physiol., 269, C1 (1995). (Review)

Charybdotoxin (ChTX)* (Scorpion, Leiurus quinquestriatus hebraeus)

PCB-4227-s-20 °C

0.1 mgvial

289

Pyr-Phe-Thr-Asn-Val-Ser-Cys-Thr-Thr-Ser-Lys-Glu-Cys-Trp-Ser-Val-Cys-Gln-Arg- Leu-His-Asn-Thr-Ser-Arg-Gly-Lys-Cys-Met-Asn-Lys-Lys-Cys-Arg-Cys-Tyr-Ser (Disulfide bonds between Cys7-Cys28, Cys13-Cys33, and Cys17-Cys35) (M.W. 4295.9) C176H277N57O55S7 [95751-30-7] Ca2+-Activated K+ Channel BlockerG. Gimenez-Gallego, et al., Proc. Natl. Acad. Sci. USA, 85, 3329 (1988). (Original) P. Lambert, et al., Biochem. Biophys. Res. Commun., 170, 684 (1990). (Chem. Synthesis & Pharmacol.)



BIOLO


Order Hotline 1-800-777-4779 502-266-8787 125

PRODUCT CODE QTY PRICE Chlorotoxin (Scorpion, Leiurus quinquestriatus)

PCN-4282-v-20 °C

0.5 mgvial

691

Met-Cys-Met-Pro-Cys-Phe-Thr-Thr-Asp-His-Gln-Met-Ala-Arg-Lys-Cys-Asp-Asp-Cys- Cys-Gly-Gly-Lys-Gly-Arg-Gly-Lys-Cys-Tyr-Gly-Pro-Gln-Cys-Leu-Cys-Arg-NH2 (Reported Disulfide bonds between Cys2-Cys19,Cys5-Cys28,Cys16-Cys33 and Cys20-Cys35) (M.W. 3995.7) C158H249N53O47S11 [163515-35-3] Small-Conductance Cl - Channel BlockerJ.A. DeBin, et al., Am. J. Physiol., 264, C361 (1993). (Original) J. Najib, et al., In, Innovation and Perspective in Solid Phase Synthesis, (R. Epton, ed.), Mayflower Worldwide, Birmingham, 1994, pp. 615-618. (Original; Amide) G. Lippens, et al., Biochemistry, 34, 13 (1995). (NMR Structure) L. Soroceanu, et al., Cancer Res., 58, 4871 (1998). (Pharmacol.) D.B. Jacoby, et al., Anticancer Res., 30, 39 (2010). (Review) K. Kesavan, et al., J. Biol. Chem., 285, 4366 (2010). (Review)

ConantokinsW.R. Gray and B.M. Olivera, Annu. Rev. Biochem., 57, 665 (1998). (Review)

Conantokin G (Marine Snail, Conus geographus)

PCO-4265-v-20 °C

0.5 mgvial

241

Gly-Glu-Gla-Gla-Leu-Gln-Gla-Asn-Gln-Gla-Leu-Ile-Arg-Gla-Lys-Ser-Asn-NH2 (Gla: l-γ-Carboxyglutamic acid) (M.W. 2264.2) C88H138N26O44 [93438-65-4] Sleeper Peptide, N-Methyl-d-Aspartate (NMDA) Receptor Antagonist Purity Information: Qx See page xivJ.M. McIntosh, et al., J. Biol. Chem., 259, 14343 (1984). (Original) L.G. Hammerland, et al., Eur. J. Pharmacol., 226, 239 (1992). (Pharmacol.) Y. Nishiuchi, et al., Int. J. Pept. Protein Res, 42, 533 (1993). (Chem. Synthesis)

Conantokin T* (Marine Snail, Conus tulipa)

PCO-4264-v-20 °C

0.5 mgvial

268

Gly-Glu-Gla-Gla-Tyr-Gln-Lys-Met-Leu-Gla-Asn-Leu-Arg-Gla-Ala-Glu-Val-Lys-Lys-Asn-Ala-NH2 (Gla: l-γ-Carboxyglutamic acid) (M.W. 2683.8) C110H175N31O45S Sleeper Peptide, N-Methyl-d-Aspartate (NMDA) Receptor Antagonist Purity Information: Qx See page xivJ.A. Haack, et al., J. Biol. Chem., 265, 6025 (1990). (Original) Y. Nishiuchi, et al., Int. J. Pept. Protein Res., 42, 533 (1993). (Chem. Synthesis)


126 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Conotoxins

B.M. Olivera, et al., Science, 230, 1338 (1985). (Review) W.R. Gray, et al., Annu. Rev. Biochem., 57, 665 (1988). (Review) R.A. Myers, et al., Chem. Rev., 93, 1923 (1993). (Review) B.M. Olivera, et al., Annu. Rev. Biochem., 63, 823 (1994). (Review)

a-Conotoxin GI*‡ (Marine Snail, Conus geographus)

PCN-4126-v-20 °C

0.5 mgvial

343

(Hydrochloride Form)Glu-Cys-Cys-Asn-Pro-Ala-Cys-Gly-Arg-His-Tyr-Ser-Cys-NH2 (Disulfide bonds between Cys2-Cys7 and Cys3-Cys13) (M.W. 1437.6) C55H80N20O18S4 [76862-65-2] Blocker for Nicotinic Acetylcholine Receptor Purity Information: Qe See page xivW.R. Gray, et al., J. Biol. Chem., 256, 4734 (1981). (Original) Y. Nishiuchi and S. Sakakibara, FEBS Lett., 148, 260 (1982). (Chem. Synthesis)

a-Conotoxin ImI‡ (Marine Snail, Conus imperialis)

PCN-4311-v-20 °C

0.5 mgvial

343

Gly-Cys-Cys-Ser-Asp-Pro-Arg-Cys-Ala-Trp-Arg-Cys-NH2 (Disulfide bonds between Cys2-Cys8 and Cys3-Cys12) (M.W. 1351.6) C52H78N20O15S4 [156467-85-5] Blocker for Nicotinic Acetylcholine Receptor in Central Nervous SystemJ.M. McIntosh, et al., J. Biol. Chem., 269, 16733 (1994). (Original) D.S. Johnson, et al., Mol. Pharmacol., 48, 194 (1995). (Pharmacol.) E.F.R. Pereira, et al., J. Pharmacol. Exp. Ther., 278, 1472 (1996). (Pharmacol.; Competitive Antagonist)

a-Conotoxin MI*‡ (Marine Snail, Conus magus)

PCN-4140-v-20 °C

0.5 mgvial

343

Gly-Arg-Cys-Cys-His-Pro-Ala-Cys-Gly-Lys-Asn-Tyr-Ser-Cys-NH2 (Disulfide bonds between Cys3-Cys8 and Cys4-Cys14) (M.W. 1493.7) C58H88N22O17S4 Blocker for Nicotinic Acetylcholine ReceptorM. Mclntosh, et al., Arch. Biochem. Biophys., 218, 329 (1982). (Original) Y. Nishiuchi and S. Sakakibara, Peptide Chemistry 1983, 191, (1984). (Chem. Synthesis)

a-Conotoxin SI*‡ (Marine Snail, Conus striatus)

PCN-4228-v-20 °C

0.5 mgvial

343

Ile-Cys-Cys-Asn-Pro-Ala-Cys-Gly-Pro-Lys-Tyr-Ser-Cys-NH2 (Disulfide bonds between Cys2-Cys7 and Cys3-Cys13) (M.W. 1353.6) C55H84N16O16S4 Blocker for Nicotinic Acetylcholine ReceptorG.C. Zafaralla, et al., Biochemistry, 27, 7102 (1988). (Original)

* The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc.‡ PLEASE NOTE: For shipping within the United States, please contact Peptides International for important information regarding the CDC Select Agent Transfer Program and additional requirements for placing orders. Conotoxin peptides are not available for export without a license from the US Department of Commerce.


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 127


m-Conotoxin GIIIB*‡ (Marine Snail, Conus geographus)

PCN-4217-v-20 °C

0.5 mgvial

503

Arg-Asp-Cys-Cys-Thr-Hyp-Hyp-Arg-Lys-Cys-Lys-Asp-Arg-Arg-Cys-Lys-Hyp-Met-Lys-Cys-Cys-Ala-NH2 (Disulfide bonds between Cys3-Cys15, Cys4-Cys20, and Cys10-Cys21) (M.W. 2640.2) C101H175N39O30S7 [140678-12-2] Na+ Channel Blocker: Specific for Skeletal MuscleS. Sato, et al., FEBS Lett., 155, 277 (1983). (Original) L.J. Cruz, et al., J. Biol. Chem., 260, 9280 (1985). (Naming) Y. Ohizumi, et al., J. Biol. Chem., 261, 6149 (1986). (Pharmacol.) S. Kubo, et al., Pept. Res., 6, 66 (1993). (Chem. Synthesis and Pharmacol.)

m-Conotoxin GS‡ (Marine snail, Conus geographus)

PCN-4263-v-20 °C

0.5 mgvial

514

Ala-Cys-Ser-Gly-Arg-Gly-Ser-Arg-Cys-Hyp-Hyp-Gln-Cys-Cys-Met-Gly-Leu-Arg-Cys-Gly- Arg-Gly-Asn-Pro-Gln-Lys-Cys-Ile-Gly-Ala-His-Gla-Asp-Val (Gla: l-γ-Carboxyglutamic acid) (Disulfide bonds between Cys2-Cys14, Cys9-Cys19, and Cys13-Cys27) (M.W. 3618.1) C139H226N52O48S7 Na+ Channel BlockerY. Yanagawa, et al., Biochemistry, 27, 6256 (1988). (Original) M. Nakao, et al., Lett. Pept. Sci., 2, 17 (1995). (Chem. Synthesis and S-S Bond)

m-Conotoxin SIIIA‡

(Marine Snail, Conus striatus)PCN-4440-v

-20 °C

0.5 mgvial

386

Pyr-Asn-Cys-Cys-Asn-Gly-Gly-Cys-Ser-Ser-Lys-Trp-Cys-Arg-Asp-His-Ala-Arg-Cys-Cys-NH2 (Reported disulfide bonds between Cys3-Cys13, Cys4-Cys19, and Cys8-Cys20) (M.W. 2207.5) C83H123N33O27S6 Tetrodotoxin-Resistant Na+ Channel Blocker with Analgesic ActivityG. Bulaj, et al., Biochemistry, 44, 7259 (2005). (Original; Primary Structure & Pharmacol.)S. Yao, et al., Biochemistry, 47, 10940 (2008). (Solution Structure & Pharmacol.)C.-Z. Wang, et al., Toxicon, 47, 122 (2006). (Pharmacol.)B.R. Green, et al., Chem. Biol., 14, 399 (2007). (Pharmacol.)

w-Conotoxin GVIA*‡ (Marine Snail, Conus geographus)

PCN-4161-v-20 °C

0.5 mgvial

487

Cys-Lys-Ser-Hyp-Gly-Ser-Ser-Cys-Ser-Hyp-Thr-Ser-Tyr-Asn- Cys-Cys-Arg-Ser-Cys-Asn-Hyp-Tyr-Thr-Lys-Arg-Cys-Tyr-NH2 (Disulfide bonds between Cys1-Cys16, Cys8-Cys19, and Cys15-Cys26) (M.W. 3037.3) C120H182N38O43S6 [106375-28-4] N-type Ca2+ Channel BlockerB.M. Olivera, J.M. Mclntosh, L.J. Cruz, F.A. Luque, and W.R. Gray, Biochemistry, 23, 5087 (1984). (Original) Y. Nishiuchi, et al., Biopolymers, 25, S61 (1986). (Chem. Synthesis and S-S Bond)

* The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc.‡ PLEASE NOTE: For shipping within the United States, please contact Peptides International for important

information regarding the CDC Select Agent Transfer Program and additional requirements for placing orders. Conotoxin peptides are not available for export without a license from the US Department of Commerce.

128 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES


w-Conotoxin MVIIA*‡ (Marine Snail, Conus magus)

PCN-4289-v-20 °C

0.5 mgvial

402

Cys-Lys-Gly-Lys-Gly-Ala-Lys-Cys-Ser-Arg-Leu-Met-Tyr-Asp- Cys-Cys-Thr-Gly-Ser-Cys-Arg-Ser-Gly-Lys-Cys-NH2 (Disulfide bonds between Cys1-Cys16,Cys8-Cys20,and Cys15-Cys25) (M.W. 2639.1) C102H172N36O32S7 [107452-89-1] Reversible N-type Ca2+ Channel BlockerB.M. Olivera, et al., Biochemistry, 26, 2086 (1987). (Original) K. Valentino, et al., Proc. Natl. Acad. Sci. USA, 90, 7894 (1993). (Pharmacol.) J.A. Fox, Pflügers Arch., 429, 873 (1995). (Pharmacol.)

w-Conotoxin MVIIC‡ (Marine Snail, Conus magus)

Cys-Lys-Gly-Lys-Gly-Ala-Pro-Cys-Arg-Lys-Thr-Met-Tyr-Asp- Cys-Cys-Ser-Gly-Ser-Cys-Gly-Arg-Arg-Gly-Lys-Cys-NH2 (Disulfide bonds between Cys1-Cys16,Cys8-Cys20, and Cys15-Cys26) (M.W. 2749.3) C106H178N40O32S7 [147794-23-8] P/Q-type Ca2+ Channel Blocker

PCN-4283-s-20 °C

0.1 mg vial

204

PCN-4283-v-20 °C

0.5 mg vial

455

D.R. Hillyard, et al., Neuron, 9, 69 (1992). (Original; cDNA and Pharmacol.) M.E. Adams, et al., Biochemistry, 32, 12566 (1993). (Pharmacol.) W.A. Sather, et al., Neuron, 11, 291 (1993). (Pharmacol.) D.B. Wheeler, et al., Science, 264, 107 (1994). (Pharmacol.)

w-Conotoxin SVIB*‡ (Marine Snail, Conus striatus)

PCN-4284-v-20 °C

0.5 mgvial

402

Cys-Lys-Leu-Lys-Gly-Gln-Ser-Cys-Arg-Lys-Thr-Ser-Tyr-Asp- Cys-Cys-Ser-Gly-Ser-Cys-Gly-Arg-Ser-Gly-Lys-Cys-NH2 (Reported disulfide bonds between Cys1-Cys16,Cys8-Cys20, and Cys15-Cys26) (M.W. 2739.1) C105H176N38O36S6 [150433-82-2] N-type Ca2+ Channel BlockerC.A. Ramilo, et al., Biochemistry, 31, 9919 (1992). (Original.)

Dendrotoxin I (Black mamba, Dendroaspis polylepis polylepis)

PDN-4330-s-20 °C

0.1 mgvial

386

Pyr-Pro-Leu-Arg-Lys-Leu-Cys-Ile-Leu-His-Arg-Asp-Pro-Gly-Arg-Cys-Tyr-Gln-Lys-Ile- Pro-Ala-Phe-Tyr-Tyr-Asn-Gln-Lys-Lys-Lys-Gln-Cys-Glu-Gly-Phe-Thr-Trp-Ser-Gly-Cys- Gly-Gly-Asn-Ser-Asn-Arg-Phe-Lys-Thr-Ile-Glu-Glu-Cys-Arg-Arg-Thr-Cys-Ile-Arg-Lys (Disulfide bonds between Cys7-Cys57, Cys16-Cys40, and Cys32-Cys53) (M.W. 7133.2) C312H487N97O84S6 [107950-33-4] Voltage-Dependant K+ Channel BlockerD.J. Strydom, Nature New Biol., 243, 88 (1973). (Original) J.-N. Bidard, et al., Biochem. Biophys. Res. Commun., 143, 383 (1987). (Pharmacol.) A.L. Harvey, et al., Biochem. Biophys. Res. Commun., 163, 394 (1989). (Pharmacol.) H. Nishio, et al., J. Pept. Res., 51, 355 (1998). (Chem. Synthesis & Correction of Sequence; Asp12)

* The biological activity of this peptide is examined by the Division of Pharmacology, Peptide Institute, Inc.‡ PLEASE NOTE: For shipping within the United States, please contact Peptides International for important

information regarding the CDC Select Agent Transfer Program and additional requirements for placing orders. Conotoxin peptides are not available for export without a license from the US Department of Commerce.


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 129

PRODUCT CODE QTY PRICE EchistatinEchistatin


ECT-3760-PI-20 °C

1 mg 5 mg

12005000

H-Glu-Cys-Glu-Ser-Gly-Pro-Cys-Cys-Arg-Asn-Cys-Lys-Phe-Leu-Lys-Glu-Gly-Thr-Ile- Cys-Lys-Arg-Ala-Arg-Gly-Asp-Asp-Met-Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Cys-Asp- Cys-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr-OH (Disulfide bonds between Cys2-Cys11, Cys7-Cys32, Cys8-Cys37, and Cys20-Cys39) (M.W. 5417.14) C217H341N71O74S9 [154303-05-6] αVβ3 Integrin AntagonistJ. Musial, et al., Circulation, 82, 261 (1990). M. Sato, et al., J. Cell.Biol., 111, 1713 (1990). C.C. Kumar, et al., J. Pharmacol.Exp.Ther., 283, 843 (1997).V. Garsky, et al., Proc Nat Acad of Sciences, 86, 4022 (1989).

EnterotoxinEnterotoxigenic E.coli are able to produce several toxic peptides which may cause acute diarrhea in humans and domestic animals. The E.coli heat-stable Enterotoxin STp is syntheszied in vivo as a 72 amino acid precursor consisting of pre-, pro-, and mature region. Mature STp is composed of 18 amino acids containing three intramolecular di-sulfide bonds, which seem to be important for the correct conformation of the biologically active structure.

K.Okamoto, et al., Infect. Immun., 55, 2121 (1987). K.Okamoto and M.Takahara, J. Bacteriol., 172, 5260 (1990). H.Ozaki, et al., J. Biol. Chem., 266, 5934 (1991). H.Yamanaka, et al., Microbiol. Immunol., 37, 195 (1993). H.Yamanaka, et al., J. Bacteriol., 176, 2906 (1994).

Enterotoxin STp(Trifluoroacetate Form)

ENT-3744-PI-20 °C

1 mg5 mg

6252500

H-Asn-Thr-Phe-Tyr-Cys-Cys-Glu-Leu-Cys-Cys-Asn-Pro-Ala-Cys-Ala-Gly-Cys-Tyr-OH (Disulfide bonds between Cys5-Cys10, Cys6-Cys14, and Cys9-Cys17) (M.W. 1972.28) C81H110N20O26S6 [115474-04-9] Mature Heat-stable EnterotoxinK.Okamoto, et al., Infect. Immun., 55, 2121 (1987). K.Okamoto and M.Takahara, J. Bacteriol., 172, 5260 (1990). H.Ozaki, et al., J. Biol. Chem., 266, 5934 (1991). H.Yamanaka, et al., Microbiol. Immunol., 37, 195 (1993). H.Yamanaka, et al., J. Bacteriol., 176, 2906 (1994).

GpTX-1 ToxinH-Asp-Cys-Leu-Gly-Phe-Met-Arg-Lys-Cys-Ile-Pro-Asp-Asn-Asp-Lys-Cys-Cys-Arg-Pro-Asn-Leu-Val-Cys-Ser-Arg-Thr-His-Lys-Trp-Cys-Lys-Tyr-Val-Phe-NH2(M.W. 4073.90) C176H271N53O45S7

TGX-3862-PI-20 °C

1 mg5 mg

17704708

Tarantula Venom Peptide Antagonist; Possible Therapeutic Target for Pain Treatment34 Amino Acid Peptide with Selective Antagonist Activity for Nav1.7 ChannelJ.K. Murray, et al., Med. Chem., 58, 2299 (2015).

130 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE GsMTx-4(Chilean Rose Tarantula, Grammostola spatulata)

PCB-4393-s-20 °C

0.1 mgvial

279

Gly-Cys-Leu-Glu-Phe-Trp-Trp-Lys-Cys-Asn-Pro-Asn-Asp-Asp-Lys-Cys-Cys-Arg- Pro-Lys-Leu-Lys-Cys-Ser-Lys-Leu-Phe-Lys-Leu-Cys-Asn-Phe-Ser-Phe-NH2 (Reported disulfide bonds between Cys2-Cys17, Cys9-Cys23, and Cys16-Cys30) (M.W. 4095.8) C185H273N49O45S6 Inhibitor for Cation-Selective Stretch-Activated Channels / Atrial Fibrillation Inhibiting Peptide

Guangxitoxin

Recent efforts for identifying new drugs for Type II Diabetes have focused on inhibitors that target the delayed-rectifier K+ current (IDR), found in insulin secreting β-cells and believed to aide in repolarizing action potentials.1 Such inhibitors may increase cytosolic calcium levels and insulin secretion.2,3 A novel peptide toxin, guangxitoxin (GxTX)-1E (PGX-4433-s), was found to inhibit mouse IDR by 90%, selectively block Kv2.1/Kv2.2 channels (IC50 ~1 nmol/l), and shift the voltage-dependence for channel activation to more positive potentials, acting as a gating modifier peptide.4 Furthermore, GxTX-1E was able to increase the duration of action potentials (30% ± 6%), calcium oscillations, and insulin secretion (3.5 fold) in a glucose dependent manner in β-cell IDR.2,3,4,5 This novel peptide may help determine the mechanism and role of β-cell IDR in insulin secretion and lead to better glucose-dependent methods for treatment of Type II Diabetes.

P.A. Smith, et al., J. Gen. Physiol., 95, 1041 (1990).P.E. MacDonald, et al., J. Biol. Chem., 277, 44938 (2002).P.E. MacDonald, et al., Mol. Endocrinol., 15, 1423 (2001).J. Herrington, et al., Diabetes, 55,1034 (2006).L. Yan, et al., Diabetes, 53, 597 (2004).

Guangxitoxin-1EGxTX-1E(Tarantula, Pleisiophrictus guangxiensis sp. nov.)

PGX-4433-s -20 °C

0.1 mgvial

279

(Trifluoroacetate Form)Glu-Gly-Glu-Cys-Gly-Gly-Phe-Trp-Trp-Lys-Cys-Gly-Ser-Gly-Lys-Pro-Ala-Cys-Cys- Pro-Lys-Tyr-Val-Cys-Ser-Pro-Lys-Trp-Gly-Leu-Cys-Asn-Phe-Pro-Met-Pro (Reported disulfide bonds between Cys4-Cys19, Cys11-Cys24 and Cys18-Cys31) (M.W. 3948.6) C178H248N44O45S7 Kv2.1/Kv2.2 Channel Blocker / Enhancer of Glucose-Dependent Insulin Secretion Purity Information: QE See page xivJ. Herrington, et al., 55, 1034-1042 (2006). P.E. MacDonald, et al., J. Biol. Chem., 277, 44938 (2002). (Pharmacol.; Role of Kv2.1 in Glucose-Dependent Insulin Secretion) J. Herrington,Toxicon, 49, 231 (2007). (Review) S. Lee, et al., Biochemistry, 49, 5134 (2010). (Solution Structure & S-S Bond)N.A. Tamarina, et al., Am. J. Physiol. Endocrinol. Metab., 289, E578 (2005). (Pharmacol.; Role of Kv2.1 in Glucose-Dependent Ca2+ response)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 131

PRODUCT CODE QTY PRICE HsTX1

H-Ala-Ser-Cys-Arg-Thr-Pro-Lys-Asp-Cys-Ala-Asp-Pro-Cys-Arg-Lys-Glu-Thr-Gly-Cys-Pro-Tyr-Gly-Lys-Cys-Met-Asn-Arg-Lys-Cys-Lys-Cys-Asn-Arg-Cys-NH2

THS-3822-PI-20 °C

1 mg5 mg

7492996

(Disulfide bonds between C3-C24, C9-C29, C13-C31, and C19-C34) (M.W. 3818.53) C149H246N54O46S9 Kv1.3 channel blocker (IC50 ~ 12pM)

Huwentoxin- IV HWTX-IV(Chinese Bird Spider, Ornithoctonus huwena)

PLL-4455-s-20 °C

0.1 mgvial

316

(Trifluoroacetate Form)Glu-Cys-Leu-Glu-Ile-Phe-Lys-Ala-Cys-Asn-Pro-Ser-Asn-Asp-Gln-Cys- Cys-Lys-Ser-Ser-Lys-Leu-Val-Cys-Ser-Arg-Lys-Thr-Arg-Trp-Cys-Lys-Tyr-Gln-Ile-NH2 (Disulfide bonds between Cys2-Cys17, Cys9-Cys24, and Cys16-Cys31)(M.W. 4106.8) C174H278N52O51S6Neuronal Tetrodotoxin-Sensitive Na+- Channel BlockerK. Peng, et al., J. Biol. Chem., 277, 47564 (2002). (Original) Y. Xiao, et al., Toxicon, 51, 230 (2008). (Pharmacol.)J. Diao, et al., Toxicon, 42, 715 (2003). (cDNA Seq)Y. Xiao, et al., J. Biol. Chem., 283, 27300 (2008). (Pharmacol.)

Huwentoxin-IV was isolated from the venom of the Chinese bird spider Ornithoctonus huwena. Its structure was elucidated to be a 35-residue peptide with three disulfide linkages which are arranged to form the inhibitor cystine knot.1,2 Huwentoxin-IV is a potent inhibitor of neuronal tetrodotoxin-sensitive Na+ channels with IC50 = 30 nM.1 Further studies clarified that i) among neuronal voltage-gated Na+ channels, human Nav1.7 is most sensitive to huwentoxin-IV where site 4 of the channel is the interacting site (IC50 = 26 nM)3), and ii) huwentoxin-IV interacts with central Na+ channel isoforms from rat hippocampus neurons, while the affinity is low (IC50 = ~ 0.4 μM).4 Interestingly, huwentoxin-IV fails to partition into the artificial membrane bilayers, indicating that the mechanism for blocking Na+ channels by huwentoxin-IV is distinct from that of ProTx-II (4450-s), another Na+ channel blocker isolated from the tarantula. 4

K. Peng, et al., J. Biol. Chem., 277, 47564 (2002). (Original) J. Diao, et al., Toxicon, 42, 715 (2003). (cDNA Seq.) Y. Xiao, et al., J. Biol. Chem., 283, 27300 (2008). (Pharmacol.) Y. Xiao, et al., Toxicon, 51, 230 (2008). (Pharmacol.)

Iberiotoxin*IbTX (Scorpion, Buthus tamulus)

PIB-4235-s-20 °C

0.1 mgvial

295

Pyr-Phe-Thr-Asp-Val-Asp-Cys-Ser-Val-Ser-Lys-Glu-Cys-Trp-Ser-Val-Cys-Lys-Asp- Leu-Phe-Gly-Val-Asp-Arg-Gly-Lys-Cys-Met-Gly-Lys-Lys-Cys-Arg-Cys-Tyr-Gln (Disufide bonds are formed between Cys7-Cys28, Cys13-Cys33, and Cys17-Cys35) (M.W. 4230.8) C179H274N50O55S7 [129203-60-7] Ca2+-Activated K+ Channel Blocker (Maxi-K+ Channel Blocker)A. Galvez, et al., J. Biol. Chem., 265, 11083 (1990). (Original) M.L. Garcia, et al., J. Bioenerg. Biomembr., 23, 615 (1991). (Review) K.M. Giangiacomo, et al., Biochemistry, 31, 6719 (1992). (Pharmacol.) G.J. Kaczorowski, et al., J. Bioenerg. Biomembr., 28, 255 (1996). (Review)


132 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Iberiotoxin IbTX

PIB-3813-PI-20 °C

1 mg5 mg

7492996

(Trifluoroacetate Form) Pyr-Phe-Thr-Asp-Val-Asp-Cys-Ser-Val-Ser-Lys-Glu-Cys-Trp-Ser-Val-Cys-Lys-Asp-Leu- Phe-Gly-Val-Asp-Arg-Gly-Lys-Cys-Met-Gly-Lys-Lys-Cys-Arg-Cys-Tyr-Gln-OH (Disulfide bonds between Cys7-Cys28, Cys13-Cys33, and Cys17-Cys35)(M.W. 4230.8) C179H274N50O55S7 [129203-60-7]Ca2+-Activated K+ Channel Blocker (Maxi-K+ Channel Blocker) A. Galvez, et al., J. Biol. Chem., 265, 11083 (1990). (Original) M.L. Garcia, et al., J. Bioenerg. Biomembr., 23, 615 (1991). (Review) K.M. Giangiacomo, et al., Biochemistry, 31, 6719 (1992). (Pharmacol.) G. J. Kaczorowski, et al., J. Bioenerg. Biomembr., 28, 255 (1996). (Review)

Imperatoxin A IpTXa (Scorpion, Pandinus imperator)

PIM-4343-s-20 °C

0.1 mgvial

289

Gly-Asp-Cys-Leu-Pro-His-Leu-Lys-Arg-Cys-Lys-Ala-Asp-Asn-Asp-Cys-Cys- Gly-Lys-Lys-Cys-Lys-Arg-Arg-Gly-Thr-Asn-Ala-Glu-Lys-Arg-Cys-Arg (Disulfide bonds between Cys3-Cys17, Cys10-Cys21, and Cys16-Cys32) (M.W. 3758.4) C148H254N58O45S6 [172451-37-5] Purity: greater than 94% by HPLC Activator of Ca2+ Release Channels/Ryanodine ReceptorsH.H. Valdivia, et al., Proc. Natl. Acad. Sci. U.S.A., 89, 12185 (1992). (Pharmacol.) R. El-Hayek, et al., J. Biol. Chem., 270, 28696 (1995). (Pharmacol.) F.Z. Zamudio, et al., FEBS Lett., 405, 385 (1997). (Original; Structure) K. Takeuchi, et al., Peptide Science, 1999, 307 (2000). (S-S Bond)

Kaliotoxin (1-37)* (Scorpion, Androctonus mauretanicus mauretanicus)

PKL-4259-s-20 °C

0.1 mgvial

316

Gly-Val-Glu-Ile-Asn-Val-Lys-Cys-Ser-Gly-Ser-Pro-Gln-Cys-Leu-Lys-Pro-Cys-Lys- Asp-Ala-Gly-Met-Arg-Phe-Gly-Lys-Cys-Met-Asn-Arg-Lys-Cys-His-Cys-Thr-Pro (Reported disulfide bonds between Cys8-Cys28, Cys14-Cys33, and Cys18-Cys35) (M.W. 4021.8) C165H271N53O48S8 High Conductance Ca2+-Activated K+ Channel BlockerM. Crest, et al., J. Biol. Chem., 267, 1640 (1992). (Original) R. Romi, et al., J. Biol. Chem., 268, 26302 (1993). (Chem. Synthesis & Pharmacol.) F.R. Romi, et al., Biochemistry, 33, 14256 (1994). (Unique Structure) A.L. Harvey, et al., Toxicon, 33, 425 (1995). (Pharmacol.)

Kurtoxin (Scorpion, Parabuthus transvaalicus)

PKT-4375-s-20 °C

0.1 mgvial

370

Lys-Ile-Asp-Gly-Tyr-Pro-Val-Asp-Tyr-Trp-Asn-Cys-Lys-Arg-Ile-Cys-Trp-Tyr-Asn-Asn-Lys-Tyr-Cys- Asn-Asp-Leu-Cys-Lys-Gly-Leu-Lys-Ala-Asp-Ser-Gly-Tyr-Cys-Trp-Gly-Trp-Thr-Leu-Ser-Cys-Tyr- Cys-Gln-Gly-Leu-Pro-Asp-Asn-Ala-Arg-Ile-Lys-Arg-Ser-Gly-Arg-Cys-Arg-Ala (Disulfide bonds between Cys12-Cys61Cys16-Cys37, Cys23-Cys44, and Cys27-Cys46) (M.W. 7386.4) C324H478N94O90S8 T-type Ca2+ Channel Blocker Purity Information: Qp See page xivR.S-I. Chuang, et al., Nat. Neurosci., 1, 668 (1998). (Original) S.S. Sidach and I.M. Mintz, J. Neurosci., 22, 2023 (2002). (Pharmacol.; Specificity for Ca2+ Channel Blocking Activity) T. Olamendi-Portugal, et al., Biochem. Biophys. Res. Commun., 299, 562 (2002). (Pharmacol.) I. López-González, et al., Biochem. Biophys. Res. Commun., 300, 408 (2003). (Pharmacol.) H. Nishio, et al., Lett. Pept. Sci., in press. (Chem. Synthesis & S-S Bond)



BIOLO


Order Hotline 1-800-777-4779 502-266-8787 133

PRODUCT CODE QTY PRICE Leiurotoxin I See Code PSC-4260-s Scyllatoxin.

Mambalgin-1 (Black Mamba, Dendrooaspis polylepis)

MAM-4473-s-20 °C

0.1mg vial

461

Mambalgin-1 (Bulk)(Trifluoroacetate Form)

MAM-3778-PI-20 °C

1 mg5 mg

18193210

H-Leu-Lys-Cys-Tyr-Gln-His-Gly-Lys-Val-Val-Thr-Cys-His-Arg-Asp- Met-Lys-Phe-Cys-Tyr-His-Asn-Thr-Gly-Met-Pro-Phe-Arg-Asn-Leu- Lys-Leu-Ile-Leu-Gln-Gly-Cys-Ser-Ser-Ser-Cys-Ser-Glu-Thr-Glu- Asn-Asn-Lys-Cys-Cys-Ser-Thr-Asp-Arg-Cys-Asn-Lys-OH (Disulfide bonds Cys3-Cys19, Cys12-Cys37, Cys41-Cys49, and Cys50-Cys55) (M.W. 6554.61) C272H429N85O84S10

S. Diochot, et al., Nature, 490, 552 (2012).M. Pan, et al., Chem. Commun., 50, 5837 (2014). (NMR Structure & S-S Bond)

Margatoxin (MgTX) (Scorpion, Centruroides margaritatus)

PAR-4290-s-20 °C

0.1 mgvial

289

Thr-Ile-Ile-Asn-Val-Lys-Cys-Thr-Ser-Pro-Lys-Gln-Cys-Leu-Pro-Pro-Cys-Lys-Ala-Gln- Phe-Gly-Gln-Ser-Ala-Gly-Ala-Lys-Cys-Met-Asn-Gly-Lys-Cys-Lys-Cys-Tyr-Pro-His (Reported disulfide bonds between Cys7-Cys29,Cys13-Cys34, and Cys17-Cys36) (M.W. 4178.9) C178H286N52O50S7 [145808-47-5] Volgate-Dependent K+ Channel Blocker (Specific for Kv1.3 Channel)R.J. Leonard, et al., Proc. Natl. Acad. Sci. U.S.A., 89, 10094 (1992). (Pharmacol.) M. Garcia-Calvo, et al., J. Biol. Chem., 268, 18866 (1993). (Original) M.A. Bednarek, et al., Biochem. Biophys. Res. Commun., 198, 619 (1994). (Chem. Synthesis & S-S Bond) H.G. Knaus, et al., Biochemistry, 34,13627 (1995). (Pharmacol.)

Martentoxin I(Scorpion, Buthus martensi Karsch)

MAR-3811-PI-20 °C

1 mg5 mg

7492996

H-Gly-Leu-Ile-Asp-Val-Lys-Cys-Phe-Ala-Ser-Ser-Glu-Cys-Trp-Thr-Ala-Cys-Lys-Lys- Val-Thr-Gly-Ser-Gly-Gln-Gly-Lys-Cys-Gln-Asn-Asn-Gln-Cys-Arg-Cys-Tyr-OH (Disulfide Bonded) (M.W. 3911.50) C162H253N49O52S6 Inhibitor of Calcium-Activated K+ Channels. J. Tao, et al., PLOS one, 6e, 15896 (2011). Y. Ji, et al., J. Neurochem., 84, 325 (2003). J. Shi, et al., Biophy. Journal., 94, 3706 (2008).Z. Cao, et al., J. Peptides Res,. 62, 252 (2003).

134 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Muscarinic Toxins

L.T. Potter, Life Sci., 68, 2541 (2001). (Review) D. Servent and C. Fruchart-Gaillard, J. Neurochem., 109, 1193 (2009). (Review) E. Karlsson, et al., 82, 793 (2000). (Review)

Muscarinic acetylcholine receptors have been classified into five subtypes (M1 to M5). These receptors are involved in various biological functions, which can be studied us-ing specific ligands to each receptor subtype, including the peptidic "muscarinic toxin" (abbreviated as MT in this short description). Muscarinic toxins are isolated from the venom of the mamba species and are composed of 65 to 66 amino acid residues with four intramolecular disulfide linkages.1 It is indicated that the activation of muscarinic acetylcholine receptors can regulate the metabolism of amyloid precursor protein, and that muscarinic agonists led to a reduction of amyloid β-protein production2,3,. For ex-ample, synthetic MT7 (PMT-4340-s) has been used to study M1 receptor's role in amyloid β-protein-induced signaling.4 We offer two muscarinic toxins bearing different receptor subtype selectivity. These are muscarinic toxin 3 (MT3) and muscarinic toxin α (MTα). We determined the disulfide arrangement of synthetic MT35 and MTα, although the experimental details have not yet published for MTα. MT3 was isolated from the green mamba Dendroaspis angusticeps and is composed of 65 amino acid residues. This peptide shows selectivity for the M4 receptor with low affinity to M1 receptor, and no binding to M2, M3, andM5 receptors.6-9 Another 66-residue peptide toxin, MTα is reported to be a component of the venomous toxins of the black mamba Dendroaspis polylepis. This peptide possesses high affinity to all five subtypes; inhibition constants for M1 through M5 are 23 nM, 44 nM, 3 nM, 5 nM, and 8 nM, respectively.8, 10, 11 As far as we know, a specific ligand to M3 and M5 does not exist, thus, MTα is attractive for this reason although the subtype selectivity is rather low. Combined utilization with already commercially available MT1 (PMT-4341-s) and MT7, the research concerning biological functions elicited through muscarinic acetylcholine re-ceptors should advance significantly, using these chemically synthesized MT3 and MTα.

K.N. Bradley, Pharmacol. Ther., 85, 87 (2000). (Review)T.G. Beach, et al., Brain Res., 905, 220 (2001). (Pharmacol.)C. Hock, et al., J. Protein Folding Disord., 10, 1 (2003). (Pharmacol.)Z. Gu, et al., J. Biol. Chem., 278, 17546 (2003). (Pharmacol.; Role in Aβ -Induced Signaling)S. Katayama, et al., Peptide Science 2004, 161 (2005). (S-S Bond of MT3)M. Jolkkonen, et al., FEBS Lett., 352, 91 (1994). (Original; MT3)J.-S. Liang, et al., Toxicon, 34, 1257 (1996). (Original; m4-toxin)A. Adem and E. Karlsson, Life Sci., 60, 1069 (1997). (Pharmacol.; Muscarinic Receptor Subtype Specificity) M. C. Olianas, et al., Eur. J. Pharmacol., 357, 235 (1998). (Pharmacol.; cAMP-Coupled M4 Receptor)M. Jolkkonen, et al., Eur. J. Biochem., 234, 579 (1995). (Original; MTα)M. Jolkkonen, et al., Toxicon, 39, 377 (2001). (Pharmacol.; Mechanism of Receptor Binding)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 135

PRODUCT CODE QTY PRICE Muscarinic Toxin 1 MTX1, MT1 (Green Mamba, Dendroaspis angusticeps)

PMT-4341-s-20 °C

0.1 mgtvial

386

Leu-Thr-Cys-Val-Thr-Ser-Lys-Ser-Ile-Phe-Gly-Ile-Thr-Thr-Glu-Asn-Cys-Pro-Asp-Gly-Gln-Asn-Leu- Cys-Phe-Lys-Lys-Trp-Tyr-Tyr-Ile-Val-Pro-Arg-Tyr-Ser-Asp-Ile-Thr-Trp-Gly-Cys-Ala-Ala-Thr-Cys- Pro-Lys-Pro-Thr-Asn-Val-Arg-Glu-Thr-Ile-Arg-Cys-Cys-Glu-Thr-Asp-Lys-Cys-Asn-Glu (Disulfide bonds between Cys3-Cys24, Cys17-Cys42, Cys46-Cys58, and Cys59-Cys64) (M.W. 7509.5) C326H499N87O101S8 Agonist for Muscarinic Acetylcholine Receptor-1 (M1 / M4 ) (Non-Specific Ligand) Purity Information: Qp See page xivM. Jolkkonen, et al., Toxicon, 33, 399 (1995). (Original-Structure) D. Jerusalinsky and A.L. Harvey, Trends Pharmacol. Sci., 15, 424 (1994). (Review; Toxin for Muscarinic Receptor) A. Adem and E. Karlsson, Life Sci., 60, 1069 (1997). (Pharmacol.) H.Nishio, et al., Peptide Science, 1999, 125 (2000). (S-S Bond )

Muscarinic Toxin 3MT3, MTX3, m4-Toxin(Green Mamba, Dendroaspis angusticeps)

PMT-4410-s-20 °C

0.1 mgvial

386

Leu-Thr-Cys-Val-Thr-Lys-Asn-Thr-Ile-Phe-Gly-Ile-Thr-Thr-Glu-Asn-Cys-Pro-Ala-Gly-Gln-Asn-Leu- Cys-Phe-Lys-Arg-Trp-His-Tyr-Val-Ile-Pro-Arg-Tyr-Thr-Glu-Ile-Thr-Arg-Gly-Cys-Ala-Ala-Thr- Cys-Pro-Ile-Pro-Glu-Asn-Tyr-Asp-Ser-Ile-His-Cys-Cys-Lys-Thr-Asp-Lys-Cys-Asn-Glu (Disulfide bonds between Cys3- Cys24, Cys17- Cys42, Cys46- Cys57, and Cys58- Cys63) (M.W. 7379.4) C319H489N89O97S8 Specific Ligand for Muscarinic Acetylcholine Receptor-4 (M4)M. Jolkkonen, et al., FEBS Lett., 352, 91 (1994). (Original; MT3) J.-S. Liang, et al., Toxicon, 34, 1257 (1996). (Original; m4-toxin) A. Adem and E. Karlsson, Life Sci., 60, 1069 (1997). (Pharmacol.; Muscarinic Receptor Subtype Specificity)S. Katayama, et al., Peptide Science 2004, 161 (2005). (S-S Bond)

Muscarinic Toxin 7 MTX7, MT7, m1-Toxin 1 (Green Mamba, Dendroaspis angusticeps)

PMT-4340-s-20 °C

0.1 mgvial

386

Leu-Thr-Cys-Val-Lys-Ser-Asn-Ser-Ile-Trp-Phe-Pro-Thr-Ser-Glu-Asp-Cys-Pro-Asp-Gly-Gln-Asn-Leu- Cys-Phe-Lys-Arg-Trp-Gln-Tyr-Ile-Ser-Pro-Arg-Met-Tyr-Asp-Phe-Thr-Arg-Gly-Cys-Ala-Ala-Thr- Cys-Pro-Lys-Ala-Glu-Tyr-Arg-Asp-Val-Ile-Asn-Cys-Cys-Gly-Thr-Asp-Lys-Cys-Asn-Lys (Disulfide bonds between Cys3-Cys24, Cys17-Cys42, Cys46-Cys57, and Cys58-Cys63) (M.W. 7472.4) C322H484N90O98S9 Specific Ligand for Muscarinic Acetylcholine Receptor-1 (M1)A. Adem and E. Karlsson, Life Sci., 60, 1069 (1997). (Original) H. Nishio, et al., Peptide Science, 1999, 125 (2000). (S-S Bond) J.M. Carsi and L.T. Potter, Toxicon, 38, 187 (2000). (Original; m1-toxin1) Z. Gu, et al., J. Biol. Chem., 278, 17546 (2003). (Pharmacol; Inhibition of b-Amyloid signaling)

Muscarinic Toxin α MTα(Black Mamba, Dendroaspis polylepis)

PMT-4424-s-20 °C

0.1 mgvial

386

Leu-Thr-Cys-Val-Thr-Ser-Lys-Ser-Ile-Phe-Gly-Ile-Thr-Thr-Glu-Asn-Cys-Pro-Asp-Gly-Gln-Asn-Leu- Cys-Phe-Lys-Lys-Trp-Tyr-Tyr-Leu-Asn-His-Arg-Tyr-Ser-Asp-Ile-Thr-Trp-Gly-Cys-Ala-Ala-Thr- Cys-Pro-Lys-Pro-Thr-Asn-Val-Arg-Glu-Thr-Ile-His-Cys-Cys-Glu-Thr-Asp-Lys-Cys-Asn-Glu (Disulfide bonds between Cys3-Cys24, Cys17-Cys42, Cys46-Cys58, and Cys59-Cys64) (M.W. 7545.4) C326H491N89O102S8 Ligand for Muscarinic Acetylcholine Receptor-3/4/5 (M3/M4/M5) (Non-specific Ligand)

136 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Neurotoxin NSTX-3 (Papua New Guinean Spider, Nephila maculata)

PNT-4195-s-20 °C

0.1 mgvial

124

2,4-Dihydroxyphenylacetyl-l-Asparaginyl-N1-(l-Arginyl-Putreanyl)-Cadaverine (M.W. 664.80) C30H52N10O7

Y. Aramaki, et al., Proc. Japan Acad., 62 (B), 359 (1986). (Original) T. Teshima, et al., Tetrahedron Letters, 28, 3509 (1987). (Chem. Synthesis, Preliminary) T. Teshima, et al., Tetrahedron, 47, 3305 (1991). (Chem. Synthesis; Total Synthesis)

* This compound is distributed through Peptide Institute, Inc. under the license of Takeda, Chemical Industries, Ltd. and the Tokyo Metropolitan Institute for Neurosciences.

OD1 Toxin(Scorpion, Odonthobuthus doriae)

ODT-3866-PI-20 °C

1 mg 2996

Asp-Lys-Asn-Cys-Val-Tyr-Thr-Cys-Ala-Ser-Asn-Gly-Tyr-Cys-Asn-Thr-Glu-Cys-Thr- Lys-Asn-Gly-Ala-Glu-Ser-Gly-Tyr-Cys-Gln-Trp-Ile-Gly-Arg-Tyr-Gly-Asn-Ala-Cys-Trp- Cys-Ile-Lys-Leu-Pro-Asp-Glu-Val-Pro-Ile-Arg-Ile-Pro-Gly-Lys-Cys-Arg-NH2 (Disulfide bonded) (M.W. 7206.21) C308H466N90O95S8 A Potent Nav1.7 Channel ActivatorA. Jalali, et al., FEBS Lett., 579, 4181 (2005). T. Durek, et al., Chem. Biol., 8, 1215 (2013).

OD1 is a scorpion peptide that was originally isolated from the venom of the scorpion Odonthobuthus doriae.1 OD1 is a 65 residue peptide stabilized by 4 intramolecular di-sulfide bonds.2 It potently inhibits fast inactivation of mammalian channels Nav1.7 (EC50 4.5 nM), Nav1.4 (EC50 10 ± 2 nM) and Nav1.6 (EC50 47 ± 10 nM).1 OD1 also blocks fast inactivation of the para/tipE insect channel (EC50 80 nM). OD1 weakly affects mammalian Nav1.3 and Nav1.5 (EC50 > 1 μM) and does not affect Nav1.2 and Nav1.8. OD1 induces spontaneous pain when injected in animal in association with or without veratridine and can be used to test the analgesic effects of Nav1.7 blockers in-vivo.3 We are pleased to offer our first α-type scorpion Nav channel toxin.

A. Jalali, et al., OD1, the first toxin isolated from the venom of the scorpion Odonthobuthus doriae active on voltage-gated Na+ channels. FEBS Lett., 579, 4181 (2005). PMID: 16038905T. Durek, et al., Chemical Engineering and Structural and Pharmacological Characterization of the α-Scorpion Toxin OD1. Chem. Biol., 8, 1215, (2013). PIMD: 3527544C. Maertens, et al., Potent Modulation of the Voltage-Gated Sodium Channel Nav1.7 by OD1, a Toxin from the Scorpion Odonthobuthus doriae. Mol. Pharmacol. (2006) PMID: 16641312

PLTX-II (Spider, Plectreurys tristes)

PPL-4300-s-20 °C

0.1 mgvial

487

Ala-Asp-Cys-Ser-Ala-Thr-Gly-Asp-Thr-Cys-Asp-His-Thr-Lys-Lys-Cys-Cys-Asp-Asp-Cys-Tyr-Thr-Cys-Arg-Cys-Gly-Thr-Pro-Trp-Gly-Ala-Asn-Cys-Arg-Cys-Asp-Tyr-Tyr-Lys-Ala-Arg-Cys-Asp-Thr(Palmitoyl)-NH2 (Disulfide bonds undetermined) (M.W. 5108.7) C208H313N61O70S10 Presynaptic Ca2+ Channel BlockerW.D. Branton, et al., J. Neurosci., 7, 4195 (1987). (Original) H.-T. Leung, et al., Neuron, 3, 767 (1989). (Pharmacol.) W.D. Branton, et al., Nature, 365, 496 (1993). (Thr(Pal)amide) J. Bódi, et al., Pept. Res., 8, 228 (1995). (Chem. Synthesis & Biological Activity) G.F. King, Toxicon, 49, 513 (2007). (Review)


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 137

PRODUCT CODE QTY PRICE ProTx-I and ProTx-II

ProTx-I and ProTx-II were first isolated and characterized from the venom of ta-rantula Thrixopelma pruriens.1-3 These peptide toxins belong to the inhibitory cystine knot (ICK) family, which is known to interact with voltage-gated ion channels. They are unique because they alter the rate of activation rather than inactivation of chan-nels. Otherwise, there is no sequence homology between ProTx-I and Pro-Tx-II. ProTx-II is the newest toxin currently offered by Peptides International and produced by the Peptide Institute in Japan. It was shown to be at least 100-fold selective for Nav1.7 channel with an IC50 of 0.3 nM.4 Sodium channel subtype Nav1.7 has a role in modulat-ing neuronal signaling for pain, and recent studies indicate loss-of-function mutations in Nav1.7 cause insensitivity to pain.5 Others have identified gain-of-function mutations in Nav1.7 as the cause of certain pain disorders.6-8 Thus Nav1.7 is a potential target for the development of analgesics.The highly sensitive nature of ProTx-II for Nav1.7 is believed to be due to the presence of a unique phenylalanine residue (F813) present in the C-terminal domain II S3 of the chan-nel, which makes it different than the other sodium channel subtypes. Indeed, mutation of the F813 residue to glycine or serine reduced the sensitivity of ProTx-II significantly.4 Evidence indicates ProTx-II may not be able to cross the blood-nerve barrier since in-travenous administration in rats did not significantly block acute pain response. In addi-tion, the toxin can block C-fiber action potential propagation in desheathed but not intact nerves.4 While this may limit the use of ProTx-II, the toxin should still act as an important tool for locating novel inhibitors for Nav1.7.

R.E. Middleton, et al., Biochemistry, 41, 14734 (2002). (Original) B.T. Priest, et al., Toxicon, 49, 194 (2007). (Review) J.J. Smith, et al., J. Biol. Chem.,282, 12687 (2007). (Pharmacol.; Novel Toxin Binding Site Coupled to Nav Activation)W.A. Schmalhofer, et al., Mol. Pharmacol., 74,1476 (2008).S.D. Dib-Hajj, et al., Trends Neurosci, 30, 555 (2007).C.R. Fertleman, et al., Neuron, 52, 767 (2006).C. Han, et al., Ann Neurol., 59, 553 (2006). Y. Yang,et al., Journal of Med. Genetics, 41171 (2004).

ProTx-I(Tarantula, Thrixopelma pruriens)

PTX-4409-s-20 °C

0.1 mgvial

300

Glu-Cys-Arg-Tyr-Trp-Leu-Gly-Gly-Cys-Ser-Ala-Gly-Gln-Thr-Cys-Cys-Lys-His- Leu-Val-Cys-Ser-Arg-Arg-His-Gly-Trp-Cys-Val-Trp-Asp-Gly-Thr-Phe-Ser (Disulfide bonds between Cys2-Cys16, Cys9-Cys21, and Cys15- Cys28) (M.W. 3987.5) C171H245N53O47S6 T-Type Ca2+ Channel / Na+ Channel / K+ Channel Blocker (Gating Modifier)R.E. Middleton, et al., Biochemistry, 41, 14734 (2002). (Original)T. Ohkubo, et al., J. Pharmacol. Sci., 112, 452 (2010). (Pharmacol.)B.T. Priest, et al., Toxicon, 49, 194 (2007). (Review)

138 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE ProTx-II(Tarantula, Thrixopelma pruriens)

PTX-4450-s -20 °C

0.1 mgvial

2680

YCQKWMWTCDSERKCCEGMVCRLWCKKKLW Tyr-Cys-Gln-Lys-Trp-Met-Trp-Thr-Cys-Asp-Ser-Glu-Arg-Lys-Cys-Cys- Glu-Gly-Met-Val-Cys-Arg-Leu-Trp-Cys-Lys-Lys-Lys-Leu-Trp(Disulfide bonds between Cys2-Cys16, Cys9- Cys21, and Cys15-Cys25) (M.W. 3826.60) C168H250N46O41S8 Na+ Channel (Especially Nav1.7) / Ca2

+ Channel Blocker (Gating Modifier)R.E. Middleton, et al., Biochemistry, 41, 14734 (2002). (Original)J.J. Smith, et al., J. Biol. Chem., 282, 12687 (2007). (Pharmacol.; Novel Toxin Binding Site Coupled to Nav Activation)W.A. Schmalhofer, et al., Mol. Pharmacol, 74, 1476 (2008). (Pharmacol.; Inhibition of Nav1.7 Channels)S.D. Dib-Hajj, et al., Trends Neurosci., 30, 555 (2007). (Review)B.T. Priest, et al., Toxicon, 49, 194 (2007). (Review) S. Sokolov, et al., Mol. Pharmacol., 73, 1020 (2008). (Pharmacol.)

PsalmotoxinThe acid-sensing ion channel (ASIC) family is involved with pain perception, learning, and memory. In addition, the ion channels may contribute to brain injury and neuronal death. ASIC is stimulated by H+ ligand, and activation is calcium dependent.1,2 Peptide toxins have been invaluable tools for inhibition of ion conductance pathways and in functional/structural studies of channels. Psalmotoxin 1 (PTX-4435-s), isolated from the venom of tarantula Psalmopoeus cambridgei, is the first potent peptide blocker shown to inhibit ASIC1a by increasing affinity of the channel for H+, leading to receptor desensitization.4,5,6 This toxin showed promise as a neuroprotective agent for ASIC1a mediated ischemic brain injury (100 ng/ml) and could selectively inhibit malignant glioma (IC50 = 36 pM) Na+ channels (both inward and outward).7,8 Further studies of Psalmotoxin ASIC1a interaction could lead to potential diagnosis and therapy of these and other ASIC1a-related diseases.

E.L. Bässler, et. al., J. Biol. Chem., 276, 33782 (2001). E. Babini, et. al., J.Biol. Chem., 277, 41597 (2002). V.I. Pidoplichko and J.A. Dani, PNAS, 203, 11376 (2006). P. Escoubas, et. al., J. Biol. Chem., 275, 25116 (2000). M. Salinas, et. al., J. Physiol., 570, 339 (2005). X. Chen, et. al., J. Gen. Physiol., 126, 71 (2005). G. Pignataro, et. al., Brain, 10, 1093 (2006). J.K. Bubien, et. al., Am. J. Physiol. Cell Physiol., 287, C1282 (2004).


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 139

PRODUCT CODE QTY PRICE Psalmotoxin 1PcTX1(South American Tarantula, Psalmopoeus cambridgei)

PTX-4435-s-20 °C

0.1 mgvial

300

(Trifluoroacetate Form)Glu-Asp-Cys-Ile-Pro-Lys-Trp-Lys-Gly-Cys-Val-Asn-Arg-His-Gly-Asp-Cys-Cys-Glu-Gly- Leu-Glu-Cys-Trp-Lys-Arg-Arg-Arg-Ser-Phe-Glu-Val-Cys-Val-Pro-Lys-Thr-Pro-Lys-Thr (Disulfide bonds between Cys3-Cys18, Cys10-Cys23, and Cys17-Cys33) (M.W. 4689.40) C200H312N62O57S6 Selective Blocker for Acid-Sensitive Ion Channel, ASIC1a Purity Information: Qe See page xivP. Escoubas, et al., J. Biol. Chem., 275, 25116 (2000). (Original; Primary Structure & ASIC Blocking Selectivity)P. Escoubas, et al., Protein Sci., 12, 1332 (2003). (Three-dimensional Solution Structure)X. Chen, et al., J. Gen. Physiol., 127, 267 (2006). (Pharmacol.; State-Dependent Function) X. Chen, et al., J. Gen. Physiol., 126, 71 (2005). (Pharmacol.; Mechanism of Channel Inhibition)J.K. Bubien, et al., Am. J. Cell Physiol., 287, C1282 (2004). (Pharmacol.; Inhibition of Malignant Glioma Na+ Channels)Z.-G. Xiong, et al., Cell, 118, 687 (2004). (Pharmacol.; Neuroprotection in Ischemia)S. Diochot, et al., Toxicon, 49, 271 (2007). (Review)Y.J. Qadri, et al., J. Biol. Chem., 284, 17625 (2009). (Pharmacol.)

Purotoxin-1(Wolf Spider, Geolycosa sp.)

PPT-4457-s -20 °C

0.1 mgvial

295

Gly-Tyr-Cys-Ala-Glu-Lys-Gly-Ile-Arg-Cys-Asp-Asp-Ile-His-Cys-Cys-Thr-Gly- Leu-Lys-Cys-Lys-Cys-Asn-Ala-Ser-Gly-Tyr-Asn-Cys-Val-Cys-Arg-Lys-Lys (Reported disulfide bonds between Cys3-Cys16, Cys10-Cys21, Cys15-Cys32, and Cys23-Cys30) (M.W. 3836.50) C155H248N50O48S8 Inhibitor of P2X3 PurinoreceptorsE.V. Grishin, et al., Ann. Neurol., 67, 680 (2010). (Original; Structure & Pharmacol.)

RhTx H-LNNPCNGVTCPSGYRCSIVDKQCIKKE-OH

RHT-3832-PI-20 °C

1 mg5 mg

6422568

(Trifluoroacetate Form)H-Leu-Asn-Asn-Pro-Cys-Asn-Gly-Val-Thr-Cys-Pro-Ser-Gly-Tyr- Arg-Cys-Ser-Ile-Val-Asp-Lys-Gln-Cys-Ile-Lys-Lys-Glu-OH (Disulfide bonds between Cys5-Cys16 and Cys10-Cys23) (M.W. 2966.45) C123H201N37O40S4 A Potent Activator of TRPV1 Capsaicin Receptor, Inducing Intense PainS. Yang, et al., Nature Communications, 6, 8297 (2015).

140 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Sarafotoxins

E. Kochva, et al., Toxicon, 31, 541 (1993). (Review) F. Ducancel, Cell. Mol. Life Sci., 62, 2828 (2005). (Review) F. Ducancel, Toxicon, 40, 1541 (2002). (Review)

Sarafotoxin S6b* (Snake, Atractaspis engaddensis)

PSF-4206-s-20 °C

0.1 mgvial

193

Cys-Ser-Cys-Lys-Asp-Met-Thr-Asp-Lys-Glu-Cys-Leu-Tyr-Phe-Cys-His-Gln-Asp-Val-Ile-Trp (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 2563.9) C110H159N27O34S5 [120972-53-4] Endothelin Related Peptide C. Takasaki, et al., Toxicon, 26, 543 (1988). (Original; Chem. Structure) Y. Kloog, et al., Science, 242, 268 (1988). (Original; Biochem.) K. Nakajima, et al., J. Cardiovasc. Pharmacol., 13 (Suppl. 5), 58 (1989). (Chem. Synthesis and Biological Activity) T.X. Watanabe, et al., J. Cardiovasc. Pharmacol., 17, S5 (1991). (Pharmacol.)

Sarafotoxin S6c* (Snake, Atractaspis engaddensis)

PSF-4246-s-20 °C

0.1 mgvial

193

Cys-Thr-Cys-Asn-Asp-Met-Thr-Asp-Glu-Glu-Cys-Leu-Asn-Phe-Cys-His-Gln-Asp-Val-Ile-Trp (Disulfide bonds between Cys1-Cys15 and Cys3-Cys11) (M.W. 2515.8) C103H147N27O37S5 [121695-87-2] Selective ETB Receptor AgonistC. Takasaki, et al., Toxicon, 26, 543 (1988). (Original; Chem. Structure) W.G. Nayler, et al., Biochem. Biophys. Res. Commun., 161, 89 (1989). (Pharmacol.) D.L. Williams, Jr., et al. Biochem. Biophys. Res. Commun., 175, 556 (1991). (Pharmacol.)

Scyllatoxin Leiurotoxin I (Scorpion, Leiurus quinquestriatus hebraeus)

PSC-4260-s-20 °C

0.1 mgvial

279

Ala-Phe-Cys-Asn-Leu-Arg-Met-Cys-Gln-Leu-Ser-Cys-Arg-Ser-Leu-Gly- Leu-Leu-Gly-Lys-Cys-Ile-Gly-Asp-Lys-Cys-Glu-Cys-Val-Lys-His-NH2 (Reported disulfide bonds betwen Cys3-Cys21, Cys8-Cys26, and Cys12-Cys28) (M.W. 3423.1) C142H237N45O39S7 [142948-19-4] Small Conductance Ca2+-Activated K+ Channel BlockerG.G. Chicchi, et al., J. Biol. Chem., 263, 10192 (1988). (Original) P. Auguste, et al., Biochemistry, 31, 648 (1992). (Pharmacol.) J.C. Martins, et al., J. Mol. Biol., 253, 590 (1995). (S-S Bond)

SNX-482 (Tarantula, Hysterocrates gigas)

PCB-4363-s-20 °C

0.1 mgvial

407

Gly-Val-Asp-Lys-Ala-Gly-Cys-Arg-Tyr-Met-Phe-Gly-Gly-Cys-Ser-Val-Asn-Asp-Asp-Cys-Cys- Pro-Arg-Leu-Gly-Cys-His-Ser-Leu-Phe-Ser-Tyr-Cys-Ala-Trp-Asp-Leu-Thr-Phe-Ser-Asp (Reported disulfide bonds between Cys7-Cys21, Cys14-Cys26, and Cys20-Cys33) (M.W. 4495.0 ) C192H274N52O60S7 [203460-30-4] Class-E (R-Type) Ca2+ Channel BlockerR. Newcomb, et al., Biochemistry, 37, 15353 (1998). (Original) L. Ürge, et al., In, Peptides 1998, Proceedings of 25th European Peptide Symposium (S. Bajusz and F. Hudecz, eds.), Akadémiai Kiadó Butapest, 1998, 748-749 (1998). (S-S Bond) A. Tottene, et al., J. Neurosci., 20, 171 (2000). (Pharmacol.) G. Wang, et al., J. Neurosci., 19, 9235 (1999). (Pharmacol.) D. Sochivko, et al., J. Physiol., 542, 699 (2002). (Pharmacol.)X. Jing, et al., J. Clin. Invest., 115, 146 (2005). (Pharmacol.)



BIOLO


Order Hotline 1-800-777-4779 502-266-8787 141

PRODUCT CODE QTY PRICE Stichodactyla Toxin (ShK) (Sea Anemone, Stichodactyla helianthus)

PSK-4287-s-20 °C

0.1 mgvial

295

Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys- His-Ser-Met-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (Disulfide bonds between Cys3-Cys35, Cys12-Cys28, and Cys17-Cys32) (M.W. 4054.8) C169H274N54O48S7 Voltage Dependent K+ Channel (A Channel) BlockerE. Karlsson, et al., Toxicon, 31, 504 (1993). (Original; in Abstract) J. Pohl, F. Hubalek, M.E. Byrnes, K.R. Nielsen, A. Woods, and M.W. Pennington, Lett. Pept. Sci., 1, 291 (1994). (S-S Bond) O. Castañeda, et al., Toxicon, 33, 603 (1995). (Pharmacol.)

Stichodactyla Toxin (ShK) (Amide) (Sea Anemone, Stichodactyla helianthus)

SHK-3770-PI-20 °C

1 mg5 mg

10704280

H-Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys- His-Ser-Met-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys-NH2 (Disulfide bonds between Cys3-Cys35, Cys12-Cys28, and Cys17-Cys32) (M.W. 4053.86) C169H275N55O47S7 Voltage Dependent K+ Channel (A Channel) BlockerE. Karlsson,et al., Toxicon, 31, 504 (1993). (Original; in Abstract) O. Castañeda, et al., Toxicon, 33, 603 (1995). (Pharmacol.)

5-Fam-ShK(Sea Anemone, Stichodactyla helianthus)

SHK-3746-PI-20 °C

1 mg 1500

(Trifluoroacetate Form)Fluorescein-5-carbonyl-AEEAc-Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe- Gln-Cys-Lys-His-Ser-Met-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys-NH2 (Disulfide bonds between Cys3-Cys35, Cys12-Cys28, and Cys17-Cys32) (M.W. 4557.33) C196H296N56O56S7

C. Beeton, et al., J. Biol. Chem., 278, 9928 (2003)R.S. Norton, et al., Curr. Med. Chem., 11, 3141 (2004)

Tertiapin (Honey Bee, Apis mellifera)

PTK-4364-s-20 °C

0.1 mgvial

193

Ala-Leu-Cys-Asn-Cys-Asn-Arg-Ile-Ile-Ile-Pro-His-Met-Cys-Trp-Lys-Lys-Cys-Gly-Lys-Lys-NH2 (Disulfide bonds between Cys3-Cys14 and Cys5-Cys18) (M.W. 2455.1) C106H176N34O23S5 Inward Rectifier K+ Channel BlockerW. Jin and Z. Lu, Biochemistry, 37, 13291 (1998). (Original; Pharmacol.) X. Xu and J.W. Nelson, Proteins Struct. Funct. Genet., 17, 124 (1993). (Structure; S-S Bond) H. Kitamura, et al., J. Pharmacol. Exp.Ther., 293, 196 (2000). (Pharmacol.) M.-D. Drici, et al., Br. J. Pharmacol., 131, 569 (2000). (Pharmacol.)

Tertiapin-Q TER-3833-PI-20 °C

1 mg5 mg


H-Ala-Leu-Cys-Asn-Cys-Asn-Arg-Ile-Ile-Ile-Pro- His-Gln-Cys-Trp-Lys-Lys-Cys-Gly-Lys-Lys-NH2 (Disulfide bonds between Cys3-Cys14 and Cys5-Cys18) (M.W. 2452.05) C106H175N35O24S4 [252198-49-5]J.P. Felix, et al., Biochemistry, 45,10129 (2006). R. Kanjhan, et al., J Pharmacol Exp Ther., 314, 1353 (2005). W. Jin, et al., Biochemistry, 38, 14294 (1999). W. Jin and Z. Li, Biochemistry, 26, 14286 (1999).

142 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE Tityustoxin Kα (TsTX-Kα) (Scorpion, Tityus serrulatus)

PTT-4313-s-20 °C

0.1 mgvial

386

Val-Phe-Ile-Asn-Ala-Lys-Cys-Arg-Gly-Ser-Pro-Glu-Cys-Leu-Pro-Lys-Cys-Lys-Glu- Ala-Ile-Gly-Lys-Ala-Ala-Gly-Lys-Cys-Met-Asn-Gly-Lys-Cys-Lys-Cys-Tyr-Pro (Reported disulfide bonds between Cys7-Cys28, Cys13-Cys33, and Cys17-Cys35) (M.W. 3941.7) C168H275N49O46S7 Voltage-Dependent K+ Channel (A Channel) BlockerT.R.Werkman, et al., Mol. Pharmacol., 44, 430 (1993). (Original) R.S. Rogowski, et al., Proc. Natl. Acad. Sci. U.S.A., 91, 1475 (1994). (Pharmacol.) W.F. Hopkins, J. Pharmacol. Exp. Ther., 285, 1051 (1998). (Pharmacol.) K.C. Ellis, et al., Biochemistry, 40, 5942 (2001). (S-S Bond)

Tylotoin TYL-3814-PI-20 °C

1 mg5 mg

210 840H-Lys-(Cys-Val-Arg-Gln-Asn-Asn-Lys-Arg-Val-Cys)-Lys-OH

(M.W. 1473.80) C59H108N24O16S2 Potential Wound Healing Peptide, Found in Salamander (Tylototriton verrucosus) Skin. Enhances Kerati-nocyte, Fibroblast and Vascular Endothelial Cell Proliferation and Migration.

TuftsinTuftsin

Thr-Lys-Pro-Arg (M.W. 500.59) C21H40N8O6 [9063-57-4]

PTF-4020-v-20 °C

0.5 mgvial

38

Tuftsin (Bulk) PTF-4020-20 °C

25 mg100 mg

156461

Thr-Lys-Pro-Arg • 2AcOH • 4H2O (M.W. 500.59 • 120.10 • 72.06) C21H40N8O6 • 2CH3COOH • 4H2O [72103-53-8] Phagocytosis-Stimulating PeptideK. Nishioka, et al., Biochem. Biophys. Res. Commun., 47, 172 (1972). (Original) K. Nishioka, et al., Biochim. Biophys. Acta, 310, 230 (1973). (Chem. Synthesis & Pharmacol.)

Urantide™ See Code PUT-3639-PI Urotensin Related Products.Urocortin See Stresscopins / Urocortin and Related Peptides.


BIOLO


Order Hotline 1-800-777-4779 502-266-8787 143

PRODUCT CODE QTY PRICE Urotensin II and Related Peptides

Urotensin II is one of the most potent vasoconstrictors known, and Urantide has been reported to be the most potent antagonist of urotensin II - until now.1,2 Recent studies replacing the Asp amino acid in Urantide led to the discovery of a new urotensin II antagonist, H-Tic-[Pen-Phe-d-Trp-Orn-Tyr-Cys]-Val-OH. It was found to be more potent than Urantide at inducing contractions in isolated rat thoracic aorta, with a pA2 value of 9.0 compared to a pA2 value of 8.3 for Urantide.3

R.S. Ames, et al., Nature, 401, 282 (1999).R. Patacchini, et al., Br. J. Pharmacol., 140, 1155 (2003). Patent N. FI2007A000032. Patent N. FI2006A000340

Urotensin II (Human) PUT-4365-v-20 °C

0.5 mgvial

257(Hydrochloride Form) Glu-Thr-Pro-Asp-Cys-Phe-Trp-Lys-Tyr-Cys-Val (Disulfide bonds between Cys5-Cys10) (M.W. 1388.6) C64H85N13O18S2 [251293-28-4] Potent Vasoconstrictor Purity Information: Qe See page xiv

Y. Coulouarn, et al., Proc. Natl. Acad. Sci. U.S.A., 95, 15803 (1998). (Original) R.S. Ames, et al., Nature, 401, 282 (1999). (Pharmacol.) M.R. MacLean, et al., Br. J. Pharmacol., 130, 201 (2000). (Pharmacol.)

Urotensin II (Rat) [Pyr110]-Prepro-Urotensin II (Rat, 110-123)

PUT-4371-v-20 °C

0.5 mgvial

257

Pyr-His-Gly-Thr-Ala-Pro-Glu-Cys-Phe-Trp-Lys-Tyr-Cys-Ile (Disulfide bonds between Cys8-Cys13) (M.W. 1663.9) C77H102N18O20S2 Vasoconstrictor Y. Coulouarn, et al., FEBS Lett., 457, 28 (1999). (Original) S.M. Gardiner, et al., Br. J. Pharmacol., 132, 1625 (2001). (Pharmacol.)

Urotensin II-Related Peptide (Human, Rat, Mouse)

PUT-4408-v-20 °C

0.5 mgvial

161

Ala-Cys-Phe-Trp-Lys-Tyr-Cys-Val (Disulfide bond between Cys2 - Cys7) (M.W. 1017.2) C49H64N10O10S2 [342878-90-4] Endogenous Hypotensive PeptideY. Coulouarn, et al., FEBS Lett., 457, 28 (1999). (Original; Rat Urotensin Precursor Sequence) T. Sugo, et al., Biochem. Biophys. Res. Commun., 310, 860 (2003). (Original: Urotensin II-Related Peptide)

Urantide™* H-Asp-[Pen-Phe-d-Trp-Orn-Tyr-Cys]-Val-OH

PUT-3639-PI-20 °C

1 mg 134

(Trifluoroacetate Form)[Pen5, D-Trp7, Orn8]-Urotensin II (Human, 4-11) (Disulfide bond between Pen2-Cys7) (M.W. 1075.28) C51H66N10O12S2 Potent Urotensin II AntagonistR. Patacchini, et al., Br. J. Pharmacol., 140, 1155 (2003). (Urantide™)

* This product is sold under exclusive license.

144 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE H-Asp-[Pen-Phe-Trp-Lys-Tyr-Cys]-Val-OH

(Disulfide bond between Pen2-Cys7) (M.W. 1089.31) C52H68N10O12S2 Potent Urotensin II AgonistP. Grieco, et al., J. Med. Chem., 45, 4391 (2002). (Urotensin Agonist)

PUT-3640-PI-20 °C

1 mg 134

H-Tic-[Pen-Phe-d-Trp-Orn-Try-Cys]-Val-OH PUT-3928-PI -20 °C

1 mg 134

(M.W. 1119.38) C57H70N10O10S2 Potent Urotensin II AntagonistM. Sala, et al., Poster Presentation at the 20th American Peptide Symposium, Montreal, Canada (2007). Patent N. FI2007A000032. Patent N. FI2006A000340

Vasoactive Intestinal Peptide (VIP)VIP (Human, Porcine)* Vasoactive Intestinal Peptide (Human, Porcine) (Bovine, Rat, Canine)

His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2 (M.W. 3325.8) C147H238N44O42S [40077-57-4]

PVA-4110-s-20 °C

0.1 mg vial

115

PVA-4110-v-20 °C

0.5 mg vial

395

V. Mutt and S.I. Said, Eur. J. Biochem., 42, 581 (1974). (Original; Porcine) R. Dimaline, et al., Peptides, 5, 183 (1984). (Original; Rat) N. Itoh, et al., Nature, 304, 547 (1983). (cDNA Seq.; Human) S.C. Wang, et al., Life Sci., 37, 979 (1985). (Original; Canine)

Vasopressin, Vasotocin, and Related PeptidesB. Berde (ed.), Neurohypophysial Hormones and Similar Polypeptides, Handbook of Experimental Pharmacology, Vol. 23, Springer-Verlag, Berlin, 1968. (Review)

[Arg8]-Vasopressin* (Human, Bovine, Ovine, Rat, Mouse)

PVP-4085-v-20 °C

0.5 mgvial

65

Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Disulfide bond between Cys1-Cys6) (M.W. 1084.2) C46H65N15O12S2 [113-79-1]E.A. Popenoe and V. Du Vigneaud, J. Biol. Chem., 205, 133 (1953). (Original; Bovine) A. Light and V. Du Vigneaud, Proc. Soc. Exp. Biol. Med., 98, 692 (1958). (Original; Human) H. Schmale, et al., EMBO J., 2, 763 (1983). (Nucleotide Seq.; Rat)

[Asu1,6,Arg8]-Vasopressin* Deamino-Dicarba-Arginine-Vasopressin

PVP-4026-v-20 °C

0.5 mgvial

75

cyclo (Tyr-Phe-Gln-Asn-Asu)-Pro-Arg-Gly-NH2 (Asu: l-a-Aminosuberic Acid) (Cyclic form between Asu w-carboxl group and Tyr a-amino group) (M.W. 1033.1) C48H68N14O12 [40944-53-4] Purity Information: Qx See page xivS. Hase, et al., J. Amer. Chem. Soc., 94, 3590 (1972). (Original)


82 Order Hotline 1-800-777-4779 502-266-8787

PEPT

IDES

INTE

RNAT

IONA

LBI

OLO

GIC

ALLY

ACT

IVE

PEPT

IDES

PRODUCT CODE QTY PRICE [Pmp1,Tyr(Me)2]-Arg8-Vasopressin* PVP-4203-v

-20 °C

0.5 mgvial

140

Pmp-Tyr(Me)-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Pmp: b-Mercapto-b,b-Cyclopentamethylene Propionic Acid) (Tyr(Me): O-Methyl-l-Tyrosine) (Disulfide bond between Cys1-Cys6) (M.W. 1151.4) C52H74N14O12S2 [73168-24-8] Potent Arginine Vasopressin V1 AntagonistM. Kruszynski, et al., J. Med. Chem., 23, 364 (1980). (Original)

[Arg8]-Vasotocin* (Frog, Chicken)

PVP-4192-v-20 °C

0.5 mgvial

65

Cys-Tyr-lle-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Disulfide bond between Cys1-Cys6) (M.W. 1050.2) C43H67N15O12S2 [74927-14-3]R. Acher, et al., Biochim. Biophys. Acta, 42, 379 (1960). (Original; Frog) J. Chauvet, et al., Biochim. Biophys. Acta, 38, 571 (1960). (Original; Chicken)

[Asu1,6,Arg8]-Vasotocin* Deamino-Dicarba-Arginine-Vasotocin

PVP-4027-v-20 °C

0.5 mgvial

75

cyclo (Tyr-lle-Gln-Asn-Asu)-Pro-Arg-Gly-NH2 (Asu: l-a-Aminosuberic Acid) (Cyclic form between Asu w-carboxl group and Tyr a-amino group) (M.W. 999.12) C45H70N14O12 [35375-13-4]S. Hase, et al., J. Am. Chem. Soc., 94, 3590 (1972). (Original)

Virus Replication Inhibiting PeptideVirus Replication Inhibiting Peptide (Bulk)

Z-d-Phe-Phe-Gly (Z: Benzyloxcarbonyl) (M.W. 503.55) C28H29N3O6 [75539-79-6]C.D. Richardson, et al., Virology, 105, 205 (1980). (Original)

PVI-4092-20 °C

25 mg100 mg

95190

XeninXenin 25 (Human)

Met-Leu-Thr-Lys-Phe-Glu-Thr-Lys-Ser-Ala-Arg-Val-Lys- Gly-Leu-Ser-Phe-His-Pro-Lys-Arg-Pro-Trp-Ile-Leu (M.W. 2971.6) C139H224N38O32S Xenopsin Related PeptideG.E. Feurle, et al., J. Biol. Chem., 267, 22305 (1992). (Original)

PXN-4279-v-20 °C

0.5 mgvial

350


product code qty price biologically active … for biosynthesis of penecillin pac-3860-pi-20 c 25 mg...

Documents